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The temporal and dose-response relationships of platelet-activating factor 
(PAF)-induced changes in the concentrations of cytosolic Ca++ ([Ca++li)/ 
lns(1,4,5)P3 and sn-1f2-diacylglycerol (DAG) were examined in platelets. These 
signal molecules increased rapidly and transiently, with peak lns(1,4,5)P3 preceding 
maximal [Ca++], elevation in high-dose PAF stimulated platelets. In low-dose PAF 
stimulated platelets [Ca++], was elevated and dense granule constituents released, 
without any increase in lns(1,4,5)P3, DAG or phosphorylation of protein kinase C 
(PKC) substrate, suggesting that mechanisms other than polyphosphoinositide 
bisphosphate hydrolysis may be utilized for platelet activation by low 
concentrations of an agonist. Exogenous activation of PKC inhibited the elevation 
of DAG, lns(1,4,5)P3 and [Ca++lj and also thromboxane (Tx) B2 generation in PAF- 
stimulated platelets. In contrast the non-selective kinase inhibitor, staurosporine 
enhanced elevations of lns(1,4,5)P3, DAG, TxB2 and the duration of the Ca+ + 
signal in high-dose PAF-stimulated platelets but not low-dose, suggesting that 
endogenously activated PKC operates as a powerful negative-feedback regulator of 
signal molecules.
In agreement with staurosporine the potent and selective inhibitors of PKC, 
namely Ro 31-7549 and Ro 31-8220 potentiated TxB2 generation and increased 
the duration of Ca+ + elevation to a much greater extent in high-dose than in low- 
dose PAF-stimulated platelets. The Ro compounds also inhibited dense granule 
release and aggregation in PAF-stimulated platelets, demonstrating a bifurcating 
role for PKC in platelet signal transduction.
The presence of proteins cross-reacting to antibodies against annexins I, II and 
V was demonstrated in human platelets. These proteins were intracellular and not 
release from the granules upon platelet stimulation.
Tyrosine phosphorylation of proteins in PAF-stimulated platelets was 
characterised using anti-phosphotyrosine antibodies, and their role in signal 
transduction was investigated using the protein tyrosine kinase inhibitor genistein. 
Upon PAF stimulation several temporal waves of protein phosphorylation were
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observed, which were differentially inhibited by genistein. Genistein inhibited 
elevation of lns(1,4,5)P3 and [Ca++]j in PAF-stimulated platelets, suggesting a role 
for endogenously activated tyrosine kinase(s) in the early stages of signal 
transduction. Moreover, genistein also inhibited PAF-induced TxB2 generation, 
dense granule release and aggregation.
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The terminally differentiated anucleate cells, known as blood platelets are 
formed from fragments of cytoplasm which bud off from multinucleate bone 
marrow megakaryocytes (Penington, 1981). Circulating platelets are uniformly 
discoid shaped cells with an equatorial diameter of 2-4 pm and a thickness of 
around 1 pm. Although they have no nucleus, they retain within their cytoplasm 
many of the subcellular features common to other cell types, such as 
mitochondria, a dense tubular membrane system, microtubules, microfilaments, 
storage granules and lysosomes. In addition platelets also contain ribosomes and 
mRNA from their parent cell, but in general it is thought that they have a limited 
capacity for protein synthesis.
The circulating platelet count is species dependent, but in man is about 2 x 
108/ml with a normal turnover rate of platelets of about 3.5 x 107/ml/day and a 
life span in the blood of about 7-10 days (Harker and Finch, 1969). However, 
platelet size, shape, count, rate of production and life span can all be altered in 
disease states, by diet manipulation or drug administration.
The first evidence of the discovery of blood platelets is a drawing made in 
1842 by Addison where platelets were represented in relation to a fibrin network 
(Addison, 1840). By 1882 with the advances made in microscopy it was 
established that platelets played a central role in haemostatic plug formation in 
response to vascular injury reviewed in (Robb-Smith, 1967). The primary role of 
platelets is to arrest bleeding from areas of damage in blood vessel walls but they 
also have the capacity to participate in numerous other physiological and 
pathological processes and exhibit a wide range of cellular reactions.
Due to the ready accessibility of platelets as a relatively homogeneous 
population of cells, and the vast range of functions they possess, platelets have 
been widely used in the study of transport, secretion, cell adhesion and signal 
transduction. The introductory chapter to this thesis has reviewed the relevant
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literature published up to the initiation of this study, in order to "set the scene" 
for the work to be executed.
1.2 Platelet Functional Responses
Platelets circulate in the blood as relatively quiescent cells only displaying 
morphological, metabolic and functional changes once they have become 
activated. Endothelial cells normally constitute an antithrombotic and anti­
coagulant surface lining the blood vessels, although these properties depend 
partially on the absence of pro-coagulant and pro-thrombotic moieties. The 
endothelium is thought to be involved in vascular haemostasis by release of 
soluble mediators or the expression of membrane-bound molecules in response to 
external stimuli. The soluble mediators include prostacyclin (PGI2) (MacIntyre et 
at. 1978) and endothelium derived relaxing factor (EDRF) (Palmer et a/. 1987). PGI2 
functions by activating adenylate cyclase and increasing cAMP levels and is the 
most potent prostaglandin to inhibit platelet aggregation (Whittle et a/. 1985). 
EDRF, now believed to be nitric oxide, is also released from endothelial cells and is 
a potent vasodilator which activates guanylate cyclase in platelets and as a 
consequence also inhibits their activation (Radomski et al. 1987a). PGI2 and EDRF 
are thought to act synergistically to block platelet aggregation with EDRF also 
inhibiting platelet adhesion (Radomski et al. 1987b). Endothelial cells also produce 
ecto-enzymes which catabolize the platelet agonist ADP in the plasma, thereby 
reducing the amount of agonist and increasing the level of adenosine which 
antagonizes platelet aggregation (Pearson and Gordon, 1985).
Platelets are capable of a very rapid response to a wide range of agonists, 
which activate these cells by occupying specific cell surface receptors. Interaction 
of physiological stimuli with their plasma membrane receptors initiates 
morphological changes in platelets including loss of their discoid shape and the 
formation of pseudopodia which is synonymous with platelet shape change and 
occurs concurrently with platelet adhesion (attachment of platelets to surfaces) 
and in advance of platelet aggregation (attachment of platelets to each other).
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Depending on the nature and concentration of the exogenous stimuli, the 
morphological changes may be accompanied by the release of dense and or-granule 
constituents by exocytosis and the generation and release of products of the 
cyclo-oxygenase pathway.
The primary function of platelets is in haemostasis, and the interaction of blood 
platelets with the subendothelium is fundamental to this process. Blood vessels 
can become damaged with the resulting exposure of their subendothelium for 
various reasons, for example by physical damage (including the site of a by pass 
or transplant operation), by the disruption or ulceration of an atherosclerotic 
plaque, by the aging process which leads to calcification and damage of the 
vessels or simply at branches of coronary arteries where there is rapid and 
turbulent blood flow leading to subtle endothelial damage. Whatever the cause of 
the vascular injury, the exposure of structures of the subendothelium, in particular 
fibrillar collagen, elastin and microfibrils is followed by platelet adhesion to these 
components (Zucker and Borrelli, 1961). Adhesion is influenced by a number of 
factors including platelet number and blood flow rate which mediates platelet 
contact with the vessel wall. A number of glycoproteins on the surface of 
platelets play an important role in adhesion. Glycoprotein lb (GPIb) serves as a 
platelet binding site for von Willebrand factor, this cofactor is synthesised almost 
exclusively by endothelial cells and is adsorbed to collagen or other components of 
the subendothelium therefore mediating platelet adherence (George et al. 1984). 
The importance of GPIb in platelet adherence is emphasized in the bleeding 
disorder known as Bernard-Soulier syndrome, where in the absence of GPIb, 
adhesion of platelets to the subendothelium does not occur (George et al. 1984). 
In parallel, the importance of von Willebrand factor is highlighted in von 
Willebrand's disease, where either von Willebrand factor is deficient from the 
plasma or is structurally or functionally defective resulting in diminished platelet 
adhesion to the subendothelium (George et al. 1984). Less is known about the 
function of GPIa on platelets, however, the finding that platelets which do not 
express GPIa also fail to respond to collagen suggests that GPIa is a receptor for
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collagen and in addition it has been reported to be important in platelet spreading 
rather than the initial adhesion (Nieuwenhuis et al. 1985). Activation of platelets 
also causes expression of a glycoprotein complex, namely GPIIb/llla, which 
functions as a key receptor for the adhesive protein cofactors of platelet 
aggregation, but which is also a receptor for von Willebrand factor, fibrinogen and 
fibronectin which helps strengthen the adhesion process (Nurden, 1987).
When platelets are transformed from discs into spiny spheres following 
activation, the circumferential band of microtubules composed of tubulin together 
with actin and associated myosin which are major proteins of the platelet 
cytoskeleton contract forcing the granules towards the centre of the cell. This 
centralisation of the electron dense amine storage granules (dense granules), a- 
granules and lysosomes is generally thought of as a preparatory stage for their 
extrusion, termed the 'release reaction' reviewed in (Holmsen, 1978; Holmsen et 
al. 1969). In general, a lower concentration of an agonist is required to release the 
constituents of a-granules than dense granules (Fuster et al. 1987), however, ADP 
and adrenaline can induce the release of dense granules with little concomitant 
release of the a-granules (Mills et al. 1968) whereas thrombin and collagen induce 
release of both types of granule (Holmsen et al. 1969). The time course for the 
release of the granules is also different with the dense granules being released in 
advance of the a-granules (Holmsen et al. 1969). A different signal transduction 
pathway is thought to exist for secretion of lysosome constituents than for 
secretion of the contents of the other two types of granule, with a role for PKC 
being proposed, and higher agonist concentrations being required for extrusion 
(Kajikawa et al. 1983). The contents of the a-granules include fibrinogen, 
fibronectin, platelet factor IV, thrombospondin and von Willebrand factor which 
will promote coagulation, but other factors notably the potent mitogen, platelet 
derived growth factor (PDGF) and transforming growth factor (TGF) which may 
have wider implications, for example in atherogenesis and inflamation. The 
contents of the dense granules include 5-HT, calcium and ADP, factors which will
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promote growth of the haemostatic plug. Table 1 lists the major contents of the 
three types of secretory granule.
ADP and serotonin released from dense granules are aggregatory agents in the 
presence of Ca+ + and fibrinogen (Born, 1962; Macmillan, 1966; Vargaftig et 
al. 1981). Release of these constituents (in particular ADP) will therefore amplify 
the original agonist signal and cause a second wave of platelet activation (Born, 
1962; Macmillan, 1966). This further recruitment of platelets and formation of 
aggregates induced by ADP release has been described as the "first pathway" of 
aggregation reviewed in Vargaftig et al. (1981). Binding of ADP to specific 
membrane receptors induces platelet shape change and exposure of fibrinogen 
binding sites, which have been identified as GPIIb/llla receptors (Peerschke, 1985). 
The GPIIb/llla complex is a major component of the platelet plasma membrane, 
with about 50,000 copies exposed on circulating platelets, although they only bind 
fibrinogen when the platelets become activated (Nurden, 1987). Cross linking of 
fibrinogen to GPIIb/llla receptors on adjacent platelets with the formation of 
bridges is the key to the platelet aggregation mechanism regardless of the agonist 
involved (Peerschke, 1985). The crucial role played by GPIIa/lllb in platelet 
aggregation is demonstrated in the condition of Glanzmann's thrombasthenia, an 
inherited disorder characterised by a deficiency or altered function of GPIIb/llla 
complexes in the platelet membrane resulting in failure of platelets to aggregate in 
response to any agonist, coupled with an abnormality of the clot reaction (George 
et a/. 1984).
Following platelet activation, the Ca++ dependent enzyme phospholipase A2 is 
stimulated to release arachidonic acid (AA) from membrane phospholipids including 
phosphatidylcholine and phosphatidylserine. AA is then metabolised by the cyclo- 
oxygenase pathway to produce the prostaglandins PGG2, PGH2 and the non­
prostaglandin thromboxane (Tx) A2 (Bakhle, 1983; Hamberg et al. 1975). The two 
pathways of AA metabolism are shown in figure 1. TxA2 is formed by the action 
of thromboxane synthetase on PGH2 and is the most abundant eicosanoid 
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TxA2 is also a potent platelet agonist and vasoconstrictor, however it is unstable 
possessing a 1/2 life of only 30 seconds once it has been released into the blood, 
after which it is converted into non-biologically active TxB2 (Hamberg et ai. 1975). 
The AA pathway has been described as the "second pathway" for platelet 
aggregation mediated by TxA2 which acts as a positive feedback causing further 
recruitment of platelets to the haemostatic plug (Vargaftig et at. 1981). Indeed an 
in vivo study in man has demonstrated that at the site of plug formation there is 
rapid and considerable platelet activation, with a 30 fold increase in TxA2 over 
plasma values in the first minute after incision which can be inhibited by a low 
dose aspirin regimen (Kyrle et ai. 1986). The ratio of products from the cyclo- 
oxygenase pathway varies from one cell type to another, for example in contrast 
to platelets (which do not form PGI2) endothelial cells form PGI2 as their major 
cyclo-oxygenase product, whilst it is thought that they do not produce TxA2, 
although TxA2 production in cultured endothelial cells has been observed (Bakhle, 
1983). Moreover, PGH2 (which can also activate platelets by binding at the TxA2 
receptor (Morinelli et ai. 1987)) derived from platelets can also be synthesised into 
PGI2 by endothelial cells causing an increase in platelet cAMP levels and therefore 
an inhibition of aggregation of neighbouring platelets (Marcus et ai. 1980). In 
addition to their inability to form PGI2 platelets are also unable to form any of the 
leukotriene products of the lipoxygenase pathway of AA metabolism (Moncada 
and Higgs, 1986).
Activation of platelets and of other cell types involved in the haemostatic plug 
formation can induce the production and release of platelet activating factor (PAF) 
[1-alkyl-2-acetyl-sn-glyceryl-3-phosphocholinel (Braquet et ai. 1987). PAF is one of 
the most potent platelet aggregating agents so far described with platelets 
possessing specific receptors for this agonist. Its production by platelets and 
other cells involved in haemostatic plug formation would suggest a high localised 
concentration (Zimmerman et ai. 1985; Touqui et ai. 1985). Experiments with 
inhibitors of prostaglandin synthesis and ADP scavengers have revealed a "third 
pathway" of platelet aggregation induced by thrombin independent of the first and
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second pathways (ie ADP release and TxA2 generation). Aggregation induced by 
PAF is not inhibited by either ADP scavengers or cyclo-oxygenase inhibitors 
suggesting an independent mechanism of platelet activation and therefore a 
possible additional pathway by which an original platelet response to a stimulus 
can be amplified (Vargaftig et al. 1981). The release of PAF at the site of 
thrombus formation by a variety of activated cells, together with its potency as a 
platelet aggregating agent and its independence from dense granule release and 
eicosanoid generation for platelet aggregation has led to the suggestion that 
release of PAF may account for the "third pathway" of platelet aggregation 
(Vargaftig et al. 1981). However, a number of studies have disputed PAF as the 
mediator of the "third pathway" of aggregation, demonstrating that inhibition of 
the cyclo-oxygenase pathway inhibits the second irreversible wave of PAF- 
aggregation, which is accompanied by dense granule release, and that 
desensitizing platelets to PAF by pretreatment with PAF has no effect on 
thrombin-induced aggregation induced by the so called "third pathway" of platelet 
aggregation (Kloprogge et al. 1983).
During the process of platelet adhesion and aggregation the blood clotting 
mechanism may be initiated and thrombin generated, further promoting platelet 
aggregation and leading to the formation and polymerisation of fibrin. This will 
lead to stabilization of the platelet mass and prevent removal of the arterial 
thrombus by the high intravascular pressure and shear forces due to blood flow. 
The formation of thrombin is the end-point of a chain of enzymic events where 
one pro-enzyme is activated into an enzyme which in turn activates another 
proenzyme (Davie and Ratnoff, 1964). The proenzymes are present in the blood 
at very low concentrations but their activation is enhanced by their being adsorbed 
and concentrated on negatively charged phospholipid surfaces, with platelets in 
vivo being a major source of these surfaces (Mann et al. 1987). Blood coagulation 
can therefore be considered as a series of surface catalysed events.
There are two pathways of coagulation, the intrinsic pathway where all 
necessary factors are present in the circulating blood and an extrinsic pathway
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where a tissue component, specifically a lipoprotein called tissue factor or tissue 
thrombospondin initiates the activation of the coagulation cascade, leading to the 
formation of thrombin (Berrettini et al. 1987). The two pathways merge at a later 
stage when factors VIII and IXa form a complex converting factor X into factor Xa 
for which platelet phospholipid (on the surface of aggregated platelets) and Ca+ + 
are essential. A prothrombinase complex is formed when factor Xa is bound to a 
negatively charged phospholipid surface in the presence of factor V and Ca++. 
Factor Xa associated with the prothrombinase complex converts prothrombin to 
thrombin, at a rate 300,000 fold greater than factor Xa alone, highlighting the 
important role for platelets in this process (Mann et al. 1987). The principle 
actions of thrombin include the cleavage of fibrinogen (a constituent released from 
the platelet a-granules) to the fibrinopeptides and fibrin monomer which 
polymerizes to form an insoluble fibrin clot, and the activation of factor XIII to 
produce factor Xllla which stabilizes fibrin. In addition, thrombin is one of the 
most potent physiological platelet aggregating agents and will therefore cause 
further recruitment of platelets to the aggregate and the release of the 
prothrombin factors V and VIII from the a-granules and the development of further 
prothrombin binding sites on the platelets (Bevers et a i 1985).
However, to counteract thrombus formation there are numerous endogenous 
inhibitors including the afore mentioned production of PGI2 and EDRF from 
endothelial cells. Thrombus formation is also limited by the activation of protein 
C, fibrinolysis and the presence of antithrombin III (Ellis et a/. 1985). Thrombin in 
association with its endothelial cofactor thrombomodulin transforms protein C to 
activated protein C which limits thrombosis by destroying factor Villa and factor 
Va, a reaction which is accelerated by the presence of protein S (Ellis et al. 1985). 
This activity initiates fibrinolysis by the release of tissue derived plasminogen 
activator which converts plasminogen to plasmin. Plasmin then cleaves fibrin into 
soluble fragments and degrades fibrinogen. Intravascular thrombosis is also limited 
by anti-thrombin III which is synthesised and expressed on the surface of 
endothelial cells and whose action is greatly increased in the presence of heparin,
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which binds to the endothelial cell surface with a high affinity (Ellis et al. 1985). 
Although heparin is not present in the blood, heparin like molecules (such as the 
glycosaminoglycan termed heparan) are associated with the vascular endothelium 
and potentiate the action of anti-thrombin III upto 20 fold (Marcum et al. 1984). 
Endothelial cells bind free thrombin by means of a cofactor which favours a 
thrombin-antithrombin III complex. A deficiency in either protein C or anti­
thrombin III is associated with thrombosis, providing evidence of the clinical 
relevance of this control mechanism (Ellis et al. 1985). A schematic drawing of 
platelet adhesion, aggregation and blood clotting is given in figure 2.
1.3 Platelets in Health and Disease
The most important physiological role of platelets in the circulation is in normal 
haemostatic processes. Platelets contribute to haemostasis in two ways, firstly 
they initiate the formation of a haemostatic plug at the site of vascular injury, and 
secondly they ensure efficient coagulation by release of factors from their storage 
granules which are involved in coagulation and also by providing a negatively 
charged phospholipid surface necessary for the activity of the prothrombinase 
complex (Mann et al. 1987).
Over activity of the haemostatic process, together perhaps with an inability of 
the endothelial cells to maintain an antithrombotic barrier, are factors responsible 
for thrombus formation which is the pathological counterpart of haemostasis. The 
pathological consequences of thrombosis are serious and may result in occlusion 
of the blood vessel or parts of the thrombus may break off and occlude smaller 
vessels downstream from the original site. Thrombosis resulting in deprivation of 
oxygen to the tissues, particularly if the tissue in question is the brain or 
myocardium may lead to disability or death through stroke or myocardial infarction 
(Harker and Ritchie, 1980; Maseri et al. 1980). Some medical conditions also 
appear to be predisposed to thrombus formation, for example renal vein 
thrombosis is a frequent complication of patients with nephrotic syndrome.
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Schematic drawing of platelet adhesion, aggregation and blood clotting
Rejection of transplanted organs is also associated with occlusion of blood vessels 
due to platelet aggregants reviewed in Gordon and Milner (1976).
Another physiological function of platelets is their role in maintaining the 
integrity of the endothelial barrier by encouraging re-endothelialisation processes at 
injury sites and thereby decreasing vascular permeability (Gimbrone et at. 1969). 
The detection of several growth factors released from the storage granules of 
activated platelets, including platelet derived growth factor (Ross, 1986), but in 
particular a novel platelet-derived factor capable of stimulating the proliferation of 
vascular endothelial cells, may have an important role in the re-endothelialisation 
process (Miyazono et al. 1985).
Problems arise when the number of circulating platelets, normally maintained 
within a narrow range, either become to few (thrombocytopenia) or too many 
(thrombocytosis). The absence of platelets in thrombocytopenia, which can be a 
side effect of chemotherapy or radiation therapy, leads to haemorrhage and 
inability of blood to clot. This is exacerbated by the inability of the remaining 
platelets to maintain the integrity of the endothelial barrier, resulting in increased 
vascular permeability and further haemorrhage (Gimbrone et al. 1969). The high 
density of platelets experienced in thrombocytosis is associated with thrombosis, 
indeed it is claimed that platelets may undergo spontaneous aggregation in the 
circulation under conditions of high density.
There is increasing evidence that platelets are also involved in the 
inflammatory process. Platelets have been demonstrated to undergo chemotaxis, 
phagocytose foreign particles and possess both IgE and IgG receptors, in addition 
they are an excellent source of a materials relevant to the inflammatory process 
which are both stored in their granules (eg platelet derived growth factor) or 
generated upon platelet stimulation (eg PAF). In addition, platelets accumulate at 
the site of vascular damage and release constituents which increase vascular 
permeability (Page, 1989). Indeed, in agreement with a role for platelets in the 
inflammatory response is the accumulating evidence that platelets participate in 
the pathological condition of asthma by either acting as inflammatory cells,
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producing powerful spasmogens (including PAF) or interacting with other cells 
potentially involved in asthma (Morley et al. 1984).
Release of the mitogen PDGF from the platelet granules is thought to play an 
important role in wound healing after tissue injury, however an abnormal release 
of this mitogen has been implicated in the genesis of pathological conditions, 
including the smooth muscle thickening which characterizes the occlusive disease 
of arteries, namely atherosclerosis (Ross, 1986). Atherosclerotic lesions are also 
sites of vascular damage, possibly as a result of plaque rupture, and therefore 
thrombus formation at these areas would be expected to contribute to the 
morbidity associated with advance atherosclerotic disease.
Most clinical studies investigating the effect of anti-platelet drugs have 
concentrated on their ability to prevent death in patients who are known to be at 
high risk from occlusive vascular disease, for example those already known to 
have myocardial infarction, or who are suffering from angina (The Aspirin 
Myocardial Infarction Study Research Group, 1980) and this may be where 
treatment is most necessary. However, many of these conditions are debilitating, 
and although anti-thrombotic drugs may increase the life of the patient, the 
underlying condition will not be cured, but simply controlled. It is possible 
therefore that other medium risk groups may also benefit from preventative 
treatment, for example in cases where a patient has a family history of premature 
coronary death, or where the patient has an illness such as diabetes or gout 
where they are predisposed to thrombotic disorders. Recently the finding that low 
dose aspirin resulted in a 44% reduction in the risk of myocardial infarction in a 
population of normal healthy males, clearly illustrates the benefits of an anti­
thrombotic treatment, and further demonstrates the potential role for platelets in 
more advanced vascular disease (Steering Committee of the Physicians' Health 
Study Research Group, 1989). However, although the risk of death from 
haemorrhagic stroke was not statistically increased in that particular study, the 
fact that the numbers were higher in the aspirin treated group stresses that the 
beneficial effects of any treatment need to be tempered against the side-effects.
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Indeed, the advantages of any antithrombotic treatment should be balanced 
carefully against its effects on normal haemostasis.
Occlusive vascular disease is the major cause of death in the Western world 
today, and there is substantial evidence that platelets are pivotal to the 
pathogenesis of stroke and myocardial infarction (Harker and Ritchie, 1980; Maseri 
et al. 1980). Therefore the development of an antithrombotic treatment which is 
specific for platelets may reduce the huge number of fatalities which result from 
occlusive vascular disease every year.
1.4 Platelet agonists
Platelets possess specific receptors on their plasma membrane surface to 
enable them to respond to blood borne and surface ligands. Specific plasma 
membrane receptors for the excitatory agonists thrombin, TxA2, PAF, collagen, 
ADP, vasopressin, serotonin (5-HT) and adrenaline have been detected on platelets 
using radioligand binding analysis, homologous desensitization and the use of 
specific antagonists. Platelets are non-electrically excitable cells (Hallam and Rink, 
1985a), therefore in order for platelets to respond to an agonist there must be a 
mechanism of information transfer, whereby the events at the cell surface are able 
to influence the biochemical activity of the signal transduction pathway, resulting 
in platelet functional responses. The expression of these functional responses is 
thought to be controlled by the intracellular concentration of second messenger 
molecules including cyclic AMP, cytosolic free Ca++ ([Ca++jj) and sn-1,2- 
diacylglycerol (sn-1,2-DAG).
Agonists vary in their potency to elicit functional responses, the rank order of 
potency of platelet agonists found to induce [Ca++], elevation has been reported as 
thrombin > PAF = U44069 (TxA2 mimetic) > vasopressin > ADP > 5-HT > > 
adrenaline = 0 and a similar rank order of potency has also been reported for 
induction of DAG elevation by these agonists (MacIntyre et a i 1985). An 
important difference between platelet agonists is in their dependency on the 
positive feedback of cyclo-oxygenase products (in particular TxA2) to induce
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secondary aggregation and promote granule release. In the presence of inhibitors 
of the cyclo-oxygenase pathway, agonists such as ADP and adrenaline will only 
cause primary aggregation and no granule release, whereas more potent agonists 
such as thrombin and PAF can elicit irreversible secondary platelet aggregation and 
stimulate secretion of granules independently of cyclo-oxygenase product 
formation (Vargaftig et al. 1981).
Platelets also possess receptors for inhibitory agonists including prostaglandins 
E,, D2 and PGI2 which exert anti-aggregating actions in platelets by virtue of their 
ability to regulate adenylate cyclase activity and thus cAMP levels (Whittle et 
al. 1985).
It is unlikely that platelets activated in vivo will be stimulated by just one 
agonist, but more likely that it will be the combined action of several different 
types of receptor occupation that will determine the degree of platelet activation. 
In vitro studies have demonstrated that platelet activation with more than one 
stimulatory agonist most often elicits a synergistic response (Adams, 1985), but 
obviously an in vivo situation would also include platelet-inhibitory agonists, 
particularly the release of PGI2 from the endothelial cells.
The platelet agonist 1-alkyl-2(R)-acetyl-glycero-3-phosphorylcholine, termed 
platelet activating factor (PAF) is the platelet agonist used in most of the studies 
in this thesis. Evidence for the existence of specific receptors for PAF on platelets 
includes its extreme potency in triggering biological responses, homologous 
desensitization of the receptors and the finding that only the naturally occurring 
stereoisomer (R) is able to bind to the receptor (Prescott et al. 1990). In addition, 
competitive binding studies utilising [3H]PAF and unlabelled PAF or PAF 
antagonists, have confirmed both the presence and specificity of PAF receptors. 
These studies have identified a high affinity binding site for PAF on human 
platelets (KD 37 nM; 240 - 1400 sites/cell) (Valone et al. 1982; Kloprogge and 
Akkerman, 1984) and rabbit platelets (Kq 16-26 nM; 150 - 300 sites/cell) (Hwang 
et al. 1986; Morrison and Shukla, 1989), although a low affinity binding site is also 
thought to exist (Valone et al. 1982; Morrison and Shukla, 1989). Moreover,
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binding of PAF to its receptor is integral to initiation of PAF-receptor coupled 
signal transduction (Morrison and Shukla, 1989), thought to be mediated via 
guanine nucleotide-binding proteins (G-proteins), and to PAF-induced functional 
responses (Kloprogge and Akkerman, 1984). Although termed platelet-activating 
factor, the agonistic effects of PAF are not limited to platelets, many other cell 
types including eosinophils, neutrophils and smooth muscle cells also possess 
specific receptors for PAF, and are activated upon PAF-receptor coupling (Braquet 
et al. 1987).
Appropriate activation of numerous cell types including platelets (using 
thrombin, collagen or ionophore but not AA or ADP), neutrophils, leukocytes and 
endothelial cells (Braquet et at. 1987; Touqui et al. 1985; Zimmerman et al. 1985) 
induces a rapid synthesis of PAF. Platelets co-operate with other cell types in the 
synthesis of PAF, for example, in response to appropriate stimuli both neutrophils 
and platelets can release PAF, however, the inclusion of platelets in a suspension 
of neutrophils results in a synergistic generation of PAF, due to the release of 
lyso-PAF from platelets which is converted to PAF by the neutrophils (Coeffier et 
al. 1984). Although it is not feasible to measure the production of PAF in vivo at 
the site of haemostatic plug formation, it is likely that in this situation, where 
there is close interaction between different activated cell types most of which are 
capable of producing PAF, that the local concentration will be high enough to 
induce platelet activation, and indeed the extreme potency of PAF as a platelet 
aggregatory agent emphasises the need for only a very small amount of PAF to be 
released in order to produce significant biological effects in vivo. Moreover, the 
potential of endothelial cells to produce PAF, and the finding that PAF remains cell 
associated, may be significant in the interaction of the endothelium with 
circulating blood cells, in particular in platelet-endothelial cell interaction in 
response to vessel injury (Zimmerman et al. 1985). Indeed, a recent study has 
demonstrated a role for PAF in primary haemostasis, reporting that the selective 
PAF-receptor antagonist L-652,731 prolongs the skin bleeding time in the rabbit,
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suggesting that locally released PAF has a physiological role in the formation of 
the haemostatic plug (Livio et al. 1988).
PAF is not stored in cells, but upon cell activation it is formed by a route 
known as the remodelling pathway (Prescott et al. 1990). In this pathway, PAF is 
formed by the sequential activities of PLA2 on alkyl-acyl-GPC (with the release of 
AA) to form lyso-PAF and the action of acetyltransferase on lyso-PAF to form 
PAF-acether, a pathway dependent on cell activation and the presence of Ca++. 
Inactivation of PAF is via deacyiation to lyso-PAF by acetylhydrolase and 
reacylation to alkyl-acyl-GPC by acyltransferase a pathway independent of the 
activation state of the cell (Figure 3). An alternative pathway for the production 
of PAF, is termed the de novo pathway. This pathway involves the synthesis of 
1-0-alkyl-2-acetyl-sn-glycerol which is converted to PAF by a unique 1 -alkyl-2- 
acetyl-sn-glycerol cholinephosphotransferase (Prescott et al. 1990). This route of 
PAF production is absent from some cell types and its function has not yet been 
established, the finding that inhibition of PLA2 suppresses PAF generation in both 
thrombin and ionophore stimulated platelets, suggests that the remodelling 
pathway is probably the main route of PAF formation in activated platelets 
(Benveniste et al. 1982).
1.5 Signal transduction pathways
Since the development of a photometric method for the semi-quantitative 
measurement of platelet aggregation by Born in the 1960's all aspects of platelet 
research have evolved considerably (Born, 1962). At around this time it was also 
discovered that following stimulation, platelets released a number of constituents 
including ADP, serotonin and fibrinogen in a process termed "the platelet release 
reaction" reviewed in (Holmsen, 1978). The importance of ADP as an agent for 
platelet aggregation, and in particular the correlation between ADP released from 
platelets and secondary aggregation was also established (Macmillan, 1966).
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It was over a century ago that Ringer demonstrated the essential role for 
extracellular Ca++ in the normal functioning of the isolated frog heart which he 
believed functioned to stabilize the plasma membrane of the heart cell reviewed in 
(Rubin, 1985). Later, Ca+ + was identified as a coupling factor between excitation 
and response in excitable tissues and it was realised that the role of Ca+ + as a 
signal molecule was not confined to the heart, but was universal with activation 
of receptors linked to the polyphosphatidyl inositol (PI) cycle increasing ionized 
Ca++ in the cytosol and thereby inducing other responses including contraction of 
smooth muscle cells and exocytosis (Michell, 1975). In the 1970's the 
importance of Ca+ + as an intracellular messenger in platelets was emerging due to 
the finding that increasing platelet [Ca++]j with the use of divalent cation 
ionophores could elicit the same functional responses of platelet granule release 
and aggregation as a physiological agonist, suggesting that [Ca++]( elevation could 
be responsible for mediating these functional events (White et a/. 1974; Feinman 
and Detwiler, 1974b).
Another important advance in that decade was the discovery of the cyclo- 
oxygenase pathway of AA metabolism, a mechanism leading to the production of 
prostaglandins and TxA2 by platelets (Hamberg et a/. 1975), and the production of 
prostaglandins including PGI2 by endothelial cells (Moncada eta /. 1976; MacIntyre 
et a/. 1978). TxA2 was found to be both a potent platelet aggregating agent and a 
potent vasoconstrictor (Hamberg et a/. 1975), but in contrast PGI2 inhibited platelet 
activity and possessed vasodilator properties (Moncada et a/. 1976). The release 
of ADP from the platelet granules together with the generation of TxA2 by 
platelets were thought to be important mediators of platelet activation (Vargaftig 
et a/. 1981). Despite the advances made in platelet research in this decade, the 
nature of the intracellular biochemical signal transduction pathway responsible for 
triggering the basic platelet functional responses following agonist-receptor 
coupling was still a black box (Holmsen, 1978).
In an attempt to understand the mechanism of stimulus-response coupling 
intracellular events were examined, and it was found that activated platelets
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selectively phosphorylated two proteins, one of 40-47 kDa and the other of 19-25 
kDa, and that their phosphorylation was temporally related to the release of 
granule constituents (Haslam and Lynham, 1977). The lower molecular weight 
protein was identified as a substrate of the Ca+ + and calmodulin-dependent 
myosin light chain kinase (Daniel et al. 1984), whilst the higher molecular weight 
protein was identified as the major substrate of protein kinase C (PKC), an enzyme 
discovered and characterised by Nishizuka and colleagues and thought to play a 
pivotal role in platelet activation (Inoue et al. 1977; Nishizuka, 1984). By the end 
of the decade it had been established that both intracellular Ca+ + and protein 
phosphorylation were important mediators of platelet signal transduction (Lyons 
and Shaw, 1980).
At this time the pace of research into signal transduction quickened with 
attention being paid to the role of inositol phosphate turnover in platelets. The 
first evidence that phosphoinositide (PI) metabolism was involved in the response 
of cells to receptor-agonist coupling was produced by Hokin & Hokin in 1955 
(Hokin and Hokin, 1955) where they demonstrated that acetylcholine accelerated 
the turnover rate of phosphoinositides in pancreatic tissue. It soon became clear 
that PI metabolism was coupled to stimulation of many different cell types, by 
many different agonists and that it was a mechanism closely related to [Ca**], 
elevation (Michell, 1979; Majerus et a/. 1985). In platelets it was soon established 
that this mechanism was commonly provoked by the coupling of agonists (except 
those which use cAMP as their second messenger) to their receptors (Lapetina, 
1983; MacIntyre and Pollock, 1983). In 1979 it was discovered that hydrolysis of 
phosphatidylinositol (Ptdlns) by phospholipase C (PLC) induced a transient 
accumulation of DAG in platelets (Rittenhouse-Simmons, 1979) and that the 
action of diglyceride lipase on DAG could release AA for metabolism by the cyclo- 
oxygenase pathway (Bell et a/. 1979).
The enzyme PKC was first described at this time, but had no obvious role in 
signal transduction (Inoue et al. 1977). Later however, it was found to be a Ca+ +
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activated and phospholipid dependent enzyme, firmly linked to the signal 
transduction pathway by the discovery that DAG greatly increased the affinity of 
PKC for Ca++ thereby activating the enzyme (Nishizuka, 1984). Before the 
discovery of PKC, the potent platelet aggregatory action of the phorbol ester, 12- 
O-tetradecanoyl-phorbol-13-acetate (TPA), had been described (Zucker et al. 1974). 
After the discovery of PKC the mode of action of phorbol esters was established 
when it was found that they could directly activate PKC, by substituting for DAG 
and greatly increasing the affinity of the enzyme for Ca++ (Castagna et a/. 1982). 
A pivotal role of PKC in signal transduction in numerous cell types was soon 
established (Nishizuka, 1984). The finding that phosphorylation of the major PKC 
substrate in platelets (40-47 kDa protein) correlated with release of various 
granule constituents, together with the finding that activation of PKC with phorbol 
ester alone also induced granule release suggested the central role of PKC in 
platelet signal transduction (Rink et al. 1983; Kaibuchi et al. 1983).
As well as producing DAG, hydrolysis of Ptdlns(4,5)P2 by phospholipase C in 
the PI cycle also produces lns(1,4,5)P3. It had been demonstrated earlier that 
activation of the PI cycle was closely associated with an increase in cytosolic 
Ca++ which was then able to evoke many physiological responses (Michell, 1975). 
The missing link in the signal transduction pathway was the association between 
activation of the PI cycle and an elevation of cytosolic Ca+ + . In 1983 it was 
suggested by Berridge that lns(1,4,5)P3 which was rapidly formed upon activation 
of the insect salivary gland with 5-hydroxytryptamine may function as a second 
messenger in the control of the release of Ca + + from intracellular pools (Berridge,
1983). This study also demonstrated that it was the polyphosphoinositides (PPI) 
and not PI which were the primary targets of hydrolysis by phospholipase C. The 
fact that the hydrolysis of Ptdlns(4,5)P2 provided the only source of lns(1,4,5)P3 
produced by the action of PLC, together with the finding that the hydrolysis of 
Ptdlns(4,5)P2 by PLC is Ca++ independent (and therefore elevation of lns(1,4,5)P3 
can precede Ca+ + elevation) (Billah and Lapetina, 1982) supported the theory of 
Berridge. A wealth of studies demonstrating that lns(1,4,5)P3 could release Ca+ +
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from the endoplasmic reticulum of numerous different types of permeabilized cell 
preparations, quickly substantiated the second messenger role of lns(1,4,5)P3 in 
regulating the mobilization of intracellular Ca + + (Berridge, 1984; Streb et al. 1983; 
Berridge and Irvine, 1984). In particular, lns(1,4,5)P3 (at concentrations of 0.5 - 5 
//M) was found to release 46Ca++ from a Ca++-transporting membrane vesicle 
fraction derived from human platelets (O'Rourke et a i 1985), and from human 
platelets permeabilized with saponin (Brass and Joseph, 1985). Moreover, 
quantification of lns(1,4,5)P3 elevation in thrombin stimulated platelets indicated 
that adequate lns(1,4,5)P3 could be formed to induce the mobilization of Ca+ + 
from intracellular stores (Rittenhouse and Sasson, 1985).
More recently, evidence has been produced for the involvement of guanine 
nucleotide-binding proteins in mediating the transduction of excitatory extracellular 
signals from receptors to the intracellular signal transduction pathway (Haslam and 
Davidson, 1984). Mechanisms of stimulus-response coupling are given in figure 4.
1.5.1 The rote of Guanine nucleotide binding-proteins in signal transduction
Guanine nucleotide-binding proteins (G-proteins) mediate transduction of 
extracellular signals (which combine with receptors) to intracellular effector 
enzymes. Some of the first G-proteins to be identified were those associated with 
adenylate cyclase, namely G, which stimulates adenylate cyclase and Gj which 
inhibits adenylate cyclase (Casey and Gilman, 1988). Platelets possess both G, 
and Gj which are heterotrimeric proteins with G, containing an or.-subunit of 45 
kDa and G, containing an Oj-subunit of 41 kDa, but both possessing a Br dimer 
that is similar or identical in all G-proteins. Activation of G-proteins (by receptor 
occupancy) stimulates the replacement of GDP tightly bound to the a subunit by 
GTP, leading to dissociation of the protein into oGTP and Br components. 
Consensus sequences implicated in the binding and hydrolysis of GTP have been 
found in the a subunits. The GTP bound form is the active conformation which is 
then thought to stimulate its target enzyme. The intrinsic GTPase activity of 
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Fig 4 Schematic drawing of the major signal transduction pathways in platelet activation
This process continues as long as there is receptor occupancy thereby causing 
amplification of the original agonist-receptor binding signal, reviewed in Casey and 
Gilman (1988).
Evidence for the importance of closely related G-proteins in mediating the 
transmembrane signalling initiated by the occupancy of certain membrane 
receptors of stimulatory agonists is accumulating (Litosch and Fain, 1986). In 
particular there is evidence for GTP-binding proteins being directly involved in the 
regulation of PLC activity. This evidence includes the finding that GTP and its 
non-hydrolysable analogues such as GTPrS can stimulate PLC activity in different 
cell types including permeabilized platelets, where the stimulatory effects of 
thrombin are also enhanced (Haslam and Davidson, 1984; Hrbolich et al. 1987). 
Conversely, GDP&S the non-hydrolysable analogue of GDP, causes a marked 
decrease in the activity of phospholipase C in permeabilized platelets (Kucera and 
Rittenhouse, 1988). Sodium fluoride (in particular the ALF4' moiety) which 
activates G-proteins in intact cells has also been demonstrated to stimulate PLC 
activity in platelets (Kienast et al. 1987).
1.5.2 Phospholipase C and the production of the two signal molecules lnsf1,4,5)P3 
and DAG
Activation of inositol phospholipid-specific phospholipase C plays a key role in 
signal transduction, and is a primary step in the major signal transduction pathway 
in platelets induced by a range of different agonists. Activation of PLC represents 
the link between agonist-receptor coupling and the PI cycle (Majerus et al. 1985). 
It appears therefore that a wide range of agonists which bind to different 
receptors use this mechanism of signal transduction to induce the same basic 
platelet functional responses. The importance of Ptdlns(4,5)P2 hydrolysis is well 
established with evidence that the products, namely lns(1,4,5)P3 and DAG are 
second messengers responsible for mobilization of intracellular Ca + + and activation 
of PKC respectively (Berridge, 1984). However, pathways of platelet activation
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independent of PI metabolism are also thought to exist for agonists such as ADP 
and adrenaline (MacIntyre et al. 1985; Fisher et al. 1985).
Early studies suggested that Ptdlns was the main substrate of PLC, with its 
hydrolysis producing DAG and lns(1)P (Rittenhouse-Simmons, 1979). However, it 
is now known that upon initial activation PLC causes preferential hydrolysis of 
Ptdlns(4,5)P2 producing both DAG and lns(1,4,5)P3 (Berridge, 1983; Majerus et 
al. 1985). Ptdlns and Ptdlns(4)P are also substrates of PLC, but in addition the 
early hydrolysis of Ptdlns(4,5)P2 causes Ptdlns to be sequentially phosphorylated 
by phosphatidyl-4-kinase to form Ptdlns(4)P which is then phosphorylated by 4- 
monophosphate 5-kinase to replenish the pool of Ptdlns(4,5)P2. The PPIs are 
minor constituents of cellular lipid with Ptdlns(4)P and Ptdlns(4,5)P2 respectively 
accounting for 1% and 0.3% of the total platelet phospholipid whilst Ptdlns 
accounts for 5-7% (Siess, 1989). Hydrolysis of Ptdlns(4,5)P2 is Ca+ + 
independent, whilst hydrolysis of Ptdlns requires elevated intracellular Ca+ + 
(Lapetina, 1983) suggesting different enzyme activities and indeed more than one 
PLC enzyme is now known to exist (Siess, 1989). Following platelet stimulation 
with an agonist such as thrombin a rapid loss of radioactivity in Ptdlns(4,5)P2 is 
observed, resulting in a subsequent elevation of lns(1,4,5)P3 and an increase in 
[Ca++li. The increase in Ca++ will then allow the Ca++ dependent hydrolysis of 
Ptdlns to proceed, the amount of Ptdlns hydrolysed is ten fold greater than 
Ptdlns(4,5)P2 and may account for the majority of the DAG produced (Majerus et 
al. 1985).
Both DAG and lns(1,4,5)P3 possess the characteristics of second messengers, 
they are formed rapidly, degraded rapidly and act at very low concentrations. In 
platelets agonist-stimulated elevation of DAG is rapid (Rittenhouse-Simmons, 
1979; Preiss et al. 1986) and transient due to both its phosphorylation by DAG 
kinase to phosphatidic acid (PA) (Tysnes et al. 1988) and its degradation by DAG 
lipase to fatty acid (AA) and glycerol (Bell et al. 1979; Mahaevappa and Holub, 
1986). PA is converted into Ptdlns through intermediate enzyme reactions (CTP- 
phosphatidate:cytidyl transferase and CDP-1,2-diacylglycerol-inositol phosphatidyl
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transferase) as part of the PI cycle (Lapetina, 1983), whereas the AA formed, 
both by the action of DAG lipase and by the action of PA specific PLA2 activity 
(Billah et al. 1981), may be metabolised through the cyclo-oxygenase pathway in 
the generation of eicosanoids. Although the hydrolysis of (P)Pls is probably the 
major source of DAG it is possible that an additional source may be via the action 
of phospholipase D (PLD) on phosphatidylcholine (Loffelholz, 1989). In platelets 
however, the presence and role of PLD has yet to be verified (Rubin, 1988). The 
short-lived elevation of DAG is thought to activate PKC, a family of ubiquitously 
distributed iso-enzymes which have been implicated as having many different roles 
including the regulation of cell activation (Nishizuka, 1984).
The only well characterised source of lns(1,4,5)P3 is the hydrolysis of 
Ptdlns(4,5)P2 (Berridge, 1983). lns(1,4,5)P3 is rapidly elevated upon agonist-
receptor coupling (Rittenhouse and Sasson, 1985; Berridge, 1983) and is transient 
due to its removal which is regulated by either phosphorylation to lns(1,3,4,5)P4 
by lns(1,4,5)P3 kinase or by degradation to lns(1,4)P2 by 5-phosphomonoesterase 
(Batty et al. 1985; Connolly et al. 1987; Mitchell et al. 1989). Inositol phosphates 
are then further metabolised by specific kinases and phosphatases, with nearly 20 
different inositol phosphates having been reported leading to the eventual 
formation of inositol (Majerus et al. 1988). There is now considerable evidence 
that the transient elevation of lns(1,4,5)P3 is responsible for the mobilization of 
Ca+ + from intracellular stores (Berridge, 1984; Streb et a/. 1983). In parallel to the 
formation of lns(1,4,5)P3 is the formation of much lower concentrations of inositol
1,2-cyclic 4,5-trisphosphate which is believed to be equipotent to lns(1,4,5)P3 at 
releasing Ca++ from intracellular stores (Tarver et al. 1987).
Several factors are thought to be important in the regulation of inositol 
phospholipid hydrolysis by PLC, and these include the regulation of PLC activity by 
G-proteins, [Ca++lj elevation and protein phosphorylation. A role for protein 
phosphorylation in regulating PLC activity has evolved for several different kinases, 
for example, exogenous activation of PKC decreases agonist induced Ptdlns(4,5)P2 
hydrolysis and inhibits lns(1,4,5)P3 elevation, suggesting the PKC is exerting its
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negative effect either at the level of PLC or an enzyme regulating the activity of 
PLC (Zavoico et al. 1985). Indeed there are reports of phosphorylation of PLC 
isoenzymes by PKC both in vitro and in vivo reviewed in (Rhee et ai. 1989). 
Increased cAMP levels have also been shown to inhibit PI breakdown induced by 
agonists (Watson et ai. 1984). The mechanism by which cAMP-dependent kinase 
prevents PLC activation in stimulated platelets is not known, but may be through 
phosphorylation of a PLC isoenzyme (Kim et ai. 1989). Receptors for growth 
factors such as EGF and PDGF contain intrinsic protein tyrosine kinase (PTKase) 
activity (Hunter and Cooper, 1985) which is responsible for phosphorylation of 
PLC and in particular PLCr. Platelets are a rich source of PTKase(s) particularly 
pp60°^c (Golden et ai. 1986), therefore it is possible that PLC activity in platelets 
could also be regulated by tyrosine phosphorylation.
1.5.3 Cytosolic calcium as a second messenger
The resting intracellular free Ca+ + concentration ([Ca++],) is low in all animal 
cells with a concentration of between 10*7 and 3x1 O'7 M as opposed to an 
extracellular concentration ([Ca++]J of Ca++ of around 10'3M (Rink et ai. 1983). 
Small changes in the absolute amount of Ca+ + in the cytosol therefore provide a 
large signal to background ratio. The 10,000 fold difference in Ca+ + 
concentration between the cell interior and the extracellular milieu relies on strict 
homeostatic mechanisms to regulate the levels of ICa + +], (Rink, 1988).
In the unstimulated platelet it is thought that the resting membrane is very 
impermeable, although the mechanism by which the inevitable leak of Ca+ + into 
the cell is counterbalanced by extrusion is still not known. One possibility for the 
removal of Ca++ would be the presence of Ca + +-ATPase activity which would 
allow Ca+ + to be actively pumped from the platelet cytosol, however whereas this 
mechanism has been identified on the intracellular membranes in platelets it is not 
believed to be a feature of the surface membranes (Hack et ai. 1986). Another 
possibility for Ca+ + homeostasis in resting platelets is the presence of Ca++:Na + 
exchange, complete replacement of Na+ with either K+ or choline was found to
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cause a small increase in basal [Ca**], in resting platelets (Sage and Rink, 1986) 
supporting Ca**:Na* exchange across the surface plasma membrane of platelets 
(Rengasamy et al. 1987). Moreover, a wide range of agonists induce a substantial 
elevation of [Ca**], which reaches a maximum concentration and then declines 
towards basal implying a powerful mechanism for the removal of Ca++ from the 
cytosol which may be either by resequestration into the intracellular stores 
(possibly by Ca**-ATPase) or by extrusion across the plasma membrane against a 
concentration gradient. Activation of platelets with a physiological agonist such 
as thrombin, followed by the addition of phorbol ester which activates PKC 
induces a much more rapid return of [Ca**], to basal levels, suggesting a possible 
role for PKC in Ca++ homeostasis (Poll and Westwick, 1986a; Pollock et a i 1987).
1.5.3.1 Advances in techniques for [Ca++], measurement
The earliest measurements of [Ca++]j in living cells were made using the 
luminescent photoprotein aequorin injected into giant muscle cells. A decade later 
bis-azo absorbance dyes (including arsenazo III) were introduced together with 
selective microelectrodes as methods of monitoring [Ca++]i, these techniques were 
however, really only suitable for use in giant invertebrate cells reviewed in 
(Cobbold and Rink, 1987).
Knowledge of the role of [Ca**], in platelet signal transduction has developed 
in parallel with the techniques available for its detection. In the presence of 
[Ca**]., divalent cation ionophores were found to induce platelet functional 
responses (Feinman and Detwiler, 1974b; White et al. 1974) and moreover, 
platelet activation with the agonist thrombin was found to be associated with an 
increase in the uptake of 4BCa** (Massini and Luscher, 1976). The development 
of cell electropermeabilization, a technique which forms small pores in the plasma 
membrane without loss of protein constituents from the cytoplasm, but allows the 
[Ca**], to be clamped, demonstrated that in platelets an elevation of [Ca**], alone 
in the range 1 - 1 0  //M induced secretory exocytosis, but that in the presence of
46
thrombin the dose-response curve was shifted to the left (Knight and Scrutton,
1984). Development of the cell permeant fluorescent indicator quin-2 (Tsien et 
al. 1982), allowed the dynamic changes in [Ca**], in response to an agonist to be 
measured for the first time in platelets (Rink et al. 1982). Studies with quin-2 
loaded platelets demonstrated that activation with a range of agonists including 
thrombin, PAF, vasopressin, ADP, TxA2 (U44069) and PGH2 (U46619) induces a 
transient elevation of [Ca**], which is larger in the presence of extracellular Ca**, 
indicating both Ca** influx across the plasma membrane and mobilization from 
intracellular stores (MacIntyre et al. 1985; Hallam and Rink, 1985a).
Second generation fluorescent indicators include fura-2, fluo-3 and indo-1, 
which have improved properties over quin-2, are increasingly used and have 
confirmed the presence of two components of [Ca**], elevation in platelets. 
Indeed the use of dual wavelength fluorimetry using Mn2* as a surrogate for Ca2* 
(which causes a quenching of the dye fluorescence) has allowed Ca** influx to be 
studied as a separate entity to mobilization (Alonso et al. 1989). Aequorin, which 
was one of the earlier dyes discovered may still prove to be a useful tool as it is 
thought to measure localised changes in [Ca**], as opposed to the average rise in 
[Ca**], which is measured by fluorescent indicators such as fura-2. Indeed, in 
aequorin loaded platelets an increase in [Ca**], has been detected upon stimulation 
with collagen, adrenaline and PMA (Erne et al. 1987) whereas no such increase is 
observed with fura-2 or quin-2 (Rink et al. 1983; Watson et a i 1985; MacIntyre et 
a i 1985).
1.5.3.2 Mechanisms of [Ca**], elevation
The three main mechanisms thought to exist to elevate [Ca**], in animal cells 
are (i) lns(1,4,5)P3 induced Ca** mobilization from intracellular stores analogous to 
the endoplasmic reticulum (termed the dense tubular system in platelets), (ii) 
receptor-mediated Ca** entry across the plasma membrane and (iii) voltage-gated 
Ca** entry across the plasma membrane in electrically excitable cells. Platelets 
are electrically non-excitable cells and as such do not possess voltage-dependent
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Ca++ channels (Hallam and Rink, 1985a). However, there is evidence that in 
agonist stimulated platelets Ca** is elevated by both mobilization (Brass and 
Joseph, 1985; Berridge, 1984) and influx across the plasma membrane (Hallam et 
al. 1984; Hallam and Rink, 1985a).
1.5.3.3 lns(1,4,5)P3 induced [Ca**], mobilization
The close association between receptor activation, lns(1,4,5)P3 formation and 
the elevation of cytosolic Ca**, led to the theory that lns(1,4,5)P3 was responsible 
for the mobilization of Ca** from intracellular stores (Berridge, 1983). There is 
now sufficient evidence to suggest that this is correct (Berridge and Irvine, 1984; 
Berridge and Irvine, 1989) including the finding that exogenously added 
lns(1,4,5)P3 can stimulate the efflux of Ca** from internal stores of many 
permeabilized cell preparations including platelets (Berridge, 1984; Streb et 
al. 1983; Berridge and Irvine, 1984; Brass and Joseph, 1985; O'Rourke et 
al. 1985). In addition, inositol 1,4,5-trisphosphorothioate, a non-hydrolysable 
synthetic analogue of Insd,4,5)P3, has also been found to mobilize Ca** from 
intracellular stores of several different permeabilized cell preparations including 
hepatocytes and is only three times less potent than lns(1,4,5)P3 (Taylor et 
a/.1989). Moreover, in support of a second messenger role for lns(1,4,5)P3 is 
evidence of specific, saturable and reversible binding sites for 32P-lns(1,4,5)P3 in 
permeabilized hepatocytes and neutrophils (Spat et at. 1986) and more recently the 
solubilization, purification and characterisation of an lns(1,4,5)P3 receptor from rat 
cerebellum (Supattapone et al. 1988).
1.5.3.4 Receptor Mediated Calcium Entry
The contribution of influx of extracellular Ca** and of mobilization of 
intracellular Ca** towards total elevated [Ca**], has been evaluated in several 
platelet studies by replacing extracellular Ca** with the Ca** chelator EGTA 
(MacIntyre et al. 1985; Hallam et al. 1984; Hallam and Rink, 1985a). In these 
studies elevation of [Ca**], induced by agonists including thrombin, PAF,
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vasopressin, U44069, ADP and 5-HT was markedly impaired when extracellular 
Ca+ + was replaced with EGTA implying that influx of Ca+ + across the plasma 
membrane is a major component of agonist-induced [Ca ++lj elevation. Moreover, 
the elevation of [Ca**], is prolonged in the presence of extracellular Ca+ + , 
suggesting that the Ca+ + influx component is responsible for sustaining the 
increase in [Ca++]j (Pollock and Rink, 1986). An influx component of [Ca ++]f 
elevation in platelets is also supported by the observation that extracellular 4BCa+ + 
is taken into platelets upon agonist stimulation (Massini and Luscher, 1976). 
Maximal stimulation of Ca++ influx in thrombin stimulated platelets occurs in the 
first few seconds, indicating rapid closure of the Ca + + channels (Poll and 
Westwick, 1986b).
In order to distinguish Ca + + entry from mobilization of Ca++ from intracellular 
stores the use of Mn2+ as a Ca++ surrogate in conjunction with dual wavelength 
excitation fluorimetry have been developed to use in conjunction with cells loaded 
with the fluorescent dye Fura-2 (Merritt and Hallam, 1988; Alonso et a/. 1989). At 
an excitation wave length of 340 nm, Mn2+ acting as a Ca2+ surrogate (at least 
through some pathways) will move into cells and quench the fluorescence, whilst 
Ca2+ will increase the fluorescence signal. At a wavelength of 360 nm however 
fluorescence of fura-2 is insensitive to [Ca**], and therefore the only signal after 
cell stimulation will be quenching caused by an influx of Mn2+. Employing this 
method Merritt and Hallam demonstrated that stimulation of platelets with 
thrombin resulted in an increase in [Ca++lj which was due to both release from 
internal stores and influx across the plasma membrane (Merritt and Hallam, 1988).
Little is known about the regulation of the Ca++ channels which exist to 
transport Ca++ across the plasma membrane and into the cytosol upon platelet 
stimulation. Two general types of receptor mediated Ca++ entry have been 
proposed, firstly entry which is modulated indirectly through some internal 
diffusible messengers (believed to be inositol phosphate(s)) and which is termed a 
second messenger operated channel (SMOC) and secondly entry which is
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regulated directly by the receptor and termed a receptor operated channel (ROC) 
(Berridge and Irvine, 1989). Using dual wave length fluorimetry and Mn+ + as a 
Ca++ surrogate, various agonists were found to cause a different rate and extent 
of Ca++ channel opening in platelets (Alonso et a/. 1989). ADP and PAF were 
found to induce rapid and transient opening of the Ca+ + channels, whereas 
thrombin caused a rapid and maintained opening and collagen caused a delayed 
opening of the channels (Alonso et a!. 1989). Using this method it would be 
possible in some cases to differentiate between Ca+ + influx regulated by a SMOC 
and influx which was through a ROC and which did not depend on the elevation 
of second messengers. Therefore, if Ca + + influx, detected by a quenching of 
fluorescence due to Mn+ + influx, preceded intracellular Ca+ + mobilization this 
would predict the presence of a ROC. Indeed ADP induced Mn2+ entry has been 
found to clearly precede internal Ca+ + discharge suggesting a ROC may be 
responsible for at least part of the Ca + + influx component in ADP stimulated 
platelets (Sage et a/. 1989).
It has recently been demonstrated that lns(1,4,5)P3 alone can activate ion 
channels responsible for mediating Ca++ influx in mitogen stimulated T-cells (Kuno 
and Gardner, 1987). Moreover, studies on sea urchin egg cells have demonstrated 
a role for lns(1,4,5)P3 and lns(1,3,4,5)P3 acting together as messengers in the 
regulation of Ca + + influx (Irvine and Moor, 1986), whilst a combination of 
lns(1,4,5)P3 and lns(1,3,4,5)P4 is required to evoke a sustained increase in Ca++- 
activated K+ current which is dependent on external Ca++ in mouse lacrimal acinar 
cell (Morris et a!. 1987). The role of second messengers as regulators of Ca+ + 
entry in platelets is unknown, however recently lns(1,4,5)P3 has been linked to the 
opening of Ca++ channels in the platelet plasma membrane (Rengasamy and 
Feinberg, 1988).
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1.5.3.5 Calcium dependent biochemical and functional responses
In the presence of extracellular Ca++, divalent cation ionophores induce similar 
functional responses to physiological agonists in platelets proposing that Ca+ + is a 
principle mediator of activation-response coupling (White et al. 1974; Feinman and 
Detwiler, 1974a; Lapetina et a!. 1978). Studies employing ionophores have been 
used to determine the [Ca++], required to elicit a particular response. Shape 
change and myosin phosphorylation were found to be most sensitive to [Ca ++], 
elevation, followed by aggregation and secretion, whilst the response requiring the 
highest [Ca++]j was PLA2 activation resulting in the liberation of AA and generation 
of Tx, however in agonist stimulated platelets these responses were elicited when 
the [Ca**]j was significantly lower than predicted, indicating a synergism between 
Ca+ + and other intracellular signal molecules in platelet activation (Hallam et 
a!. 1985; Rink and Hallam, 1984; Rink, 1988).
Platelet adhesion and aggregation are dependent on extracellular Ca+ + as it is 
required for the binding of fibrin, von Willebrand factor and fibrinogen to their 
receptor sites on platelets (Siess, 1989). However, many agonist-induced platelet 
functional responses are also dependent on an increase in intracellular Ca+ + in 
order to elicit a full response. Secretion of granule constituents is believed to be 
dependent on a rise in lCa++]j, although granule release has been observed in 
platelets stimulated with phorbol esters, with no concomitant increase in [Ca**], 
suggesting that factors other than Ca+ + are also involved in their release (Rink et 
al. 1983). Many platelet enzymes including PLA2, PKC and MLCKase are also 
dependent on an increase in [Ca++]j for their activation, however, as with dense 
granule release the relationship between [Ca++]j elevation and enzyme activation is 
not a simple one, but probably involves many other factors.
1.5.4 Annexins
Annexins (previously termed lipocortins/calpactins) are a widely distributed 
family of at least seven cytoskeletal proteins capable of binding phospholipids in 
the presence of Ca++ (Crumpton and Dedman, 1990; Russo-Marie, 1991).
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Members of the annexin family share substantial sequence homology, with all 
except one member namely annexin VI, having a molecular weight of 32 - 38 KDa 
and consisting of 4 internal repeats of 70 amino acids (8 for annexin VI) 
(Russo-Marie, 1991).
The physiological role of annexins is unknown, although it has been suggested 
that they may be the mediators of glucocorticoid action (Flower and Blackwell, 
1979; Flower, 1988) and that they could act as specific inhibitors of 
phospholipase A2 (PLA2) (Parents et al. 1984; Wallner et al. 1986). If annexins 
possess the ability to inhibit PLA2 this would mean that they would be central to 
the control of prostaglandin, leukotriene and eicosanoid production and could thus 
in turn play a role in regulating the inflammation response. The ability of annexins 
to inhibit PLA2 is however controversial (Davidson and Dennis, 1989) and may be 
due to substrate sequestration, moreover inhibition of PLA2 has only been 
demonstrated in vitro.
The possibility that annexins may be important in intracellular signal 
transduction is also emerging with increasing evidence that annexins are cellular 
substrates for PTKases and PKC. Annexin I and II are substrates for the epidermal 
growth factor receptor and pp60*rc respectively, whilst annexins I,II,III,IV and VI 
are also substrates for PKC reviewed in Russo-Marie (1991). However, 
phosphorylation by these kinases has been found mainly in vitro with few 
examples of phosphorylation within whole cells (Com6ra et al. 1989; Khanna et 
al. 1986; Gould et al. 1986).
There is little information on the subtypes of annexins possessed by platelets 
or their possible functions in platelets (Touqui et al. 1986; Crouch and Lapetina, 
1986). Annexins are believed to function extracellularly (Flower and Blackwell, 
1979; Russo-Marie, 1991), and platelets are known to release a variety of granule 
constituents upon activation, therefore it is possible that any annexins possessed 
by platelets may be released via the same route. The identity of annexins
possessed by human platelets has been determined in this study, together with 
their ability to be released by several factors which induce granule release.
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7.5.5 Protein phosphorylation
It is becoming increasingly evident that phosphorylation of proteins is a critical 
mechanism in the control of intracellular signalling in many different cell types 
including platelets. The main reasons for this are probably two fold, firstly, the 
addition of the phosphate group to a protein can substantially change its 
character, its conformation and its interaction with ions and with other proteins. 
Thus phosphorylation can make an inactive enzyme active or conversely an active 
enzyme inactive. The second important feature of protein phosphorylation is that 
due to the presence of phosphatases within cells the reaction is readily reversible 
and therefore can be closely controlled. Phosphorylation therefore controls the 
activation state of proteins which are responsible for the activation or inhibition of 
cellular responses.
The main mechanism by which receptor-coupled platelet activation is mediated 
is thought to be through protein phosphorylation. The calcium, calmodulin- 
dependent protein kinase, myosin light chain kinase, PKC and PTKase are several 
examples of protein kinases present in platelets. There are also signal 
transduction pathways in platelets which are linked to the inhibition of platelet 
functional responses and mediated by protein phosphorylation for example, an 
increase in cAMP caused by inhibitory platelet agonists such as prostacyclin or 
PGD2 activates PKA. The first two phosphorylated proteins detected in agonist 
stimulated platelets were of 40-47 kDa and 20 kDa (Lyons and Shaw, 1980), now 
known to be the substrates of PKC and MLCKase respectively (Daniel et ai. 1984; 
Nishizuka, 1984).
1.5.6 Protein kinases in Platelets
1.5.6.1 Protein Kinase C
Protein kinase C (PKC) was discovered in 1977 by Nishizuka and colleagues 
and at that time was believed to be a single entity (Inoue et al. 1977). However, 
subsequent molecular cloning and enzymological analysis has revealed ,the 
existence of at least seven isoenzymes of PKC (Nishizuka, 1988).
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The putative endogenous activator of PKC is the physiologically relevant sn-
1,2-diacylglycerol, a signal molecule produced by the hydrolysis of Ptdlns(4,5)P2, 
Ptdlns(4)P and Ptdlns (Nishizuka, 1984). Neither the sn-1,3-diacylglycerol 
enatiomer nor the 1,3-diglyceride diastereomer are capable of activating PKC. 
Activation of PKC is Ca + + and phospholipid, in particular phosphatidylserine, 
dependent (Nishizuka, 1986). Activated PKC phosphorylates its target proteins on 
their serine or threonine amino acid residues thereby regulating these proteins and 
their individual functions. In platelets two endogenous proteins of 40 kDa and 20 
kDa are rapidly phosphorylated upon agonist-receptor coupling and their 
phosphorylation has been associated with granule release and platelet aggregation 
(Haslam and Lynham, 1977; Lyons and Shaw, 1980). The 20 kDa protein is 
myosin light chain (MLC) whilst the 40 kDa protein is the major substrate of PKC, 
although this protein has been sequenced and cloned its exact function still 
remains unknown (Touqui et a/. 1986; Connolly et al. 1986). Once PKC is 
activated by DAG it is translocated from the cytosol to the membrane, where it is 
thought to be subjected to proteolytic cleavage by calpains to release a 
catalytically fully active fragment that is subsequently removed from the cell.
All isoenzymes of PKC are composed of a single polypeptide chain comprising 
several conserved and variable regions, the amino terminal half of all isoenzymes 
contain the conserved regions C, and C2 which form the regulatory domain. The 
carboxy terminal half which contains C3 and C4 is the protein kinase domain. The 
conserved region C3 also has an adenosine trisphosphate (ATP)-binding region, 
however, the sites involved in DAG and phospholipid binding have not yet been 
absolutely established (Nishizuka, 1988).
Although the functions of individual members of the PKC family have not yet 
been distinguished the roles attributed to PKC as a family in a variety of different 
cell types include involvement in secretion and exocytosis, modulation of ion
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conductance, smooth muscle cell contraction, gene expression, down regulation of 
receptors, cell proliferation and regulation of signal transduction. In particular for 
platelets a role for PKC has been suggested in agonist-induced granule release, 
aggregation and AA release (Nishizuka, 1986).
1.5.6.1.1 Exogenous PKC activation and inhibition
It is now firmly established that phorbol esters such as 12-0-tetradecanoyl 
phorbol-13-acetate (TPA) which are well known tumour promoters directly activate 
PKC (Nishizuka, 1984; Castagna et al. 1982). TPA has a DAG like structure and is 
able to substitute for DAG at extremely low concentrations. Similarly to DAG, 
TPA dramatically increases the affinity of the enzyme for Ca2+ which can result in 
full PKC activation without detectable mobilization of calcium (Rink et al. 1983).
Phorbol esters and membrane permeant DAGs have been used in numerous 
studies to try and elucidate the role of PKC, however many of these studies have 
been carried out in either permeabilized cells, or cells where [Ca++]j has been 
elevated using Ca+ + ionophores (Halenda et al. 1989; Halenda et al. 1985). In 
addition, phorbol esters have different characteristics to endogenous DAG 
including their permeability and longevity, with phorbol esters causing a sustained 
activation of PKC. Therefore it is important to confirm that activated PKC really 
does possess the functions attributed to it from the extrapolations made from the 
results of experiments using, for example, phorbol esters as exogenous activators 
of PKC. One way of investigating the function of endogenously activated PKC is 
to use a PKC inhibitor. Some of the earliest PKC inhibitors described include 
chlorpromazine, dibucaine and other phospholipid interacting drugs including 
polymyxin B (Mazzei et al. 1982) which inhibit PKC by competing with 
phospholipid. Later it was found that members of the isoquinoline sulfonamide 
family, particularly H-7, were capable of inhibiting PKC by competing with ATP for 
its binding site on PKC (Yamamoto and Hidaka, 1984). In 1985 the non-steroidal 
triphenylacrylonitrile (TPE) tamoxifen used in the treatment of breast cancer was 
shown to inhibit PKC (O'Brian et al. 1985) and more recently was shown to be 
relatively selective for PKC (Spacey et al. 1990). Depending on the structure of
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the TPE, it inhibits PKC either at the regulatory or the catalytic domain (Bignon et 
al. 1989). In order for the role of PKC to be unambiguous however, an inhibitor 
would need to be both potent and selective for PKC above other protein kinases. 
Until the discovery of staurosporine (Tamaoki et al. 1986) and members of the 
same family including K252a and UCN01 (Ruegg and Burgess, 1989) all inhibitors 
of PKC had low potency and except tamoxifen were non-selective. Staurosporine 
and related compounds were found to be potent inhibitors of PKC but because 
they inhibited by competing with ATP for the ATP-cosubstrate site common to all 
protein kinases they had limited selectively for PKC (Ruegg and Burgess, 1989). 
Since the introduction of staurosporine other PKC inhibitors including amino 
acrides (Hannun and Bell, 1988), pseudo substrate analogues of PKC (Ricouart et 
al. 1989) and calphostin C (Kobayashi et al. 1989) have been produced which are 
thought to inhibit PKC at the catalytic and regulatory sites, at the substrate 
binding site and at the regulatory domain respectively. Recently several potent 
and selective inhibitors of PKC have been described (Davis et al. 1989). Two of 
these compounds namely, Ro 31-7549/001 and Ro 31-8220/002, which although 
structurally based on staurosporine and inhibit PKC by competing with ATP for the 
co-substrate site, have been demonstrated to be selective for PKC over both 
protein kinase A and Ca+ + calmodulin dependent kinase (Davis et al. 1989) and 
have been used in this study in order to examine the role of endogenously 
activated PKC in the signal transduction pathway in PAF-stimulated rabbit 
platelets.
1.5.6.2 Myosin Light Chain Kinase
Following platelet activation and the ensuing increase in [Ca ++]j, myosin light 
chain kinase (MLCKase) is activated resulting in phosphorylation of MLC. Once 
MLC has been activated by phosphorylation it associates with actin filaments of 
the cytoskeleton resulting in the contractile activity of platelets. Phosphorylated 
MLC is therefore involved in platelet morphological changes including shape 
change (Daniel et al. 1984). Like PKC, MLCKase phosphorylates at either the
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serine or threonine amino acid residues, its activation is Ca+ + and calmodulin- 
dependent. Centralisation of granules before their release from the platelets is 
also associated with the movement of microfilaments surrounding the granules, 
phosphorylated myosin is believed to be a central component of the microfilament 
mass produced by this contractile wave (Fox, 1987). MLC is also phosphorylated 
by PKC although on a site distinct from that phosphorylated by MLCKase (Naka et 
al. 1983).
1.5.6.3 Protein tyrosine kinase
Many phosphorylation events observed in platelets have been attributed to the 
role of PKC and MLCKase, both of which are serine/threonine specific kinases. 
However it is possible that recently discovered protein tyrosine kinases (PTKases) 
in platelets may also have a role in signal transduction.
Until recently PTKases were classified either as those whose genes had 
become part of oncogenic retroviruses or those associated with growth factor 
receptors (Hunter and Cooper, 1985). The most well studied PTKase oncogene 
product is probably ppeo™0, coded by the transforming gene of the Rous sarcoma 
virus. Growth factor receptors which possess intrinsic PTKase activity include 
those for EGF, PDGF and also insulin and insulin-like growth factor 1 (IGF-1). 
These receptors possess intrinsic PTKase activity such that binding of the growth 
factor causes autophosphorylation of the receptor and the PTKase activity 
increases towards other substrates. Both groups of PTKases are therefore 
associated with either normal or abnormal cell growth (Hunter and Cooper, 1985). 
The cellular homolog of pp60v'*rc namely pp60Mrc can also be activated by 
phosphorylation. In this case however a dephosphorylation of Tyr 527 results in a 
10 fold increase in kinase activity coupled to an activation of its transforming 
activity.
However, more recently non-proliferating and terminally differentiated cells 
such as platelets (Tuy et al. 1983) and post mitotic differentiated or differentiating 
neurons (Brugge et al. 1985) have been found to possess PTKase activity,
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suggesting therefore that PTKase may have some other role in cellular function 
distinct from cell growth or differentiation.
The first PTKase to be discovered in platelets was ppBO0^ 6 where it is 
expressed in exceptionally high levels of 0.2-0.4 percent of the total cellular 
protein (Golden et al. 1986). The c-src gene which is homologous to the 
transforming gene v-src is highly conserved across the vertebrate species 
suggesting the product of the c-src gene has a role of fundamental importance. It 
is known that tyrosine phosphorylation is reversible and phosphotyrosine can be 
dephosphorylated with specific phosphatases, which although previously thought 
of as "house keeping" enzymes, may also play an essential role in intracellular 
regulatory mechanisms (Tonks and Charbonneau, 1989).
Tyrosine-specific phosphorylation of proteins represents the major kinase 
activity in human and rabbit platelet membranes intimating pp60c'*rc might serve a 
specific function in the platelet membrane. Compared to other cell types, platelet 
lysates contained 3-7 fold higher levels of pp60c'*fc than in brain or peripheral blood 
lymphocyte lysates, and 30-50 fold higher levels than in muscle, spleen, thymus, 
lymph node, bone marrow or erythrocyte lysates (Golden et al. 1986). Indeed, the 
precursor cell of platelets, the megakaryocyte, also possesses elevated levels of 
the pp60‘" rc specific kinase activity (Golden et al. 1986).
It has only been relatively recently demonstrated that activation of platelets 
with agonists including thrombin and collagen induce rapid tyrosine 
phosphorylation on a number of proteins by stimulating one or more PTKase in 
intact human platelets (Nakamura and Yamamura, 1989; Ferrell and Martin, 1988).
1.5.6.4 Protein phosphorylation associated with inhibition of platelet activation
Inhibitory agonists for example PGI2, PGD2 and adenosine suppress platelet 
responsiveness by activating adenylate cyclase and increasing the concentration of 
cytosolic cAMP which activates cAMP dependent kinase (protein kinase A) to 
phosphorylate its target proteins. The increase in cAMP levels is transient, with
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platelets possessing cyclic nucleotide phosphodiesterases specific for cAMP 
(Crawford and Scrutton, 1987).
The site of action of PKA has not been identified, but one of the mechanisms 
by which cAMP regulates platelet functions is through regulating the level of 
[Ca++]j (Feinstein et al. 1985). Cyclic AMP exerts two types of effect on [Ca ++]„ 
firstly it inhibits elevation of [Ca++]s induced by a number of different agonists and 
secondly it stimulates resequestration of [Ca**], which has already been elevated 
reviewed in Feinstein et al. (1985). It has been suggested that activated PKA may 
promote resequestration of Ca+ + into the endoplasmic reticulum by increasing the 
Ca2+ Mg2+-ATPase activity possessed by that membrane, believed to be one of the 
mechanisms of Ca+ + homeostasis in platelets. However, other mechanisms must 
also play a role as sequestration of Ca+ + could only explain a dampening of the 
response but not a complete prevention of agonist-induced [Ca++]j elevation. It 
has also been suggested that increasing cAMP levels may inhibit agonist-induced 
Ptdlns(4,5)P2 hydrolysis and therefore suppress elevation of the two second 
messengers lns(1,4,5)P3 and sn-1,2-DAG (Rittenhouse-Simmons, 1979; Knight and 
Scrutton, 1984; Siess, 1989). Moreover, the finding that an increased level of 
cAMP totally prevents agonist-induced [Ca++], elevation suggests cAMP is able to 
exert an effect on Ca++ influx across the plasma membrane, this may be due to a 
cAMP-induced inhibition of agonist binding as has been demonstrated in thrombin- 
stimulated platelets (Lerea et al. 1987). However, in PAF-stimulated platelets a 
much lower level of cAMP is required to inhibit aggregation and secretion than to 
cause inhibition of Ptdlns(4,5)P2 hydrolysis or [Ca++]j elevation suggesting a 
mechanism distal to inhibition of PLC activity (Bushfield et al. 1985). Indeed, 
recently it has been demonstrated that activation of PKA inhibits platelet 
aggregation at steps distal to PKC and Ca + +-dependent protein phosphorylation 
(Siess and Lapetina, 1989). Activation of platelets by excitatory agonists is not 
believed to be caused by decreasing cAMP levels, although several agonists, for 
example ADP, adrenaline and TxA2 can decrease cAMP elevation induced by an 
inhibitory agonist such as PGD2 reviewed in Feinstein et al. (1985).
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Exposure of platelets to EDRF (nitric oxide) released from endothelial cells 
(Palmer et al. 1987) causes an activation of guanylate cyclase and increases cyclic 
GMP. As a result of cGMP elevation platelet responses are inhibited, however, 
little is known of the mechanisms by which cGMP depresses platelet 
responsiveness or indeed whether it involves protein phosphorylation. Moreover, 
excitatory agonists such as ADP, collagen and thrombin also cause an increase in 
cGMP levels and it is therefore possible that it may act as a negative feedback 
pathway. Its mechanisms of action are however, separate from those used by 
cAMP as there are differences in the pattern of responses inhibited by the two 
cyclic nucleotides, for example, adhesion to collagen is markedly inhibited by an 
increase in cGMP but affected little by increases in cAMP (Radomski et al. 1987a).
60
1.6 AIMS
To further elucidate the signal transduction pathway of PAF-stimulated platelets 
and to investigate the role of protein phosphorylation in platelet signal 
transduction, in particular, to investigate the role of protein kinase C and tyrosine 
kinase in PAF-induced platelet activation.
1. To investigate the modulatory role of PKC in PAF, ionomycin and arachidonic 
acid-induced platelet functional responses.
It was proposed to examine the role of protein kinase C in platelets by 
investigating the effect of both activation and inhibition of PKC on the functional 
responses of platelets induced by three different mechanisms. Platelets were 
stimulated with an agonist (platelet-activating factor), by direct elevation of 
cytosolic Ca++ (ionomycin) or by arachidonic acid (AA) which is metabolised 
directly into measurable thromboxane B2. This study was designed to elucidate 
where in the signal transduction pathway PKC-induced protein phosphorylation 
may have a regulatory role.
2. To characterise signal molecule elevation in PAF stimulated platelets and to 
investigate the role of PKC on signal molecule production
Few studies using intact cell preparations have been performed to evaluate the 
relationship between the signal molecules [Ca++lj, lns(1,4,5)P3 and sn-1,2-DAG. In 
this study therefore the aim was to determine the temporal and dose-dependent 
relationships of PAF-induced elevations in [Ca2*], to changes in the levels of 
lns(1,4,5)P3 and sn-1,2-DAG in intact rabbit platelets. As an alternative 
experimental approach it was proposed to use the potent, although non-specific, 
PKC inhibitor staurosporine to examine the role of endogenously activated PKC in 
the regulation of receptor-mediated changes in the intracellular concentrations of 
Ca++, lns(1,4,5)P3 and DAG.
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3. To investigate the role of endogenously activated PKC in platelet functional 
responses using selective inhibitors of PKC.
Throughout the course of this study there have been an increasing number of 
reports describing the development of selective inhibitors of PKC. These selective 
inhibitors included calphostin C (Kobayashi et al. 1989) and the Roche compounds 
Ro 31-8220/002 and Ro 31-7549/001 (Davis et aL 1989). Using these 
compounds it is likely that a more accurate insight could be gained into the role of 
endogenously activated PKC than when using a non-selective inhibitor. The aim 
was therefore to investigate the role of endogenously activated PKC using these 
newly developed PKC inhibitors and to compare their effects on platelet functional 
responses in PAF-stimulated platelets to the findings for staurosporine.
4. To determine the identification and location of annexin isoforms in human 
platelets
The ability of annexins to inhibit PLA2 was the first functional response attributed 
to them in which they were linked to signal transduction. Annexins are believed 
to be phosphorylated by PKC and PTKase and therefore it is possible that they 
may be involved in the regulation of phospholipid hydrolysis and be regulated 
themselves by their state of phosphorylation. The identity of annexins in platelets 
has not been determined and therefore the aim of this study was to determine the 
identification and location of annexin isoforms in human platelets, and to 
determined whether they could be released from the granules upon platelet 
stimulation.
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5. To characterise tyrosine phosphorylation of proteins in PAF-stimulated platelets 
and to investigate the role of endogenously activated tyrosine kinase(s) in platelet 
signal transduction using the tyrosine kinase inhibitor genistein.
It has only been relatively recently that the presence of tyrosine kinase(s) in 
terminally differentiated cells such as platelets has been recognised. Their role is 
usually associated with cel! growth and proliferation, however in platelets due to 
the rapidity of tyrosine phosphorylation of protein substrates upon receptor-agonist 
coupling it is possible that they may have a role in signal transduction. In this 
part of the study the aim was to determine the temporal and dose-dependent 
relationship of PAF-induced elevation of tyrosine phosphorylated proteins induced 
by tyrosine kinase activity. It was also proposed to use an inhibitor of tyrosine 
kinase(s) in an attempt to identify the role of endogenously activated tyrosine 
kinase(s) both in signal molecule production and platelet functional responses.
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2. MATERIALS AND METHODS
2.1 MATERIALS
2.1.1 GENERAL REAGENTS
Albumin Bovine (fraction V, protease-free); Arachidonic Acid (sodium salt); ARG- 
GLY-ASP-SER (acetate salt), Adenosine 5'-trisphosphate (ATP, disodium salt); 
Coomassie Brilliant Blue R-250; Dextran; 3,3'-diaminobenzidine (DAB); 
Diethlenetriaminepenta-acetic acid; ethylenediamine-tetraacetic acid (EDTA); 
ethylene glycol-bislG-aminoethyl etherl N,N,N,N-tetraacetic acid (EGTA); Gelatin 
(type A: from porcine skin); N-2-hydroxyethylpiperazine-N-2-ethanesulfonic acid 
(HEPES); Human-or-thrombin; Imidazole; Indomethacin; High Molecular weight 
markers (SDS 6H);0-phospho-DL-serine (DL-2-amino-3-hydroxypropanoic acid 3- 
phosphate); O-phospho-DL-tyrosine (DL-3-[Hyroxyphenul]alanine 4'-phosphate); 0 - 
phospho-DL-threonine (DL-2-Amino-3-hydroxybutanoic acid 3-phosphate); Sodium 
dodecyl sulphate (lauryl sulphate); 12-0-tetradecanoylphorbol-13-acetate (TPA); 
Sodium ethylmercurithiosalicylate (thiomersal); Tris[hydroxymethyl]aminomethane 
(TRIZMA BASE); polyoxyethylenesorbitan monolaurate (Tween 20) and TxB2 
standard were all purchased from Sigma Chemical Company Ltd., Poole, Dorset, 
UK.
Acetic acid (AnalaR); Acrylamide (Electran); Ammonium peroxodisulphate 
(Electran); Calcium Chloride (AnalaR); Charcoal ('Norit GSX'); Digitonin (AnalaR); 
D-Glucose (AnalaR); Glycerol (AnalaR); Hydrogen Peroxide solution (Analar); 
Potassium chloride (AnalaR); Magnesium chloride hexahydrate (AnalaR); 2- 
mercaptoethanol (Biochemical); NN -methylenebisacrylamide (Electran); Ponceau S 
(Electran); Sodium dihydrogen orthophosphate; Sodium hydroxide; Tri-sodium 
citrate (AnalaR) were all purchased from BDH Ltd., Bristol, Avon UK. Chloroform 
(HPLC solvent); Hydrogen chloride; Methanol (HPLC solvent); Heparin (Heparin 
Sodium, mucous) and Sodium chloride (Analytical Reagent) were purchased from 
Fisons, FSA Laboratory Supplies, Loughborough, Leicester, UK. Ionomycin (free 
acid) was purchased from Calbiochem Company, Novabiochem (UK) Ltd.,
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Nottingham, UK and PAF (1-0-Octadecyl-2-0-acetyl-sn-glycero-3-phosphocholine) 
was from Bachem Bioscience Inc. Bubendorf, Switzerland. Staurosporine was 
purchased from Fluka Chemicals, Glossop, Derbyshire UK and Genistein was 
obtained from Gibco BRL, Uxbridge, Middlesex, UK. Bromophenol Blue and 
N,N,N,N-Tetramethylethylenediamine (TEMED) were purchased from Bio-Rad, 
Hemel Hempstead, Hertfordshire, UK.
5-[14C]Hydroxytryptamine creatinine sulphate (54 mCi/mmol, 50 //Ci/ml), [32P]Pi (10 
mCi/ml), [32P]-ATP (3 Ci/mmol) and [3H]PAF (80 Ci/mmol, 250 //Ci/ml) were 
purchased from Amersham International, Aylesbury, Bucks, UK. [3H]Thromboxane 
B2 (125 Ci/mmol, 50 nCi/ml) was obtained from NEN Research Products, DuPont 
(UK) Ltd., Stevenage, Hertford, UK.
Inositol (1,4,5)-Trisphosphate assay system (TRK 1000) and the sn-1,2- 
Diacylglycerol assay system (RPN 200) were purchased from Amersham Life 
Sciences, Aylesbury Bucks, UK. Fura-2-acetoxymethyl ester, Fluo-3- 
acetoxymethyl ester, Fura-2 free acid, Fluo-3 free acid and pluronic acid (F-127) 
were purchased from Molecular Probes, Eugene, Oregon, USA. X-ray film was 
obtained from Fuji Photo Film Co.Ltd., X-ray film developer (kodalith liquid 
developer) and fixative were purchased from Kodak, Hemel Hempsted, England. 
Thin layer chromatography plates (silica gel 60 HPTLC aluminium, 20 x 20 cm) 
were purchased from E.Merck, Darmstadt, FRG. Nitrocellulose paper (0.45 jjm) 
was obtained from Schleicher & Schuell, Dassel, Germany, whilst Whatman 3MM  
filter Paper was purchased from Whatman Laboratory Sales, Maidstone, Kent, UK. 
Sagital was purchased from May & Baker Laboratory Products, Rhone-Poulenc, 
Mancester, UK and Hypnorm was purchased from Janssen Pharmaceuticals Ltd., 
Oxon, UK.
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2.1 .2  SOLUTIONS
Aggregation inhibitor
ARG-GLY-ASP-SER was dissolved (50 mg/ml) in normal saline as required. 
Fluorescent Probes
Fura-2-AM, fura-2 free acid, fluo-3-AM and fluo-3 free acid were stored solid and 
dry at -20°C. Stock solutions of fura-2-AM and fluo-3-AM were dissolved in 
anhydrous DMSO at a concentration of 5 x 10'3M and stored in darkness at - 
20°C. Stock solutions of fura-2 free acid and fluo-3 free acid were dissolved in 
distilled water, subaliquoted and stored at -20°C. Pluronic acid (F-127) was 
dissolved 1:3 (W:W) in DMSO by warming at 37°C for 30 minutes it was then 
stored at room temperature.
PAF antagonist
WEB 2086 a gift from Dr H. Huer, Boehringer, Ingelheim, Germany was dissolved 
at a concentration of 10'3M in PBS (37°C) on the day required.
PKC activators
12-O-tetradecanoyl 13-phorbolacetate was dissolved in dry acetone (1 mg/ml) and 
stored at -20°C, further dilutions were made in PBS.
1,2-dihexanyl-sn-diacylglycerol was a gift from Dr L. Garland, Wellcome 
Laboratories, Beckenham, Kent. A stock solution was stored in chloroform, this 
was aliquoted and dried under nitrogen and then dissolved in ethanol (50 mg/ml). 
Further dilutions were made in normal saline.
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PKC inhibitors
Calphostin C was a gift from Dr.T.Tamaoki, Kyowa Hakko Kogyo Co., Ltd. Toyko, 
Japan. A stock solution at a concentration of 10'2 M was dissolved DMSO and 
stored at -20°C. The stock was diluted to 10‘3M in ethanol and further dilutions 
were made into HBT.
Ro 31-7549/001 and Ro 31-8220/002 were gifts from Dr. J S Nixon, Roche, 
Herts. They were stored solid and dry at -20°C. When required they were 
dissolved at 10 2M in DMSO, further dilutions were made in PBS.
Staurosporine was dissolved in 70% ethanol and stored at -20°C in darkness, 
further dilutions were made in PBS.
Platelet stimulants
Arachidonic acid (free acid) - A stock solution was dissolved in absolute ethanol (5 
x 1 02 M) and stored under nitrogen and in the dark at -20°C.
Ionomycin - A stock solution of 5 x lO^M was dissolved in DMSO and stored at 
4°C.
PAF (1-0-Octadecyl-2-acetyl-sn-glycero-3-phosphorylcholine) - A 10*2M stock 
solution was dissolved in chloroform:methanol (4:1 v/v) and stored at -20°C. 
Subaliquots (10 //I) were taken, dried under nitrogen and then made up to 1 ml in 
PBS containing 2.5 mg/ml BSA to give a final concentration of lO^M PAF. The 
aliquots were then stored at -20°C.
Human-a-Thrombin - The stock solution containing 60 NIH units/ml was stored in 
0.1 M Triethanolamine, 0.1M NaCI, 0.1% polyethyleneglycol (6000 MW), pH 7.8, 
at -20°C.
Tyrosine Kinase inhibitor
Genistein was stored solid and dry at -20°C. As required it was dissolved at a 
concentration of 10 mg/ml in DMSO, further dilutions were made in distilled H20 .
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2 .2  METHODS
2.2.1  ANIMALS
New Zealand white rabbits 2.5 - 3 Kg either male or female were used. They 
were caged either singly or doubly or in groups in floor pens and food and water 
were freely available.
2 .2 .2  BLOOD COLLECTIONS
Blood was collected by either of two methods:- 
Method 1
Rabbits were anaesthetized by an intravenous injection of anaesthetic into the ear 
vein of 2 ml/Kg of 20 mg/ml pentobarbitone (Sagital), giving a final concentration 
of 40 mg/Kg rabbit. Due to the variability in response experienced between 
individual rabbits the anaesthetic was administered slowly and the degree of 
anaesthesia assessed until the required depth was attained.
The rabbits were then bled by cannulation of the carotid artery and the blood 
collected into 3.2% trisodium citrate (9:1, v/v). The blood and anticoagulant were 
then gently mixed.
Method 2
New Zealand White rabbits 3.5 - 4 Kg were sedated with an intramuscular 
injection of 0.25 ml/Kg of Hypnorm (0.315 mg fentanyl citrate/ml and 10 mg 
fluanisone/ml). After sedation (about 30 minutes) a rabbit was bled up to 35 mis 
from the ear artery using a 19 gauge needle and the blood was collected into 
3.2% trisodium citrate (9:1, v/v). The blood and anticoagulant were gently mixed.
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2.2 .3  PREPARATION OF WASHED RABBIT PLATELETS
2.2.3.1 Prostacyclin
Prostacyclin (PGI2) a gift from Dr Whittle, Wellcome Laboratories, Kent, was stored 
solid and dry at -20°C. Stock aliquots were dissolved in 0.5 M Tris-HCI (pH 10.5) 
and were stored at a concentration of 40 //g/40 j j \  at -20°C. Immediately prior to 
use an aliquot was thawed and diluted as required in 0.01 M Tris-HCI (pH 10.5) 
and kept on ice.
2.2.3.2 HEPES Buffered Tvrode's solution
(per litre)
10 mM HEPES (2.4 g)
145 mM NaCI (8.4 g)
5 mM KCI (375 mg)
1 mM MgCI2 (200 mg)
0.5 mM Na2HP04 (101 mg)
The constituents were dissolved in 900 ml of distilled H20  and the pH adjusted to
7.4 with NaOH and the total volume made up to 1 litre. On the day of an 
experiment 5.5 mM glucose and 0.25%  bovine serum albumin was added to the 
required volume of buffer.
2.2.3.3 Preparation of platelet rich plasma
Washed platelets were prepared essentially as described by Poll et al. (1986) for 
human platelets, using a modification of the method of Blackwell et al. (1982b). 
After collection rabbit blood was centrifuged immediately at 185 x g (rt) for 10 
minutes. The top layer of platelet rich plasma (PRP) was removed from the lower 
red blood cell layer.
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2.2.3.4 Washed platelet preparation
PGI2 (300 ng/ml) was added to the PRP which was gently mixed and then 
centrifuged at 1256 x g (rt) for 15 minutes to precipitate a platelet pellet. The 
plasma was removed from the platelet pellet which was gently resuspended into 
HBT using a pastette, 100 ng/ml of PGI2 was then added to the suspension. The 
platelet suspension was centrifuged at 1256 x g (rt) for 15 minutes to precipitate 
a platelet pellet.
2.2.3.5 Preparation of washed human platelets
Human venous blood was collected by forearm venepuncture from normal 
volunteers (who denied having taken any medication for the previous 14 days) into 
1 unit heparin/ml of blood. Washed human platelets were prepared as described 
for rabbit platelets in sections 2.2.3 using HBT containing 1 mM CaCI2.
2 .2 .4  GENERAL EXPERIMENTAL CONDITIONS
Platelets were allowed to 'recover' for 90 minutes after they had been 
resuspended in PGI2 free HBT to allow increased cAMP levels induced by PGI2 to 
decline to basal levels and full functional activity to return. Except where stated 
[Ca++], was adjusted to 1 mM before experimentation. In all experiments platelets 
were allowed to equilibrate to 37°C before being activated.
2 .2 .5  PLATELET COUNTING
Platelet counts were made using an electronic particle counter (coulter counter) 
calibrated for platelet size. Platelets were diluted (1:1000) with isoton II azide 
free diluent and the total platelet count assessed. The coulter counter measured 
the number of platelets in 50 //I therefore in order to determine the number of 
platelets/ml the count on the digital readout was multiplied by 20 x 1000.
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2 .2 .6  AGGREGOMETRY
The technique used to examine platelet aggregation in this study was the 
turbidimetric method described by Born (1962). This method uses an optical 
aggregometer to detect changes in light transmission through the platelet 
suspension in response to an agonist. Platelet shape change in response to an 
agonist will cause a decrease in light transmission whilst aggregation causes an 
increase in transmission.
2.2.6.1 Platelet preparation
Platelets were prepared as described in section 2.2.3 and the washing procedure 
repeated once more in order to wash the platelets twice before use. After the 
final centrifugation the platelets were resuspended to a concentration of 2 x 
108/ml.
2.2.6.2 Aggregation assay
Aggregation assays were carried out in a Chronolog dual channel ionized Ca+ + 
aggregometer (Born, 1962). The calibration of the light transmission was carried 
out by making a 10 fold dilution of washed platelets (2 x 107/ml), the light 
transmission through this suspension represented maximum light transmission 
termed 100%. Basal (0%) light transmission was obtained using 2 x 108 
platelets/ml. The platelets were stirred at 900 rpm for the duration of the 
experiment. Platelet shape change was measured as a decrease in light 
transmission whilst aggregation was monitored as an increase in light transmission 
and recorded using a two channel potentiometric chart recorder (chart speed 3 
cm/min). Aggregometry traces were quantified by measuring the rate of 
aggregation.
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2 .2 .7  DETERMINATION OF CYTOSOLIC CALCIUM 
2.2.7.1. Loading with ceil permeant Fura-2-acetoxvmethvl ester 
Platelets were prepared as described in section 2.2.3. The platelet pellet was 
resuspended to 8 x 10® platelets/ml and 0.5 //I/ml (2.5 //M final concentration) 
fura-2-AM added. The platelets were then incubated at 37°C for 30 minutes. The 
platelets were occasionally agitated gently to aid fura-2-AM loading, whilst the 
BSA contained in the HBT aided dye dispersal. The platelet suspension was then 
washed three times in HBT to remove excess fura-2-AM and the platelet count 
adjusted to 2 x 10®/ml. Aliquots of platelets (1 ml) were dispensed into 
fluorimeter cuvettes and changes in [Ca++lj fluorescence were recorded using an 
Aminco Bowman Spectrophotofluorimeter (ex = 339 nm; emission = 500 nm; 4 
nm slit width) fitted with a thermostatted cuvette compartment holder with stirring 
attachment.
2.2.7.2 Calibration
The Ca++-fura-2-fluorescence was calibrated as previously described (Pollock et 
al. 1986; Grynkiewicz et al. 1985). At the beginning of an experiment and every 
30 minutes thereafter, the Ca++-fura-2-fluorescence was calibrated by measuring 
the maximal fluorescence signal (Fmax) and the minimum fluorescence signal 
(Fmin). The Fmax was achieved by lysing platelets in the presence of 1 mM 
[Ca ++1, with 50 //M digitonin (taken from a stock of 1 mM digitonin in 70%  
ethanol). Digitonin caused complete lysis of the platelets and released intracellular 
fura-2 which then had access to excess [Ca++je and therefore caused maximal 
possible fluorescence. Subsequently adjusting the cell lysate pH to > 8 .5  with 
NaOH and chelating [Ca++1, with 6 mM EGTA the fluorescence signal in Ca++ free 
medium will cause the fluorescence to drop to minimum [Fmin]. To assess the 
amount of fluorescence due to extracellular non-loaded or leaked fura-2, 1 mM 
NiCI2 was added to 1ml of platelets. The quench in the fluorescence observed 
was due to extracellular fura-2-AM as NiCI2 is not cell permeant (Hallam and Rink, 
1985b).
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Changes in fluorescence were recorded on a potentiometric chart recorder 
(Rikadenki) which was linked up to the fluorimeter.
In order to convert the fluorescence values (F) from the chart recording into 
cytosolic calcium concentration ( [ C a + + ] j ] )  the fluorescence values in arbitrary units 
were put into the equation:
F(-Ni) - Fmin x Kd = [Ca++]i (nM)
Fmax - F-(Ni)
Kd = the dissociation constant of the Ca++-fura-2 complex which is equal to 224 
nM (Grynkiewicz et al. 1985). The dissociation constant of the Ca++-fluo-3 
complex is equal to 400 nM (Kao et al. 1989).
The results for Ca+ + studies have either been given as maximal [Ca+]j 
elevation (nM) or as the T1/2/ which is the time taken for [Ca++lj to decline to 1/2 
maximal above basal levels. A representative trace of [Ca ++]j elevation is given in 
figure 5, demonstrating the concepts of maximal [Ca++]j elevation and T1/2. The 
T1/2 was calculated by working out the maximal [Ca++]j, and the basal [Ca ++]| 
then:-
maximal rCa**l, - basal fCa**l, = the [Ca++]j at T 1/2 ([Ca++]jT1/2) termed Y 
2
the arbitrary fluorescence reading at T1/2 was termed B and put into the equation 
B - Ni - Fmin x 224 = Y
Fmax - [B - (-Ni)l
then:-
B - Ni - Fmin = YFmax + Yni - YB 
224
then:- B + YB = YFmax + YNi +  Ni + Fmin
224
this will then give an arbitrary number on the trace from which the measurement 
































Figure 5 Cytosolic Ca++ elevation demonstrated as fluorescence output from fura- 
2 loaded platelets and as [Ca + +], (nM). (a) Representative trace of fluorescence
output from fura-2-loaded platelets stimulated with 10 nM PAF (b) the same trace 
as (a) but the fluoresence has been converted to [Ca + +lj (nM). Panel (b) also 
demonstrates the concepts of maximal cytosolic calcium elevation and t 1/2 (the 
time taken for Ca+* levels to decline to 1/2 maximal above basal).
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2.2.7.3  The fluorescent Ca** indicator fura-2-AM
The fluorescent Ca + + indicator fura-2-acetoxymethyl ester was first described in 
1985 by Tsien and colleagues (Grynkiewicz et al. 1985). The fluorescence of fura- 
2 is about 30 times brighter than its predecessor quin-2 (about 6 times the 
absorbance and 5 time the quantum yield) therefore a much lower concentration 
of fura-2 is needed to adequately load cells. Whereas quin-2 requires about 1 mM 
of trapped probe for an adequate signal fura-2 only requires between 10 to 50 
//M. The acetoxymethyl ester is membrane permeant, but once inside the cells is 
hydrolysed by non-specific esterases giving formaldehyde and acetic acid and 
liberating the free chelator which is not membrane permeant and therefore 
concentrates within the cell. The lower concentration of fura-2 compared to quin- 
2 results in less acidification and toxicity by the cells caused either by the 
chelator, acetic acid or formaldehyde which are released by intracellular enzymatic 
hydrolysis of the acetoxymethyl (AM) esters. Fura-2 therefore also causes less 
buffering of Ca++ than quin-2 and subsequently less damping of the Ca+ + 
transient.
The maximum absorbance of fura-2 shifts from 362 nm for the Ca++-free chelator 
to about 335 nm for the Ca++ saturated form with the highest dynamic range for 
Ca++ measurement being obtained by comparing the ratio of maximal chelator 
fluorescence at 510 nm with exc near 340 & 380 nm. However it is important 
that all four AM esters on the chelating acetic acids are hydrolysed in order to 
achieve Ca++ sensitive emission.
2.2.7.4 Concentration of intracellular fura-2
A standard curve of fluorescence output against concentration of cell impermeant 
fura-2 free acid (10 nM - 100 nM) was performed in the presence of 1 mM 
[Ca++].. Platelets loaded with fura-2-am as described in section 2.2.7.2  were 
counted and then lysed with 50 i jW \  digitonin. The suspension was centrifuged, 
the supernatant removed and the fluorescence in the supernatant measured in the
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presence of 1 mM [Ca++]e. The concentration of fura-2 in the supernatant was 
then read from the standard curve. On the basis that the intracellular volume of 
109 platelets is equal to 10 //I (Rittenhouse and Sasson, 1985) it was then 
possible to calculate the intracellular concentration of fura-2 in the platelet 
preparation. The intracellular concentration of fura-2 was found to be between 10 
- 20 //M , which is at the lower end of the recommended range, therefore reducing 
the problem of artifacts due to incomplete hydrolysis of fura-2-AM, and reducing 
the Ca++ buffering effects of fura-2.
2.2.7.5 Fluo-3-AM
Fluo-3-AM (Minta et a/. 1989) is a new long wavelength indicator of intracellular 
Ca+ + . Platelets were loaded with fluo-3-AM essentially as described for fura-2. 
However, before adding fluo-3 to the platelets it was first diluted in 1 ml of HBT 
to which 5 //I pluoronic F-127 had been added. The mixture was then added to 
the platelets (8 x 108/ml) to give a final concentration of 5 /vM fluo-3. The 
platelets were then incubated for one hour at 37°C before washing as described 
for fura-2 loaded platelets. Addition of pluronic F-127 (which is a low ionic, low 
toxicity detergent) during incubation of fluo-3 increases solubilization and dispersal 
of the dye. Aliquots of platelets (2 ml) were dispensed into fluorimeter cuvettes 
and changes in [Ca++lj fluorescence measured using a PTI dual excitation 
spectrophotometer (ex 506 nm; emission 526 nm; 4 nm slit width).
2 .2 .8  DETERMtNA TION OF DENSE GRANULE RELEASE IN PLA TELETS
2.2.8.1 5-HT uptake into granules
Platelets accumulate 5-hydroxytryptamine (5-HT, serotonin) against a 
concentration gradient by several mechanisms into their dense granules (Pletscher, 
1968). The assay used in this study to determine dense granule release has taken 
advantage of this accumulation of 5-HT by using 14C-5-HT which is accumulated 
upon incubation into the granules and then released upon platelet activation with 
an excitatory agonist to act as a marker for release of dense granule constituents.
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2 .2 .8 .2  Platelet preparation
Platelets were prepared as described in section 2 .2 .3 . The platelet pellet was 
suspended to 8 x 108 platelets/ml and incubated with 200  nCi/ml 5 -[14C]-HT  
at 37°C for 30 minutes. The platelets were then washed three times to 
remove extracellular [UC]-5HT and the final platelet count was adjusted to 2 
x 108/ml. Aliquots of platelets (1 ml) were dispensed into eppendorf tubes 
and treated as described for individual experiments. [14C]-5HT release was 
terminated 3 minutes after platelet activation by removing a subaliquot of 400  
//I into ice-cold tubes containing 40  //I of 100 mM EDTA and 30 //M  
indomethacin. The samples were then centrifuged at 12000  x g (2 minutes) 
and 2 x 100 //I samples of the supernatant removed. The amount of [14C]-5- 
HT was determined by liquid scintillation spectroscopy counting each sample 
for 3 minutes.
Percentage release of 5-HT from platelets (Ts) was calculated using the 
following equation (Holmsen and Dangelmaier, 1989):- 
% 5-HT release = Ts(dpm) - Bo(dom) x 100
Tc(dpm) - Bo(dpm) 
where Tc =  the total dpm in a sample of 100 j j \  of uncentrifuged platelets 
where Bo =  the dpm due to extracellular [14C]-5HT in untreated, centrifuged 
platelets. [14C]-5HT release was terminated 3 minutes after platelet activation 
as at this time, for all platelet stimulants used, 5-HT release had reached 
maximal and further incubation caused no further release of 14C-5HT.
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2.2 .9  THROMBOXANE GENERATION
2.2.9.1 Materials
Anti-TxB2 antibody was a gift from Dr.F.Carey, ICI, Macclesfied, UK.
Buffers
Buffer A (for dilution of antibody and [3H]TxB2)
NaH2P04.H20  6.2 g
Thiomersal 0.25 g
BSA fraction V 5.1 g
pH to 7.4 with NaOH, made up to 1 L with distilled H20  
Buffer B (for dilution of samples and standards)
NaCI 1.8 g
made up to 200 mis with Buffer A,
[3H]TxB2 label was stored as a stock solution in ethanol (10 //Ci/ml). Further
dilutions were made by adding 100 //I [3H]TxB2 to 20 mis of buffer A to give a
final count of 10,000 dpm/100 //I. TxB2 standard was made to a concentration
of 20 ng/ml in PBS buffer and anti-TxB2 antibody was diluted 1:500 in Buffer A.
Dextran coated charcoal
0.5 % w/v dextran T70
1% (w/v) charcoal GSX
made in buffer A (4°C, continually stirred).
2.2.9.2 Preparation of samples
Platelets were prepared as described in section 2.2.3 and washed twice before 
suspension to a final count of 2 x 108 pl/ml. Aliquots of platelets (1 ml) were 
dispensed into eppendorfs, and treated as described for individual experiments. 
Platelet activation was terminated at equilibrium (3 minutes) by removing a 400  
//I subaliquot of platelets into an ice-cooled tube containing 40 //I of 100 mM 
EGTA and 30 //M indomethacin. The samples were then centrifuged at 12000 x 
g (2 minutes), and the supernatant removed and stored at -20°C for 
radioimmunoassay (Johnston et a/. 1984).
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2.2.9.3 Radioimmunoassay
Serial dilutions of the TxB2 standard from 1 to 1000 pg/100 j j \  and a range of 
dilutions of each of the samples to be assayed were made in Buffer B. The 
samples (or standards), [3H]TxB2 and anti-TxB2 antibody were added to each 
eppendorf respectively in a ratio of 1:1:2. In order to calculate TxB2 generation 
the total count (Tc), total [3H]TxB2 binding to the antibody (Tb) and non-specific 
binding (Nsb) were also required.
After all additions had been made, the tubes were mixed and incubated at 4°C for 
1 8 - 2 4  hours. Dextran coated charcoal (the same volume as the TxB2 antibody) 
was then added to each tube except the Tc and after incubation at 4°C for 15 
minutes the tubes were centrifuged at 2000 x g for 15 minutes (4°C). The 
supernatant from each was decanted into a scintillation vial to which 4 mis of 
scintillant was added and the [3H]TxB2 in each was determined by liquid 
scintillation spectroscopy with each sample counted for 3 minutes.
From the counts a standard curve was constructed using % binding which was 
calculated by
% [3H] binding = dpm(standards) - Nsb x 100
Tb - Nsb
The amount of TxB2 for each sample (pg/100 //I) was then determined from the 
standard curve and converted to pmol/108 platelets. In common with dense 
granule release, TxB2 generation was terminated at 3 minutes after platelet 
activation. At this time TxB2 generation had reached maximal for all of the 
platelet activators being used, and further incubation caused no measurable 
increase in TxB2 generation.
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2 .2 .10  INOSITOL (1,4,51-TRISPHOSPHATE
2.2.10.1 Sample preparation
Platelets were prepared as described in section 2.2.3, washed twice and the final 
platelet count adjusted to 109/ml. Aliquots of platelets (0.5 ml) were dispensed 
into aggregometer cuvettes and the platelets stirred continuously throughout 
experimentation at 900 rpm. Platelets were treated and activated as described for 
individual experiments and at predetermined times platelet activation was 
terminated by the addition of 0.2 v/v ice cold 20% perchloric acid. The samples 
were kept on ice for 20 minutes to allow protein precipitation. The proteins were 
then sedimented by centrifugation for 15 minutes at 2000 x g (4°C). The 
supernatants containing the water soluble lns(1,4,5)P3 were removed from each 
sample and titrated to pH 7.5 with 1.5 M KOH containing 60 mM HEPES buffer 
and universal indicator (Palmer et al. 1986). The precipitated KCI04 was then 
sedimented and removed as described above. lns(1,4,5)P3 standards (0.19 - 25 
pmol/100 j j \ )  were diluted into the same buffer as the samples (ie HBT to which
0.2 v/v ice cold 20% PCA had been added, which was then centrifuged, the 
supernatant titrated to pH 7.5 with 1.5 M KOH containing 60 mM HBT and 
universal indicator and which was then centrifuged again to remove precipitated 
KCI04). Therefore standards and samples were in the same final media. To 
minimise loss of phosphorylated inositol species plasticware rather than glass was 
used throughout the extraction procedure.
2 .2.10.2 Insd .4.5)P» assay
The samples were then assayed for lns(1,4,5)P3 using the D-myo- 
inositold ,4,5)trisphosphate assay system using an adaptation of a previously 
described method (Challiss et al. 1988). The assay is based on competition 
between unlabelled lns(1,4,5)P3 and a fixed quantity of [3H]lns(1,4,5)P3 for a 
limited number of binding sites on a bovine adrenal protein preparation. The 
amount of [3H]lns(1,4,)P3 binding is inversely proportional to the concentration of 
non-radiolabelled ligand. Bound [3H]lns(1,4,5)P3 was separated from non-bound
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[3H]lns(1,4,5)P3 by centrifugation. The supernatant was decanted and any 
adherent drops of supernatant removed using a swab to avoid disturbing the 
pellet. The pellet was then resuspended, transferred to a scintillation vial and 4 
mis of scintillant added. The bound [3H]lns(1,4,5)P3 was counted in a B 
scintillation counter and the amount of unlabelled lns(1,4,5)P3 per tube was 
determined by interpolation from a standard curve. A representative standard 
curve is given in figure 6.
In summary:-
[3H]lns(1,4,5)P3 I  [3HIIns(1,4,5)P3-bound
+ binding protein = 
t  lns(1,4/5)P3 lnsd,4,5)P3-bound
The sensitivity of the assay was < 0 .2  pmols, whilst the working range was 0.19 - 
25 pmol/tube. The assay is specific for the (1,4,5)-isomer of IP3 with the ability 
to cross react with lnsd,3,4)P3 500 times less than for lns(1,4,5)P3.
2.2.10.3 Recovery of Insd .4.5)P7
The recovery of lns(1,4/5)P3 using the extraction system described in this assay 
was examined by extracting a known concentration of Insd ,4,5)P3 from a sample 
using the same method as employed to extract Insd ,4,5)P3 from a platelet sample. 












Figure 6 A standard curve for the measurement of lnsd,4,5)P3. The
concentration of lnsd,4,5)P3 in the standards is inversely proportional to the 
binding of [3HJInsd,4,5)P3 to the specific binding sites for lnsd,3,4)P, on the 
bovine adrenal protein preparation.
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2.2 .11 sn-1,2-DAG DETERMINATION
2.2.11.1 Sample preparation
Washed platelets were prepared as described in section 2.2.3 and washed twice 
before the final platelet count was adjusted to 108/ml. Aliquots of platelets (1 ml) 
were dispensed into aggregometer cuvettes and were continuously stirred at 900 
rpm throughout experimentation. After the platelets had been treated (as 
described in individual experiments), activation was terminated and DAG extracted 
using a modification of the method of Bligh and Dyer (1959). At a pre-determined 
time a sub-aliquot of platelets (0.8 ml) was transferred into 3 mis of ice-cold 
chloroform:methanol 1:2 (v/v) and the monophase mixed thoroughly. Chloroform 
(1ml) and NaCI (1ml) were added to break phase and the samples were centrifuged 
at 2000 x g for 5 minutes. The lower chloroform phase was dried under nitrogen. 
The samples were then assayed for sn-1,2-DAG within 24 hours using the sn-
1,2-diacylglycerol assay reagent system which is based on the method described 
by Preiss eta! (1986).
2.2.11.2 Assay for DAG
The technique used was a radio-enzymic assay using E.coli DAG kinase and 
defined mixed micelle conditions to solubilize the DAG present (in either standards 
or samples) and allow its quantitative conversion to I32P]phosphatidic acid in the 
presence of [32P]-r-ATP. In brief, the samples were resuspended in detergent 
solution reagent (supplied with the assay), sonicated and reaction mixture 
(containing DAG kinase and assay buffer) was added (also supplied). The reaction 
was initiated by adding *5 mM ATP containing 1 //Ci [32P]-r-ATP to each tube and 
incubated at 25°C for 30 minutes. The reaction was terminated by adding 
perchloric acid and chloroformimethanol (1:2, v/v). The free [32P]-ATP was then 
separated from the [32P]-PA by washing and centrifugation finally leaving [32P]-PA 
dissolved in chloroform.
*The concentration of ATP was crucial for the assay and therefore the 
concentration was confirmed using the absorbance of the ATP solution at 259 nm 
(where 15.4 x 103 is the molar extinction coefficient of ATP).
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After conversion of sn-1,2-DAG to [32P1PA, standards which contained 
predominantly I32P]PA (figure 7) were counted without need for further processing. 
The [32P]PA contained in samples from platelet extracts however, contained other 
[32P] labelled species (most prominently ceramide phosphate, known to be a 
substrate for E.coli DAG kinase (Preiss et al. 1986)) which needed to be separated 
using thin layer chromatography (TLC). TLC plates were pre-activated in acetone 
and air dried. After addition of samples and authentic phosphatidic acid (both 
dissolved in chloroformrmethanol (95:5 v/v)) the TLC plates were placed in paper 
lined tanks where the atmosphere was pre-saturated with the developing solvent 
(Chloroform:methanol:acetic acid/65:15:5 v/v/v). When the solvent reached the 
top of a TLC plate the plate was removed and air dried. The authentic PA was 
visualised by placing the TLC plates in a tank containing iodine and the area 
corresponding to phosphatidic acid marked.
2.2.11.3 Autoradiography
The TLC plates were subjected to autoradiography for 18 h at - 80°C. The 
autoradiograph film was developed and the areas on the TLC plates corresponding 
to [32P]PA (RF value = 0.35) were cut from the TLC plate and placed into 
correspondingly labelled scintillation vials. After addition of 10 mis of scintillant 
the radioactivity attributable to [32P]PA was determined by scintillation counting. 
The amount of DAG present in a sample was then calculated from the amount of 
[32P]PA produced, taking into consideration the specific activity of the [32Pl-r-ATP 
and after correcting for the proportion of the total volume of the sample which 
was taken for TLC separation.
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The concentration of PA produced (pmol/tube) for each standard was calculated 
and plotted against the original concentration of DAG. The conversion of PA in 
each sample tube was then read for each sample directly from the standard curve 
(figure 7).
The assay is specific for biologically relevant sn-1,2-diacylglycerols as opposed to
1,3 -disteroyldiacylglycerol, however, it is possible that the assay may also be 
converting 1-alkyl,2-acyl glycerols and dialkylglycerols into [32P]-Phosphatidic acid 
(Thompson et a/.1990). The range of this assay is from 31 - 1000 pmols/tube 
and the sensitivity is 10 pmols/tube.
2.2.11.4 Improvements made to assay
1. Addition of nonradioactive PA to samples before running on TLC, allowed 
visualisation of PA using iodine without the need to undergo autoradiography.
2. A total count of [32P]-r-ATP was taken, counting the exact amount added to 
each of the reactions (about 1 jjC\) as this was more accurate than calculating the 
specific activity.
2 .2.11.5 Recovery of DAG
The recovery of DAG was determined by extracting a known concentration of 
DAG from a sample using the same method employed for the extraction of DAG 
from a platelet sample. Extraction of DAG from a sample using the Bligh and Dyer 
method (Bligh and Dyer, 1959) as previously described followed by the conversion 
of DAG to [32P]PA, and the extraction of this by thin layer chromatography gave a 
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Figure 7 A standard curve for the conversion of sn-1,2-DAG to [32P]PA in the 
presence of [32P]ATP and DAG kinase. The phosphorylated PA shown in the 
autoradiographs was excised and subject to scintillation counting and the 
results given in the upper panel.
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10% SDS 0.5 ml
glycerol 0.5 ml
1 M Tris pH 6.8 0.4 ml
Distilled H20  3.1 ml
2-mercaptoethanol 5% final
bromophenol blue added to attain desired depth of colour +
Platelets were prepared as described in section 2.23 and the platelet pellet 
resuspended to 8 x 109 pl/ml in phosphate and BSA free HBT. The suspension 
was then incubated for 2 hours (rt) with 200 //Ci [32P]Pi/ml platelets. Excess 
[32P]Pi was removed by washing the platelets 3 times in normal HBT and the final 
platelet count adjusted to 108/ml. Aliquots of platelets (300 jA, 109/ml) were 
dispensed into eppendorfs and treated as described in individual experiments. At 
a pre-determined time platelet activation was terminated and the protein in each 
sample solubilized by the addition of an equal volume of 2 x Laemmli SDS 
reducing gel-sample buffer (100°C) (Laemmli, 1970). The samples were then 
boiled for 5 minutes and centrifuged at 8000 x g to remove any particles.
2 .2.12.2 SDS oel stock solutions
1. 30% acrylamide +  0.8% bisacrylamide, dissolved volumetrically in distilled 
water. Stored in dark at 0-4°C.
2. Running gel buffer: - 1 M Tris-HCI pH 8.8
3. Stacking gel buffer: - 1 M Tris-HCI pH 6.8
4. 10% SDS in distilled water
5. Molecular weight markers were dissolved in 1 x SDS sample buffer (37°C for 


























The numbers given are the quantity of solutions required to run two 16 cm x 16 
cm gels. The numbers given in brackets are the quantity of solutions required to 
run 2 of the mini-gels (see later).
Running Buffer
25 mM Tris base (3.03g/L)
192 mM glycine (14.42g/L)
0.1%  SDS (1 g/L)
Coomassie Blue Stain 
40% methanol 
53% distilled H20  
7% acetic acid





In this study one dimensional gel electrophoresis was used which under denaturing 
conditions (in the presence of 0.1% SDS) separates proteins based on molecular 
size as they move through a polyacrylamide gel matrix toward the anode (Laemmli, 
1970). After solubilizing all the proteins in a sample by boiling in the presence of 
SDS and 2-mercaptoethanol (which reduces disulphide bonds) an aliquot of the 
protein sample was applied to a gel lane and the individual proteins were separated 
electrophoretically using a Biorad Protean II system.
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2.2.12.3 Gel preparation and one dimensional SDS ael electrophoresis
Polyacrylamide SDS gels (16 cm x 16 cm x 1mm) were poured using a 10% 
polyacrylamide SDS gel as the running gel and a 5% polyacrylamide SDS gel as 
the stacking gel. After pouring the running gel a 50% solution of methanol was 
layered onto it to prevent the formation of a meniscus and also to prevent 
oxidisation of the gel, the methanol was removed before the stacking gel was 
poured. Standard molecular weight markers were prepared as described in 
materials and 100 //I loaded into one of the tracks, whilst samples (containing 100 
fjg protein) were loaded into every other available track. The power supply was 
then connected to the cell (Biorad Protean llxi system) and run at 160 volts until 
the bromophenol blue tracking dye entered the separating gel, the voltage was 
then increased to 300 volts. When the tracking dye reached the bottom of the 
separating gel, the power was disconnected and the gel removed and placed into 
Coomassie brilliant blue stain.
The sensitivity of Coomaissie blue staining is 0.3 - 1 jjq  protein/band. Coomaissie 
blue stain binds non-specifically to protein but not to the acrylamide gel. The gels 
were immersed in Coomaissie blue stain for 4 hours and gently agitated. The 
stain was then decanted off and the gels were immersed in destain solution. The 
destain solution was changed regularly until the blue bands of protein on a clear 
background were visible on the gels.
After staining, the gels were sandwiched between a sheet of Whatman 3MM filter 
paper (backing) and a sheet of clear cellophane (front) and dried at 80°C for 80 
minutes using a gel dryer (Biorad, model 853). When dry the gels were subject 
to autoradiography in order to detect the [ 32P]Pj  containing protein bands. The 
autoradiograph film was sandwiched between the dried gel and an intensifying 
screen, and the corners of the gel were marked on the film. The gel, film and 
intensifier were then positioned into a light sealed autoradiography cassette and 
placed at -80°C for 18 hours. The autoradiograph film was then developed until
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the required intensity of darkness was obtained and after washing was then fixed 
for 2 minutes. The film was then washed and the area on the gel corresponding 
the phosphorylated PKC substrate was excised and placed in a correspondingly 
labelled scintillation vial. Scintillant (10 mis) was then added to each vial and the 
radioactivity from each sample was assessed by scintillation spectroscopy in a B- 
scintillation counter.
2 .2.12.4 Percentage gels
Depending on whether it is high molecular weight proteins which are of interest or 
low molecular weight proteins, by varying the percentage of acrylamide in the gel, 
the proteins will either move more quickly through the open matrix of a lower 
percentage acrylamide gel or more slowly through the closer matrix of a higher 
percentage acrylamide gel. The higher the molecular weight of the protein of 
interest therefore, the lower the percentage of acrylamide in the gel which is 
required in order for that protein to be separated from others of a similar molecular 
weight on the gel.
2.2 .13  WESTERN BLOTTING
2.2.13.1 Antibodies 
Primary antibodies
Anti-phosphotyrosine (PY20) (Glenney et al. 1988) monoclonal antibody from 
mouse hybridomas (1 mg/ml in PBS) was purchased from ICN Biochemicals and 
stored at 4°C. It was used at a 1:500 dilution.
Anti-phosphotyrosine (06-123) polyclonal antibody produced in rabbit (1 mg/ml in 
PBS) was purchased from Upstate Biotechnology Inc. Lake Placid, New York. The 
antibody was sub-aliquoted, stored at -20°C and used at a 1:500 dilution. 
Anti-annexin I antibody (code 842), anti-annexin IV antibody (code 179) and anti- 
annexin V antibody (code 890) all produced in rabbit were gifts from Professor R. 
Flower, The William Harvey Institute, St.Bartholomews Hospital, London. The 
antibodies were stored at -20°C and used at a dilution of 1:5000.
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Anti-annexin I (against amino acid sequences 1-188 [code I], 24-37 [code 13] and 
38-50 [code 31]) and anti-annexin II [code II] antibodies produced in rabbit were 
gifts from Dr. F. Carey, ICI, Macclesfield, U.K. They were sub-aliquoted, stored at 
-20°C and used at a dilution of 1:500.
Anti-vinculin antibody produced in mouse was a gift from Dr. M. Wilkinson, Royal 
College of Surgeons. It was used at a 1:1000 dilution and stored at 4°C.
Second antibodies
Goat Anti-Mouse IgG (H + L) horseradish peroxidase conjugate and Goat Anti- 
Rabbit IgG (H + L) horseradish peroxidase conjugate were purchased from Bio-Rad 
Laboratories, stored at 4°C used at a 1:500 dilution.
Peroxidase anti-peroxidase antibodies
Peroxidase anti-peroxidase complex antibody (rabbit) and Peroxidase anti­
peroxidase complex antibody (mouse) were purchased from Sigma, stored at 4°C 
and at -20°C respectively, and used at a 1:10,000 dilution.
2.2.13.2 Western Blotting - Theory
Western blotting allows the identification of a particular protein by using the 
specificity inherent in antigen:antibody recognition. Using this method <  1 ng of 
antigen can be detected. In order to detect an antigen by Western blotting the 
proteins in a sample first have to be separated using one dimensional gel 
electrophoresis and then transferred from the gel to nitrocellulose transfer 
membrane. The non-specific binding sites on the nitrocellulose are then blocked to 
prevent non-specific binding of antibody and then probed with the antibody of 
interest. The antibody is then detected by a horseradish peroxidase (HRPO) anti­
immunoglobulin (Ig) conjugate and visualised by incubating the nitrocellulose in the 
presence of 3,3'diaminobenzidine. Before starting the Western blotting technique 
it was necessary to optimise the conditions in order to achieve the best 
sensitivity, but to avoid non-specific binding of antibodies.
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2.3.13.3 Optimising Conditions for Western blotting
(a) Determination of an optimal time for transfer of proteins from the 
polyacrylamide SDS gel to the nitrocellulose membrane. In order to determine an 
optimal time for transfer of proteins, different lengths of time were tested for the 
transfer. At predetermined times the amount of protein remaining in the 
polyacrylamide SDS gel was detected using Coomassie blue stain, the protein 
transferred to the nitrocellulose was detected using Ponceau S staining, and any 
protein which had passed through the nitrocellulose, was detected by placing a 
second sheet of nitrocellulose behind the first when transferring the proteins, and 
then detecting protein by staining with Ponceau S. Using this system, the 
optimum time for the transfer of protein was found to be 2 hours 30 minutes 
using a constant current of amps equal to the number of cm2 of the gels to be 
transferred. At this time point, only the very highest molecular weight proteins 
remained on the polyacrylamide SDS gel, and no protein had passed through to 
reach the second sheet of nitrocellulose. Ponceau S staining showed that most 
of the protein was transferred to the nitrocellulose sheet in direct contact with the 
gel. As a control the SDS polyacrylamide gel was routinely stained with 
Coomaissie Blue after the transfer of protein to the nitrocellulose in order to ensure 
adequate transfer of protein had taken place.
(b) Determining the best blocking solution to use to prevent binding of antibodies 
to the non-specific binding sites on the nitrocellulose. From the literature the most 
commonly used methods for blocking non-specific binding include the use of 
gelatin, BSA, non-ionic detergents and milk powder, or a combination of these 
(Stott, 1989). Experiments were performed to determine which of these methods 
was the best to prevent non-specific binding in the system being used in this 
study. Several permutations were assessed, using each of these agents alone and 
in combination with each other. Of the blocking solutions tried, the one which 
was best at preventing non-specific binding in this system used was 3% gelatin 
dissolved in 170 mM NaCI + 10 mM Tris (pH7.4).
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(c) Determining the optimal time and conditions for the incubation of the 
antibodies. It was found that if the nitrocellulose was incubated overnight with 
the first antibody at room temperature, detection of the antigen was improved 
over an incubation period of one hour at room temperature. However, it was 
found that if the nitrocellulose was gently agitated during incubation of the primary 
antibody, non-specific binding to the nitrocellulose increased. Increasing the 
incubation time of the second antibody to greater than one hour 30 minutes at 
room temperature did not improve detection of the antigen. To determine the 
concentration of the primary antibody to use for Western blotting, dilutions of the 
antibody were made as recommended from their source, and then changed if 
necessary to improve detection or prevent non-specific binding.
(d) Ascertaining the best solution for washing the nitrocellulose. Washing of the 
nitrocellulose membranes between antibody incubations was important to prevent 
non-specific binding. Several methods were tried to determine optimum washing 
conditions. These methods included:-
a. Phosphate buffered saline ( + 0.1% Tween-20)
b. 170 mM NaCI + 10 mM Tris (pH 7.4) (+  0.05%  Tween-20)
c. 30 mM NaCI + 10 mM Tris (pH 7.4) + (0.1% Tween-20)
The method which gave the cleanest results was 170 mM NaCI + 10 mM Tris 
(pH 7.4) (+  0.05%  Tween-20).
(e) Enhancement of the antigen signal. Several techniques are available which will 
enable enhancement of the antigen signal on Western blotting, including the use 
of peroxidase anti-peroxidase antibody (Frazer and Wisdom, 1985) and nickel and 
cobalt enhancement (Stott, 1989). The use of peroxidase anti-peroxidase antibody 
was found to significantly enhance the antigen signal when used at a very low 
concentration (1 in 10,000) [see figure 8]. However, using nickel and cobalt 
increased the colour of the background and therefore reduced the differential 
between signal and background.
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(c) Determining the optimal time and conditions for the incubation of the
/
antibodies. It was found that if the nitrocellulose was incubated overnight with 
the first antibody at room temperature, detection of the antigen was improved 
over an incubation period of one hour at room temperature. However, it was 
found that if the nitrocellulose was gently agitated during incubation of the 
primary antibody, non-specific binding to the nitrocellulose increased. Increasing 
the incubation time of the second antibody to greater than one hour 30 minutes at 
room temperature did not improve detection of the antigen. To determine the 
concentration of the primary antibody to lise for Western blotting, dilutions of the 
antibody were made as recommended from their source, and then changed if 
necessary to improve detection or prevent non-specific binding.
(d) Ascertaining the best solution for washing the nitrocellulose. Washing of the 
nitrocellulose membranes between antibody incubations was important to prevent 
non-specific binding. Several methods were tried to determine optimum washing 
conditions. These methods included:-
a. Phosphate buffered saline (+  0.1% Tween-20)
b. 170 mM NaCI + /1 0  mM Tris (pH 7.4) (+  0.05%  Tween-20)
c. 30 mM NaCI + /1 0  mM Tris (pH 7.4) +  (0.1% Tween-20)
The method which gave the cleanest results was 170 mM NaCI +  10 mM Tris 
(pH 7.4) (+  0.05%  Tween-20)./
, /
(e) Enhancement of the antigen signal. Several techniques are available which will
enable enhancement of the antigen signal on Western blotting, including the use of 
> ^  
peroxidase anti-peroxidase antibody (Frazer and Wisdom, 1985) and Nickle andj _^J
Cobalt enhancement (Stott, 1989). The use of peroxidase anti-peroxidase
/
antibody was found to significantly enhance the antigen signal when used at a
/ ■ 
very Iqw concentration (1 in 10,000) [see figure 8]. However, using Nickle and
Cobalt increased the colour of the background and therefore reduced the
differential between signal and background.
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The method given below for Western blotting is a combination of the optimal 
conditions found for transferring protein and blocking, incubating and washing the 
nitrocellulose.
2 .2.13.4 Stock solutions
Tris buffered saline 
170 mM NaCI 
10 mM Tris (pH 7.4)
Blocking Buffer
3% gelatin in Tris buffered saline
Blotting Buffer 
50 mM Tris-Base 
40 mM glycine 
0.02%  SDS 
20% methanol
Ponceau S stain
0.1 % Ponceau S
1 % aqueous acetic acid
Ponceau S destain 
200 /vM NaOH
3.3'diaminobenzidine substrate solution 
50 mg DAB in 200 mis PBS (filtered) 
100 iA H20 2 added directly before use.
2.2.13.5 Preparation of samples for Western blotting
Western blotting was used for probing washed human platelet lysates for annexins 
(I,II,IV and V) and for probing washed rabbit platelet lysates for phosphotyrosine. 
Human platelets were isolated and prepared as described in section 2.2.3.4 and 
rabbit platelets were isolated and prepared as described in section 2.2.3.
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2.2.13.5.1 Preparation of human platelet samples to probe for annexins
Total platelet protein was obtained by resuspending human platelets to a 
concentration of 5 x 10*/ml and adding an equal volume of 2 x Laemmli SDS 
reducing gel-sample buffer (100°C) (Laemmli, 1970). In order to detect 
EDTA/EGTA releasable annexin from the outer surface of the plasma membrane, 5 
x 10* platelets were washed in 5 mM EGTA/5 mM EDTA and an equal volume of 
2 x Laemmli SDS reducing gel-sample buffer (10Q°C) added to the supernatant. 
The remaining platelet pellet was resuspended to its original volume in 1 x 
Laemmli SDS reducing gel-sample buffer (100°C). In order to assess for the 
release of annexins from the platelet granules, platelets were stimulated with 
various agents in the presence of 1 mM [Ca++]j whilst being continually stirred 
(900 rpm). The reaction was terminated at 3 minutes after activation by removing 
a sub-aliquot of platelets into 5 mM EGTA/5 mM EDTA centrifuging and then 
adding an equal volume of 2 x Laemmli SDS reducing gel-sample buffer (100°C) to 
the supernatant. The remaining pellet was resuspended to its original volume in 1 
x Laemmli SDS reducing gel-sample buffer (100°C). All samples were boiled for 5 
minutes and then centrifuged (12,000 x g, 2 minutes) before the supernatants 
were run on polyacrylamide SDS gels.
2.2.13.5.2 Preparation of rabbit platelet samples to probe for phosphotvrosine 
Washed rabbit platelets were resuspended to 1-2 x 108 platelets/ml and all 
experiments were carried out at 37°C. Platelets were continuously stirred (900 
rpm) throughout experimentation. To terminate the reactions an equal volume of 
2 x Laemmli SDS reducing gel sample buffer (100°C) was added and the samples 
were boiled for 5 minutes and centrifuged (12,000 x g, 2 minutes) before the 
supernatants were run on polyacrylamide SDS gels.
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2.2 .13.5.3 Treatment of U937 cells with TPA
U937 cells were grown in 10 % fetal calf serum and 90 % RPM-I in the presence 
of low concentrations of fungizone (5 //g/ml), penicillin (10 //g/ml) and 
streptinomycin (10 units/ml). When they reached a concentration of 108 cells/ml 
they were transformed by the addition of 50 ng TPA/ml for 24 hours. The 
transformed U937 cells were used as a positive control for the presence of 
annexins on Western blots (Isacke et al. 1989). After transformation the cells 
were washed in HBT containing 1 mM CaCI2 and they were then resuspended to 5 
x 10s cells/ml in Laemmli SDS reducing gel-sample buffer, boiled for 5 minutes 
and centrifuged (12,000 x g) for 5 minutes before being run on the Western blots. 
I would like to acknowledge Mr R. Pleass for growing the U937 cells.
2 .2.13.6 One dimensional oel electrophoresis of proteins
Mini-gels (8 cm x 8 cm x 0.75 mm) were poured using the volume of reagents 
described in section 2.2.12.5 (the figure in brackets is sufficient for 2 minigels). 
The percentage of the polyacrylamide SDS gel used as the separating gel varied 
depending on the individual experiments and is given in the figure legends. 
However the stacking gel was always a 5% polyacrylamide SDS gel. Protein 
samples of interest were solubilized by adding an equal volume of 2 x Laemmli 
SDS reducing gel sample buffer (100°C) and boiled for 5 minutes (Laemmli, 1970). 
Molecular weight markers (10//I) were added to one track, whilst the samples 
(containing about 10 /yg protein/track) were dispensed into the remaining tracks. 
The power supply was then connected to the cell (Biorad miniprotean lltm) and the 
gels were run at 150 volts until the bromophenol blue tracking dye reached the 
bottom of the separating gel. The power was then disconnected and the gels 
placed in blotting buffer for 15 minutes.
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2.2.13.7 Transferring Proteins from gels to nitrocellulose
Proteins were transferred from gel to nitrocellulose membrane (Towbin et at. 1979) 
using a Semi-Dry Blotter (Sartorius, Sartoblot ll-S). Twelve sheets of Whatman 3 
MM filter paper and one piece of nitrocellulose were cut to the same size as the 
gel and were soaked in blotting buffer. The filter paper (6 pieces) was placed on 
the cathode side of the semi-dry blotter, followed by the gel, then the 
nitrocellulose and finally by another six pieces of the filter paper. Any air bubbles 
in the 'sandwich' were expelled and the anode side 'lid' of the semi-dry blotter 
was closed. The direction of transfer is from the cathode side to the anode side 
and therefore protein was transferred from the gel onto the nitrocellulose.
The number of mAMPs used to transfer protein depended on the surface area of 
the total number of gels to be transferred with 1 cm2 of gel requiring 1 mAMP for
2.5 hours. Therefore 2 gels of 6 x 8 cm equalling a total surface area of 96 cm2 
were transferred at 96 mAMPs for 2.5 hours. After removing them from the 
semi-dry blotter, the gels were stained using Coomaissie Blue stain in order to 
assess protein transfer whilst the nitrocellulose membranes were (as required) 
stained in Ponceau S in order to check transfer or to enable cutting them into 
tracks. The nitrocellulose was then destained for 10 minutes and placed in 
blocking solution for a further 1.5 hours in order to block non-specific antibody 
binding sites on the nitrocellulose.
2.2.13.8 Western Blotting
After blocking the non-specific binding sites the gels were washed twice in Tris- 
buffer (170 mM NaCI, 10 mM Tris-HCI [pH 7.4]) for 10 minutes each, followed by 
two washes in Tris-buffer plus 0.05%  tween-20 (TBT-20). For each of the 
nitrocellulose membranes a square petri dish lined with parafilm was prepared, the 
nitrocellulose was placed on the parafilm (which repels any moisture) and the 
primary antibody (diluted in TBT-20) was gently pipetted onto the membrane. The 
lid was then placed on the dish and the primary antibody incubated overnight at 
room temperature.
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The non-specifically bound primary antibody was removed by washing the 
nitrocellulose three times in TBT-20. The second antibody (horseradish peroxidase 
anti-IgG conjugate) was diluted in TBT-20, added to the gels (5 mls/gel) and 
incubated for 1 h at rt. Non-specifically bound second antibody was washed 
away by rinsing the membrane three times (10 minutes each) in TBT-20, a 
1:10000 dilution of peroxidase-anti-peroxidase antibody was then added to the 
gels and incubated for 1 hour. This was washed away with TBT-20 followed by 
washing twice in Tris-buffer (10 minutes each) and finally rinsing briefly in PBS. 
DAB substrate solution (50 mis per gel) was added to the nitrocellulose and when 
the colour had developed it was transferred to distilled H20  to stop the reaction. 
Figure 8 demonstrates the enhancement of the signal which is achieved by the 
addition of the peroxidase anti-peroxidase antibody compared to developing the 
Western blot without using peroxidase anti-peroxidase enhancement.
2 .2.13.9 Relative Optical Densitometry
The relative optical density of tyrosine phosphorylated protein bands on the 
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Figure 8 To demonstrate the enhancement of the signal for the proteins detected 
by Western blotting by using a peroxidase anti-peroxidase antibody, (a) A time 
course of tyrosine phosphorylation of platelet proteins induced by 300 nM PAF in 
the absence of peroxidase anti-peroxidase antibody (b) the same time course as in 
(a) using a 1:10,000 dilution of peroxidase anti-peroxidase antibody as a third 
antibody to enhance the signal.
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2.2.14 ELISA FOR ANNEXIN 1
The enzyme-linked immunosorbent assay (ELISA) for annexin 1 (Smith eta/. 1990) 
was carried out, on samples prepared by myself, by Dr S. Peers at the William 
Harvey Institute, St. Bartholomews Hospital, London.
2.2.14.1 Preparation of samples for ELISA
Washed human platelets were prepared as described in section 2.2.3.5 and 
resuspended to a final concentration of 5 x 109/ml. In order to determine the total 
annexin I concentration in the platelets, they were suspended in HBT containing 
5 mM EGTA/5mM EDTA and subjected to rapid freeze/thawing at least five times 
before centrifugation (12,000 x g, 2 mins). The supernatant was then assessed 
for annexin I.
In order to release cell surface annexin, cells were treated with 5 mM EGTA/5 mM 
EDTA and then centrifuged (12,000 x g, 2 mins) to remove the supernatant which 
was assessed for annexin I. The remaining platelet pellet was subjected to 
freeze/thawing at least 5 times and then centrifuged (12,000 x g, 2 minutes) and 
the supernatant assessed for annexin I.
In order to examine for release of annexin I from the dense granules, platelets 
were stimulated with various agonists, whilst being continually stirred (37°C) in 
the presence of 1 mM [Ca + +]e. The reactions were terminated at three minutes 
after platelet activation by removing a subaliquot into ice-cold tubes containing 5 
mM EDTA/5mM EGTA. The samples were centrifuged as described above and the 
supernatant assessed for annexin I. In order to determine how much granule 
release had occurred, a parallel experiment was performed using 14C-5HT loaded 
platelets as described in section 2.2.8.1 which were treated in an identical way 
to those to be assessed for release of annexin I. From this it was possible to 
determine the percentage 14C-5HT for each individual treatment.
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2.2.14.2 ELISA assay for annexin I
The ELISA assay for annexin I (Smith et a/. 1990) has a sensitivity range of 0.1 - 
2000 ng/ml. The ELISA used was a sandwich assay with a monoclonal anti- 
annexin I antibody (code 1A) used to coat the plate, the samples were added and 
any annexin I contained in them was bound to the plate, a polyclonal anti-annexin 
I antibody (code 842) was then added to recognise the bound annexin I. This two 
antibody method is thought to be specific for only annexin I and its degradation 
products.
2 .2 .15  LACTATE DEHYDROGENASE
Leakage of the enzyme lactate dehydrogenase from cells is an indicator of cell 
damage and increased permeability. In this study lactate dehydrogenase activity 
has been assessed from the supernatants of platelets which have been stimulated 
with AA or ionomycin.
2.2.15.1 Preparation of Samples
Platelets were prepared as described in sections 2.2.3 and were resuspended to a 
final concentration of 5 x 108/ml. 1 ml aliquots were dispensed into eppendorfs, 
[Ca++J. adjusted to 1 mM and the platelets allowed to equilibrate to 37°C before 
activation. The platelets were then activated with a dose range of ionomycin or 
AA and mixed. The platelets were centrifuged at 12,000 x g for 2 minutes and 
the supernatant removed and placed on ice until lactate dehydrogenase 
assessment. As a positive control platelets were lysed with 1% triton-X-100 and 
the supernatant removed as described above. Release of lactate dehydrogenase 
from untreated platelets was determined in order to assess basal levels of lactate 
dehydrogenase.
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2.2.15.2 Lactate Dehvdroaenase Assay
Lactate dehydrogenase activity was determined using a kit from Sigma which is 
based on the spectrophotometric method of Wroblewski and LaDue (1955). This 
assay measured the rate at which the substrate pyruvate was reduced to lactate 
by lactate dehydrogenase.
Pyruvate +  NADH Lactate dehydrogenase Lactate
[High A340] +  NAD
[low A340]
The reaction is coupled with the oxidation of nicotinamide adenine dinucleotide 
reduced form [NADH] which is followed spectrophotometrically in terms of reduced 
absorbance at 340 nm every 30 s for 3 minutes. The change in absorbance was 
measured at a linear part of curve.
The activity in a sample was calculated using the formula:-
Serum LD activity (u/ml) = change absorbance/minute x 20000 x TCF 
TCF = 1 at 25°C
2.2 .16  STATISTICS
The number of times each experiment was performed is given in the respective 
figure legends and where possible the data is given as the mean result _±_ S.E.M 
of the total number of experiments. To determine if there were significant 
differences between the sets of data an Anova test was performed. If significant 
differences were found in the data, a paired Student's T test was employed to 
find which treatments caused these significant differences. The levels of 
significance are denoted by * = P <0.05 , * *  = P<0.01 and * * *  = <0 .005 . 
The Bonferroni correction was applied where necessary, ie. when comparing 
several sets of data to a single set of control data (Wallenstein et a!. 1980).
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3. RESULTS
3.1 Investigation of the ro/e of PKC in PAF-stimuiated functional responses
3.1.1 Characterisation of PAP, ionomycin and arachidonic acid-induced platelet 
functional responses
In order to investigate the effect of PKC activation or inhibition on either PAF, 
ionomycin or AA induced platelet functional responses it was important to 
determine a concentration of each of these platelet activators which would elicit a 
sub-maximal response for each of the functional assays in which it was to be 
used. The effects of increasing concentrations of PAF, ionomycin and AA on 
[Ca++]i elevation and TxB2 generation are shown in Figs 9, 10 and 11 respectively, 
and the effect of increasing concentrations of PAF and ionomycin on 5-HT release 
is shown in Fig 12.
Increasing concentrations of each of the three platelet stimulants PAF, 
ionomycin or AA caused a dose dependent increase in [Ca++]j elevation, TxB2 
generation and 5-HT release. A concentration of 3 nM PAF caused a submaximal 
elevation of [Ca++], and a submaximal release of 5-HT (Fig 9 & 12). This 
concentration of PAF however, only caused trace amounts of TxB2 generation 
above the basal level of 0.1 pmol/108 platelets (Fig 9), therefore a suboptimal 
concentration of 30 nM PAF was used for the TxB2 experiments. A concentration 
of 5 //M ionomycin was found to be suboptimal for all three functional responses, 
[Ca++]j elevation, TxB2 generation and 5-HT release (Fig 10, 12). A concentration 
of 30 /;M AA was sub-optimal for both [Ca++]( elevation and TxB2 generation (Fig 
11). Pre-incubation of platelets with 2.8 //M of the cyclo-oxygenase inhibitor 
indomethacin caused total inhibition of TxB2 generation in platelets stimulated with 
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Fig 9 The effect of increasing concentrations of PAF on [Ca++], elevation and 
TxB2 generation. Increasing concentrations of PAF were added to Fura-2 loaded 
platelets in the presence of 1 mM lCa++]e. [Ca++lj is the value obtained by 
subtracting the basal pre-PAF value from the peak value for [Ca++]f after platelet 
activation. TxB2 generation was determined at 3 minutes post-stimulation. Also 
shown as the closed triangle is the effect of 2.8 //M indomethacin on 30 nM PAF- 
induced TxB2 generation. Each value represents the mean _+_ S.E.M. of at least 
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Fig 10 The effect of increasing concentrations of ionomycin on [Ca++], elevation 
and TxB2 generation. Increasing concentrations of ionomycin were added to fura-2 
loaded platelets in the presence of 1 mM [Ca++le. [Ca++]j is the value obtained by 
subtracting the basal pre-ionomycin value from the peak value for [Ca++]j after 
platelet activation. TxB2 generation was determined at 3 minutes post-stimulation. 
Also shown as the closed triangle is the effect of 2.8 //M indomethacin on 5//M 
ionomycin-induced TxB2 generation. Each value represents the mean +_ S.E.M. of 
at least three experiments each performed in triplicate.
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Fig 11 The effect of increasing concentrations of arachidonic acid on [Ca++], 
elevation and TxB2 generation, increasing concentrations of arachidonic acid were 
added to fura-2 loaded platelets in the presence of 1 mM [Ca++]e. [Ca++]j is the 
value obtained by subtracting the basal pre-arachidonic acid value from the peak 
value for [Ca++]j after platelet activation. TxB2 generation was determined at 3 
minutes post-stimulation. Also shown as the closed triangle is the effect of 2.8 
//M indomethacin on 30 //M arachidonic acid-induced TxB2 generation. Each value 
represents the mean ±_ S.E.M. of at least three experiments each performed in 
triplicate.
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Fig 12 The effect of increasing concentrations of PAF or ionomycin on platelet 
dense granule release. 5-HT release was determined at three minutes post­
stimulation. The points are the mean +_ S.E.M of three experiments performed in 
triplicate.
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3.1 .2  Inhibition of PKC substrate phosphorylation by staurosporine
To determine whether staurosporine inhibits PKC activity and to find a suitable 
dose range of staurosporine to use in order to investigate the effect of PKC 
inhibition on platelet functional responses, the effect of a range of concentrations 
of staurosporine was examined on the phosphorylation of the major 40-47 kDa 
substrate of PKC. Addition of 300 nM PAF caused a 250% increase in 
phosphorylation of the PKC substrate (40-47 kDa) above basal levels (Fig 13, 
lanes 1 +  2). Increasing concentrations of staurosporine caused inhibition of 
phosphorylation of the PKC substrate in a dose dependent manner (Fig 13, lanes
3-6) over the range 30-1000 nM staurosporine with an ICB0 of 500 nM.
3.1 .3  PKC modulation and PAF-induced platelet activation
Activation of PKC in platelets with a 2 minute pretreatment using either 1-30 
nM of 12-0-tetradecanyl phorbol-13-acetate (TPA) or 6.8-68 pM of the membrane 
permeant diacylglycerol sn-1,2-dihexanyl-sn-diacylglycerol (sn-1,2-DHG) caused a 
dose dependent inhibition of both the rate and maximal height of [Ca++], elevation 
induced by 3 nM PAF (Fig 14). In contrast 30-1000 nM staurosporine had no 
significant effect on either the rate or maximal height of 3 nM PAF-induced [Ca++lj 
elevation (Fig 14). Neither TPA, DHG nor staurosporine had any effect on basal 
levels of [Ca ++]j which remained at 152 _±. 11 (n = 30). Concentrations of the 
non-esterified precursor molecule of TPA, namely 4B-phorbol at concentrations of 
1000 fold greater than those found to be active for TPA, had no effect on PAF- 
induced [Ca++]j elevation (Fig 15). Similar to the results for [Ca++], elevation, 
stimulation of PKC with TPA caused a dose dependent inhibition of TxB2 
generation (Fig 16), whilst conversely, inhibition of PKC significantly potentiated 
TxB2 generation but only at the highest concentration of 1 //M staurosporine in 
platelets stimulated with 30 nM PAF (Fig 16). Neither 30 nM TPA nor 1 //M  
staurosporine alone increased levels of TxB2 above the basal level of 0.1 pmol/108 
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Fig 13 Inhibition of phosphorylation of the 40-47 kDa substrate of PKC by 
staurosporine in platelets. Right panel: autoradiograph representing track 1 = 
phosphorylation in resting platelets, track 2 = 300 nM PAF induced
phosphorylation in the presence of staurosporine vehicle (0.01% DMSO) and 
tracks 3-6 = pretreatment with 30,100,300 & 1000 nM staurosporine
respectively followed by 300 nM PAF stimulation. Platelet activation was 
terminated at 30s post-PAF. Left panel: Phosphorylation of the PKC substrate as 
a percentage of that phosphorylated by 300 nM PAF (in the presence of vehicle). 






























Fig 14 Effect of PKC modulation on [Ca**], elevation induced by PAF. Platelets 
were preincubated for 2 minutes with the PKC activators TPA (upper panel), sn- 
1,2-DHG (middle panel) or the PKC inhibitor staurosporine (lower panel) and then 
stimulated with 3 nM PAF. The [Ca++lj value was obtained by subtracting the 
basal pre-PAF value from the peak post-PAF value. The values for each of the 
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Fig 15 The effect of 4-ft-phorbol on PAF-induced [Ca++], elevation. Platelets were pretreated 
with 30 /;M 4-0-phorbol for two minutes before stimulation with 3 nM PAF. The traces are 

















Fig 16 Effect of PKC modulation on TxB2 generation induced by PAF. Platelets 
were pretreated for 2 minutes with the PKC activator, TPA (upper panel) or with 
staurosporine (lower panel) and then stimulated with 30 nM PAF. TxB2 generation 
was determined at 3 minutes after PAF addition. The values are the mean ±
S.E.M of three experiments each performed in triplicate.
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The dependence of TxB2 generation and 5-HT release on [ C a + + ], elevation was 
determined by replacing [ C a + + ]j with the C a ++ chelator EGTA (Fig 17). Removal 
of [ C a  ++], caused an inhibition of [ C a  ++]( elevation and both TxB2 generation and 
5-HT release induced by a range of concentrations of PAF (Fig 17), this would 
indirectly suggest that TxB2 generation and 5-HT release are dependent on [ C a + + ]j 
elevation.
The ability of staurosporine to inhibit phosphorylation of the major 40-47 kDa 
PKC substrate demonstrated it was causing inhibition of PKC. In order to 
demonstrate that both staurosporine and TPA are working at the level of PKC, the 
ability of staurosporine to inhibit the effect of TPA or sn-1,2-DHG on PAF-induced 
[ C a + + ]j elevation is shown in Fig 18. The inhibition of [Ca++lj elevation induced by 
30 nM TPA (or 68 //M sn-1,2-DHG) was dose dependency abrogated by 
staurosporine in 3 nM PAF stimulated platelets (Fig 18) indicating that the 
inhibition of [Ca++li elevation by TPA and sn-1,2-DHG was probably mediated by 
PKC.
3 .7.4 PKC modulation and ionomycin-induced platelet activation
In contrast to its effect on [Ca ++1, elevation induced by PAF, TPA had no 
effect on [Ca++lj elevation in platelets stimulated with a submaximal concentration 
of ionomycin (Fig 19). Staurosporine also had no effect on ionomycin induced 
[Ca ++lj elevation (Fig 19). In addition, inhibition of the cyclo-oxygenase pathway 
with 2.8 pW\ of indomethacin also had no significant effect on [Ca++lf elevation 
induced by 5 //M ionomycin (Fig 19), indicating that elevation of [Ca++lj in 
ionomycin stimulated platelets was not dependent on TxA2 generation. TxB2 
generation in ionomycin stimulated platelets was however modified by both PKC 
activation and inhibition. TPA (1-30 nM) caused a dose dependent potentiation of 
TxB2 generation (Fig 20) whilst PKC inhibition with staurosporine caused a dose 
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Fig 17 The effect of replacing 1 mM extracellular calcium with 2 mM EGTA on 
PAF-induced [Ca++], elevation (upper panel), TxB2 generation (middle panel) and 
dense granule release (lower panel). [Ca**]; is the value obtained by subtracting 
the basal pre-PAF value from the peak value for [Ca ++lj after platelet activation. 
TxB2 generation and 5-HT release were determined 3 minutes after the addition of 
PAF. Open circles denote the presence of 1 mM [Ca + +], and closed circles the 
presence of 2 mM [EGTA]e. These values are the means ±  S.E.M of three 
separate experiments each performed in triplicate.
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Fig 18 Reversal of TPA (upper panel) and sn-1,2-DHG (lower paneO-induced 
inhibition of [Ca++lj elevation by staurosporine in 3 nM PAF-stimulated platelets.
Staurosporine was added 2 minutes before TPA (30 nM) or sn-1,2-DHG (68 //M) 
which was added 2 minutes prior to stimulation with 3 nM PAF. [Ca++]j is the 
value obtained by subtracting the basal pre-PAF value from the maximal post-PAF 
value. The values in these experiments are the mean ± S.E. from two separate 
experiments each performed in triplicate.
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Fig 19 Effect of modulating PKC on ionomycin induced [Ca+ + ], elevation. The traces represent the 
fluorescent output from fura-2 loaded platelets which have been pretreated for two minutes with (a) 30 
nM TPA, (b) 1 //M staurosporine or (c) 2.8 //M indomethacin and then stimulated with 5 /yM ionomycin. 
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Fig 20 PKC modulation on 5 |/M  ionomycin-induced TxB2 generation. Platelets 
were pretreated for 2 minutes with either TPA (upper panel) or staurosporine 
(lower panel) before stimulation with 5 //M ionomycin. TxB2 generation was 
determined 3 minutes post-ionomycin stimulation. The values are the mean ±  
S.E.M. of three separate experiments each performed in triplicate.
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Although 5 //M ionomycin was a submaximal concentration for cell functional 
responses it was important to establish that this concentration of ionomycin was 
not causing non-specific cell permeabilization or cell lysis. Therefore the 
supernatant of ionomycin stimulated cells was examined for lactate dehydrogenase 
activity which is a marker for cell damage. The supernatant was also examined 
for low molecular weight molecule leakage by testing for leakage of fura-2 from 
the cells. At 5 pM ionomycin, there was no lactate dehydrogenase activity in the 
supernatant nor did any fura-2 leak from the cells into the extracellular medium 
until a concentration of above 50 //M ionomycin was added to the platelets.
3 .1 .5  PKC modulation and arachidonic acid-induced platelet activation
In agreement with the findings for PAF stimulated platelets, pretreatment of 
platelets with TPA caused a dose dependent inhibition of [Ca++]( elevation whilst 
staurosporine had no effect on [Ca++]j elevation in platelets stimulated with AA 
(Fig 21). Neither PKC activation nor inhibition had any effect on TxBa generation 
in platelets stimulated with AA (Fig 22). A concentration of 30 pM  AA was found 
to be submaximal for both [Ca ++], elevation and TxB2 generation. It was important 
to establish that 30 //M AA was not causing non-specific cell permeabilization or 
lysis, therefore the supernatant of AA stimulated platelets was examined for 
lactate dehydrogenase activity and for fura-2 leakage from the cells upon AA 
stimulation. No lactate dehydrogenase activity was detected in the supernatant 
















1 nM  
TPA 10 pM AA
3 nM  
TPA
1 1 m in u te  1




10 nM  A 
TPA lOpMAA
A 300 nM A 1000 nM A
30 pM AA SS 30 pM AA SS 30pM AA
Fig 21 PKC modulation on arachidonic acid-induced [Ca++], elevation. The traces represent the fluorescent output 
from fura-2 loaded platelets which have been pretreated for two minutes with a dose range of TPA then 
stimulated with 10 //M arachidonic acid (a) or a dose range of staurosporine and then stimulated with 30 //M  
arachidonic acid (b). The traces are taken from a single experiment which was representative of two similar 
experiments each performed in triplicate.
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Fig 22 PKC modulation on arachidonic acid-induced TxB2 generation. Platelets 
were pretreated for 2 minutes with either TPA (upper panel) or staurosporine 
(lower panel) and then stimulated with 30 //M arachidonic acid. TxB2 generation 
was measured at 3 minutes post-stimulation. The results are taken from a single 
experiment which is representative of two other similar experiments.
120
3.1.6 PKC modulation on PAF and ionomycin-induced 5-HT release
Washed platelets released 5-HT from their dense granules in response to 
stimulation with either PAF or ionomycin (Fig 23). Activation of PKC with TPA 
alone also caused a small amount of dense granule release, with up to 6 percent 
of 5-HT released by addition of 30 nM TPA. In platelets stimulated with 
submaximal PAF (3 nM) activation of PKC with 1 - 3 0  nM TPA had no significant 
effect on 5-HT release (Fig 23a). Staurosporine however inhibited 5-HT release 
with an IC60 of 800 nM, causing up to 70 percent inhibition with 1 //M  
staurosporine (Fig 23b).
In ionomycin stimulated platelets TPA caused a significant potentiation of 5- 
HT release with 100% release at 30 nM TPA (Fig 23a). This potentiation 
however was not due to the increased generation of TxA2 caused by TPA in 
ionomycin stimulated platelets (see Fig 20) as inhibition of TxA2 generation with 
2.8 //M indomethacin did not inhibit the potentiation of 5-HT release caused by 
TPA in ionomycin stimulated platelets (Fig 24). In contrast, staurosporine caused 
a significant inhibition of 5-HT release with an IC60 of 150 nM, and produced 
almost 100% inhibition at only 300 nM staurosporine (Fig. 23b). Staurosporine 
was therefore a weaker inhibitor of 5-HT release in platelets stimulated via a 
receptor operated mechanism (PAF) than in platelets directly activated via Ca+ + 
elevation (ionomycin).
In order to assess whether loading platelets with the fluorescent dye fura-2 
was causing a significant chelation of cytosolic Ca++, 5-HT release experiments 
were investigated in platelets either loaded with fura-2 or in platelets not loaded 
with fura-2 (Fig 23). Fura-2 loading had no effect on 5-HT release in either PAF 
or ionomycin stimulated platelets, indicating that fura-2 was not chelating 
cytosolic Ca++ to an extent where Ca++-dependent functional responses were 
suppressed.
Table 2 gives a summary of the effects of staurosporine and TPA on PAF, 
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Fig 23 The effect of (a) TPA or (b) staurosporine on PAF or ionomycin-induced 
5HT release in platelets either loaded or not loaded with fura-2. Platelets either 
loaded with fura-2 or not loaded were pre-incubated for 2 minutes with 1-30 nM 
TPA (or TPA vehicle) or 30 -1000 nM staurosporine (or staurosporine vehicle) 
before the addition of either 3 nM PAF or 5 //M ionomycin. In all cases 5-HT 
release was terminated 3 minutes after platelet activation. The significant 
differences shown are due to a statistically significant difference between 5-HT 
release from platelets treated with the vehicle control compared to treatment with 
a particular concentration of either TPA or staurosporine in platelets not loaded 
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Fig 24 The effect of indomethacin on ionomycin-induced 5-HT release in platelets 
pre-treated with TPA. Platelets were pretreated with 2.8 //M indomethacin 2 
minutes before the addition of TPA vehicle or increasing concentrations of TPA (1- 
30 nM) which were added 2 minutes prior to stimulation with 5 //M ionomycin. In 
all cases 5-HT release was terminated 3 minutes post-ionomycin. The points 
represent the means ±  S.E.M. of 3 experiments each performed in triplicate.
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PAF IONOMYCIN ARACHIDONIC ACID
SS TPA SS TPA SS TPA
Calcium elevation t (^1/2) l(Ht) ND ND t (t1/2) i(Ht)
TxB2 generation t I i t ND ND
5-HT release 1 ND t — —
- = not determined 
ND = not different
I decrease 
t increase
Table 2 Summary of the effects of staurosporine or TPA on PAF, ionomycin and arachidonic 
acid induced [Ca++]i elevation, TxB2 generation and dense granule release.
3 .1 .7  Inhibition of PKC on PAF-induced platelet desensitization
It is known that upon stimulation with PAF, platelets are specifically 
desensitized and lose their ability to become activated by a further exposure to 
PAF (Keraly and Benveniste, 1982). Platelets are however still capable of being 
activated by other agonists binding at different receptor sites. It has been 
demonstrated in this study that activation of PKC inhibits PAF-induced [Ca++]j 
elevation (Fig 14) but that this inhibition can be reversed by pre-incubation with 
the PKC inhibitor staurosporine (Fig 18). It is possible therefore that PKC 
activation is responsible for the desensitization of platelets to PAF once they have 
been stimulated by PAF and if so inhibition of PKC with staurosporine may prevent 
this desensitization.
Stimulation of platelets with either 0.3, 3 or 30 nM PAF caused a transient 
elevation in [Ca**], which was allowed to decline to near basal levels before the 
addition of a second dose of PAF at the same concentration as the first. The 
second dose of PAF caused a much smaller increase in [Ca++]j than the first dose, 
for example, addition of 3 nM PAF caused an elevation of 450 nM [Ca + +lj 
whereas the second dose caused an elevation of only 20 nM. Peak [Ca++]f 
elevation induced by the second dose of PAF was inversely proportional to the 
concentration of the first dose of PAF added, such that the peak [Ca ++]j elevation 
induced by the second dose of 30 nM PAF was smaller than the peak [Ca++]j 
elevation induced by the second dose of 0.3 nM PAF. This may indicate that at 
the lower concentration of PAF (0.3 nM) not all PAF receptors were desensitized 
therefore allowing [Ca + +]j elevation when the platelets were stimulated with a 
second dose of PAF. Inhibition of PKC with 300 nM staurosporine however did 
not prevent desensitization of PAF-induced [Ca + +]j elevation to further stimulation 
















□ □  response to first PAF stimulation 
123 response to second PAF stimulation 
ESS response to first PAF stimulation 










Fig 25 Effect of staurosporine on PAF-induced desensitisation. Platelets 
were either pretreated with 1 //M staurosporine or staurosporine vehicle 
two minutes before addition of the first dose of PAF (0.3, 3 or 30 nM) and 
a second dose of the same concentration of PAF was added when [Ca++J, 
levels reached near basal levels. The values are the mean ± S.E. of two 
experiments each performed in triplicate.
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3 .2  Characterisation o f signal molecule elevation in PAF stimulated platelets and
investigation o f the rote of PKC on signal molecule production
3 .2 .1  PAF-induced elevation of the concentration of [C a**], ins(1,4,5)P3 and DAG
Addition of 300 nM PAF induced a rapid elevation of platelet [Ca**], from a 
basal concentration of 152 ±  11 nM (n = 30) to a peak elevation of 1023 ±  72 
nM at 7.3 ±  0.6s (n = 13) post-PAF. This elevation was transient and quickly 
declined (Fig 26). Similarly, in the same platelet preparations 300 nM PAF 
induced a rapid elevation in the concentration of lns(1,4,5)P3 with a peak increase 
at 2s of 38.9 ±  2.2 pmol/10* platelets above a basal level of 9.77 ±  1.72 
pmol/10* platelets (Fig 26). This elevation rapidly declined to basal levels by 15s 
after PAF, followed by a gradual increase at 30 and 60s post PAF.
Superimposition of the lns(1,4,5)P3 and [ C a + + 1, time curves demonstrates that 
the lns(1,4,5)P3 peak clearly precedes the peak [ C a + + ]j by approximately 5 
seconds.
Platelets had a basal concentration of 117 ±  3 pmol of DAG in 109 platelets. 
Following the addition of 300 nM PAF, there was a rapid and transient increase in 
the platelet DAG concentration which peaked at 10s with a value of 280 ±  52 
pmol/10* platelets (n = 9) above basal. After 10 s the concentration of DAG 
rapidly declined and by 15s reached a level above basal at which it remained for 
the duration of the time course (60s) (Fig 26).
Addition of PAF vehicle did not produce changes in the basal concentration of 
[ C a + + ]i ,  lns(1,4,5)P3, or DAG.
Table 3 demonstrates that pretreatment of the platelets with the PAF receptor 
antagonist WEB 2086 (300 nM) inhibited to the same degree PAF-induced 





























Fig 26 Time courses for the production of DAG, lns(1,4,5)P3 and [Ca**], in 300 
nM PAF-stimulated platelets. DAG production induced by 300 nM PAF is shown 
in the upper panel, and cytosolic calcium ([Ca++]j) elevation together with 
lns(1,4,5)P3 elevation are shown in the lower panel. The values in all figures have 
been obtained by subtracting the basal pre-PAF value from the values obtained at 
the stated times after 300 nM PAF administration. The values are the mean ±  
S.E.M. of at least three experiments. The S.E.M. bars are absent when symbols 
are larger than the S.E.M.
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Treatment
Generation (% control) 
lns(1,4,5)P3 * DAG**
Vehicle +  300 nM PAF 100
30 nM WEB 2086 + 300 nM PAF 24.0 ±  14
300 nM WEB 2086 +  300 nM PAF 4.7 ±  3.2
* measured 5s after PAF addition 
## measured 10s after PAF addition
Table 3 Effect of a 2 minute pre-incubation with the PAF receptor antagonist WEB 
2086 on PAF-induced lns(1,4,5)P3 and DAG generation.
100 
22.5 ±  16 
0
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In order to establish that PAF was not itself being converted into [32P]- 
phosphatidic acid two control experiments were performed. In the first 
experiment different concentrations of PAF were added to the DAG standards and 
the resultant [32P]PA produced was compared to normal standards not 'spiked' 
with PAF. Addition of PAF to standards had no effect on the final [32P]PA count 
obtained indicating that PAF could not be directly converted into phosphatidic acid 
(PA). Secondly, platelets were stimulated with [3H]PAF, the DAG produced was 
then converted into PA using DAG kinase, but instead of using [32P]-labelled ATP, 
non-radiolabelled ATP was used. Because of the position of the radiolabel ([1-0- 
[3H]Octadecyl-2-acetyl-sn-glycerol-3-phosphocholine) then any PAF which was 
eventually converted to PA would produce [3H]PA. Scintillation counting showed 
no [3H] contained in the PA derived from [3H]PAF stimulated platelets. This 
indicated that the PAF used to stimulate the platelets was not being converted 
into DAG and ultimately not producing PA.
3 .2 .2  Dose-response relationship of PAF-induced platelet activation
The relationship of the concentrations of the three putative signal molecules, 
namely [Ca + +]j, lns(1,4,5)P3 and DAG to the release of 5-HT was determined (Fig 
27).
PAF is a powerful dense granule releasing agent and the dose-response 
relationship is shown in the lower panel of Fig 27. The higher doses of PAF, 30 
and 300 nM which are maximal and supra-maximal for 5-HT release, produced 
highly significant (P < 0.005) elevations in [Ca++]j, in addition to a rise in the 
concentration of lns(1,4,5)P3 (measured at 5s) and DAG (measured at 10s) (Fig 
27).
However, a lower concentration of PAF, such as 3 nM which induced 
approximately 60 percent 5-HT release and a 400 nM increase above the basal 
[Ca**]jf induced no detectable increase in either lns(1,4,5)P3 or DAG (Fig 27). 
Indeed, over a time course of 60 s no increase in lns(1,4,5)P3 levels above basal 



































































Fig 27 Effect of increasing concentrations of PAF on production of DAG, 
ins(1,4,5)P3 (upper panel), [Ca++], elevation and 5-HT release (lower panel). DAG
incubations were terminated at 10s after PAF and those for lns(1,4,5)P3 at 5s. 
5-HT release was terminated at 3 minutes after activation and [Ca++]j elevation is 
peak elevation after stimulation. The values have been obtained by subtracting 
the basal pre-PAF value from those obtained after the addition of PAF. The values 
are the mean ±  S.E.M. of at least 3 experiments.
131
Replacing [Ca ++], with the Ca++ chelator EGTA inhibited [Ca + +], elevation at all 
concentrations of PAF tested (Fig 17). At the higher concentrations of PAF, 30 
and 300 nM, and to a lesser extent 3 nM, [Ca++lj elevation was due to two 
components, the major component being dependent on extracellular Ca++, whilst 
the minor component was independent of [Ca++J.. At the lower concentration of 
0.3 nM PAF however, [Ca ++]( elevation was completely dependent on the 
presence of [Ca++J. (Fig 17).
Replacing lCa++], with the Ca+ + chelator EGTA also caused a small inhibition 
of lns(1,4,5)P3 production when examined over a 60 s time course (Fig 28). 
Removing [Ca ++]# reduced basal levels of lns(1,4,5)P3 and at 5 s after platelet 
activation with 300 nM PAF lns(1,4,5)P3 levels were 75 % of those for platelets 
in the presence of 1 mM [Ca++],. After reaching maximal, lns(1,4,5)P3 levels in 
platelets either in the presence and absence of [Ca++], declined towards basal and 
by 10 seconds after activation there was no difference between the level of 
lns(1,4,5)P3 in platelets either in the presence or absence of [Ca++], (Fig 28). In 
order to ensure that the presence of EGTA per se was having no influence on the 
lns(1,4,5)P3 binding assay, a standard curve was performed in the presence of the 
same concentration of EGTA as would be contained in experimental samples. 
There was no difference between a standard curve performed in the presence of 
EGTA compared to one performed in the absence of EGTA. This indicated that 
the presence of EGTA was not affecting the binding assay.
In relation to the findings for DAG (Fig 27), activation of PKC measured as 
phosphorylation of its 40 kDa substrate was increased dose dependency with 
increasing concentrations of PAF; 3 nM PAF induced some activation of PKC after 
30s, but again in agreement with the findings for DAG, no phosphorylation with 
0.3 nM PAF was detected (Fig 29).
These results suggest that there is a good correlation with the products of 
Ptdlns(4,5)P2 hydrolysis and Ca+ + mobilization with granule release at higher 









Fig 28 The effect of replacing [Ca++]# with 2 mM of the calcium chelator EGTA 
on lns(1,4,5)P3 production induced by 300 nM PAF. lns(1,4,5)P3 production was 
stopped at predetermined times over a one minute time course. The values are 




Fig 29 The effect of increasing concentrations of PAF on phosphorylation of the 
40 KDa substrate of PKC. (a) Autoradiograph showing phosphorylation of the 40 
KDa substrate of PKC by PAF vehicle (track 1), 0.3, 3, 30 and 300 nM PAF 
respectively (tracks 2-5) and with 100 nM TPA (track 6). Platelet activation has 
been terminated at 30s post-PAF addition. The phosphorylated PKC substrate 
band has been excised and subject to scintillation counting, and the results are 
given in (b) as a percentage of phosphorylation with PAF vehicle.
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3 .2 .3  Protein kinase C and PAF-induced platelet activation
To explore the role of endogenous activators of PKC on the regulation of PAF- 
induced formation of lns(1,4,5)P3, DAG, TxB2 and changes in Ca++ homeostasis, 
the effect of the potent PKC inhibitor staurosporine on these parameters was 
examined: 1 //M staurosporine was used as this concentration inhibits PKC 
activation by at least 70% (Fig 13).
3.2 .3 .1  lns(1,4,5)P3 and DAG
Pretreatment of the platelets with 1 /yM staurosporine did not modify the basal 
concentrations of either lns(1,4,5)P3 or DAG (Fig 30). Thus PKC does not exert a 
tonic control over these parameters in the unstimulated platelets. The effect of 
staurosporine on PAF-stimulated formation of lns(1,4,5)P3 and DAG was 
dependent upon the concentration of PAF employed. Staurosporine produced a 
two and three fold enhancement of lns(1,4,5)P3 and DAG formation respectively in 
response to 300 nM PAF (Fig 30). When 3 nM PAF was used, which alone failed 
to produce an increase of lns(1,4,5)P3 or DAG over the basal levels, pretreatment 
with staurosporine did not produce any detectable increase over this.
Pretreatment of the platelets with the PKC activator TPA (100 nM) produced a 
significant reduction in PAF-stimulated levels of lns(1,4,5)P3 and DAG (Fig 30).
The effect of 1 //M staurosporine on 300 nM PAF-induced lns(1,4,5)P3 
elevation over a 60 second time course demonstrates the transient elevation of 
lns(1,4,5)P3 both in the presence and absence of staurosporine (Fig 31a). 
Although at different levels, maximal elevation of lns(1,4,5)P3 has been reached by 
5 s both in staurosporine treated or untreated platelets after which levels of 
lns(1,4,5)P3 decline at similar rates towards basal. This may indicate that PKC is 
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Fig 30 Effect of PKC activation or inhibition on generation of DAG and 
lns(1,4,5)P3 induced by 3 nM PAF or 300 nM PAF. PKC was activated with 100 
nM 12-0-tetradecanylphorbol 13-acetate or inhibited with 1 //M staurosporine for 
two minutes prior to stimulation with PAF. DAG incubations (b) were terminated 
10s after the addition of PAF, whilst lns(1,4,5)P3 incubations (a) were terminated 
at 5s. Each value represents the mean ± S.E.M. of at least three experiments 
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Fig 31 (a) Effect of staurosporine on PAF-induced lns(1,4,5)Ps elevation over a 1 
minute time course (b) Effect of staurosporine on the maximal height and duration 
of decline of [Ca++], in platelets in the absence of [Ca++].. Platelets were 
pretreated with either 1 //M staurosporine (open circle) or staurosporine vehicle 
(closed circle) for two minutes prior to activation with 300 nM PAF. lns(1,4,5)P3 
production was terminated at predetermined times over a 1 minute time course. 
On the left of panel .(b) [Ca + +]j is the value obtained by subtracting the basal pre- 
PAF value from the peak post-PAF value and on the right the duration of the 
decline of [Ca + +]j to basal levels (t) is given as a percentage of the control. Each 




Pretreatment of platelets with 1 //M staurosporine did not modify the basal 
[Ca++], of platelets. In addition, pretreatment of platelets with staurosporine also 
had no significant effect on the rate of elevation (not shown) or the maximum 
elevation of [Ca++]i, stimulated with either 3 or 300 nM PAF (Fig 32).
Conversely, the duration of the Ca+ + signal, measured as the time taken to 
return to Vz maximum elevation above basal (t1/2), was significantly potentiated by 
staurosporine for both concentrations of PAF (Fig 32). However, the increase in 
t1/2 in platelets stimulated with 3nM PAF was only 30% in contrast to the 200%  
increase in t 1/2 observed in 300 nM stimulated platelets. Moreover, in platelets 
where the extracellular Ca+ + had been replaced by EGTA the T1/2 was also 
significantly potentiated in platelets stimulated with 300 nM PAF (Fig 31b).
At this point it is important to consider the effects of staurosporine on PAF- 
induced platelet aggregation. Pretreatment of platelets with staurosporine (60 - 
2000 nM) caused a dose dependent inhibition of PAF-induced aggregation, 
although it did not affect PAF-induced platelet shape change. At a concentration 
of 2 //M, staurosporine inhibited PAF-induced platelet aggregation by 60%, and it 
had an ICgo of 1.75 jjM (Fig 33a). It is therefore possible that the shorter duration 
of [Ca++], elevation observed in platelets not pretreated with staurosporine may be 
due to the presence of platelet aggregants, which could possibly interfere with and 
reduce the fluorescence signal and therefore the calculated duration of [Ca**], 
elevation. Conversely in staurosporine pretreated platelets removal of the 
interference of platelet aggregants would therefore increase the duration of the 
fluorescence signal. To remove this factor, the duration of [Ca++], was 
investigated in platelets which were prevented from aggregating. Prevention of 
platelet aggregation was effected either by terminating platelet stirring 10 s after 
the addition of PAF or pretreating platelets with 870 jjM of the tetrapeptide ARG 
GLY ASP SER (Fig 33b). This short peptide sequence (termed RGDS) inhibits 
cellular attachment to fibrinogen and fibronectin to the platelet GPIIb/llla complex, 
thereby inhibiting platelet aggregation (Plow et a/. 1985).
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Fig 32 Effect of staurosporine on PAF-induced [Ca++], elevation. Effect of 1 //M  
staurosporine on the peak elevation of [Ca++], is shown in the upper panel and the 
effect of 1 jjM staurosporine on the t1/2 (time for decay of elevated [Ca++lj to half 
maximal elevation over basal) is given in the lower panel, both in platelets 
stimulated with 3 nM or 300 nM PAF. [Ca++]j is the value obtained by 
subtracting the basal pre-PAF value from the peak post-PAF value. Each value 
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Fig 33 Effect of staurosporine or the tetrapeptide ARG GLY ASP SER on PAF-induced platelet aggregation. Upper 
panel, platelets were preincubated with staurosporine for two minutes prior to the addition of 0.6 nM PAF. Lower 
panel, platelets were preincubated with the tetrapeptide for two minutes prior to the addition of 3 nM PAF. Traces 
are taken from single experiments which are representative of two other similar experiments.
Inhibition of platelet aggregation either by preventing stirring or addition of RGDS 
had no effect on the duration of PAF-induced [Ca++], in platelets either pretreated 
with staurosporine or staurosporine vehicle (Fig 34).
3 .2 .3 .3  Thromboxane B2 formation
Addition of 300 nM PAF induced a rapid generation of TxB2 with maximal rate 
of production over the first 10 s after platelet stimulation and with almost 80 
percent of total release by 20 s post-PAF. At 2 minutes after PAF stimulation 
there was no further release of TxB2 (Fig 35a). Only trace amounts of TxB2 (<1  
pmol/ml) were detected after platelet activation with either 0.3 or 3nM PAF, and 
these levels were not affected by staurosporine (Fig 35b). However, at higher 
concentrations of PAF (30-300nM) there was a dose dependent increase in the 
TxB2 generated and this was potentiated at least 2-fold with staurosporine (Fig 
35b).
To determine whether the staurosporine-enhanced TxA2 formation was 
responsible for (a) the potentiation in the duration of elevated [Ca++], (see Fig 32) 
or (b) the increased formation of DAG (see Fig 30), the effect of indomethacin on 
these systems was examined (Fig 36). Pretreatment of the platelets with 2.8 //M  
indomethacin, which caused >99%  inhibition of TxB2 formation (see Fig 9), had 
no significant (p>0.05) effect on either basal levels of [Ca**], (Fig 36a) or DAG 
(Fig 36b & c). PAF-induced or staurosporine-enhanced duration of the [Ca ++]j 
























Fig 34 Effect of inhibiting platelet aggregation on the rate of decline of [Ca+ + 1, in 
PAF-stimulated platelets either in the presence or absence of staurosporine.
Platelet aggregation was either not prevented (a) or was prevented by either 
stopping platelet stirring 10 s after PAF addition (b) or by the addition of 870 /yM 
ARG GLY ASP SER (c). Platelets were pretreated with 1 /yM staurosporine or 
staurosporine vehicle two minutes prior to platelet activation with 3 nM PAF. The 
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Fig 35 Time course of TxB2 generation and the effect of 1 //M  staurosporine on 
PAF-induced TxB2 generation, (a) TxB2 generation induced by 300 nM PAF over a 
three minute time course, (b) The effect of a 2 minute pre-incubation with 
staurosporine on TxB2 generation induced PAF (0.3, 3, 30 & 300 nM) was 
determined at 3 minutes post-PAF. The points represent the mean +_ S.E.M. of 3 
experiments each performed in triplicate.
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Fig 36 The effect of 2.8 jjM  indomethacin on DAG generation and the t1/2 of 
[Ca**]j in the presence and absence of staurosporine. Platelets either in the 
presence or absence of 2.8 jjM  indomethacin were pretreated with either 1 / j M  
staurosporine or staurosporine vehicle for two minutes prior to stimulation with 
300 nM PAF. Upper panel, the effect of indomethacin on PAF-induced DAG 
elevation, measured 10 s post-PAF stimulation. Middle panel, autoradiographies 
demonstrating the effect of 2.8 //M indomethacin on PAF-induced DAG production 
(after conversion to [32]P-Phosphatidic acid) either in the presence or absence of 
staurosporine. Lower panel, the effect of indomethacin on the t1/2 of [Ca + + ]j in 
PAF-stimulated platelets either in the presence or absence of 1 //M  staurosporine. 
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3 .3  Investigation of the ro/e of endogenously activated PKC in platelet functional 
responses using selective inhibitors of PKC.
Staurosporine has been widely used to investigate the role of PKC in many 
different cell types. However, although it is a potent protein kinase inhibitor it is 
not selective for PKC. During the course of this study inhibitors of PKC which are 
both potent and selective were developed. Therefore, it was important to look at 
the effects of these inhibitors on platelet functional responses in order to assess 
the role of endogenously activated PKC in platelets where other kinases were not 
being inhibited and also to compare the results with the findings we and others 
have obtained when using staurosporine. The structures of the four PKC inhibitors 
staurosporine (Tamaoki et ai. 1986), calphostin C (Kobayashi et ai. 1989) and 
Roche 31-7549/001 and 31-8220/002 (Davis et ai. 1989) are given in Fig 37.
3.3.1 Calphostin C
A 20 minute preincubation of platelets with the selective PKC inhibitor 
calphostin C inhibited 300 nM PAF-induced phosphorylation of the 40-47 kDa 
major PKC substrate dose dependency with an IC60 of 1 //M (Fig 38).
In contrast to staurosporine (see Figs 14 & 16) calphostin C caused a dose 
dependent inhibition of both [Ca**], elevation and TxB2 generation in platelets 
stimulated with PAF (Fig 38). However, in common with staurosporine (see Fig 
23b), calphostin C inhibited 5-HT release in PAF-stimulated platelets (Fig 39). 
Calphostin C caused inhibition of both ionomycin-induced TxB2 generation and 5- 
HT release similar to the results obtained with staurosporine in ionomycin 
stimulated platelets (Fig 40).
3.3 .2  Ro 31-7549/001 and Ro 31-8220/002
A 20 minute pre-incubation with the selective PKC inhibitors Ro 31-7549/001  
and Ro 31-8220/002 inhibited 300 nM PAF-induced phosphorylation of the 40-47 
KDa major PKC substrate in a dose dependent manner (Fig 41). Ro 31-7549/001 
inhibited phosphorylation with an IC50 of 2.5 jl/M whilst Ro 31-8220/002 inhibited 












Ro 31-7549/001 R = (CH2)3NH2
Ro 31-8220/002 R = (CH2)SC( = NH)NH2
Fig 37 The structures of the 4  PKC inhibitors staurosporine, calphostin C, Ro 31- 
7549/001 and Ro 31-8220/002.
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\[Calphostin C] (nM )
Fig 38 The effect of calphostin C on PAF-induced phosphorylation of the 40 kDa 
substrate of PKC. (Right panel) Autoradiograph showing phosphorylation of 
platelet proteins. Track 1, resting platelets; track 2, 300 nM PAF stimulated 
platelets; tracks 3-6 respectively, platelets pretreated for 20 minutes with 100, 
300, 1000 and 3000 nM calphostin C and then stimulated with 300 nM PAF. 
The phosphorylated PKC substrate was excised and subjected to scintillation 
counting and the results are given in the left panel as a percentage of the 
phosphorylation in the presence of 300 nM PAF. The autoradiography shown is 
representative of four individual experiments and the data are the mean values 
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Fig 39 The effect of calphostin C on PAF-induced [Ca++], elevation, 5-HT release 
and TxB2 generation. Platelets were preincubated with calphostin C for 20 
minutes prior to PAF stimulation. [Ca++]j elevation (upper panel) is the peak 
elevation induced by 3 nM PAF after subtracting the basal pre-PAF value. 5-HT 
release induced by 3 nM PAF (middle panel) and TxB2 generation induced by 30 
nM PAF (lower panel) were terminated 3 minutes after the addition of PAF. Each 


























Fig 40 The effect of calphostin C on 5 //M  ionomycin-induced 5-HT release and 
TxB2 generation. Platelets were pre-treated with calphostin C for 20 minutes 
before stimulation with 5 //M ionomycin. 5-HT release (upper panel) and TxB2 
generation (lower panel) were terminated 3 minutes after ionomycin-induced 
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Fig 41 Inhibition of PAF-induced phosphorylation of the 40-47 kDa substrate of 
PKC by Ro 31-7549/001 (upper panel) and Ro 31-8220/002 (lower panel). The
right side of the panels are autoradiographs representing phosphorylation in resting 
platelets (track 1), 300 nM PAF-induced platelet phosphorylation in the presence 
of the respective PKC inhibitor vehicle (track 2), and a 20 minute pre-incubation 
with either 0.3,1,3,10 //M Ro 31-7549/001 (upper panel) or 0.1,0.3,1,3 pM Ro 
31-8220/002 (lower panel) followed by 300 nM PAF stimulation for 30 seconds 
(tracks 3-6 respectively). Phosphorylation was quantified by scintillation counting 
of the excised [32P]Pj labelled substrate. The results are given on the left of each 
panel as a percentage of phosphorylation induced by 300 nM PAF. Each point is 
the mean ± S.E. of three separate experiments.
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3.3 .3  Effect of PKC inhibition by Ro 31-7549/001 and Ro 31-8220/002 on PAF- 
induced functional responses
3.3.3.1 [Ca**], elevation
The effect of inhibition of PKC on [Ca + +], elevation was investigated using 
both submaximal (3 nM} and maximal (300 nM) PAF-stimulated platelets (Fig 42). 
10 //M of Ro 31-7549-001 and 3 //M of Ro 31-8220-002 were used as these 
concentrations were found to inhibit PKC activation by > 90%  (see Fig 41). 
Pretreatment with either Ro 31-7549/001 or Ro 31-8220'002 for 20 minutes had 
no effect on maximal height of [Ca ++]j elevation induced by either 3 or 300 nM 
PAF however, both inhibitors significantly increased the duration of the Ca+ + 
signal (Fig 42). Moreover, whereas in 300 nM PAF stimulated platelets inhibition 
of PKC caused 180% increase in duration of the Ca++ signal, it only caused about 
a 50% increase with 3 nM PAF (Fig 42). These findings were comparable to 
those found when using staurosporine to inhibit PKC (see Fig 32).
3.3.3.2 Reversal of TPA-induced PKC activation by using Ro 31-7549/001 and Ro 
31-8220/002
The ability of the PKC inhibitors to abrogate the effect of PKC activation was 
studied by investigating their ability to reverse the effect of the PKC activator TPA 
on PAF induced [Ca++li elevation (Fig 43). Activation of PKC with 30 nM TPA 
inhibited [Ca++]j elevation (Fig 43) in PAF-stimulated platelets. A 20 minute pre­



























Fig 42 Effect of the Roche compounds on maximal [Ca++], elevation and on the 
duration of [Ca++], elevation in 3 and 300 nM PAF stimulation platelets. Platelets 
were incubated with either 10 jt/M Ro 31-7549/001 or 3 //M  Ro 31-8220/002 or 
their appropriate vehicle (< 0 .1%  DMSO) 20 minutes prior to the addition of PAF. 
[Ca++]j is the maximal elevation in cytosolic calcium after subtracting the basal 
pre-PAF value. T 1/2 is the time for calcium to decline to 1/2 maximal above basal 
levels. Results are expressed as a % of the control t1/2. The values are the means 
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Fig 43 Abrogation of TPA-induced inhibition of [Ca++], elevation by Ro 31- 
7549/001 (a) or Ro 31-8220/002 (b). Platelets were pretreated with the PKC 
inhibitors or vehicle 20 minutes before addition of the PKC activator TPA (30 nM) 
which was incubated for 2 minutes before stimulation with 3 nM PAF. [Ca++]j is 
the value obtained by subtracting the basal pre-PAF value from the maximal post- 
PAF value. Data is from 3 separate experiments each performed in triplicate.
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3.3 .3 .3  TxB2 generation
Using 10 //M Ro 31-7549/001 and 3 //M Ro 31-8220/002 (concentrations 
which inhibited PKC substrate phosphorylation by >90% ) the effect of inhibition 
of PKC on TxB2 generation was investigated in platelets stimulated with 30 nM 
PAF (Fig 44). Both PKC inhibitors caused a 3 - 5 fold potentiation of TxB2 
generation induced by 30 nM PAF. Similarly to the results for [Ca + +]j elevation, 
inhibition of TxB2 generation by TPA was abrogated by the PKC inhibitors (Fig 44). 
These findings indicate that the inhibition of [Ca + +]j elevation and TxB2 generation 
by TPA in PAF stimulated platelets is mediated by PKC and can be reversed by 
pretreatment with either PKC inhibitor.
3.3.3 .4  5-HT release
5-HT release induced by 3 nM PAF was dose-dependently inhibited when 
platelets were subjected to a 20 minute pretreatment with increasing 
concentrations of Ro 31-7549/001 (0.3,1,3,10 //M) or Ro 31-8220/002  
(0.1,0.3,1,3 jjM ) .  The IC60 for Ro 31-7549/001 was 4.7 //M whilst for Ro 31- 
8220/002 it was 0.55 //M (Fig 45).
3.3 .3 .5  Aggregation
Aggregation of platelets induced by a submaximal concentration of PAF (1 
nM) was dose-dependently inhibited with increasing concentrations of either PKC 
inhibitor, with almost total inhibition of platelet aggregation at 10 /sM Ro 31- 
7549/001 or 3 //M Ro 31-8220/002. The IC50 for Ro 31-7549/001 was 1.8 //M  
whilst for Ro 31-8220/002 it was 0.47 //M (Fig 46). The PKC inhibitors did not 
however affect 1 nM PAF-induced shape change in platelets.
Table 4 is a summary of the effects of the different inhibitors of PKC, namely 
staurosporine, Ro 31/7549-001, Ro 31/8220-002 and calphostin C on PAF- 
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Fig 44  The effect of 10 fiM  Ro 31-7549/001 or 3 /iM  Ro 31-8220/002 on TxB2 
generation in 30 nM PAF-stimulated platelets and the abrogation of TPA-induced 
inhibition of TxB2 generation by each of the PKC inhibitors. Platelets were 
pretreated with the PKC inhibitors or vehicle 20 minutes before the addition of the 
PKC activator TPA (30 nM) which was incubated for 2 minutes prior to 
stimulation with 30 nM PAF. TxB2 generation was measured at 3 minutes post- 
PAF. Ro 31-7549/001 and Ro 31-8220/002 are abbreviated to -001 and -002  
respectively in the figure. Control = platelets stimulated with 30 nM PAF. The 
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Fig 45 The effect of the PKC inhibitors on dense granule release induced by PAF. 
Platelets were treated for 20 minutes with Ro 31-7549/001 (upper panel) or Ro 
31-8220/002 (lower panel) prior to activation with 3 nM PAF. The % 5-HT 
release induced by the highest concentration of each PKC inhibitor alone is shown 
as the closed square in each panel, whilst the effect of the PKC inhibitor vehicle 
on 3 nM PAF-induced granule release is shown as the closed circle and the closed 
triangle for Ro 31-7549/001 and Ro 31-8220/002 respectively. Dense granule 
release was terminated 3 minutes after the addition of PAF. The values are the 




















-001 = Ro-31 /7549-001
0*3 pM 
-001vehicle
1 nM PAF 1nM PAF 1 nM PAF 1 nM PAF 1 nM PAF
-0 0 2  =ro-3 1 /8 2 2 0 -0 0 2
2 minutes
vehicle
1 nM PAF1 nM PAF1 nM PAF1 nM PAF1 nM PAF
Fig 46 Traces showing the effect of PKC inhibition on PAF-induced platelet shape change and aggregation.
Platelets were pretreated for 20 minutes with either Ro 31-7549/001 (top panel) or Ro 31-8220/002 (lower 
panel). The traces are taken from a single experiment but are representative of two other similar experiments.
ICgo values
4 0  kDa substrate fold Increase fold increase aggregation
phosphorylation in [Ca++], T 1/2 in TxB2
Staurosporine 0 .5  J/M 200 % *  200  % *(1  //M) I
Ro 31 /7 549 -001  2 .5  //M 200 %  *  210  %  * (1 0  //M) 1
Ro 31 /82 20 -001  0 .4 5  j/M  180 % *  3 00  %  * (3  //M ) I
Calphostin C 1 .0 //M  I  1
*  the concentration of inhibitor to give this fold increase in [Ca++], T 1/2 and TxB2 generation.
Table 4  Summary of the effects of the four PKC inhibitors staurosporine, Ro 3 1 /7 5 4 9 -0 0 1 , Ro 3 1 /8 2 20 -0 0 2  and 
calphostin C on PAF-induced PKC substrate phosphorylation, duration of [Ca++], and TxB2 generation.
3.4  Development of the technique of Western Blotting
Several different techniques were explored in order to determine optimal 
conditions for Western blotting (see section 2.3.13.3). These included finding an 
optimal time for transferring protein from the SDS gel to the nitrocellulose, and 
optimal conditions for blocking the non-specific binding sites on the nitrocellulose. 
In order to determine the conditions which would give the clearest results for the 
Western blots, it was also necessary to find the best length of time for incubating 
with the primary and secondary antibodies and the optimal concentrations at 
which to use them. The washing procedure used to remove antibody which was 
not specifically bound to the Western blot was also investigated. In addition 
several methods reported to enhance detection of the antigen of interest were 
investigated, and it was found that using peroxidase anti-peroxidase antibody 
enhanced the 'signal' for the antigen. Having determined optimal conditions in 
which to perform Western blotting this technique was then used to determine the 
presence of a number of different annexins in platelets and also to investigate 
tyrosine kinase activity using an anti-phosphotyrosine antibody.
3 .5  Identification and location of annexin isoforms in human platelets
The finding that inhibition of PKC with staurosporine caused potentiation of 
TxB2 generation whilst PKC activation caused inhibition suggested that PKC may 
be one of the factors responsible for regulating PLA2. It has previously been 
demonstrated that annexins are inhibitors of PLA2 and it is possible that, if present 
in platelets, they may be controlled by protein kinases and be responsible for 
regulating PLA2 activation. In this study the presence of annexins I,II,IV and V in 
human platelets was determined by Western blotting. Human platelets as opposed 
to rabbit platelets were used, as the antibodies available to annexins do not cross- 
react with rabbit.
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3.5.1 Identification of the annexins present in platelets
The presence of annexins 1,11,1V and V in platelets and U937 cells was 
determined by Western blotting (Fig 47). Using the polyclonal antibody against 
whole recombinant annexin I and against amino acids 1-188 of annexin I, it was 
identified as a 36 kDa protein in both platelets and U937 cells. Probing with 
antibodies against smaller sequences of annexin I (amino acids 24-37 and 38-50), 
however revealed higher molecular weight species of 70 kDa and 55 kDa 
respectively in platelets, whilst remaining at 36 kDa in U937 cells. The antibody 
to annexin II also revealed a higher molecular weight species of 68 kDa in platelets 
compared to U937 cells where annexin II had an apparent molecular weight of 35 
kDa. Annexin IV was not detected in either total platelet lysates or U937 cell 
lysates, whilst annexin V appeared in both as a protein of 32 kDa molecular 
weight. Moreover in U937 cells (which had been pretreated with TPA see section 
2.2.13.5.3) anti-annexin I antibody detected a doublet of 36 kDa and 32 kDa, 
whilst anti-annexin V antibody detected a doublet of 32 kDa and 29 kDa. In 
untreated platelets however the lower molecular band (of the doublet seen in 
U937 cells) was either missing or gave a much weaker signal than seen for U937 
cells (Fig 47).
3.5.2 The location of annexins in platelets
In order to determine whether annexins I,II and V were located on the external 
surface of the plasma membrane, platelets were washed with EGTA which by 
chelating Ca+ + should release the annexins since they bind to phospholipids in a 
Ca+ + dependent manner. No annexin (I,II or V) was released by EGTA (Fig 48) 
suggesting that either they are not located on the outer surface of the plasma 
membrane, or that the membrane association is not Ca+ + sensitive.
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Fig 47 Western blot for annexins I, II, IV and V in total protein from transformed 
U937 cell lysates (left lane of panels) and platelet lysates (right lanes of panels).
Proteins were separated on a one dimensional 10 % polyacrylamide SDS gel. 
Panels 1 to 4 respectively were probed for annexin I using four different anti­
peptides to annexin I (amino acids 1-188; whole peptide; amino acids 24-37; 
amino acids 38-50 respectively). Panels 5,6 and 7 were probed for annexins II, IV 
and V respectively, whilst panel 8 has been probed using an antivinculin antibody 






Fig 48 Western blots for annexins I, II and V of proteins associated with the 
external surface of the plasma membrane and released with EGTA. Panels 1,2 
and 3 are Western blots for annexins I, II and V respectively. The left lane of 
each panel is annexin in total platelet lysates, the middle lane of each panel is 
annexin released from the surface of the plasma membrane by 5 mM EGTA/ 5 mM 
EDTA and the right lane is the annexin contained in the platelet pellet after 
removing any EGTA releasable external surface bound annexin. Anti-annexin 
antibodies were used at the concentrations described in section 2.2.13.1. Goat 
anti-rabbit IgG (H + L) horseradish peroxidase conjugate was used as the 2° 
antibody. The blots are representative of three separate experiments.
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Activation of platelets with the receptor operated agonists PAF (300 nM) and 
thrombin (0.3 unit/ml), or the divalent cation ionophore, ionomycin (5 //M) caused 
between 40%  and 70% of dense granule release, whilst the PKC activator TPA 
caused only a small amount of release (Fig 50). The supernatant and the 
remaining platelet pellet were then probed by Western blotting for annexins Ml and 
V (Fig 49). Western blotting of the platelet supernatant and the remaining platelet 
pellet showed that neither the platelet activators nor the PKC activator caused 
release of annexins 1,11 or V into the supernatant suggesting that they are not 
located within dense granules in platelets. Platelet activation however, caused 
some degradation of annexin I to a lower molecular weight of 32 KDa which was 
most noticeable in platelets stimulated with ionomycin (Fig 49).
The whole annexin I peptide was used as a standard and is shown in Fig 49 
(panel 1, track A) as a protein of 36 kDa. A final concentration of around 5 ng of 
the annexin 1 protein was added to the lane which gives an indication of the 
sensitivity of this Western blotting method.
3.5 .3  The use of ELISA for determining the location of annexin 1
Using the ELISA method the concentration of annexin I contained in total 
platelet lysates, was found to be around 10 ng/109 platelets. No significant 
amount of annexin I (<0.1  ng/108 platelets) was released from the surface of 
platelets upon washing with the Ca++ chelators EGTA/EDTA.
The ELISA detection system was also used to investigate for the release of 
annexin I from the dense granules upon platelet stimulation with various platelet 
activators. Using ELISA the amount of annexin I released from platelets 
stimulated with PAF (300 nM), thrombin (0.3 units/ml), ionomycin (5 //M) or TPA 
(100 nM) was found to be < 0 .2  ng/108 platelets despite the fact that these 






Fig 49 Western blots of the granule \releasate from activated platelets for 
annexins I, II and V. Panels 1,2 and 3 are Western blots probed for annexins I 
(amino acids 1-188), II and V respectively. Track A is annexin in total protein 
from unstimulated platelets (in panel 1 the annexin I peptide (5 ng) was run on the 
left side of track A as a control). Tracks B to E are granule releasate on the left 
with the remaining platelet pellet on the right for platelets stimulated with 300 nM 
PAF (track B), 0.3 units/ml thrombin (track C), 5 //M ionomycin (track D) and 100 
nM TPA (track E). Anti-annexin antibodies are used at the concentrations 























Fig 50 Comparison of 14C-5HT release and of annexin I release in platelets treated 
with either PAF, thrombin, ionomycin or TPA. In column 1 is the total annexin 1 
detected by ELISA in the total lysate of 109 platelets. Column 2 represents the 
annexin 1 detected in the supernatant of 10® platelets which had been treated 
with 5 mM EGTA/5 mM EDTA to remove external surface bound EGTA/EDTA 
releasable proteins, track 3 is the annexin 1 in the remaining platelet pellet after 
the treatment described for column 2. The four groups of columns numbered 4-7 
are annexin I release (left column) and dense granule release (shown as % 5-HT 
release) (right column) of platelets stimulated with 300 nM PAF (group 4), 0.3 
units/ml thrombin (group 5), 5 //M ionomycin (group 6) and 100 nM TPA (group 
7). The values are determined from three different experiments each performed in 






It is possible that glucocorticosteroids (which induce the synthesis of annexin 
1 in some nucleated cell types) may have another role and induce release of 
annexins. However, the introduction of 1 pM of the glucocorticoid steroid 
dexamethasone for 60 minutes had no effect on release of annexins, either in non­
stimulated platelets or in platelets stimulated with ionomycin (results not shown).
3 .6  Characterisation of tyrosine phosphorylation of proteins in PAF-stimuiated 
platelets and the investigation of the rote of endogenously activated tyrosine 
kinasefs) in the signal transduction pathway using the tyrosine kinase inhibitor 
genistein.
The presence of protein tyrosine kinase(s) (PTKase) in terminally differentiated 
cells such as platelets has only been recognised relatively recently. Their role is 
usually associated with cell growth and proliferation, however in platelets due to 
the rapidity of tyrosine phosphorylation upon receptor-agonist coupling it is 
possible that they have a role in signal transduction unrelated to proliferation.
3.6.1 PAF-induced tyrosine phosphorylation in intact platelets
Western blotting using the monoclonal anti-phosphotyrosine antibody (PY20) 
(Glenney et al. 1988) detected at least 4 tyrosine phosphorylated proteins between 
the molecular weights of 52 - 62 kDa in unstimulated platelets (Fig 51). Within 5 
seconds of platelet stimulation with 300 nM PAF phosphorylation of two groups 
of proteins between the molecular weight ranges 35 - 45 kDa and 66 - 90 kDa 
was induced. Within 30 seconds after 300 nM PAF stimulation a third molecular 
weight range of tyrosine phosphorylated proteins between 90 - 150 kDa was 
detected. It appears therefore that there are three sets of phosphorylation, firstly, 
tyrosine phosphorylation in unstimulated platelets (mw 52 - 62 kDa), secondly, 
tyrosine phosphorylation 2 - 5 seconds after PAF stimulation (mw 35 - 45 kDa 
and 66 - 90 kDa) and thirdly tyrosine phosphorylation 1 5 - 3 0  seconds after PAF 
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Fig 51 Time course of PAF-induced tyrosine phosphorylation in intact platelets.
Western blot of tyrosine phosphorylated proteins from platelets stimulated with 
300 nM PAF over a 5 minute time course. Platelet proteins were separated on a 
one dimensional 9.5% polyacrylamide SDS gel. A 1:500 dilution of anti- 
phosphotyrosine (PY20) monoclonal antibody was used as the 1° antibody, a 
1:500 dilution of goat anti-mouse IgG horseradish peroxidase conjugate was used 
as the 2° antibody and the blots were enhanced using a 1:10,000 dilution of 
peroxidase anti-peroxidase antibody (mouse). The blot shown is representative of 
4 similar experiments.
169
At least 17 tyrosine phosphorylated proteins were detected by Western blotting 
using the monoclonal anti-phosphotyrosine antibody PY20, however, as this 
system used a one dimensional SDS gel, tyrosine phosphorylation of proteins of 
the same molecular weight were not differentiated from each other, and therefore 
the total number of tyrosine phosphorylated proteins could be higher.
Comparing the total relative optical density of each of the four groups of 
tyrosine phosphorylated proteins over a two minute time course (Fig 52} the 
phosphorylation and dephosphorylation patterns of each group can be examined. 
300 nM PAF-stimulation caused a noticeable dephosphorylation of the group of 
proteins (52-62 kDa) originally detected in non-stimulated platelets. However, 
over the two minute time course the proteins returned to their original level of 
phosphorylation. The two groups of proteins 35-45 kDa and 66-90 kDa were 
rapidly phosphorylated upon PAF-stimulation followed in both groups by a degree 
of dephosphorylation. In the group of proteins 90-150 kDa examination of the 
total relative optical density demonstrated a lag phase before phosphorylation 
could be detected, after which there was rapid phosphorylation followed by a 
plateau phase.
3.6 .2  Validation o f the technique for detection of phosphotyrosine
It was important to confirm that the proteins being detected on the Western 
blots were tyrosine phosphorylated and not serine or threonine phosphorylated. 
As demonstrated in Fig 53 excess phosphotyrosine (1mM) added to the primary 
antibody incubation (ie anti-phosphotyrosine antibody) completely blocked the anti- 
phosphotyrosine antibody (PY20) from binding to tyrosine phosphorylated proteins 
induced by PAF over a 5 minute time course. Conversely addition of 1 mM 
phosphoserine and 1 mM phosphothreonine had no effect on the phosphorylation 
pattern induced by PAF over a 5 minute time course when compared to Fig 51. 
These results strongly suggest that all the protein bands detected using PY20 are 






mw 6 6 -9 0  kDa
mw 5 2 -6 2  kDa
A* A
30 60 90 120
Time (seconds)
Fig 52 Optical densitometry of PAF-induced tyrosine phosphorylation in intact 
platelets over a five minute time course. The Western blots of the time course of 
tyrosine phosphorylation in 300 nM PAF stimulated platelets were scanned by 
optical densitometry. Each of the four figures represents the sum of the relative 
optical densities of all the proteins contained in one of the four different groups of 
proteins detected either in unstimulated platelets (52-62 kDa) or detected upon 
platelet activation with 300 nM PAF (35-45 kDa; 66-90 kDa; 90-150 kDa) over a 
two minute time couse. The data are taken from one experiment which is 
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Fig 53 Effect of free phosphotyrosine (a) or free phosphoserine/phosphothreonine 
(b) on binding of antiphosphotyrosine antibody to nitrocellulose bound tyrosine 
phosphorylated proteins. Both the Western blots (a) and (b) were performed using 
the same protein samples representing a 5 minute time course after platelet 
stimulation with 300 nM PAF. Conditions were as described in Fig 51, except 
incubation with the 1° antibody was carried out in the presence of either 1 mM 
phosphotyrosine (a) or 1 mM phosphoserine and 1 mM phosphothreonine (b). 
Each blot shown is representative of 2 similar experiments.
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3.6 .3  Dose response relationship of PAF-induced tyrosine kinase phosphorylation 
Increasing concentrations of PAF (0.3 * 300 nM) caused a dose dependent 
increase in phosphorylation of PTKase substrates (Fig 54) when measured at 30 
seconds after PAF-induced platelet activation.
3.6 .4  Effect of genistein on tyrosine kinase activity
The effect of genistein on PTKase activity was determined by investigating the 
effect of genistein on phosphorylation of the substrates of PTKase (Fig 55). 
Platelets were pretreated with a range of concentrations of genistein for 20 
minutes before activation with 300 nM PAF. Genistein (300 pM) alone had no 
effect on tyrosine phosphorylation of the substrates of PTKase normally found in 
unstimulated platelets. Genistein (30 - 1000 //M) did however dose dependency 
inhibit tyrosine phosphorylation of several of the protein substrates of PTKase(s) 
whose phosphorylation was induced by 300 nM PAF. The most noticeable 
inhibition by genistein were the groups of proteins of the molecular weight ranges 
35 - 45 kDa and 68 - 90 kDa. Genistein had less effect on phosphorylation of the 
proteins of the 90 - 150 kDa molecular weight range. It was possible to examine 
the extent to which phosphorylation of each of the 17 tyrosine phosphorylated 
proteins detected was inhibited by genistein with the use of relative optical 
densitometry (Fig 56). Scanning the Western blot demonstrated that at a 
concentration of 300 //M genistein phosphorylation of the proteins in the groups 
35-45kDa and 66-90 kDa had been inhibited by 90% , whilst phosphorylation of 
proteins in the group 90-150 kDa had been inhibited to a lesser extent of 50%. 
The tyrosine phosphorylated proteins which were first observed in unstimulated 
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Fig 54 Effect of increasing concentrations of PAF on tyrosine phosphorylation.
Platelets were stimulated with 0, 0.3, 3, 30 and 300 nM PAF and activation 
terminated at 30 seconds post-PAF. Platelet proteins were separated on a one 
dimensional 9.5% polyacrylamide SDS gel. A 1:500 dilution of anti- 
phosphotyrosine (PY20) monoclonal antibody was used as the 1° antibody, a 
1:500 dilution of goat anti-mouse IgG horseradish peroxidase conjugate was used 
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Fig 55 The effect of genistein on PAF-induced tyrosine phosphorylation. Platelets 
were pretreated with either genistein (30, 100, 300, 1000 /yM) or genistein 
vehicle for 20 minutes prior to platelet activation with 300 nM PAF. Platelet 
activation was terminated at 30 seconds post-PAF. In both panels platelet 
proteins were separated on a one dimensional 9.5% polyacrylamide SDS gel. In 
the upper panel a 1:500 dilution of anti-phosphotyrosine (PY20) monoclonal 
antibody was used as the 1° antibody, a 1:500 dilution of goat anti-mouse IgG 
horseradish peroxidase conjugate was used as the 2° antibody and the blots were 
enhanced using a 1:10,000 dilution of peroxidase anti-peroxidase antibody. In 
panel (b) a 1:500 dilution of antiphosphotyrosine polyclonal antibody was used as 
the 1° antibody whilst a 1:500 dilution of goat anti-rabbit IgG horse radish 
peroxidase conjugate was used as the 2° antibody, and the blot enhanced using a 
1:10,000 dilution of peroxidase anti-peroxidase antibody. Each Western blot 
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Fig 56 Densitometry of the tyrosine phosphorylated proteins in platelets 
pretreated with genistein. Western blots (probed using monoclonal anti- 
phosphotyrosine antibody) demonstrating the effect of a dose range of genistein 
on tyrosine phosphorylation (as described in Fig 48) were scanned by optical 
densitometry. Each of the four figures represents the sum of the relative optical 
densities of all the proteins contained in one of the four different groups of 
proteins detected either in unstimulated platelets (52-62 kDa) or detected upon 
platelet activation with 300 nM PAF (35-45 kDa; 66-90 kDa; 90-150 kDa).
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3.6 .5  The use of a polyclonal anti-phosphotyrosine antibody
It was also important to consider the possibility that a polyclonal anti-
phosphotyrosine antibody would have a more inclusive recognition of all 
phosphotyrosine containing proteins than a monoclonal antibody. The polyclonal 
preparation by definition, a family of antibodies may recognise more
phosphotyrosine containing proteins than a monoclonal, particularly when the 
amino acid sequence in the vicinity of the phosphotyrosine influences the 
immunoreactivity of the epitope itself. However, using a polyclonal anti-
phosphotyrosine antibody, the same number of tyrosine phosphorylated proteins 
were detected in total platelet proteins as when using the monoclonal anti- 
phosphotyrosine antibody and genistein inhibited phosphorylation of the same
molecular weight protein bands (Fig 55). The only difference in the Western blots
probed using either a monoclonal or a polyclonal anti-phosphotyrosine antibody 
was that the relative density of some of the proteins varied with the antibody 
used. The pattern of genistein inhibition of tyrosine phosphorylated proteins was 
similar in Western blots probed with the monoclonal antibody or the polyclonal 
antibody as is shown in Fig 55.
3.6 .6  Effect of genistein on PAF induced signal molecule elevation and platelet 
functional responses
Using the range of concentrations of genistein which inhibited PTKase(s), the 
effect of preincubation with genistein on signal molecule production and platelet 
functional responses induced by PAF were investigated.
177
3.6.6.1 Effect of Genistein on lns(1,4,5)P3 production
A 20 minute preincubation with genistein (300 /sM) had no effect on the basal 
level of lns(1,4,5)P3 which was 8.5 pmol/109 platelets (Fig 57). The effect of 
inhibition of PTKase(s) was investigated on lns(1,4,5)P3 levels in platelets 5 
seconds after stimulation with 300 nM PAF as at this time after PAF stimulation 
lns(1,4,5)P3 levels were known to be significantly elevated above basal (see Fig 
26). Increasing concentrations of genistein caused a dose dependent inhibition of 
lns(1,4,5)P3 elevation, with 300 pM genistein completely inhibiting any elevation 
of lns(1,4f5)P3 above basal. The ICB0 for inhibition of lns(1,4,5)P3 elevation with 
genistein was 80 pM.
3.6.6.2 Effect of Genistein on fCa*+], elevation
As lns(1,4,5)P3 is believed to be the signal molecule which is responsible for 
release of Ca++ from intracellular stores, the effect of genistein on Ca+ + 
mobilization from intracellular stores was investigated.
For these experiments platelets were loaded with the fluorescent dye fluo-3- 
AM instead of fura-2-AM, as initial experiments indicated that genistein was 
interfering with the fluorescence signal at the wavelengths required to measure 
emission of fura-2 fluorescence. In the presence of 1 mM [Ca++] the fluorescence 
signal from fura-2 free acid but not fluo-3 free acid was reduced by the addition of 
genistein.
To investigate the effect of genistein on Ca++ mobilization from intracellular 
stores platelets were suspended in HBT where the [Ca++], had been replaced by 2 
mM of the Ca++ chelator EGTA (Fig 58). Stimulation of platelets with 3 nM PAF 
caused a transient increase of [Ca + +]j above basal due to release of Ca++ from the 
intracellular stores. Pretreatment with genistein had no effect on basal levels of 
[Ca++]jf but as with lns(1,4,5)P3 elevation caused a dose dependent inhibition of 
[Ca++]j mobilization induced by PAF with an IC50 of 120 //M , similar to that found 
for the inhibition of lns(1,4,5)P3 by genistein.
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Fig 57 Effect of genistein on the basal level of Ins (1,4,5)P, or PAF-induced 
lns(1,4#5)P3 elevation. Platelets were pre-treated with either genistein vehicle or 
genistein (30, 100, 300 //M) for 20 minutes prior to activation with 300 nM PAF. 
Platelet activation was terminated at 5 seconds post-PAF. The values are the 
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Fig 58 Effect of genistein on 3 nM PAF-induced [Ca++]| elevation in platelets in 
the presence of 1 mM EGTA. Platelets were pretreated for 20 mins with genistein 
vehicle or genistein before activation with 3 nM PAF. Left: fluorescent output 
from fluo-3 loaded platelets. Right: fluorescence has been converted to [Ca++]f. 
[Ca + +]j is the peak elevation of cytosolic calcium in fluo-3 loaded platelets after 
the basal pre-PAF value has been subtracted. The traces are taken from a single 
experiment and the data for the right figure are the mean _+ S.E. of three separate 
experiments each performed in triplicate.
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The effect of inhibiting PTKase(s) on both components of [Ca + +], elevation, 
namely Ca++ influx and Ca++ mobilization from intracellular stores in platelets 
stimulated with 3 nM PAF was investigated in the presence of 1 mM [Ca++].. 
Stimulation of platelets with 3 nM PAF induced a transient increase in [Ca++lj 
above basal levels. Genistein (300//M) had no effect on basal levels of [Ca++]„ 
but pre-incubation with a dose range of genistein from 10-300 //M caused a dose 
dependent inhibition of [Ca**], elevation induced by 3 nM PAF, with almost 
complete inhibition of [Ca**]{ elevation in platelets pretreated with 300 //M  
genistein (Fig 59). The IC60 for the inhibition of [Ca ++], elevation induced by 3 nM 
PAF in the presence of 1 mM [Ca++]. was 100 //M genistein. It therefore appears 
that genistein is inhibiting both Ca+ + mobilization from intracellular stores, and 
influx of Ca+ + across the plasma membrane.
In platelets stimulated with 0.3 nM PAF [Ca++], elevation is due solely to Ca+ + 
influx and not Ca++ mobilization (see Fig 17). Therefore in order to further 
establish whether the influx component of [Ca**], was also inhibited by genistein, 
the effect of genistein on [Ca++], was investigated in platelets stimulated with 0.3 
nM PAF. Pre-activation of platelets with a dose range of genistein from 30 - 300 
jjM  caused a dose dependent inhibition of [Ca++]j elevation (Fig 60). The IC60 for 
inhibition of influx of Ca+ + induced by 0.3 nM PAF by genistein was 60 //M.
3.6 .6 .3  Effect of inhibiting tyrosine kinasefs) on PAF-induced platelet functional 
responses
The effect of inhibiting PTKase(s) with genistein was investigated on PAF- 
induced TxB2 generation, 5-HT release (Fig 61) and platelet aggregation (Fig 62). 
Pre-incubation of platelets with genistein (300 pWi) did not induce TxB2 generation, 
nor did it cause any release of dense granule constituents (Fig 61). The presence 
of genistein vehicle also had no affect on either 5-HT release or TxB2 generation 
induced by suboptimal concentrations of PAF. Platelets were pre-incubated with a 
dose range of genistein (10 - 300 pN\) for 20 minutes before stimulation with 


































Fig 59 Effect of genistein on 3 nM PAF-induced [Ca++1, elevation in platelets in 
the presence of 1 mM [Ca++].. On the left is the fluorescent output from fluo-3 
loaded platelets, on the right the fluorescence has been converted to ICa ++]j. 
[Ca + +]j is the peak elevation of cytosolic calcium in fluo-3 loaded platelets after 
the basal pre-PAF value has been subtracted. The traces are taken from a single 
experiment and the data from the figure on the right are the mean jh S.E. of three 
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Fig 60 Effect of genistein on 0.3 nM PAF-induced ICa++], elevation. Platelets 
were pretreated with either genistein vehicle or genistein (10, 30, 100, 300 //M) 
for 20 minutes before platelet activation with 0.3 nM PAF. The traces in the 
upper panel represent the fluorescent output of fluo-3 loaded platelets and are 
from an individual experiment. In the lower panel fluorescence has been 
converted to [Ca + +]j which is the peak [Ca + +1( elevation after the pre-PAF value 
has been removed. The data are taken from two separate experiments each 
performed in triplicate.
183






Fig 62 The effect of genistein on PAF-induced platelet aggregation. Platelets were pre-treated with genistein for 20 
minutes before platelet aggregation was induced with 1 nM PAF. The traces are from an individual experiment but 
are representative of four similar experiments each performed in triplicate.
Inhibition of PTKase(s) with genistein caused a dose dependent inhibition of 5-HT 
release with an ICB0 of 60 //M close to the value found for both inhibition of 
lns(1,4,5)P3 and Ca++ elevation (see Figs 57 & 58). Genistein also caused a dose 
dependent inhibition of TxB2 generation but with an IC60 of around 1 0 //M (Fig 60).
In addition, genistein vehicle had no affect on 1 nM PAF induced platelet 
aggregation whereas a 20 minute pretreatment with a range of concentrations of 
genistein inhibited platelet aggregation (Fig 62). The ICB0 of 120 j/M genistein for 
the inhibition of 1 nM PAF-induced aggregation was similar to that found for the 
inhibition of lns(1,4,5)P3 elevation and [Ca++]j elevation.
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4. DISCUSSION
4 .1 Prostacyclin washed platelets
Platelets have receptors for PGI2 which when stimulated by receptor-PGI2 coupling 
cause activation of adenylate cyclase and increase cyclic adenosine monophosphate 
(cAMP) which activates PKA (Whittle et al. 1985). Activation of this signal 
transduction pathway and the accumulation of cAMP causes an inhibition of platelet 
functional responses including elevation of [Ca++]j, aggregation, granule release and 
prostaglandin generation. Elevation of cAMP is transient due to its removal from the 
system by cAMP phosphodiesterase and as cAMP is removed the physiological 
responses of platelets to agonists return (Blackwell et al. 1982b).
In this study platelets have been washed in the presence of PGI2 according to the 
method of Blackwell et a! (Blackwell et al. 1982b). Their study demonstrated that 
addition of PGI2 during the washing procedure inhibited platelet activation during 
platelet preparation (measured as TxB2 generation and liberation of labelled oleate 
from intracellular lipid stores) but that once platelets were resuspended in PGI2 free 
HBT, cAMP levels declined rapidly reaching basal between 90 and 120 minutes later 
with full functional activation restored. This method of platelet isolation also 
improved platelet viability and maintained platelet sensitivity to aggregating agents 
over a longer period of time after washing compared to platelets washed in the 
absence of PGI2.
Washed platelets were used in this study, as opposed to PRP, because the 
responses of platelets in plasma are reduced due to binding of the agonist to plasma 
proteins. The use of washed platelets allows the manipulation of extracellular ion 
concentrations and in these investigations allowed the concentration of extracellular 
Ca+ + to be modified. Moreover, studies using the fluorescent dye fura-2 need to be 
done in the absence of plasma proteins which interfere with the fluorescence signal 
of fura-2. Furthermore, most of the work carried out in platelet research now uses 
washed platelets, therefore in order for the work in this study to be comparable to 
other published investigations, it was important to use a similar method of platelet
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preparation. Rabbit platelets were used for the majority of the investigations reported 
here. PAF is a potent agonist for rabbit platelets (Hwang et al. 1983; Morrison and 
Shukla, 1989) and many investigations concerning the study of signal transduction 
have been performed using rabbit platelets (Morrison and Shukla, 1989; Shukla et 
al. 1987). The use of rabbit platelets rather than human alleviated the problems 
caused in the recruitment of human donors and the handling and disposal of human 
blood. Moreover using rabbit blood removed the variability which could be 
encountered when working with human blood, such as whether the donor smoked, 
whether they were on any drugs, the sex of the donor and any differences in diet and 
exercise between individual donors all of which could potentially affect platelet 
responses.
4.2  The role of protein phosphorylation in platelet activation
4.2.1 Comparison of the role of protein kinase C in platelet functional responses
induced by three different mechanisms PAF, ionomycin and arachidonic acid
Platelets possess membrane receptors for the agonist PAF and, as demonstrated 
in this study, PAF-receptor coupling elicits a wide range of functional responses, 
which are likely to be triggered at different stages of the intracellular signal 
transduction pathway. In this study we have demonstrated that PAF induces a dose 
dependent elevation in lCa++]j elevation, TxB2 generation and dense granule release. 
Alternatively, in the presence of extracellular Ca+ + , divalent cation ionophores also 
elicit a wide range of functional responses in platelets which are due to the increase 
in [Ca++]j. Activation of platelets by directly increasing [Ca++lj with the use of 
ionophores has been shown to be independent of PLC activation (ie activation of PLC 
is dependent upon cyclo-oxygenase products) (Rittenhouse, 1984; Halenda et 
al. 1989) therefore providing a mechanism of activating the signal transduction 
pathway downstream of PLC. In this study we demonstrate that ionomycin can 
induce a dose-dependent elevation in [Ca++]j, TxB2 generation and dense granule 
release. Platelets do not possess membrane receptors for AA, but it is readily 
metabolised by the cyclo-oxygenase pathway, for which the most abundant
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product is TxA2 (Hamberg et al. 1975). Platelets do however possess membrane 
receptors for TxA2 which is a potent platelet agonist and platelets can also be 
activated by PGH2, the precursor of TxA2 (Morinelli et al. 1987). AA therefore 
provides a mechanism for generation of Tx, which is downstream of both PLC and 
PLA2. A schematic drawing of the different mechanisms of platelet activation by the 
three agents PAF, ionomycin and AA is given in figure 63.
It is well established that activation of PKC followed by platelet stimulation with 
a variety of agonists causes an inhibition of [Ca**], elevation (Poll and Westwick, 
1986a; Zavoico et al. 1985). In agreement, the findings of this study demonstrate 
that pretreatment of platelets with the phorbol ester, 12-0-tetradecanoylphorbol- 13- 
acetate (TPA) which directly activates PKC by substituting for DAG and increasing 
the affinity of the enzyme for Ca++ and for phospholipid (Castagna et al. 1982), 
causes an inhibition of the subsequent [Ca + +]f elevation in platelets stimulated by 
PAF. The non-esterified precursor molecule of TPA, namely 48-phorbol (at a 
concentration of 1000 fold greater than that found to be active for TPA) was 
however ineffective at inhibiting PAF-induced [Ca++]j elevation, inferring that PKC is 
involved in the modulation of [Ca++1, elevation. In support of this, the concentration 
range of TPA found to inhibit PAF-induced [Ca + +]j elevation in this study correlates 
well with the concentrations found to activate PKC in intact platelets in other studies 
(Zavoico et al. 1985) and indeed in this study it was found that 30 nM TPA caused 
a significant level of PKC activation as demonstrated by the phosphorylation of the 
40-47 kDa substrate of PKC. Moreover, the inhibitory effect of TPA on [Ca++]j 
elevation is prevented by pretreatment with the PKC inhibitor staurosporine, which 
further suggests that the effects observed with TPA are a consequence of PKC 
activation.
It is known however, that TPA possesses many different properties compared to 
endogenously produced sn-1,2-DAG (Bazzi and Nelsestuen, 1989). One difference 
is the longevity, whereas DAG is rapidly metabolized and activates PKC in a transitory 
fashion, phorbol esters are degraded slowly and cause a prolonged activation of PKC 
(Nishizuka, 1986). In addition, phorbol esters are more permeant than DAGs raising
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Fig 63 A schematic drawing of the different mechanisms of platelet activation by the three agents PAF, 
ionomycin and AA.
the possibility that phorbol esters may activate PKC at sites unavailable to DAG and 
therefore present different substrates to PKC. In order to examine whether TPA was 
a suitable substitute for DAG with which to investigate the role of PKC, the effect 
of PKC activation with a membrane permeant DAG, namely, 1,2-dihexanyl-sn- 
diacylglycerol (DHG) on PAF-induced [Ca**], elevation was investigated. Pretreating 
platelets with DHG, which possesses a greater similarity to physiologically relevant 
sn-1,2-DAG, caused the same inhibitory effect on [Ca**], elevation as TPA, which 
could also be prevented by pretreatment with staurosporine again suggesting a 
modulatory role for PKC in [Ca**], elevation.
It is unlikely that inhibition of [Ca**], elevation by activation of PKC in PAF 
stimulated platelets is due to TPA or membrane permeant DAG affecting binding of 
[3H]PAF to platelets as concentrations of either TPA or DAG higher than used in this 
study, have no effect on [3H]PAF binding to platelets (Valone and Johnson, 1987). 
In addition, phorbol esters have the same effect on [Ca**], elevation in platelets 
activated with a variety of agonists including thrombin, ADP, vasopressin and the Tx 
mimetic U46619 (Poll and Westwick, 1986a; Powling and Hardisty, 1986) which 
stimulate different receptors. Moreover, in platelets where the signal transduction 
pathway has been stimulated at a post-receptor level using NaF, in particular the AIF4 
moiety, which is thought to stimulate G-protein activation, pretreatment with phorbol 
ester had the same effect as in agonist-stimulated platelets indicating that modulation 
of [Ca**], by PKC is a post-receptor event (Poll et a/. 1986).
From studies where PKC has been exogenously activated using either phorbol 
esters, or membrane permeant DAGs, it has been suggested that PKC exerts a 
negative feedback pathway which by inhibiting the production of the signal molecules 
produced by PLC-induced Ptdlns(4,5)P2 hydrolysis (Zavoico et al. 1985; Watson and 
Lapetina, 1985; Rittenhouse and Sasson, 1985) will subsequently inhibit Ca** 
mobilization. As further evidence of a negative feedback role of activated PKC, 
increasing the endogenous concentration of DAG by the use of the DAG kinase 
inhibitor R44949 has also been shown to inhibit [Ca**], elevation in thrombin
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stimulated platelets, suggesting endogenously activated PKC is also capable of 
exerting a negative feedback (De Chaffoy de Courcelles et al. 1989).
In addition to inhibiting [Ca**], elevation, pretreatment of platelets with TPA also 
caused an inhibition of TxB2 generation in PAF stimulated platelets. TxB2 is the stable 
metabolite of TxA2 which is generated from AA via the cyclo-oxygenase pathway and 
TxA2 synthetase (Hamberg et al. 1975). AA is produced from two sources, it is either 
released from membrane phospholipids such as phosphatidylcholine by the action of 
the Ca** and phospholipid dependent enzyme PLA2 (thought to be the major source 
of AA (Bishop and Bell, 1986)) or by the action of di- and monoacylglycerol lipases 
on 1-stearoyl-2-arachidonyldiacylglycerol produced from the hydrolysis of 
Ptdlns(4,5)P2 by PLC (believed .to be a minor source of AA in platelets (Bell et 
al. 1979; Mahaevappa and Holub, 1986)). Many platelet functional responses are 
dependent to some degree on [Ca**],. Replacing [Ca**], with the Ca++ chelator 
EGTA caused an inhibition of [Ca++lj elevation, TxB2 generation and dense granule 
release, in platelets stimulated with a range of concentrations of PAF suggesting that 
these functional responses are dependent on [Ca**], elevation. It is possible that in 
PAF-stimulated platelets the inhibition of TxB2 caused by the PKC activation may be 
a direct consequence of the inhibition of [Ca**], elevation, particularly as it is known 
that PLA2 is a Ca** dependent enzyme (Baron and Limbird, 1988). However, this 
may not be true for all agonists, as collagen has been shown to activate PLA2 
independently of changes in [Ca**], (Pollock et al. 1986).
Other possibilities for the regulation of Tx generation by PKC also exist. There 
is now increasing evidence that PLA2 activation may be directly coupled to membrane 
receptors by GTP-binding proteins (Silk et al. 1989) therefore by-passing PLC 
activation and suggesting that not all PLA2 activation is subsequent to PLC activation, 
but may be a separate event. Evidence for the presence of G-proteins which couple 
PLA2 to receptors in platelets includes the finding that the dose response profiles of 
both pertussis toxin and GDPI3S required to inhibit thrombin-induced AA release (and 
therefore PLA2 activity) in permeabilized platelets were different from those required 
to inhibit DAG production (therefore PLC activity) suggesting a G-protein coupled to
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PLA2 which is pertussis toxin sensitive and may be distinct from the G-protein 
responsible for modulation of PLC (Kajiyama et at. 1989; Nakashima et al. 1987). In 
addition, PGI2 has a differential ability to inhibit PLC activity compared to PLA2 
activity in thrombin activated platelets indicating these enzymes may be activated by 
separate mechanisms during thrombin stimulation (Crouch and Lapetina, 1988). It 
is possible therefore that in the same way as the G-protein(s) which couples the 
receptor to PLC may be regulated by PKC-induced phosphorylation, the G-protein 
which couples the receptor to PLA2 may also be regulated by PKC.
As an alternative experimental approach the potent, although non-specific, protein 
kinase inhibitor staurosporine (Tamaoki et al. 1986) was employed to investigate the 
role of endogenously activated PKC. Inhibition of PKC activity by staurosporine was 
confirmed by investigating its ability to inhibit PAF-induced PKC substrate 
phosphorylation. Staurosporine was found to cause a dose-dependent inhibition of 
300 nM PAF-induced phosphorylation of the 40-47 kDa substrate of PKC with an ICgo 
of 500 nM. Other studies have also shown inhibition of phosphorylation of the 40- 
47 kDa PKC substrate over the same range of concentrations of staurosporine in 
platelets stimulated with different agonists (Watson et al. 1987). In the original study 
of Tamaoki et al. (1986) the IC60 for the inhibition of PKC by staurosporine was 
determined as 2.7 nM. This value was obtained using isolated PKC in an in vitro 
assay where the effect of staurosporine on DAG-induced PKC-mediated histone 
phosphorylation was investigated. It is now known that staurosporine inhibits PKC 
activity by competing with ATP for its binding site on the catalytic subunit of PKC 
(Ruegg and Burgess, 1989). The concentration of < 10 //M ATP used in the in vitro 
assay of Tamaoki et al. is therefore much lower than the mM concentration of ATP 
in intact cells (Burt et al. 1976) and would explain the much lower potency of 
staurosporine at inhibiting PKC in an intact cell preparation. The ATP binding site of 
protein kinase C has a high homology with the ATP binding site of other protein 
kinases (Ruegg and Burgess, 1989), therefore inhibitors which act by competing with 
ATP are likely to be only poorly selective at inhibiting protein kinase C and this is true 
for staurosporine. Indeed, staurosporine has previously been shown to inhibit
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phosphorylation of the 20 kDa protein known to be the substrate of myosin light 
chain kinase (Watson et a/. 1987) which is phosphorylated in parallel with the 40-47 
kDa protein upon agonist-receptor coupling in platelets (Kaibuchi et al. 1983).
If endogenously activated PKC is exerting a negative feedback and inhibiting PLC 
activity it would be expected that removal of this inhibitory effect would result in the 
opposite effect. Pretreatment with a range of staurosporine known to inhibit 
phosphorylation of the 40-47 kDa substrate had no significant effect on the maximal 
elevation of [Ca**], induced by 3 nM PAF. However, in contrast to the effect of PKC 
activation with TPA, staurosporine caused a potentiation in TxB2 generation, 
suggesting endogenously activated PKC is inhibiting TxB2 generation and supporting 
a negative feedback role for endogenously activated PKC.
Earlier observations have demonstrated that elevation of [Ca**], using either an 
ionophore or a permeabilized platelet preparation in combination with PKC activation 
causes a synergistic increase in platelet activation (Mobley and Tai, 1985; Halenda 
et al. 1989). These findings suggest that PKC has a positive role in platelet 
activation, requiring both PKC activation and [Ca**], elevation to elicit full platelet 
activation (Nishizuka, 1984). The results of this study confirm and extend these 
observations by demonstrating that whilst pre-incubation with the PKC activator TPA 
had no effect on maximal [Ca**], elevation induced by ionomycin, both 5-HT release 
and TxB2 generation were significantly potentiated. A recent study demonstrated that 
the potentiation of AA release by phorbol esters in platelets was not due to inhibition 
of [3H]AA uptake into platelets or incorporation into phospholipids (Banga et al. 1991) 
but probably due to promoted release of AA. Staurosporine also had no effect on 
maximal [Ca**], elevation in ionomycin stimulated platelets, however in contrast to 
the effects of PKC activation both 5-HT release and TxB2 generation were 
significantly inhibited. Therefore in ionomycin stimulated platelets activation of PKC 
potentiates functional responses whilst inhibition of PKC suppresses them. Ionomycin 
has been demonstrated to liberate AA directly (Rittenhouse, 1984; Halenda et 
al. 1989), and in agreement with this inhibition of the cyclo-oxygenase pathway by 
indomethacin had no significant effect on either ionomycin induced [Ca**], elevation
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or dense granule release. This would indicate that ionomycin induced release of AA 
and therefore products of the cyclo-oxygenase pathway, in particular TxA2, were not 
influencing either of these processes and that ionomycin-induced platelet activation 
and AA-induced platelet activation can be thought of as separate mechanisms of 
platelet activation.
Several studies have used a combination of ionophores (to mimic lns(1/4 /5)P3 
production by increasing [Ca++]j) and either membrane permeant DAGs or phorbol 
esters (to mimic endogenously produced sn-1,2-DAG by activating PKC) and have 
suggested that using these agents a model is manifested which reproduces the effect 
of agonist-induced platelet activation (Kaibuchi et al. 1983; Nishizuka, 1984). The 
results presented in this thesis demonstrate that the effects of PKC modulation in 
platelets stimulated with ionomycin differ greatly from those observed in agonist- 
stimulated platelets (figure 64), and make the use of ionophores together with PKC 
activators a poor model to use to investigate the role of endogenously activated PKC 
in a physiological system.
In ionomycin-stimulated platelets therefore [Ca + +]j elevation is not affected by PKC 
modulation but TxB2 generation is affected. The finding that ionomycin is able to 
induce the generation of TxB2 suggests that an increase in [Ca++]j alone is able to 
directly activate PLA2 and cause the release of AA from phospholipids. Both cyclo- 
oxygenase and TxA2 synthetase are Ca + + independent enzymes and therefore an 
increase in [Ca++]j would not be expected to increase the metabolism of AA to TxA2. 
Phorbol ester and staurosporine respectively potentiate and inhibit TxB2 generation in 
ionomycin stimulated platelets, but not by affecting [Ca++]j nor by influencing PLC 
activity (Rittenhouse, 1984). Instead, it is possible that PKC directly regulates PLA2 
activity (as AA production is independent of PLC activation) or influences the activity 
of an intermediate protein responsible for the regulation of PLA2 activity. Such an 
intermediate protein may be an annexin (previously termed lipocortins/calpactins) 
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Fig 64 Flow diagram showing the differential effect of exogenous PKC activation 
in either agonist or ionomycin stimulated platelets.
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Members of the annexin family are proteins which were thought to be 
endogenous inhibitors of PLA2 (Parente et al. 1984; Wallner et a/. 1986) although this 
is now controversial (Davidson and Dennis, 1989). Several annexins are substrates 
for PKC (at least in vitro) (Comdra et ai. 1989; Khanna et al. 1986) and it has been 
suggested that phosphorylated annexin does not inhibit PLA2 (Hirata, 1981). Indeed, 
in this study evidence is presented, for the presence of several members of the 
annexin family in platelets (discussed later).
Another possibility worthy of consideration is the finding that activation of PKC 
with phorbol esters or membrane permeant DAGs increases cytosolic pH by 
stimulating Na+/H + exchange (Siffert and Akkerman, 1988b), and that addition of a 
Ca+ + ionophore to platelets also triggers a proton efflux which has all the 
characteristics of Na+/H + exchange (Siffert and Akkerman, 1988a). This Na+/H+ 
exchange results in alkalinization of the cytosol which favours PLA2 activity (Baron 
and Limbird, 1988). However, inhibition of the Na+/H + antiporter by 
dimethylamiloride had no effect on the potentiation of ionophore-induced AA release 
by phorbol ester in human platelets suggesting that phorbol ester/ionophore synergism 
is not mediated by the Na+/H + antiporter (Halenda et ai. 1989). Moreover, the effect 
of alkalinization by the Na+/H + antiporter on PLA2 activity in agonist-stimulated 
platelets is more doubtful, as TxB2 generation and therefore PLA2 activation is 
inhibited by phorbol ester treatment, suggesting that the potentiating effect of 
alkalinization is overcome by some more powerful factor.
It is unlikely that the cyclo-oxygenase pathway or Tx synthetase are the sites of 
PKC modulation, as neither phorbol ester nor staurosporine modified AA-induced TxB2 
generation. However similar to PAF, TxA2-induced [Ca++]j elevation was dose- 
dependently inhibited by pretreatment with TPA, whilst staurosporine had no 
significant effect on maximal [Ca++]j elevation.
PKC modulates dense granule release since activation and inhibition respectively 
potentiate and inhibit dense granule release in ionomycin-stimulated platelets. 
Inhibition of the cyclo-oxygenase pathway with indomethacin had no effect on the 
TPA-potentiated dense granule release in ionomycin stimulated platelets indicating
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that the potentiation was not due to the parallel enhanced generation of TxA2. In 
PAF-stimulated platelets TPA had no significant effect on 5-HT release, whilst in 
comparison to its effect in ionomycin stimulated platelets, staurosporine caused only 
a weak inhibition of 5-HT release. A good correlation is thought to exist between the 
phosphorylation state of the major 40-47 kDa protein substrate of PKC and dense 
granule release although a cause-effect relationship has not yet been demonstrated 
(Rink etai. 1983). There is also some evidence that phosphorylation of MLC (20 kDa 
protein) is also correlated with dense granule release (Lyons and Shaw, 1980) and 
that phosphorylation of the 20 kDa protein may be a pre-requisite for the initiation 
of receptor-mediated dense granule secretion, although this correlation has also been 
disputed (Daniel et al. 1984). Staurosporine can inhibit MLCKase activity (Watson et 
a!. 1987), therefore the inhibitory effect of staurosporine on dense granule release in 
this study may also be attributed to its inhibition of MLCKase. However, in this 
study using fura-2 loaded platelets and in previous studies which used quin-2 loaded 
platelets, activation of PKC with TPA was found to induce dense granule release and 
platelet aggregation despite no detectable increase in [Ca++], (Rink et al. 1983; 
Yamada et al. 1987) and both could be inhibited by non-selective PKC inhibitors 
(Yamada et al. 1987). This would indicate a role for PKC in dense granule release 
independent of MLCKase activation, as MLCKase is Ca+ + dependent (Hallam et 
al. 1985). To add confusion however, in studies using the Ca+ + probe aequorin to 
monitor [Ca**], levels, a transient elevation of [Ca++lj was detected upon phorbol 
ester treatment (Salzman et al. 1985). It is possible that the conflicting findings for 
the different Ca++ probes may be due to either the Ca++ buffering capacity of fura- 
2 and quin-2 masking the [Ca++]j elevation induced by PKC activation, or that 
aequorin is able to monitor changes in [Ca++1; in compartments not available to fura- 
2 or quin-2.
The findings in this study indicate that dense granule release, as opposed to TxB2 
generation may have a closer affinity to the phosphorylation state of PKC substrates. 
The finding that inhibition of PKC had the same effect on PAF-induced as on 
ionomycin-induced dense granule release makes it unlikely that modulation of PLC by
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PKC is of primary importance in this particular functional response. However, 
staurosporine is a weaker inhibitor of PAF-induced (IC60 800 nM) than of ionomycin- 
induced (IC60 150 nM) dense granule release indicating that perhaps PKC has a less 
important role in modulating agonist-induced than ionomycin-induced dense granule 
release.
PAF itself has been described as the most active and specific inhibitor of PAF- 
induced platelet activation (Chignard et al A 985). Early work described how PAF- 
stimulated rabbit platelets did not respond to a second challenge with PAF, but would 
still respond to other agonists (Keraly and Benveniste, 1982). The mechanism of 
desensitization of PAF to a second challenge is unknown, but it is possible that PKC 
may be involved as activation of PKC and subsequent protein phosphorylation causes 
an inhibition of many functional responses. Activation of PKC has been demonstrated 
to exert a negative feedback inhibiting PLC activity and this may be due to uncoupling 
the receptor from the G-protein which activates PLC (therefore making the response 
specific for a particular receptor). Challenging platelets with the first dose of PAF 
would therefore endogenously activate PKC and cause a negative feedback inhibiting 
either directly or indirectly the action of PLC and preventing activation of platelets by 
challenge with a second dose of PAF. It is possible that removal of this negative 
feedback by PKC may also prevent desensitization to a second PAF stimulation. It 
has been demonstrated in this study that staurosporine is able to inhibit PKC 
activation induced by PAF and is also able to abrogate the effect of PKC activation 
by TPA in PAF stimulated platelets. Therefore it is possible that if desensitization 
was due to inhibition of an early portion of the signal transduction pathway caused 
by PKC activation, that inhibition of PKC could block desensitization. Stimulation of 
platelets with a range of concentrations of PAF caused a dose dependent elevation 
of [Ca ++], and in agreement with previous studies, a second dose of the same 
concentration of PAF produced either a much smaller increase in [Ca++]j (with the 
lower concentrations of PAF), or no elevation in [Ca ++]j (with the higher 
concentrations of PAF) indicating desensitization of PAF receptors to PAF-stimulation. 
However, inhibition of PKC by pretreatment with staurosporine did not remove the
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desensitization of the PAF receptor, inferring that PKC activation is not likely to be 
the mechanism underlying the desensitization process. This is in agreement with 
findings which have since been published by Morrison etal (Morrison et a i 1989).
The results of this study suggest that PKC has a modulatory role in both PAF and 
ionomycin-activated platelets, but that the sites of modulation are different. The 
results infer that the phosphorylation of substrate(s) by PKC has a more important 
influence on platelet functional responses in ionomycin stimulated platelets where 
cytosolic Ca+ + levels are not affected by PKC activation or inhibition and where 
modulation of PLC activity (upon TxA2-receptor coupling) is not likely to be of primary 
importance. In PAF-stimulated platelets however, the effect of PKC modulation on 
PLC activity and on [Ca++]j elevation are probably more important factors in 
modulating TxB2 generation, but other factors as discussed may also play a role. The 
different effects of PKC modulation on PAF-induced TxB2 generation and dense 
granule release suggest a different relationship between PKC and dense granule 
release than between PKC and TxB2 generation in PAF-stimulated platelets.
4 .2 .2  The relationship between signal molecule elevation and the influence of PKC 
on production of signal molecules in PAF-stimulated platelets
The relationship between the three putative signal molecules, namely Insd ,4,5)P3, 
DAG and [Ca++]j has been examined in PAF-stimulated rabbit platelets and in addition 
the effects exerted by inhibition of PKC with staurosporine have also been 
determined.
A very rapid and transient elevation of all three signal molecules was induced by 
the addition of a high concentration of PAF. The concentration of lns(1,4,5)P3 
reached a peak at 2 s after PAF addition, which preceded the peak concentration of 
[Ca++]j by 5 s. In addition, the peak concentration of lns(1,4,5)3 was 45 pmol/109 
platelets, which is equivalent to 4.5 //M (assuming that 10s platelets have a cytosolic 
volume of *\0/A (Rittenhouse and Sasson, 1985)), close to the 5/yM lns(1,4,5)P3that 
is required for maximum release of 46Ca2+ from permeabilized human platelets (Brass 
and Joseph, 1985) and membrane vesicles (O'Rourke et al. 1985). Thus our
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observations in intact platelets provide good support for the proposal that lns(1,4,5)P3 
is responsible for mobilizing intracellular Ca2+ (Berridge and Irvine, 1989).
The time course and the amount of DAG formed, compared with lns(1,4,5)P3 
suggests that Ptdlns(4,5)P2 hydrolysis may not be the only source of DAG. Possible 
additional sources include the hydrolysis of other phosphoinositides 
(Rittenhouse-Simmons, 1979; Majerus et at. 1985) or the action of PLD on 
phosphatidylcholine (Rubin, 1988; Huang et aL 1991). Whatever the source of DAG, 
the 3 fold increase over basal levels reported in the present study with PAF- 
stimulated rabbit platelets corresponds well to the 2-3 fold DAG elevation found in 
thrombin-stimulated human platelets, when the same assay for DAG was used (Preiss 
et a!A 986). The parallel inhibition of PAF-induced elevations of lns(1,4,5)P3 and DAG 
by WEB 2086 (Casals-Stenzel, 1987) indicated that these events are coupled to a 
single class of PAF receptor.
The higher concentrations of PAF (30 and 300 nM) produced dose-related 
increases in the amounts of [Ca ++]j, lns(1,4,5)P3, DAG, 40 kDa phosphorylation and 
granule release. However, sub-maximal concentrations of PAF (0.3 and 3 nM), which 
caused considerable dense-granule release and elevation of [Ca++]j, failed to induce 
a detectable increase over basal levels in the concentration of either lns(1,4,5)P3 or 
DAG. Thus, in platelets activated with sub-maximal levels of PAF, neither the 
lns(1,4,5)P3-dependent mobilization of Ca++ from intracellular stores nor the DAG- 
dependent activation of PKC would be expected. The lack of [Ca ++]j elevation in the 
absence of [Ca++]# at low levels of PAF, together with the decreased phosphorylation 
of PKC substrate with sub-maximal levels of PAF, supports this.
These findings have several implications. Firstly, at higher concentrations of PAF, 
there is a good correlation between products of Ptd(4,5)lnsP2 hydrolysis and platelet 
activation, but at the lower concentrations of PAF, platelet activation, including Ca+ + 
mobilization, occurs independently of Ptdlns(4,5)P2 hydrolysis. Indeed, in other cell 
types a lack of correlation between PKC activation and functional response, or 
lns(1,4,5)P3 elevation and [Ca + +]j elevation, has been found. A lack of correlation 
between DAG accumulation and superoxide-anion production after stimulation of
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is responsible for mobilizing intracellular Ca2+ (Berridge and lrvine, 1989).
/
The time course and the amount of DAG formed,^compared with lns(1,4,5)P3
/
suggests that Ptdlns(4,5)P2 hydrolysis may not be the only source of DAG. Possible
/
additional sources include the hydrolysis/ of other phosphoinositides
/
(Rittenhouse-Simmons, 1979; Majerus et ah1985) or the action of PLD on
/
phosphatidylcholine (Rubin, 1988; Huang et a l 1991). Whatever the source of DAG,
, c 'CSLO S-r
the 3 fold increase over basal /reported in the present study with PAF-stimulated
- ^
rabbit platelets corresponds well to the 2-3 fold DAG elevation found in thrombin-
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a l 1986). The parallel inhibition of PAF-induced elevations of lns(1,4,5)P3 and DAG 
by WEB 2086 (Casals-Stenzel, 1987) indicate^that these events are coupled to a 
single class of PAF receptor.
The higher concentrations of PAF (30 and 300 nM) produced dose-related 
increases in the amounts of [ C a + + ]j ,  lns(1,4,5)P3, DAG, 40 kDa phosphorylation and 
granule release. However, sub-maximal concentrations of PAF (0.3 and 3 nM), which 
caused considerable dense-granule release and elevation of [ C a + + ]j, failed to induce 
a detectable increase over basal^ /m the concentration of either lns(1,4,5)P3 or DAG. 
Thus, in platelets activated with sub-maximal levels of PAF, neither the lns(1,4,5)P3- 
dependent mobilization of C a + + from intracellular stores nor the DAG-dependent 
activation of PKC would be expected. The lack of [Ca**], elevation in the absence 
of [Ca ++], at low levels of PAF, together with the decreased phosphorylation of PKC 
substrate with sub-maximal levels of PAF, supports this.
These findings have several implications. Firstly, at higher concentrations of PAF, 
there is a good correlation between products of Ptd(4,5)lnsP2 hydrolysis and platelet 
activation, but at the lower concentrations of PAF, platelet activation, including Ca+ + 
mobilization, occurs independently of Ptdlns(4,5)P2 hydrolysis. Indeed, in other cell 
types a lack of correlation between PKC activation and functional response, or 
lns(1,4,5)P3 elevation and [Ca++lj elevation, has been found. A lack of correlation 
between DAG accumulation and superoxide-anion production after stimulation of
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neutrophils with either concanavalin A (Rider and Niedel, 1987) or N-formylmethionyl- 
leucyl-phenylalanine has been observed (Koenderman et al. 1989). In vascular 
smooth-muscle cells stimulated with PAF, the time to peak [Ca ++]( elevation is 
reached before any elevation in lns(1,4,5)P3, and it has been suggested that other 
mechanisms are responsible for regulating PAF-induced Ca++ mobilization, namely a 
receptor-operated Ca+ + channel independent of phosphatidylinositol polyphosphate 
hydrolysis (Schwertschlag and Whorton, 1988). Similarly in ADP stimulated platelets 
Ca+ + entry was found to clearly precede internal discharge, and it was suggested that 
receptor occupancy is closely coupled to the opening of plasma-membrane bivalent- 
cation channels (Sage et al. 1989). Furthermore, in hepatocytes the formation of 
lns(1,4,5)P3 has been found to require a higher concentration of receptor-operated 
hormone than does [Ca++]j elevation (Lynch et al. 1985). This finding has been 
explained as either lns(1,4,5)3 elevation and [Ca++]( elevation not being causally 
related, or by the presence of separate receptors for agonist that mobilize Ca+ + . 
Moreover, PAF has been shown to increase [Ca + +]j in neutrophils where PLC 
activation and therefore lns(1,4,5)P3 production, have been inhibited by pertussis 
toxin (Naccache et al. 1985).
The reduced elevation of [Ca ++]j by PAF upon replacement of [Ca + +1. with the 
Ca++ chelator EGTA demonstrated that [Ca + +I| elevation in PAF-stimulated platelets 
was due to two components. One component is the mobilization of Ca + + from 
intracellular stores, which in the absence of [Ca++], was found to be transient and 
quickly returned to basal levels. Indeed, in this study [Ca++lj elevation was 
demonstrated to follow lns(1,4,5)P3 production therefore supporting the role of 
lns(1,4,5)P3 in the mobilization of Ca++ from internal pools. Moreover, during the 
course of this study the cloning and sequencing the lns(1,4,5)P3 receptor (Furuichi 
etal. 1989; Mignery etal. 1989) together with the revealed homologies with the Ca+ + 
releasing channel of skeletal muscle known as the ryanodine receptor (Fill and 
Coronado, 1988) were major advances in establishing the Ca++ mobilizing role of 
lns(1,4,5)P3. In addition the development of synthetic and stable analogues of 
lns(1,4,5)P3 including lns(1,4,5)P[S]3 which have been demonstrated to mobilize
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intracellular Ca++ have also substantiated the role of lns(1,4,5)P3 in Ca++ mobilization 
and will also facilitate in separating the functions of lns(1,4,5)P3 from those which 
require the presence of its metabolic products (Taylor et al. 1989). However, a 
combination of the small size of platelets, together with the necessity for a 
permeabilized cell preparation in order to use the synthetic analogues of lns(1,3,4)P3 
has resulted in a lack of studies so far in this field in platelets. The other component 
of [Ca ++], elevation in PAF-stimulated platelets is Ca++ influx across the plasma 
membrane, which was responsible for the sustained duration of [Ca++]j elevation. It 
is known that platelets lack voltage-dependent Ca++ channels such as those described 
in nerve and muscle (Hallam and Rink, 1985a). The mechanism(s) of Ca++ influx 
across the plasma membrane in agonist-stimulated platelets is unknown, but in other 
cell types there is evidence that Ca++ influx may be through receptor operated 
channels (ROCs) which are either tightly coupled directly to the receptor or which are 
regulated by receptor-coupled G-proteins (Rink, 1990). An additional mechanism of 
Ca++ influx may be through Ca + + channels which are modulated indirectly through 
some internal diffusible messenger (possibly a combination of lns(1,4,5)P3 and 
lns(1,3,4,5)P4) and which are termed second messenger operated channels (SMOC) 
(Berridge and Irvine, 1989; Rink, 1990). Several models have been suggested for 
Ca++ influx through SMOC(s) including a capacitative model where Ca++ enters into 
an intracellular pool before entering the cytosol, with the Ca + + concentration in the 
pool somehow regulating Ca + + entry, reviewed in (Berridge and Irvine, 1989; Irvine, 
1990). Only part of the intracellular Ca + + pool appears to be lns(1,4,5)P3-sensitive 
(Ghosh et al. 1989) and it is thought that lns(1,3,4,5)P4 may regulate the transfer 
between intracellular stores and indeed, if some of these pools regulate Ca + + entry 
across the plasma membrane, this may explain the requirement for lns(1,3,4,5)P4 as 
described in the 'quanta!' model of Irvine (Irvine, 1990). The key aspect of this 
model however is the possession on the lns(1,4,5)P3 receptor of an intraluminal 
allosteric Ca++ binding site which interacts with the plasma membrane (Irvine, 1990). 
Possible evidence for the presence of SMOCs in platelets includes a study 
demonstrating that an increase in cAMP levels with forskolin, which inhibited
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Ptdlns(4,5)P2 hydrolysis and therefore lns(1,4,5)P3 elevation, also inhibited the second 
phase of ADP-induced [Ca + +lj elevation observed in the presence of [Ca++1. and in 
addition inhibited the second phase ADP-evoked Mn++ quench, indicating that Ca + + 
entry may be dependent either directly or indirectly on second messenger production, 
although not dismissing the possibility that influx maybe due to the state of filling of 
the intracellular stores (Sage et al. 1990). It is believed that SMOC(s) are only 
responsible for a small influx of Ca++ but that they drive Ca++ oscillations in many 
cells (Berridge and Irvine, 1989). In most studies, (including this study) which have 
investigated the dynamic changes in [Ca++], uponagonist stimulation, cell populations 
are used, however, if [Ca++]j is oscillating asynchronously in the cells, Ca+ + 
oscillations of individual cells would be masked. Figure 65 demonstrates some of the 
possible mechanisms responsible for elevating [Ca++]j.
In this study, at the higher concentrations of PAF, [Ca++]j elevation was found 
to be more dependent on Ca + + influx than Ca++ mobilization, with mobilization of 
Ca++ from the intracellular stores reaching a plateau, whilst [Ca++]j continued to rise 
with increasing concentrations of PAF. Sub-maximal concentrations of PAF induced 
[Ca++1, elevation as a result of a combination of both Ca++ mobilization and influx, 
whilst at low concentrations of PAF where no PLC activity was detected, [Ca++]j 
elevation was found to be totally dependent on Ca++ influx. This finding supports 
the presence of ROCs for Ca + + coupled to the PAF-receptor independent of elevation 
of lns(1,4,5)P3 or its metabolites. One possible explanation for this could be the 
presence of two binding sites for PAF, with one being a high affinity binding site 
coupled to the ROCs, however, from the literature it appears that there is only one 
binding site which has an affinity for PAF in the nM range on rabbit platelets, which 
must therefore also be coupled to PLC (Hwang et al. 1986), this finding is also true 
of human platelets (Valone et at. 1982). However, there is evidence for the 
availability of multiple conformational states of a single type of PAF receptor on rabbit 
platelets (Hwang et al. 1989). There is also evidence that ADP receptors in platelets 
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In studies where Mn** was used as a surrogate for Ca** ADP-induced platelets 
Ca** entry clearly preceded Ca** discharge from the internal stores suggesting the 
presence of ROCs for Ca** entry linked to the ADP receptor (Sage et at. 1990; Sage 
etal. 1989). These findings correlate well with studies which demonstrate that ADP 
is able to activate single channels permeable to Ba** in intact human platelets 
(Mahaut-Smith et al. 1990). Moreover, it is interesting that the characteristics of 
Ca** influx in platelets stimulated with PAF and ADP were found to be similar to 
each other both temporally and in their longevity but different to those induced by 
either thrombin or collagen (Alonso et al. 1989).
To determine the role of PKC in the regulation of early post-receptor events, the 
potent, although non-specific, PKC inhibitor staurosporine was used (Tamaoki et 
al. 1986; Watson et al. 1987). A concentration of 1 //M staurosporine was selected, 
as this concentration inhibited by at least 70% 300 nM PAF induced PKC substrate 
phosphorylation. Both DAG and lns(1,4,5)P3 production induced by 300 nM PAF 
were significantly potentiated by PKC inhibition; however, there was no effect on 
DAG or lns(1,4,5)P3 levels in platelets stimulated with 3 nM PAF.
Conversely, pretreatment of platelets with the PKC activator TPA caused an 
inhibition of both DAG and lns(1,4,5)P3 in platelets stimulated with either 3 or 300 
nM PAF. This finding agrees with previous studies where pretreatment with phorbol 
esters or membrane permeant DAG resulted in an increase in the levels of 
Ptdlns(4,5)P2 and Ptdlns(4)P in agonist stimulated platelets predicting an inhibition of 
their hydrolysis (Watson and Lapetina, 1985; Zavoico et al. 1985). The inhibitory 
effects of pre-activation of PKC on platelet functional responses demonstrated in this 
and other studies in both agonist and fluoride stimulation platelets (Poll and 
Westwick, 1986a; Poll et al. 1986; Krishnamurthi et al. 1986) lends increasing 
evidence to the theory that, when activated, PKC exerts a negative feedback 
inhibiting generation of both DAG and lns(1,4,5)P3 at the level of production (at either 
PLC or a regulating G-protein) (Watson and Lapetina, 1985; Zavoico eta l. 1985).
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The findings of this study suggest that in our system, where PKC is activated by 
higher concentrations of PAF, DAG and Insd ,4,5)P3 levels are depressed by negative 
feedback. However, when PKC is inhibited the negative feedback is removed and a 
full elevation of DAG and lns(1,4,5)P3 induced by 300 nM PAF stimulation results. 
At lower concentrations of PAF no negative feedback would be exerted by PKC, and 
therefore the inhibition of PKC would, as observed, have no effect. Although these 
findings suggest that PKC is exerting its effect on the production of lns(1,4,5)P3 and 
DAG, as they are both formed from the hydrolysis of Ptd(4,5)lnsP2 by PLC, the 
findings do not dismiss the possibility that PKC may also have a role in the removal 
of lns(1,4,5)P3 and DAG. Indeed King & Rittenhouse have demonstrated that 
inhibition of PKC by staurosporine decreases inositol 5-phosphomonoesterase activity 
and is therefore at least partially responsible for the potentiation in lns(1,4,5)P3 in 
human platelets exposed to thrombin (King and Rittenhouse, 1989). However, 
Watson and colleagues have demonstrated that 1 //M staurosporine has no effect on 
the conversion of the membrane permeant DAG, namely DC8 to PA, indicating 
inhibition of PKC does not modulate DAG kinase activation (Watson et at. 1987). In 
addition in our system the potentiation of lns(1,4,5)P3 by staurosporine is very 
transient, which would not be expected if the metabolism of lns(1,4,5)P3 was being 
significantly inhibited by removal of PKC activity with staurosporine. Another 
interesting point from these findings is that the activator of PKC namely DAG would 
appear to be self-regulating.
These findings are however in contrast to those presented by Watson e 
(Watson etal. 1987) where, in platelets stimulated with thrombin, pretreatment with 
1 /;M staurosporine had no effect on either PA formation (as a marker of DAG 
elevation; although PA may also be directly produced by the action of PLD on 
phosphatidylcholine (Huang et al. 1991)) or inositol phosphate levels. From the 
findings of their study they suggested that PKC activation did not exert a negative 
feedback over PLC. An important reason for this difference in the two studies is 
probably that the time chosen to measure PA and inositol phosphate levels after 
thrombin stimulation in their study (60 s) may have been too late and that, at 60 s
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post-thrombin, levels of PA and inositol phosphates may have already declined. 
Indeed at this time point in our system both DAG and lns(1,4,5)P3 levels had already 
reached near basal levels. Moreover, in our system the potentiation of lns(1,4,5)P3 
by staurosporine was only transient, and at 60 s post-PAF there was no significant 
difference in lns(1,4,5)P3 levels in platelets either pretreated or not pretreated with 
staurosporine, and in this respect our findings would agree with those of Watson 
(Watson et al. 1987).
An attempt was also made to correlate the effect of PKC inhibition and activation 
on generation of DAG or lns(1,4,5)P3 with the effect on the functional responses of 
[Ca++], elevation and TxB2 generation. Activation of PKC inhibited lns(1,4,5)P3 and 
DAG production which would account for the inhibition of [Ca**]; mobilization induced 
by PKC activation in PAF stimulated platelets described earlier in this study. In 
addition activated PKC has also been demonstrated to increase the rate of 
lns(1,4,5)P3 dephosphorylation to inactive lns(1,4)P2 by phosphorylating 5'- 
phosphomonoesterase (Molina y Vedia and Lapetina, 1986; Connolly et al. 1986) 
again reducing Ca** mobilization from the intracellular stores. Influx of Ca** across 
the plasma membrane via signal-molecule-operated Ca** channels may also be 
regulated by lns(1,4,5)P3, working in concert with one of its phosphorylated products.
namely lns(1,3,4,5)P4 (Irvine, 1990)i1therefore reduction of lns(1,4,5)P3 by inhibition 
of PLC may also inhibit second messenger operated Ca** channels. Moreover, 
activation of PKC may also stimulate removal of [Ca**]; by activating the Ca**- 
ATPase on the membrane of the storage sites and also the Na*/Ca** exchange 
system on the plasma membrane (Nishizuka, 1986). A study using Mn2* as a 
surrogate for Ca2* (Valone and Johnson, 1987) demonstrated that PAF-induced Ca** 
mobilization was more sensitive to the inhibitory effects of TPA than Mn2* influx, 
perhaps indicating different mechanisms of modulation of the two pathways of 
[Ca**], elevation by PKC.
Staurosporine had no significant effect on either 3 nM or 300 nM PAF-induced 
peak [Ca**], elevation, despite a potentiation in levels of lns(1,4,5)P3 upon stimulation 
with 300 nM PAF. This could be due to the limits of detection of [Ca**], elevation
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being reached after stimulation with 300 nM PAF and therefore any further increase 
in [Ca**], being indistinguishable, or that maximal intracellular Ca2* mobilization had 
already been achieved. Indeed, in support of the latter theory, staurosporine had no 
effect on the maximal mobilization of [Ca**]; from intracellular stores in platelets 
stimulated with 300 nM PAF in absence of [Ca**]# (where [Ca**], had been replaced 
with the Ca** chelator EGTA). There was no increase in lns(1,4,5)P3 at 3 nM PAF 
however, and although it would have been possible to detect a potentiation in [Ca**], 
by staurosporine at this concentration of PAF, no significant increase was observed. 
However, when investigating the t1/2 of the decay of [Ca**], it was found that PKC 
inhibition produced a 200% increase in the t1/2 of elevated [Ca**], in 300 nM PAF- 
stimulated platelets but only a 30% increase in t1/2 in platelets stimulated with 3 nM 
PAF. These findings are in agreement with the work of Watson & Hambleton 
(Watson and Hambleton, 1989), where an increase in t1/2 of [Ca**], decay was 
observed in thrombin-stimulated platelets pretreated with 1 jjM staurosporine, despite 
no evidence of a potentiation of lns(1,4,5)P3 (Watson et al. 1987).
At this point it is important to consider the effects of staurosporine on PAF- 
induced platelet aggregation. Pretreatment of platelets with staurosporine caused a 
dose-dependent, although only partial, inhibition of PAF-induced aggregation, without 
affecting shape change, which is in agreement with other studies (Watson and 
Hambleton, 1989; Siess and Lapetina, 1989). Indeed it has been suggested that 
platelets possess two pathways of platelet aggregation, a phosphorylation dependent 
one which can be inhibited by staurosporine, and a phosphorylation independent 
pathway which is induced by [Ca**], mobilization and which staurosporine is not able 
to inhibit (Watson and Hambleton, 1989). It has previously been demonstrated that 
in platelets loaded with fura-2, aggregation of platelets may interfere with and reduce 
the fluorescence signal and therefore the calculated [Ca**], (Cobbold and Rink, 1987). 
It is therefore possible that the longer duration of [Ca**], elevation observed in 
platelets pretreated with staurosporine may be due to the partial inhibition of platelet 
aggregation. To examine this possibility, the duration of [Ca**], elevation either in 
the presence or absence of staurosporine was determined in platelets which were
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prevented from aggregating. Prevention of platelet aggregation was achieved by (a) 
terminating platelet stirring 10 s after the addition of PAF or (b) pretreating platelets 
with 8 7 0 //M of the tetrapeptide ARG GLY ASP SER preventing fibrinogen binding to 
GPIIb/llla receptors which is a prerequisite for aggregation (Plow et al. 1985). The 
absence of platelet aggregation was found to have no effect on the t,/2 of the decay 
of [Ca ++] indicating a real role for PKC in platelet Ca++ homeostasis.
Indeed, the potentiation of the t1/2 by inhibiting PKC, supports earlier findings (Poll 
and Westwick, 1986a; Pollock et al. 1987) where activation of PKC was found to 
increase the rate of decline of [Ca**]{ to basal levels in agonist stimulated platelets. 
These findings further suggests that the role of PKC in Ca++ homeostasis may be in 
the restoration of the elevated [Ca + +]j to basal levels. Whether the increase in the 
duration of elevated [Ca**]{ by staurosporine is due to an increased duration of Ca+ + 
influx or mobilization, or a decrease in Ca++ efflux or resequestration into the 
intracellular Ca++ stores is however, not known.
The findings in this study are also in agreement with those of King & Rittenhouse 
(King and Rittenhouse, 1989), in respect of PKC inhibition potentiating lns(1,4,5)P3 
levels, although conversely they found that this caused an increase in ICa++]( 
elevation. In their study they demonstrated that staurosporine also inhibited 
phosphorylation of MLC, however to determine the role of MLCKase in potentiating 
lns(1,4,5)P3 levels, they inhibited MLCKase using ML-7 and demonstrated that this 
had no effect on the potentiation of lns(1,4,5)P3. More importantly however, they 
found that 10 //M staurosporine caused no potentiation in thrombin-induced DAG 
levels. This is interesting because Bishop et a! (Bishop et at. 1990) found that, with 
a high concentration of the PKC inhibitor sphingosine, the DAG elevation induced by 
thrombin was abolished, but at lower concentrations of sphingosine the DAG level 
was potentiated, and they attributed the inhibition by sphingosine to an inhibition of 
proximal portions of the signal-transduction pathway at this higher concentration of 
the inhibitor. Therefore it may be that the concentration of 10 //M staurosporine 
used in the study by King & Rittenhouse (1989), which is 10 fold greater than used
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in this study, has masked any potentiatory response which may have been observed 
at a lower concentration of staurosporine.
The effect of staurosporine on PAF-induced TxB2 generation was also examined. 
At lower concentrations of PAF (0.3-3 nM), only trace amounts of TxB2 were 
detected, but at higher PAF concentrations (30 nM and 300 nM) TxB2 was dose- 
dependently increased, and this increase was potentiated by inhibition of PKC. In this 
and other studies it has been demonstrated that in either agonist or fluoride 
stimulated platelets activation of PKC causes an inhibition of TxB2 generation (Poll et 
al. 1986). Inhibition of PKC, and therefore inhibition of the negative feedback exerted 
by endogenously activated PKC, would indeed predict a potentiated TxB2 generation.
The increase in TxB2 induced by PKC inhibition may be attributed to a number of 
events. Firstly, PLA2 is Ca + +-dependent, and it may be that the sustained duration 
of elevation of [Ca++]t induced by PKC inhibition is increasing the activation of this 
enzyme and thus causing the observed potentiation in TxB2. Alternatively, the 
increased production of DAG could provide, via DAG lipase, increased levels of AA 
and ultimately TxB2 production (conversely, the use of indomethacin provided 
evidence that the increase in TxA2 was not responsible for the increase in DAG 
production). Finally it is also possible that PKC is exerting a direct regulatory effect 
on PLA2 or a closely coupled GTP-binding protein (Silk et al. 1989) or that it is 
affecting TxB2 production by modulating the activity of annexins which may be
responsible for inhibiting PLA2 activity (Touqui etal. 1986).
Several conclusions can be drawn from the present work. The relationship 
between the concentrations of the signal molecules and platelet functional responses 
is very dependent on the dose of PAF employed. In high-dose PAF-activated 
platelets, the elevation of lns(1,4,5)P3 clearly precedes the [Ca + +]j elevation, 
supporting the proposal that lns(1,4,5)P3 is responsible for this mobilization of
intracellular Ca + + stores. In contrast, in low-dose PAF-activated platelets, elevation 
of [Ca + +]j and granule release occurs in the absence of detectable increases in the 
concentration of lns(1,4,5)P3 or DAG, as well as the absence of Ca++ mobilization 
from intracellular stores or PKC-substrate phosphorylation.
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These results suggest that in platelet activation induced by low concentrations 
of agonist, mechanisms other than Ptdlns(4,5)P2 hydrolysis are utilized for platelet 
activation. The existence of these separate mechanisms is supported by the 
experiments with staurosporine, which result in a marked potentiation of DAG, 
lns(1,4,5)P3 and TxB2 production as well as a protracted Ca++ signal induced to a 
much greater extent by the higher doses of PAF. Finally, the results demonstrate 
that endogenously activated PKC operates as a powerful negative feedback regulator 
of signal molecules (figure 66).
During the course of this study it has become clear that rather than being a single 
enzyme (Inoue et al. 1977) PKC is infact a family of isoenzymes (Nishizuka, 1989) of 
which at least 7 namely, o, IS,, I32, t , 6 ,  e  and theca are now known to exist (Table 
5) and indeed several additional undefined species may also exist. PKC isoenzymes 
consist of a catalytic (carboxy-terminal half) and a regulatory domain (amino-terminal 
half). The catalytic domain contains sequences, including the ATP binding site, which 
are similar to other proteins kinases (Nishizuka, 1989). The regulatory domain of the 
a, S and r  isoenzymes is thought to contain a Ca++ binding region (Parker et 
al. 1986), indeed the finding that the activity of the other PKC isoenzymes (6, e and 
theca) is Ca++ independent (Ono et al. 1988) and that these isoenzymes do not 
possess the C2 conserved region (Ono et al. 1987) suggests that it is this region 
which contains the Ca++ binding site. The finding that some PKC isoenzymes are 
Ca+^independent may provide an explanation for the ability of phorbol esters to 
activate PKC in the absence of any detectable elevation in [Ca++]j (Rink et al. 1983).
Human and rabbit platelets possess both the a and 13 subtypes of PKC (of which 
13 is the major subtype) but not the r  subtype (Watanabe et al. 1988; Pelech et 
al. 1991; Tsukuda et al. 1988). These proteins were resolved using hydroxylapatite 
column chromatography and found to have a similar chromatographic property to 
Type II and Type III PKC from the rabbit brain which have been identified as the PKC 
isoenzymes IS and a respectively (the IS1 and IS2 isoenzymes cannot be separated on 
this technique) (Kikkawa et al. 1987). Moreover, monoclonal antibodies against the 
or, IS and r  isoenzymes identified only a and IS in platelets (Watanabe et al. 1988).
212
p"
p h o rb o l
ester
R ecep to r
* t







P td /n s (4 )P
P td /ns
sn -1 ,2 -D A G h ^ L  P K C '
PLA2  g ran u le
+ ve
DAG \  DAG  
lipase \  u n ase
-► re lease  
aggregation
-ve
AA phosphatid ic  substrate







ln s (1 ,4 )P  l
*  4
*  p oss ib le  substrates o f PKC











































type I NA NA
19
PS + DG + Ca2+ PS + DG PS + DG















Table 5 Subspecies of PKC from mammalian tissues (Taken in part from Nishizuka 1989).
Platelets have also been found to possess several undefined subspecies of PKC 
(Tsukuda et al. 1988) and it is known that at least one of these isoenzymes is 
insensitive to Ca** (Nishizuka, 1988). Indeed it has recently been suggested that the 
phosphorylation state of the PKC isoenzyme will determine its Ca** dependence, 
and in particular phosphorylation of PKC-B in phorbol ester treated rabbit platelets 
produces several new forms of the B-isoenzyme which are Ca* ^ independent (Pelech 
et a/. 1991). Whether platelets possess the 6, e or theca-isoenzymes of PKC has not 
yet been determined.
It has been demonstrated that the PKC isoenzyme B is less sensitive to Ca** than 
either a or r, and that a and r  are less activated by DAG in the presence of PtdS than 
B (Nishizuka, 1988; Nishizuka, 1989). Moreover, the r  isoenzyme is readily activated 
with //M concentrations of AA (without requirement for Ca**, PtdS or DAG) which 
in comparison has limited ability to activate the PKC B subtype but will active PKC 
a in conditions of elevated Ca**. However, it is important to remember that the in 
vitro dependency of PKC on Ca**, DAG and phospholipid varies with the phosphate 
acceptor (Bazzi and Nelsestuen, 1987), such that comparisons made in limited and 
defined conditions to compare PKC isoenzymes may not be physiologically accurate.
In this study using low concentration PAF it has been determined that there is 
a significant elevation of [Ca**]{ in the absence of lns(1,4,5)P3 or DAG production, 
these conditions would therefore favour an isoenzyme which was sensitive to Ca** 
and responsive to any small increases in DAG. At higher concentrations of PAF 
however, there is a good correlation between DAG elevation and [Ca**]j elevation and 
in addition AA is released, providing conditions which would perhaps activate a 
greater proportion of the isoenzymes. The finding that platelets possess the 
isoenzyme B which is thought to be less sensitive to Ca** than either a or r, and in 
addition possess another, as yet unidentified, Ca** insensitive isoenzyme, suggests 
an opportunity for PKC to be activated independently of lns(1,4,5)P3 or [Ca**li 
elevation. This would introduce the prospect of a novel signal transduction pathway 
independent of Ptdlns(4,5)P2 hydrolysis by PLC, and therefore hydrolysis of any 
phospholipid which resulted in the generation of DAG would induce PKC activation,
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this may include activation of PLD (Loffelholz, 1989). The finding that inhibition of 
PKC with staurosporine only had an effect when platelets were stimulated with higher 
concentrations of PAF, would indicate perhaps that only activation of platelets with 
higher concentrations of PAF was able to create the conditions necessary for PKC 
activation. The homologous ATP binding site of the PKC isoenzymes would predict 
that PKC inhibitors which act by competing with ATP for its binding site will inhibit 
all species of PKC with equal affinity, and indeed this is the case for H-7 (Watanabe 
et al. 1988) and for staurosporine (Schaap and Parker, 1990).
4 .2 .3  To investigate the role of endogenously activated PKC in platelet functional 
responses using selective inhibitors of PKC.
Although advances were made in the potency of PKC inhibitors with the 
development of staurosporine (Tamaoki etal. 1986) and K252a (Yamada et al. 1988), 
these inhibitors are still known to be only very poorly selective for PKC, indeed in 
support of this the IC50 values for staurosporine of 8 nM for cAMP-dependent protein 
kinase, 6 nM for the PTKase pp60v'*'c and 3 nM for PKC have been quoted (Tamaoki 
et al. 1986; Tamaoki, 1991).
Throughout the course of this study there has been an increasing number of 
reports describing the development of selective inhibitors of PKC. These selective 
inhibitors include calphostin C (Kobayashi et al. 1989) and the Roche compounds Ro 
31-8220/002 and Ro 31-7549/001 (Davis etal. 1989). Calphostin C (UCN-1028C), 
a compound isolated from Cladosporium dadosporioides, was reported to be 1000 
time more potent at inhibiting PKC (IC60 50 nM) than other protein kinases including 
cAMP-dependent protein kinase and tyrosine specific protein kinase (IC60 > 50 //M) 
(Kobayashi et al. 1989). Calphostin C was not able to inhibit PKC activity after PKC 
had been subjected to proteolysis by calpain (thereby causing removal of the 
regulatory domain), indicating that calphostin C interacted with the regulatory domain 
of PKC. The sensitivity of calphostin C to the isozymes of PKC and r  has been 
examined and was found to inhibit them all equally (Kobayashi etal. 1989). Although 
Ro 31-8220/002 and Ro 31-7549/001 were based on the structure of staurosporine
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(Tamaoki et al. 1986) and K252a (Yamada et al. 1987) modification of the sugar 
moieties in the production of the Ro compounds was reported to result in a 
modulation of potency and selectivity (Davis et al. 1989). In support of this Ro 31- 
8220/002 and Ro 31-7549/001 were found to be > 8 0  fold more selective for PKC 
than cAMP dependent kinase and > 10 00  fold more selective for PKC than 
Ca++/calmodulin-dependent kinase. In common with staurosporine both Ro 31- 
8220/002 and Ro 31-7549/001 compete with ATP for its binding site, it is possible 
that their modified structure is able to take advantage of the small differences in the 
otherwise homologous ATP-binding sites of protein kinases to make them selective 
for PKC. Indeed, it is reported that the C3 region of PKC which contains the ATP 
binding site has a greater homology between the isoenzymes of PKC, than between 
PKC and other kinases (Ono et at. 1987), this would therefore suggest that Ro 31- 
8220/002 and Ro 31-7549/001 are likely to inhibit the isoenzymes of PKC with equal 
potency. Using these compounds it is therefore likely that a more accurate insight 
could be gained into the role of endogenously activated PKC than when using a non- 
selective inhibitor.
Calphostin C caused a dose-dependent inhibition of 300 nM PAF-induced 
phosphorylation of the 40-47 kDa substrate of PKC in an intact platelet preparation 
with an IC60 of 1 //M confirming its ability to inhibit PKC activation. Apart from the 
effects of calphostin C on platelet activation in this study, there has only been one 
other report regarding the effect of Calphostin C on intact cells (Bruns et a/. 1991). 
Other studies, have only examined the ability of calphostin C to inhibit 
phosphorylation of exogenous substrates using an isolated PKC enzyme preparation 
(Kobayashi et al. 1989; Tamaoki, 1991). PKC phosphorylation of the EGF receptor 
has been demonstrated to decrease its affinity for l126l]EGF binding, therefore 
inhibition of PKC (with Calphostin C) was examined, for its ability to reverse the 
negative effect of PDBu on EGF binding in A431 cells (Bruns et a/. 1991). In this 
assay which used intact cells, calphostin C had no effect until around 80 nM after 
which it increased EGF binding from around 60% (in absence of calphostin c) to 
around 85% with 250 nM calphostin C, and this reaction was found to be light
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dependent. Concentrations of higher than 250 nM calphostin C, inhibited EGF 
binding and it was stated that this was due to a cytotoxic effect of calphostin C 
above this concentration and that the cytotoxicity was also light dependent (Bruns 
et al. 1991). It was explained by Bruns et al. (1991) that similar compounds to 
calphostin C, namely perylenequinones (in the presence of light) react with molecular 
oxygen, generate singlet oxygen and form endoperoxides. It is thought that the 
cytotoxicity of calphostin C may be due to lipid peroxidation by the singlet oxygen. 
In their study Bruns et al. state that there is a 5 fold difference in the concentration 
of calphostin C which causes PKC inhibition and that which causes cytotoxicity 
(despite the fact that both reactions are light dependent) and that therefore PKC 
inhibition is not due to cytotoxicity.
Calphostin C inhibited PKC activation in PAF stimulated platelets, but in contrast 
to the effects of staurosporine and the selective PKC inhibitors (see below) it also 
inhibited PAF-induced [Ca++Jj elevation and TxB2 generation, these experiments were 
all carried out in light. It is possible that the concentration of calphostin C required 
to inhibit PKC in an intact cell preparation where it would need to pass through the 
plasma membrane is higher than required in a isolated enzyme system, as indeed has 
been demonstrated with platelets in this study. Therefore the narrow margin 
between the ability of calphostin C to inhibit PKC in the absence of cytotoxic effects 
and the concentration at which it becomes cytotoxic may have been lost in this 
study, and its inhibitory effect seen on platelet functional responses may be due to 
cytotoxicity, although, the fact that there was no leakage of fura-2 from the cells 
even at the higher concentrations of calphostin C indicate that it did not cause cell 
lysis. Moreover, in over two years since the first publication on calphostin C 
(Kobayashi etal. 1989) only one other non-review paper has been published on this 
compound (Bruns et al. 1991). It is possible that due to the cytotoxic side-effects of 
calphostin C it is not being considered as a good investment for further research.
Both Ro compounds inhibited PAF-induced phosphorylation of the 40-47 kDa 
major PKC substrate in a dose dependent manner with Ro 31-7549/001 inhibiting 
phosphorylation with an IC50 of 2.5 jjM whilst Ro 31-8220/002 inhibited
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phosphorylation with an ICB0 of 0.45 //M. These figures agree with other values for 
the inhibition of TPA-induced (Davis et al. 1989) and thrombin-induced (Walker and 
Watson, 1992) phosphorylation of the 40-47 kDa substrate of PKC in intact platelet 
preparations. It is known that both PKC and MLCKase phosphorylate MLC (20 kDa) 
but at distinct sites (Naka et at. 1983). Indeed it has been demonstrated that, in 
thrombin stimulated platelets, concentrations of the Ro compounds which inhibit 
phosphorylation of the 40-47 kDa protein substrate of PKC by 100 % only inhibit 
MLC phosphorylation by 20%, whereas a concentration of staurosporine which 
inhibits phosphorylation of the PKC substrate by 100% also inhibits phosphorylation 
of MLC by 100%. Further, in platelets stimulated by the specific PKC activator TPA 
(where [Ca**], is not elevated and therefore MLCKase not activated), both 
phosphorylation of the 40-47 kDa substrate of PKC and MLC were totally inhibited 
by the Ro compounds (Walker and Watson, 1992). This would suggest that the Ro 
compounds are only inhibiting the PKC-induced phosphorylation of MLC and not the 
MLCKase induced phosphorylation.
In common with staurosporine the Ro compounds possessed the ability to 
abrogate the inhibitory effect of activation of PKC with TPA on PAF-induced [Ca + +]j 
elevation, providing evidence that PKC is the site of action of both these agents. 
Moreover, and also in agreement with the results for staurosporine, both the Ro 
compounds were found to have no effect on the maximal height of [Ca**], elevation 
in platelets stimulated with either low or high concentrations of PAF, but to 
potentiate the duration of the [Ca**], signal which was increased by 180% in 
platelets stimulated with 300 nM PAF whilst only by 50% in platelets stimulated by 
3 nM PAF. This finding suggests that inhibition of PKC is removing the negative 
feedback exerted by endogenously activated PKC upon PAF stimulation therefore 
potentiating the duration of [Ca**], elevation. This finding provides further evidence 
that PKC is involved in Ca** homeostasis, indeed without the negative feedback 
exerted by PKC it is possible that Ca** would reach cytotoxic levels.
As predicted, if endogenously activated PKC is exerting a negative feedback over 
PLC and/or PLA2, TxB2 generation was potentiated by inhibition of PKC, again
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agreeing with the effects observed with staurosporine. it must be considered 
however, that in vivo the three to five fold increase in TxB2 production, and thus 
TxA2 and prostaglandin endoperoxides, could have considerable effects, depending 
upon the availability of prostacyclin synthetase or vascular tissue responsive to the 
vasoconstrictor actions of TxA2 (Moncada and Higgs, 1986).
In contrast to the above results, but again in agreement with the findings for 
staurosporine, the Ro compounds caused an inhibition of both dense granule release 
and aggregation in PAF-stimulated platelets with similar ICgoS to those for the 
inhibition of PAF-induced 40-47 kDa protein phosphorylation in intact platelets. 
These findings together with the data demonstrating the specificity of these 
compounds (Davis etal. 1989; Walker and Watson, 1992) support the contention that 
inhibition of dense granule release and aggregation is a result of an inhibition of PKC 
activity. However, although there is obviously a correlation between inhibition of 
dense granule release/aggregation and inhibition of the 40-47 kDa protein substrate 
of PKC, there is no evidence of a cause-effect relationship. Unlike their effects on 
aggregation and dense granule release, the Ro compounds had no effect on platelet 
shape change induced by sub-maximal PAF.
Comparing the effects of these selective PKC inhibitors on PAF-induced platelet 
activation to the effects of the non-selective PKC inhibitor staurosporine, many of the 
findings were similar. Both selective and non-selective inhibitors potentiated TxB2 
generation and the duration of the Ca++ signal whilst inhibiting 5-HT release and 
platelet aggregation. However, whilst in platelets activated with submaximal 
concentrations of PAF, staurosporine was found to only partially inhibit platelet 
aggregation (Watson and Hambleton, 1989), the Ro compounds caused total 
inhibition of platelet aggregation whilst not affecting platelet shape change. It is 
possible therefore that staurosporine was inhibiting another protein kinase which was 
counteracting the effect of PKC inhibition on platelet aggregation. For example, 
activation of adenylate cyclase increases cAMP levels causing activation of PKA and 
inhibiting platelet aggregation (Whittle etai. 1985), inhibition of PKA by staurosporine 
would therefore remove this inhibitory effect leading to only a partial possible
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inhibition of aggregation by staurosporine. The findings suggest therefore that sub- 
maximal dose PAF-induced platelet aggregation is PKC dependent whilst PAF-induced 
platelet shape change is PKC independent.
In conclusion the findings observed using the selective PKC inhibitors Ro 31- 
7549/001 and Ro 31-8220/002 agree with the previous findings for staurosporine, 
and support the proposal that PKC has a bifurcating role in activated platelets with 
endogenously activated PKC exerting a negative feedback on PLC activity, [Ca++Jj 
elevation and TxB2 generation whilst exerting a positive role on platelet dense granule 
release and aggregation.
4.2.4 Determination of the identification and location of annexin (lipocortin/calpactin) 
isoforms in human platelets
In this study it has been demonstrated that PKC has a role in modulating TxB2 
generation, which is not through modification of the cyclo-oxygenase pathway or 
TxA2 synthetase, but which may be due to its regulation of PLA2 activity. One 
possibility for the regulation of PLA2 by PKC, is that activated PKC may phosphorylate 
an intermediate protein which, depending on its state of phosphorylation, may 
regulate PLA2 activity. Candidates for this intermediate protein include members of 
the annexin family, which are also known by many other terms (Table 6). Annexins 
have been described as specific inhibitors of PLA2 (Parente et al. 1984; Wallner et 
a/. 1986), although their ability to directly inhibit PLA2 activity is controversial and may 
be due to substrate sequestration (Davidson and Dennis, 1989). However, it has 
been suggested that phosphorylated annexin does not inhibit PLA2, therefore this may 
be one way that the action of annexins is regulated by protein kinases (Hirata, 1981).
There is sparse literature on the presence of annexins in platelets. An early paper 
by Touqui and colleagues identified the major 40-47 kDa protein substrate of PKC as 
annexin (Touqui et al. 1986). However, this finding has been disputed for many 
reasons, firstly, the molecular weights of known annexins (of approximately 35-37 
kDa) are different from that of the PKC substrate (40-47 kDa), secondly, in a study
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A NOMENCLATURE GUIDE TO THE LIPOCORTIN FAMILY
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Taken from the "Biology of Lipocortin 1” meeting at The Royal Society, November 1991
by Crouch & Lapetina (Crouch and Lapetina, 1986) it was found that both a and r- 
thrombin were capable of activating PKC and phosphorylating the 40-47 kDa 
substrate of PKC, but only or-thrombin was capable of releasing AA (which would not 
be the case if phosphorylated annexin removed the inhibitory effect over PLA2), but 
thirdly and conclusively, the 40-47 kDa substrate has now been cloned and the 
sequence was found not to be similar to any other known sequence including that 
of annexin (Tyers et al. 1988). A recent study however, has demonstrated the 
presence of annexin V (PAP I) in platelets by the use of ELISA (Flaherty et al. 1990).
In this study the presence of proteins cross-reacting to antibodies against 
annexins I, II and V in human platelets has been demonstrated. Immunoblots of 
U937 cells were probed in parallel since they have previously been demonstrated to 
contain several annexins, which are increased by protein synthesis when the cells are 
differentiated in culture (Isacke et al. 1989). Probing total platelet protein and total 
U937 cell protein using either antibodies against the whole amino acid sequence of 
annexin I or against the amino acid sequence 1-188, a protein of 36 kDa was 
detected in both platelets and U937 cells. However, probing platelets for annexin I 
using antibodies against the smaller amino acid sequences 24-37 and 38-50, the 
molecular weight of the proteins detected were around 70 kDa and 55 kDa 
respectively, therefore different from that detected using the whole amino acid 
sequence, and despite the fact that annexin I was detected in U937 cells with 
antibodies against the smaller sequences remained at 36 kDa. It has been suggested 
that higher molecular weight bands detected by anti-annexin I antibodies may be due 
to recognition of dimers made up of one native and one proteolysed annexin I 
molecule (which would account for bands detected of around 60 kDa) or of one 
annexin I molecule cross-linked to a molecule of another annexin, forming an 
asymmetrical dimer (which would account for bands of around 66-72 kDa) (Pepinsky 
et al. 1989). However, this would not explain why antibodies against the smaller 
amino acid sequences have detected the higher molecular weight bands but not the 
36 kDa band corresponding to the uncomplexed native annexin I. An alternative 
explanation is that the anti-peptide ABs are recognising other proteins with
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sequences similar to that of the 24-37 and 38-50 amino acid sequences in annexin 
I, although again this would not explain why these antibodies did not detect the 
protein of 36 kDa which was detected by the anti-annexin I antibody against the 
whole annexin I amino acid sequence.
The antibody against annexin II detected a protein in platelets which had a larger 
molecular weight (68 KDa) than that of 35 kDa found in U937 cells which is the 
usual molecular weight for annexin II. Annexin II is, however, thought to be one 
member of the annexin family able to form a multimeric protein complex and it may 
be that it is a dimeric form which is present in platelets (Glenney et a/. 1986). There 
was no evidence for the presence of annexin IV in platelets, although as there was 
no positive control for this antibody (ie no annexin IV was found in U937 cells either), 
the presence of annexin IV in platelets cannot be totally dismissed. However, both 
platelets and U937 cells were found to possess annexin V at the molecular weight 
of 32 kDa, in agreement with the findings of Flaherty e^/JFIaherty et al. 1990).
The concentration of annexin I was determined in whole platelets lysates by 
ELISA (Smith efa /.1990) and found to be around 10 ng/108 platelets (6.67 ng/mg 
protein). The ELISA method has only recently been developed and therefore the 
number of studies where the concentration of annexin has been assayed is limited 
(Smith et al. 1990; Goulding et al. 1990). In one study untreated human mononuclear 
leukocytes were found to have a basal level of around 0.8 - 2 ng of annexin 1/10® 
cells and human polymorphonuclear leukocytes were found to have a basal level of 
between 0.7 - 4.2 ng of annexin 1/10® cells (Goulding et al. 1990). However, it must 
be considered that whereas other cell types possess the ability to synthesise annexin 
I, the annexin in platelets is unlikely to be increased by protein synthesis because of 
the platelets limited ability to synthesise new protein.
The amount of EGTA/EDTA releasable annexin I from the external surface of the 
plasma membrane of platelets was found to be less than 0.1 ng/109 platelets (<  1 % 
of total annexin I) whilst the annexin I in the remaining pellet after removal of the 
surface annexin was not significantly different to that found in the lysates of 
untreated platelets. Therefore the findings using the ELISA method correlated well
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with the findings for the Western blots. However recently it has been reported that 
a CHO cell line transfected with the human annexin I gene possessed a novel EDTA 
resistant form of annexin I, which accounted for the bulk of the surface annexin I 
(about 5% of total annexin I), and indeed EDTA resistant forms of annexins I,II,IV and 
VI were reported on the surface of several cultured cell types. It is not possible from 
the experiments carried out in this study to say whether this EDTA resistant form of 
annexin I is present on the external surface of the platelet plasma membrane.
Annexins are believed to be released from cells in order to inhibit eicosanoid 
production and therefore terminate inflammation at an early stage (Flower and 
Blackwell, 1979; Blackwell et al. 1982a). However, annexins have also been shown 
to inhibit blood coagulation in vitro by competing with factor Xa and prothrombin for 
binding to procoagulant phospholipid surfaces (Funakoshi et ai. 1987) and an 
interesting idea may be that they are functioning as natural anticoagulants. Indeed, 
an amino acid sequence of annexin, homologous to a sequence from uteroglobulin, 
has been demonstrated to inhibit platelet aggregation induced by thrombin (Vostal et 
ai. 1989). The method by which annexins could be released from cells is controversial 
however, since the amino-acid sequences determined from cDNA clones for at least 
annexins I and II do not reveal an N-terminal hydrophobic region of a signal peptide 
usually required for secretion (Wallner et ai. 1986; Pepinsky et ai. 1988). Thus it may 
be that previous extracellular detection was due to leakage of annexin from dead or 
damaged cells. More recently however, annexin I has been demonstrated to be 
secreted by the human prostate gland through what has been described as a novel 
secretory pathway of high sorting efficiency (Christmas et ai. 1991). The most likely 
route for the release of annexins from platelets would be if they were contained 
within platelet granules which are released during platelet activation. In platelets 
activated using the agonists PAF or thrombin, a Ca++ ionophore or phorbol ester 
which caused varying degrees of platelet granule release, no significant release of 
annexin I was detected using ELISA (<  1% of total annexin I) and in agreement no 
release of either annexin I, II or V was detected by Western blotting. However, 
annexin I was observed to undergo proteolysis, particularly in icnomycin stimulated
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platelets, resulting in the appearance of a lower molecular weight band of 32 kDa. 
In another study stimulation of human platelets with maximal concentrations of ADP, 
thrombin, collagen and epinephrine did not release annexin V from human platelets 
and although AA was found to cause some release, it should be cautioned that the 
concentrations of AA employed in the study of Flaherty et al (1-3 mM) would almost 
certainly have caused some cell lysis which probably accounts for the release 
(Flaherty et a/. 1930). The finding that activated platelets did not cause any 
significant release of annexins would suggest that annexins probably do not act as 
platelet-derived naturally occurring anticoagulants, which indeed would have been 
contrary to the primary role of platelets in haemostatic plug formation.
It has also been suggested that secretion of the annexins could occur in response 
to steroids (Goulding et at. 1990; Blackwell et al. 1982a). In this study, the 
glucocorticoid steroid dexamethasone did not cause any detectable release of 
annexins I,II or V from human platelets, nor did it have any effect on the ability of 
ionomycin-stimulated platelets to release annexin I.
There is evidence that annexins are involved in signal transduction and may act 
as second messengers possibly by regulating PLC or PLA2 by sequestration of their 
substrates (Machoczek et al. 1989; Davidson and Dennis, 1989) or they may regulate 
PKC by interacting in a Ca++ dependent manner with phosphatidylserine which is 
required for PKC activity, however, the physiological significance of their ability to 
interact with the substrates of PLA2 and PLC is not known. Recently it has also been 
suggested that annexin III is inositol 1,2-cyclic phosphate 2-phosphohydrolase (Ross 
et al. 1990), again intimating a role for annexins in the regulation of signal 
transduction pathways. There is now increasing evidence that annexins are cellular 
substrates for PTKases reviewed in (Russo-Marie, 1991) and PKC (Comgra et 
al. 1989; Khanna et a/. 1986). Phosphorylation by these kinases has been found both 
in vitro (Gould et al. 1986; Comgra et al. 1989; Khanna et al. 1986) and in intact cell 
preparations (Gould et al. 1986). The fact that signal transduction in platelets has 
been widely studied and that platelets are a rich source of PKC and the PTKase
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PP60'™0 (Golden et al. 1986) suggest that platelets may be a useful model in which 
to investigate the role of annexins and their regulation by phosphorylation in signal 
transduction.
In summary, human platelets have been demonstrated to contain proteins which 
are recognised by antibodies against annexins I,II and V. These annexins do not 
appear to be released from the platelets upon stimulation, which agrees with earlier 
immunological studies which show no evidence for the presence of annexins within 
secretory organelles of other cell types (Nakata et al. 1991) and may suggest an 
intracellular role for annexins. It is not possible to say from this study whether 
annexins are important in the regulation of PLA2 activity by PKC in platelets, but 
having identified their presence, it would be interesting to determine whether they are 
substrates for PKC or PTKase in an intact platelet preparation.
4.2.5 Characterisation of tyrosine phosphorylation of proteins in PAF-stimulated 
platelets and investigation into the role of endogenously activated tyrosine kinase(s) 
in platelet signal transduction using the tyrosine kinase inhibitor genistein.
In this study a Western blotting technique for detecting tyrosine phosphorylated 
proteins was further developed to improve its sensitivity and was examined and 
found to be specific for detecting only tyrosine phosphorylated proteins, and not 
those phosphorylated on either serine or threonine (for example by the action of PKC 
or PKA).
The temporal relationship of PAF-induced tyrosine phosphorylation was examined 
over a five minute time course. In unstimulated platelets 4 tyrosine phosphorylated 
proteins were detected, all of which were in the molecular weight range of 52-62 
kDa. This finding agrees with previous studies where resting platelets have been 
found to possess resident tyrosine phosphorylated proteins within the same molecular 
weight range (Golden and Brugge, 1989; Nakamura and Yamamura, 1989; Ferrell and 
Martin, 1988; Nakashima et a/. 1991). Following PAF stimulation, tyrosine 
phosphorylation of proteins was very rapid with detection of two groups of tyrosine 
phosphorylated proteins at 5 s after stimulation. One group was between 35-45 kDa
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and the other between 66-90 kDa. Within 30 s of stimulation with PAF a further 
group of tyrosine phosphorylated proteins was detected and these were in the larger 
molecular weight range of 90-150 kDa. In total, at 30 s following PAF-stimulation 
around 17 bands of tyrosine phosphorylated proteins could be detected. By 
determining the relative optical densities of the groups of tyrosine phosphorylated 
proteins it was possible to examine the patterns of phosphorylation and 
dephosphorylation over the time course after PAF-stimulation. One of the tyrosine 
phosphorylated proteins in the group detected in unstimulated platelets was 
immediately dephosphorylated following PAF-stimulation, although it was then 
gradually phosphorylated over the ensuing two minutes back to basal levels. This 
dephosphorylation upon agonist stimulation has previously been found in thrombin 
stimulated human platelets of a protein of a similar molecular weight, again the 
immunoreactivity of this protein was quickly restored (Golden and Brugge, 1989). 
The other three tyrosine phosphorylated proteins in this group were not significantly 
affected following platelet activation. The two groups of proteins of 35-45 and 66- 
90 kDa were rapidly phosphorylated, but within two minutes some dephosphorylation 
of proteins in both groups was detected. Tyrosine phosphorylation of the larger 
molecular weight group appeared to reach a plateau and did not dephosphorylate over 
the first two minutes following PAF-stimulation.
Tyrosine phosphorylation of proteins has been detected in platelets stimulated 
with thrombin (Nakamura and Yamamura, 1989; Ferrell and Martin, 1988; Golden and 
Brugge, 1989), collagen (Nakamura and Yamamura, 1989; Nakashima eta/. 1991) and 
the TxA2 analogs U46619 and STA2 (Nakashima et a/. 1991) indicating that tyrosine 
phosphorylation is not a specific response to PAF-stimulation. In agreement with the 
findings for this study, tyrosine phosphorylation of proteins in thrombin-stimulated 
platelets was also detected in temporal waves, with at least 11 proteins from 27 kDa 
to 250 kDa phosphorylated following thrombin stimulation (Golden and Brugge, 1989; 
Ferrell and Martin, 1988; Nakamura and Yamamura, 1989). Indeed, the rate of 
increase in [32P]phosphotyrosine after thrombin stimulation was 30-100 times greater 
than in resting cells (Ferrell and Martin, 1988). Therefore it was surprising that in the
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study of Dhar & colleagues (Dhar et al. 1990), that only two tyrosine phosphorylated 
proteins (of 50 kDa and 60 kDa) could be detected in PAF-stimulated rabbit platelets. 
They explained the low number of tyrosine phosphorylated bands detected in their 
study compared to a greater number detected in previous studies (Ferrell and Martin, 
1988; Nakamura and Yamamura, 1989; Golden and Brugge, 1989) as being due to 
the fact that a polyclonal anti-phosphotyrosine antibody had been used in previous 
studies which might have exhibited broader specificity, compared to the monoclonal 
anti-phosphotyrosine antibody used in their study. However, this seems an unlikely 
explanation, as in our study both a monoclonal anti-phosphotyrosine antibody and a 
polyclonal anti-phosphotyrosine antibody have been employed and were both found 
to detect at least 17 tyrosine phosphorylated proteins following platelet stimulation 
with PAF.
The finding that proteins are phosphorylated at different times following PAF- 
stimulation suggests the activation of more than one PTKase, although the possibility 
that platelet activation with PAF may be inhibiting more than one tyrosine specific 
phosphatase (PTPase) should not be dismissed (Smilowitz et al. 1991; Lerea et 
al. 1989). Recently, platelets have been found to contain at least five different 
PTKases, namely, pp60^*rc, pp60fyn, pp61hck, pp62ye“ and pp54/58lyn all of which are 
members of the src family (Huang et al. 1991; Horak et al. 1990; Feder and Bishop, 
1990). Platelet lysates contain 3-7 fold higher levels of the tyrosine kinase ppeO0- 
(which is the cellular homolog of the retroviral transforming protein pp60v'*fC) than 
either brain or peripheral blood lymphocytes and 30-50 fold more pp60°^c than 
muscle, spleen, thymus, lymph node, bone marrow or erythrocyte lysates (Golden et 
al. 1986). Indeed ppeo0-*'0 is believed to account for 0.2-0.4%  of total platelet 
protein levels comparable to structural proteins. PPeO*" is also abundant in platelets, 
with a 20-40 fold higher concentration than that in fibroblasts, but with a 5-10 fold 
lower concentration than that of ppeo0^ 0 in platelets (Horak et al. 1990). Indeed the 
levels of ppeO0*"6 are higher than any of the other PTKases so far detected in platelets 
(Huang et al. 1991). Due to its relative abundance in platelets, pp60Mrc has now been
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purified and enzymatically characterised (Feder and Bishop, 1990), and has been 
demonstrated to be one of the major proteins phosphorylated in vitro in membranes 
isolated from platelets (Golden et ai. 1986).
The src family of PTKases, unlike those associated with the EGF and PDGF 
receptors, do not have an extracellular ligand-binding domain, or a membrane 
spanning domain, which suggests that they function at intracellular sites. PP60*"C 
is associated with the cytoplasmic face of cellular membranes (Ferrell et ai. 1990) 
although PTKase activity has also been detected in the cytosolic fraction (Nakamura 
et ai. 1985) of platelets. In particular, ppGO**” has been found to bind to membrane 
proteins of 32, 50, 92 and 105 kDa in a manner which is dependent on amino- 
terminal myristylation and which has a strong preference for pp60°'*rc amino-terminal 
sequences, indeed 10“ of these 50 kDa saturable bindings sites for ppGO0^ 0 have 
been estimated per platelet (Feder and Bishop, 1991). In platelets ppGO*”” is 
translocated from the cytosolic to the membrane fraction upon PAF-stimulation (Dhar 
and Shukla, 1991), although PP60™0 has also been detected in the membranes of 
resting platelets (Ferrell et ai. 1990). It is possible that platelet PTKases may be 
discriminately located on the plasma membrane in order to convey signals from 
transmembrane receptors which have no intrinsic PTKase activity, for example PAF 
receptors (Nakamura et ai. 1991) or thrombin receptors (Vu et ai. 1991). Indeed this 
hypothesis has been demonstrated for the src-like kinase p56lck which is associated 
with the T lymphocyte CD4 and CD8 surface proteins and which is involved in 
relaying intracellular signals (Rudd et ai. 1988). Indeed the rapidity with which 
proteins were tyrosine phosphorylated in PAF-stimulated platelets in this study (<  5 
seconds) would indicate that PTKase(s) was associated either with the PAF receptor 
or a closely associated protein.
It must be considered however, that the increase in tyrosine phosphorylation 
observed in PAF-stimulated platelets could be attributed, even if only in part, to 
inhibition of phosphotyrosine specific phosphatase (PTPase) activity. It must also be 
considered that PTPases may function simply to ensure the transient nature of 
tyrosine phosphorylation. Several protein PTPases have now been identified either
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as integral membrane forms or non-receptor forms and sequence analysis has 
revealed that they possess highly conserved catalytic domains (Tonks and 
Charbonneau, 1989). The structural organisation of CD45, which is the major 
leukocyte-specific antigen and a leukocyte specific member of the PTPase family, 
resembles that of several integral membrane PTKases such as the EGF receptor 
(Trowbridge et at. 1991). This would suggest that CD45 and its transmembrane 
homologs may be capable of initiating a novel mechanism of signal transduction in 
which the early events involve ligand-induced dephosphorylation of tyrosyl residues 
in proteins. Whether transmembrane PTPases are receptors, and if so what the 
identity of their regulatory ligands is, are questions which remain unanswered.
Platelets contain significant amounts of PTPase activity and although the enzymes 
responsible have not yet been identified over 80% of the PTPase activity is 
associated with the membrane particulate fraction (Smilowitz eta/. 1991). Subcellular 
distribution analysis and DEAE Sephacel chromatography suggest that platelets 
contain more than one form of PTPase (Smilowitz et a/. 1991). PTPase activity in 
whole platelets can be almost completely inhibited by sodium orthovanadate and 
ammonium molybdate. In support of this both sodium vanadate and molybdate were 
found to increase tyrosine phosphorylation of several protein and to stimulate 
secretion from the dense granules and a-granules of electropermeabilized platelets 
(Lerea et al. 1989). In relation to the PAF-induced tyrosine phosphorylated proteins 
detected in platelets, it is not possible to say whether their phosphorylation is due to 
PTKase activity or inhibition of PTPase activity. However, the finding that the 
distinct groups of tyrosine phosphorylated proteins were dephosphorylated at different 
times following PAF stimulation would support the presence of more than one PTPase 
enzyme in rabbit platelets. Indeed, one of the tyrosine phosphorylated proteins 
detected in unstimulated platelets (54 kDa) underwent immediate (detected at 2 s) 
dephosphorylation following PAF stimulation. In relation to this, ppGO0^ 0 is normally 
phosphorylated on Tyr-527 in vivo which acts as a negative regulator of its kinase 
activity, and therefore dephosphorylation may be one potential way to activate PP60* 
and other members of the src family (Okada and Nakagawa, 1989). The molecular
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weight of the rapidly dephosphorylated protein in platelets would certainly compare 
well with members of the src family of PTKases possessed by platelets (Huang et 
at. 1991; Horak et al. 1990; Gutkind et al. 1990; Feder and Bishop, 1990). Therefore 
it would be interesting to directly investigate the phosphorylation state and kinase 
activity of ppBO^0 after platelet activation.
Several inhibitors of PTKases have now been developed, these include the 
isoflavone compound genistein (Akiyama et al. 1987), herbimycin A (Uehara and 
Fukazawa, 1991), erbstatin (Umezaka and Imoto, 1991) and ST638 (Watanabe et 
al. 1989). In this study the PTKase inhibitor genistein has been used to investigate 
the role of endogenously activated PTKases. Firstly, it was established that genistein 
inhibited PTKase activity and this was achieved by investigating the effect of 
genistein on tyrosine phosphorylation of proteins following PAF stimulation. Genistein 
alone was found to have little effect on tyrosine phosphorylation of proteins detected 
in unstimulated platelets. However, tyrosine phosphorylation of the three groups of 
proteins which were induced by stimulation with PAF were dose dependency inhibited 
by genistein. Phosphorylation of the two groups of proteins 35-45 kDa and 66-90 
kDa was inhibited by around 90% with 300 //M genistein, whereas this concentration 
inhibited phosphorylation of proteins of the mw range 90-150 kDa but only by around 
50%. This finding further indicates that more than one PTKase is activated following 
PAF stimulation and that there is differential inhibition of these PTKases by genistein. 
The IC60 value for genistein required to inhibit phosphorylation of the two groups of 
tyrosine phosphorylated proteins of 35-45 and 66-90 kDa was around 100 //M and 
that required to inhibit phosphorylation of the 90-150 kDa group was around 300 
jjfsA. These IC60 values are higher than those quoted for genistein to inhibit 
autophosphorylation of the EGF receptor in an A431 cell membrane fraction (2.6 //M) 
or to inhibit phosphorylation of an exogenous substrate in an in vitro assay by the 
EGF receptor (20.4 jjM ) .  Moreover, the IC60 value for genistein to inhibit the 
phosphorylation of exogenous substrates in an in vitro assay by the pp60wc PTKase 
was 30 j jM (Akiyama et al. 1987). However, other studies investigating the effects 
of genistein in intact platelets have found concentrations similar to, or higher than,
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those used in this study were required to inhibit PTKase activity, (Nakashima et 
a/. 1991; Gaudette and Holub, 1990; Dhar et al. 1990), and indeed the ICB0 value for 
inhibition of phosphorylation of the EGF receptor in vivo was 111 jjM (Akiyama et 
ai. 1987). Genistein is a competitive inhibitor with respect to ATP, and therefore the 
concentration of ATP in an in vitro assay will affect the concentration of genistein 
required to inhibit PTKase activity (Akiyama et ai. 1987). In the in vitro assays 
described above, 10 //M ATP was present, as opposed to the mM concentrations 
present in intact cells (Burt et ai. 1976), this would explain the reason why higher 
concentrations of genistein are required to inhibit PTKase activity in an intact platelet 
preparation than in the in vitro assays.
In comparison to its effects on PTKases, genistein is much less potent at 
inhibiting other protein kinases. In an in vitro assay system, genistein was at least 
15 fold more potent at inhibiting PTKase than at inhibiting either PKC or cAMP- 
dependent kinase (Akiyama et ai. 1987). It is believed that this specificity may be due 
to the fact that the structure of genistein is unlike ATP, and therefore although 
competitive with ATP, genistein does not bind to exactly the same site and may 
in fact bind in multiple places in the reaction pathway. It has been suggested that 
genistein can discriminate the dissimilarities in the catalytic site for ATP of the 
different protein kinases (Akiyama et ai. 1987).
Genistein was found to have no effect on basal levels of lns(1,4,5)P3, but pre­
incubation with genistein inhibited PAF-induced lns(1,4,5)P3 elevation measured at 5s 
after PAF addition with an IC50 of 80 /;M. lns(1,4,5)P3 elevation produced by the 
hydrolysis of Ptdlns(4,5)P2 upon activation of PLC is one of the earliest events in the 
signal transduction pathway in PAF stimulated platelets (MacIntyre and Pollock, 1983; 
Murphy et a/. 1991), indicating that genistein sensitive PTKase(s) is exerting an effect 
early in the signal transduction pathway. It is unlikely however, that genistein is 
working by blocking binding of PAF to its receptor as it has been reported that 
[3H]PAF binding was not affected in the presence of either 200 or 500 //M genistein 
(Dhar et ai. 1990).
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In the presence of EGTA to chelate extracellular Ca+ + , genistein inhibited PAF- 
induced [Ca++]j mobilization from the intracellular stores with an ICgo of 120 jjM ,  
similar to the ICB0 value found to inhibit lns(1,4,5)P3. From observations made in this 
thesis it has been suggested that at low concentrations of PAF, there is Ca++ influx 
across the plasma membrane in the absence of lns(1,4,5)P3 elevation and therefore 
that this Ca+ + influx may be due to a ROC. Genistein was also found to inhibit 
[Ca++]j elevation through this pathway although the IC60 for this was slightly lower 
at around 60 /sM. Moreover, [Ca++]( elevation resulting from both mobilization and 
influx across the plasma membrane, was also inhibited by genistein with an IC60 of 
100 //M.
The effect of genistein on lns(1,4,5)P3 elevation agrees with other studies 
demonstrating that both genistein (Dhar et al. 1990) and erbstatin (Salari et al. 1990) 
are capable of inhibiting elevation of total [3H]lnsP3 (as opposed to the physiologically 
relevant lns(1,4,5)P3 investigated in this study) in PAF stimulated rabbit platelets. 
However, this study is the first to demonstrate the effect of genistein on [Ca + +], 
elevation in platelets. The inhibitory effect of genistein on lns(1,4,5)P3 elevation and 
[Ca++], is in direct contrast to the potentiating effects of the selective PKC inhibitors 
(Ro 31-7549/001 and Ro 31-8220/002) or the non-selective PKC inhibitor 
staurosporine on these two signal molecules. This would further suggest that these 
inhibitors are selective for a particular protein kinase. However, as yet it has not 
been determined whether genistein is more selective for one particular PTKase than 
another.
It is interesting to note that whilst genistein has an inhibitory effect on platelet 
activation induced by several agonists, it appears that in thrombin stimulated platelets 
PTKase activity may not have such an important role (Nakashima et al. 1991; Dhar 
etal. 1990). Genistein pretreatment has been found to only partially reduce thrombin- 
induced [3HllnsP3 elevation (Dhar et al. 1990), whilst having no effect on thrombin 
induced sn-1,2-DAG or PA elevation in rabbit platelets (Nakashima et at. 1991). 
Moreover, in our laboratory concentrations of genistein found to almost completely 
inhibit sub-maximal PAF-induced dense granule release had no effect on either
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submaximal a or r-thrombin-induced dense granule release, suggesting that production 
of these signal molecules and platelet functional responses are, at best, only partially 
dependent on PTKase activity in thrombin-stimulated platelets.
One study has produced evidence that genistein is responsible for the inhibition 
of T x A 2 binding to its receptors on platelets (Nakashima et al. 1991) and therefore 
agonists, such as collagen, which depend on the production of TxA2 and on the 
subsequent binding of TxA2 to its receptors in order to elicit platelet activation, will 
not activate platelets in the presence of genistein. In their study Nakashima & 
colleagues demonstrated that genistein only had a slight inhibitory effect on thrombin- 
induced tyrosine phosphorylation, signal molecule production and functional 
responses, and it was suggested that this may be due to the fact that thrombin- 
induced platelet activation is for the most part independent of TxA2 production and 
the subsequent binding to its platelet receptors (Nakashima et al. 1991). In PAF 
stimulated platelets, PLC activity is also independent of TxA2 generation (as has been 
demonstrated by the lack of effect of indomethacin on PAF-induced sn-1,2-DAG 
production), however, despite this genistein inhibited tyrosine phosphorylation, signal 
molecule production and the functional responses: dense granule release, TxB2 
generation and aggregation. Indeed, genistein inhibited TxB2 generation more potently 
than other functional responses with an IC50 of 10 //M and to such an extent that 
there is almost complete inhibition of TxB2 generation by 30 //M genistein. At this 
concentration of genistein, dense granule release and [Ca++]j elevation were only 
marginally inhibited, which would again suggest that PAF-induced platelet activation 
is independent of TxA2 production. Moreover it would suggest that neither inhibition 
of T x A 2 generation nor inhibition of its binding to specific receptors could be 
responsible for the effects of genistein in PAF-stimulated platelets.
It has previously been demonstrated that as well as being present in surface 
membrane and cytosol, pp60c'*rc is present in the dense granule membranes of 
platelets (Rendu et al. 1989) and in the chromaffin granule membrane of adrenal 
medullary cells (Parsons and Creutz, 1986). This would suggest that PTKase may
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have a role in granule secretion, and indeed in this thesis it is demonstrated that 
inhibition of PTKase activity with genistein inhibits dense granule release.
In agreement with the effect of genistein on PAF-induced functional responses, 
it has recently been demonstrated that genistein inhibits platelet aggregation in 
platelets stimulated with other agonists including collagen or the TxA2 analogs 
U46619 and STA2 (Nakashima eta/. 1991) or with PAF (Dhar eta/. 1990) and indeed 
the PTKase inhibitor erbstatin also inhibits PAF-induced aggregation of rabbit platelets 
(Salari et a/. 1990). Recent studies suggest a functional relationship between several 
PTKases and the specific adhesive receptor, namely GPIIb/llla, a receptor for 
fibrinogen and von Willebrand factor (Ferrell and Martin, 1989; Golden eta /. 1990). 
Agonist-induced platelet activation causes GPIIb/llla to undergo a conformational 
change and allow binding of fibrinogen and von Willebrand factor, the mechanism 
responsible for this conformational change is unknown, however it is possible that 
it may be due either directly or indirectly to phosphorylation (Elmore et a/. 1990).
Two separate groups have found that phosphorylation of specific platelet proteins 
is dependent on GPIIb/llla activation and fibrinogen binding (Golden eta/. 1990; Ferrell 
and Martin, 1989). In one study Golden et a! found that three proteins of 84,95 & 
97 kDa (Golden eta/. 1990) were phosphorylated within 30 seconds which coincided 
with platelet aggregation (Golden and Brugge, 1989), in another study Ferrel & Martin 
found that phosphorylation of three proteins of 100,108  and 126 kDa also coincided 
with platelet aggregation (Ferrell and Martin, 1989) and it is probable that despite the 
differences in the electrophoretic mobilities of the proteins the two groups were 
reporting the same event. Phosphorylation of these proteins could be inhibited if 
binding of fibrinogen was prevented with the addition of the peptide Arg-Gly-Asp or 
an inhibitory monoclonal antibody, or indeed if the GPIIb/llla receptor was disrupted 
by EGTA (Golden et a/. 1990). Furthermore, phosphorylation of these proteins was 
not induced if thrombasthenic platelets congenitally deficient in GPIIb/llla were used 
(Ferrell and Martin, 1989). Moreover, although GPIIb/llla activation and fibrinogen 
binding are necessary for activation of this PTKase activity, they are not sufficient 
alone, as only in conditions where platelets were stirred and allowed to aggregate
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was phosphorylation of these proteins observed (Golden et al. 1990). It is possible 
that this aggregation dependent phosphorylation may be required for events 
associated with aggregation, or downstream of aggregation.
In agreement with these findings, in this study tyrosine phosphorylation of several 
larger molecular weight proteins of 90-150 kDa was detected and also found to 
coincide with aggregation in PAF-stimulated platelets. In all experiments investigating 
tyrosine phosphorylation, platelets were continually stirred and allowed to aggregate, 
therefore fulfilling the conditions required for phosphorylation of aggregation 
dependent PTKase substrates (Golden et al. 1990). Therefore it is possible that the 
larger molecular weight tyrosine phosphorylated proteins detected in PAF stimulated 
platelets may be the same as those described in previous studies (Ferrell and Martin, 
1989; Golden et al. 1990). It is possible that genistein, in preventing platelet 
aggregation, may be subsequently preventing aggregation dependent phosphorylation 
of these larger molecular weight proteins. Indeed the incomplete inhibition of 
aggregation by 300 jjM genistein, which completely inhibits lns(1,4,5)P3 elevation, 
correlates with the finding that 300 jjM\ genistein only inhibits phosphorylation of 
these higher molecular weight proteins by 50 percent.
Several studies have investigated the substrates for PTKases activity, and many 
of the substrates are signal molecules in their own right. Members of the src family 
contain two protein domains, namely the SH2 and SH3 regions, and it appears that 
many of the substrates also possess a SH2 sequence and this region may mediate 
the interaction between the substrate and the PTKase. PLC-r has been demonstrated 
to contain a SH2 region and has been shown to be a substrate for both the PDGF 
and EGF receptor PTKases in vitro and in vivo (Meisenhelder et at. 1989). The 
molecular weight of PLC-r is around 130 kDa, and indeed the presence of PLC-r2 has 
been detected in platelets (Banno et al. 1990). Although there is no direct evidence 
that PLC is a substrate of PTKase in platelets, it is possible that certain receptors 
may be capable of recruiting a soluble PTKase and activating PLC-r by a mechanism 
similar to that described for the EGF receptor. In addition, annexins are also 
phosphorylated by PTKases both in vitro and in vivo, and the finding in this study
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that platelets possess several members of the annexin family would make them 
possible contenders as substrates of PTKase. Moreover, it is known that PTKases 
are capable of autophosphorylation (Feder and Bishop, 1990; Cantley et ai. 1991) and 
are themselves substratesJof other PTKases (Okada and Nakagawa, 1989). The 
molecular weight of the PTKases known to exist in platelets of 54-62 kDa correlates 
well with the tyrosine phosphorylated proteins detected in unstimulated platelets of 
52-62 kDa in this study. Therefore, considering their abundance in platelets, it is 
possible that some of the proteins detected by anti-phosphotyrosine antibodies may 
be PTKases of the src family. Other abundant proteins in platelets are the 
cytosketetal proteins including actin, myosin, vinculin and tubulin, PTKases are known 
to associate with the cytoskeleton, and it is possible that these proteins may also be 
substrates for PTKases in platelets, as found in Rous sarcoma virus transformed cells, 
reviewed in (Burridge et al. 1988). It is possible that phosphorylation of these 
structural proteins may alter the local conformation of the cytoskeleton, possibly 
increasing anchoring points for enzymes associated with PTKase activity (Grondin et 
al. 1991).
Investigations into the interactions between PTKases and PKC have demonstrated 
that ppBO^0 is a substrate for PKC, being rapidly phosphorylated at Ser-12 in 
platelets treated with thrombin (Ferrell and Martin, 1988). Although, as 
phosphorylation at Ser-12 did not alter the kinase activity of ppBO**"5 either in vitro 
or in vivo the purpose of this phosphorylation is not apparent (Ferrell and Martin, 
1988). However, activation of PKC with the phorbol ester TPA did cause an 
increased translocation of PTKase activity to the platelet membrane (Ishihara et 
ai. 1989).
Associated with the cytoskeleton of A431 cells are Ptdlns kinases, DAG kinase 
and PLC. Treatment of the cells with EGF increases the activity of these kinases 
suggesting that their association may play a role in signal transduction induced by 
EGF by providing a matrix for the various components involved in signal transduction 
(Payrastre et ai. 1991). Platelet PTKases have also been demonstrated to form 
multimeric complexes, for example, ppBO^0 and pp59fyn have been demonstrated to
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associate with phosphatidyiinositol 3-kinase activity within 5 s of platelet activation 
with thrombin, and this correlates with the increase in 3-phosphorylated 
phosphoinositides, suggesting a role for nonreceptor PTKases in platelet signal 
transduction (Gutkind et a!. 1990). Ptdlns(3)kinase, only recently described in 
platelets, is activated upon platelet stimulation with a number of agonists to generate 
both Ptdlns(3,4)P2 (Nolan and Lapetina, 1990) and Ptdlns(3,4,5)P3 (Kucera and 
Rittenhouse, 1990). The function of these novel phosphoinosito! lipids is unknown 
at present, although it is thought that they do not provide a substrate for PLC 
(Nozawa et al. 1991), but may be signal molecules in their own right (Gutkind et 
al. 1990). Moreover, it has been demonstrated that upon platelet activation there is 
not only a translocation of pp60°'*rc (Dhar and Shukla, 1991) to the membrane, but 
the cytoskeletal activities of Ptdlns(4)kinase, Ptdlns(3)kinase, DAG kinase and PLCr 
are also increased, and it is possible that these enzymes may be regulated by 
phosphorylation (Gutkind et al. 1990; Grondin efa/.1991). Recently the membrane 
glycoprotein IV (CD36), was found to be physically associated with three platelet 
PTKases, namely pp59fyn, pp62y#* and pp54/58hrn (Huang et a i 1991). The natural 
ligand of CD36 is uncertain but it is thought possibly to be either thrombospondin 
or collagen, for review see Shattil and Brugge (1991). Thrombospondin is the major 
protein secreted from or-granules and is believed to serve as an extracellular bridge 
between GPIV and the fibrinogen liganded form of GPIIb/llla, indeed, the finding that 
monoclonal antibodies to CD36 induce platelet aggregation and secretion, support a 
role for CD36 as a signalling receptor (Shattil and Brugge, 1991). This finding 
therefore supports the possibility that receptors which do not contain intrinsic PTKase 
activity may, upon stimulation, recruit soluble PTKase(s), which then regulate 
enzymes involved in signal transduction.
In this study inhibition of PTKase activity with genistein caused an inhibition of 
lns(1,4,5)P3 elevation, which would indicate either an inhibition of PLC activity or 
substrate availability, and indeed in another study evidence is provided that PTKase 
regulates the levels of Ptdlns(4,5)P2 and Ptdlns(4)P, which are the substrates of PLC 
(Gaudette and Holub, 1990). The rapidity at which proteins are phosphorylated on
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tyrosine, and the finding that lns(1,4,5)P3 elevation is inhibited by genistein together 
with the knowledge that the PAF receptor has no intrinsic PTKase activity would 
suggest that PTKase is activated at a very early post-receptor level. Indeed, drawing 
an analogy from the CD36 receptor, it is possible to speculate that activation of the 
PAF receptor is able to induce and possibly complex with PTKase(s) of the src family, 
which then regulate critical enzymes of the signal transduction pathway, (figure 67) 
either by the formation of complexes as has been demonstrated with pp60<s‘*fC, p59fyn 
and Ptdlns(3)kinase in platelets (Gutkind et al. 1990), or by an association of the 
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Fig 67 Schematic diagram showing the putative role of PTKase(s) in platelet signal transduction
4.2.6 Summary of Discussion
The aim of this study was to further elucidate the signal transduction pathway 
of PAF-stimulated platelets and to investigate the role of protein phosphorylation in 
platelet signal transduction, in particular, to examine the role of PKC and PTKase in 
PAF-induced platelet activation. This work has been performed by determining the 
modulatory role of PKC and PTKase on signal molecules elevation, including sn-1,2- 
DAG, lns(1,4,5)P3, [Ca++]j and protein phosphorylation together with the modulatory 
role of PKC and PTKase on platelet functional responses including aggregation, dense 
granule release and Tx generation.
Initially, the role of PKC in modulating platelet functional responses was 
investigated. To assess where in the signal transduction pathway PKC was exerting 
its effects platelets were activated either with a receptor-operated stimulus, namely 
PAF or by direct elevation of [Ca++]j (ionomycin) or with AA which is converted into 
TxB2. PKC activity was modified either by exogenously activating PKC (using either 
a phorbol ester (TPA) or a membrane permeant DAG) or by inhibiting its action with 
the use of a non-specific protein kinase inhibitor, namely staurosporine. Activation 
of PKC caused an inhibition of PAF-induced [Ca + +], elevation and TxB2 generation 
whilst having no significant effect on dense granule release, whilst staurosporine 
increased the duration of [Ca++], and potentiated TxB2 generation whilst inhibiting 
dense granule release and platelet aggregation. In ionomycin stimulated platelets 
modulation of PKC activity had no effect on [Ca++]j elevation, but in contrast to PAF- 
stimulated platelets, activation of PKC potentiated both dense granule release and 
TxB2 generation whilst staurosporine caused an inhibition of TxB2 generation and 5- 
HT release. Thus the effect of PKC modulation in platelets stimulated with ionomycin 
differs greatly from that in receptor-activated platelets, and makes the use of 
ionophores together with PKC activators a poor model to use to investigate the role 
of endogenously activated PKC. Modulation of PKC did not affect AA-induced TxB2 
generation suggesting the site of PKC modulation was not at the level of the cyclo- 
oxygenase pathway or thromboxane synthetase.
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The findings from this part of the study produced evidence that endogenously 
activated PKC was exerting a negative feedback role in PAF-stimulated platelets, 
however, when [Ca**], elevation was not modified (as in ionomycin stimulated 
platelets) the relationship between the state of PKC activation and subsequent 
platelet functional responses corresponded more closely. It appeared that in PAF- 
stimulated platelets the effect of PKC activation/inhibition on [Ca++], elevation was 
important in modulating TxB2 generation. Moreover, the findings of this study also 
demonstrated that a different type of relationship existed between PKC and dense 
granule release than between PKC and TxB2 generation in PAF-stimulated platelets.
Next, the temporal and dose-response relationships of PAF-induced changes in 
the concentration of [Ca++]j, lns(1,4,5)P3 and sn-1,2-DAG were examined together 
with the influence of PKC on production of these signal molecules. In high-dose PAF- 
activated platelets, all three signal molecules increased rapidly and transiently, with 
the peak lns(1,4,5)P3 concentration preceding maximal elevation of [Ca++1, by 5s, 
supporting the proposal that lns(1,4,5)P3 is responsible for the mobilization of 
intracellular Ca+ + stores. In low-dose PAF-activated platelets there was an increase 
in [Ca++]j and dense granule release, without any increase in lns(1,4,5)P3, sn-1,2- 
DAG or 40-47 kDa protein phosphorylation. Staurosporine, caused potentiated 
elevations in the concentrations of lns(1,4,5)P3, DAG, TxB2 generation and the 
duration of the Ca+ + signal in platelets stimulated with high dose, but not low-dose 
PAF suggesting that inhibition of PKC was removing the negative-feedback exerted 
by endogenously activated PKC over PLC. These results suggest that in platelets 
activated by a low concentration of agonist, mechanisms other than Ptd!ns(4,5)P2 
hydrolysis are utilized for platelet activation, with the possibility that low-dose PAF 
stimulation may increase [Ca ++]j through the opening of ROCs. In addition, the 
findings also demonstrate that endogenously activated PKC operates as a powerful 
negative-feedback regulator of signal molecules.
During the course of this study several selective inhibitors of PKC were developed 
including calphostin C and the Roche compounds Ro 31-8220/002 and Ro 31- 
7549/001. Until their development most studies investigating the role of PKC in
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intact cells had employed either activators of PKC (such as phorbol esters or 
membrane permeant DAG) or non-specific inhibitors of PKC. It was important to 
confirm that the findings made in this study using staurosporine could be attributed 
to its inhibitory effects on PKC rather than its non-specific inhibitory effects on other 
protein kinases. Experiments performed with the Ro compounds gave essentially the 
same results as those using staurosporine. In common with staurosporine the Ro 
compounds caused a potentiation in both the duration of the Ca+ + signal and TxB2 
generation, whilst inhibiting both dense granule release and aggregation, confirming 
a bifurcation role for PKC in PAF-stimulated platelets. One difference however, was 
in the ability of the Ro compounds to totally inhibit PAF-induced platelet aggregation, 
whilst staurosporine was found to only be capable of partial inhibition. It is possible 
that staurosporine was inhibiting another protein kinase which was counteracting the 
effect of PKC inhibition on platelet aggregation. Experiments performed with 
calphostin C however produced very different results to those obtained with either 
staurosporine or either of the Ro compounds. It is interesting that since the time of 
the first report on calphostin C in 1989, there has been only one other publication 
regarding calphostin C, where it was found that the margin between the 
concentration of calphostin C able to inhibit PKC and that which was found to be 
cytotoxic was very narrow and indeed in an intact cell preparation this margin 
became even smaller. It is probable therefore that the effects of calphostin C on 
platelet functional responses observed in this study were not due to its inhibitory 
effect on PKC.
The finding that PKC was able to modulate PLA2 activity introduced the possibility 
that annexin, whose activation has been reported to depend on its state of 
phosphorylation may be responsible for the regulation of PLA2 activity. Platelets were 
demonstrated to possess molecules related to annexins I, II and V, with a total 
concentration of 10 ng annexin 1/109 platelets. The annexin-like proteins were 
intracellular in location, and were not released from granules upon platelet activation 
with a number of stimulants which possessed separate mechanisms of platelet
244
activation. Having now identified the presence of annexins in platelets, it would be 
interesting to determine if they are substrates of either PTKase or PKC in an intact 
platelet preparation.
Finally, tyrosine phosphorylation of proteins in PAF-stimulated platelets was 
characterised and the role of endogenously activated PTKase(s) in platelet signal 
transduction was investigated using the PTKase inhibitor genistein. One group of 
tyrosine phosphorylated platelets was present in unstimulated platelets, but following 
PAF stimulation there were several further temporal waves of tyrosine 
phosphorylation, with two groups of protein substrates phosphorylated within 5s 
post-PAF and a further group phosphorylated at 30s post-PAF. This finding, together 
with the observation that genistein inhibited all groups of PAF-induced tyrosine 
phosphorylation but to different extents, may suggest that PAF is responsible for the 
activation of more than one PTKase. Genistein inhibited elevation of lns(1,4,5)P3 and 
[Ca++], in PAF-stimulated platelets, indicating that endogenously activated genistein- 
sensitive PTKase(s) has a pivotal role in the early stages of PAF-induced platelet 
activation. Moreover, genistein also caused the inhibition of PAF-induced TxB2 
generation, dense granule release and aggregation, whether this was due to a direct 
modulatory role of PTKase(s) on these functional responses, or whether their 
inhibition was as a result of the inhibition of [Ca ++], elevation is not yet known. 
These findings suggest that PTKase(s) holds a modulatory role in the signal 
transduction pathway, the extent of that role will be revealed with the future 
identification of which PTKases are activated following agonist stimulation, together 
with the identification of their substrates and the determination of the endogenous 
regulators of PTKase activity, coupled with their relationship to platelet PTPase 
activity.
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5. INHIBITORS OF PLA TELET FUNCTION AS ANTITHROMBOTIC DRUGS
5.1 Modulation of aspects of platelet activation and signal transduction as
mechanisms of regulating platelet function.
Occlusive vascular disease is the major cause of death in the Western World, and 
there is overwhelming clinical and experimental evidence that platelets contribute to 
the pathogenesis of stroke, pulmonary embolism, myocardial infarction and 
atherosclerosis (Harker and Ritchie, 198C; Maseri et ai. 1980). Appreciation of the 
contribution of platelets in thromboembolic disorders has increased immensely during 
the past 25 years. With increasing knowledge of platelet activation has been 
progress into the development of drugs to counteract their pathological role. Platelet 
functional responses involved in both haemostasis and intravascular thrombosis 
include a) the adhesion of platelets to the vascular wall at sites of vessel injury, b) 
the ensuing formation of platelet aggregates, c) the release of pro-aggregatory 
substances (as well as platelet derived growth factor which will induce proliferation 
of smooth muscle cells of the vessel wall) from the granules and d) the generation 
of arachidonic acid metabolites including TxA2 and PGH2 (and also possibly PAF). 
Identification of these components has enabled the development of drugs capable of 
inhibiting different platelet functional responses. An agent designed as an 
antithrombotic drug, by its property of inhibiting platelet activation should be selective 
for platelets over all other cell types. For example, aspirin which is an inhibitor of the 
cyclo-oxygenase pathway is thought, at certain concentrations, to spare the 
generation of PGI2 by endothelial cells whilst inhibiting the TxA2 generation by 
platelets, and moreover whilst aspirin irreversibly acetylates platelet cylo-oxygenase, 
the cells of the vessel wall are able to resynthesize cyclo-oxygenase and therefore 
regain the ability to generate PGI2. An ideal antiplatelet drug would, however, be 
specific for platelets whilst having no affect on the function of any other cell type. 
Another important consideration in employing an inhibitor of platelet function as an 
antithrombotic treatment is recognising the balance between controlling thrombosis 
whilst allowing the role of platelets in haemostasis to proceed in as near normal a 
manner as possible. As thrombosis is known to be the pathological extension of
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normal haemostasis, this may be a difficult criteria to accomplish, unless differences 
can be distinguished between platelets involved in normal haemostasis and those 
involved in thrombosis. The balance between the beneficial role of antiplatelet drugs 
in treating thrombosis and the disadvantage to normal haemostasis will obviously 
depend on the extent to which platelet function is inhibited. It will also depend on 
the particular requirements of a patient, for example the benefits of an antiplatelet 
treatment to a patient who is already suffering from occlusive vascular disease and 
who is at risk of death from this may outweight the disadvantages of imperfect 
haemostasis.
In order to assess the ability of a drug to inhibit platelet function, several in vitro 
assays are available. The development of the Born aggregometer (Born, 1962) 
enabled the ability of putative antiplatelet drugs to be assessed in vitro on platelet 
aggregation. Other in vitro assays include adherence of platelets to artificial surfaces, 
collagen and subendothelium. However, although in vitro assays will give some 
indication of the ability of a compound to inhibit platelet function, in vivo testing will 
allow the effect of agents to be examined on platelets which are present in 
physiological conditions, with all blood components present, with vessel wall/platelet 
interactions preserved and in the absence of anticoagulant which is present in most 
in vitro studies. In addition, it allows the drug to be tested at concentrations which 
can be achieved clinically, the active metabolites of the drug as well as its side 
effects can also be assessed, together with information on the length of time for 
which the drug will remain active (Fuster et al. 1987). The in vivo platelet functions 
are then assessed by measuring bleeding time, platelet survival and turnover and 
examination of plasma for materials released from platelets such as thromboxane B2 
(Kyrle et ai. 1986).
In addition to identifying the functional responses of activated platelets, which 
lead to thrombosis, and which can be assayed in vitro in the search for 
antithrombotic drugs, research over the past 20 years has done much to clarify the 
biochemical mechanisms responsible for stimulus-response coupling. One of the most 
important breakthroughs was the elucidation of the pathway for AA metabolism, and
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the identification of its active metabolites including cyclic endoperoxides and TxA2 
which are responsible for platelet activation and vasoconstriction (Hamberg et 
al. 1975). It seems paradoxical therefore that aspirin was identified as a platelet 
inhibitor (O'Brian, 1968) in advance of it being identified as an irreversible inhibitor 
of AA metabolism and ironic that in parallel with a further twenty years of platelet 
research, aspirin has probably been one of the most clinically researched 
antithrombotic drugs. Other drugs have been developed to modulate the AA pathway 
and these include inhibitors of the cyclo-oxygenase pathway and TxA2 synthetase, 
reviewed in (Fuster et al. 1987). A highly specific antagonist of the TxA2/PGH2 
receptors may also prove useful in eliminating the effects of TxA2 whilst sparing the 
effects of PGI2. These drugs however have the disadvantage that they will only 
affect TxA2-dependent thrombus formation.
Platelets are now known to be inhibited in vivo by the physiological agents PGI2 
and EDRF which are derived from endothelial cells and inhibit platelet activation 
respectively by increasing cAMP and cGMP levels (Whittle et al. 1985; Radomski et 
al. 1987b). Advantage has been taken of the mechanism of action of these natural 
inhibitors in the development of longer lasting analogues of PGI2 working at the same 
receptor as PGI2. However, the use of PGI2 clinically is limited by its host of other 
biological activities, including a lowering of diastolic pressure by reducing arteriolar 
resistance due to the potent vascular smooth muscle relaxing properties of 
prostacyclin (Moncada et al. 1976). Another drug which works on the same principle 
of elevating cAMP levels is the phosphodiesterase inhibitor dipyridamole in addition 
this drug is believed to inhibit vascular and erythrocyte adenosine uptake, elevating 
the plasma adenosine level, which is also inhibitory to platelets (Packham and 
Mustard, 1980). Moreover, a nitric oxide (NO) pathway is now believed to be 
present in platelets, which is inhibited by NG-Monomethyl-L-arginine, a selective 
inhibitor of NO synthesis (Radomski et al. 1990). The NO pathway is activated by 
several agonists to form NO which modulates platelet activity by increasing cGMP. 
It is possible that modulation in the activity of this pathway may introduce a novel 
mechanism of therapeutic significance.
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The platelet surface is now known to be the location of the surface-catalysed 
conversion of pre-enzymes into enzymes in the coagulation cascade, which also 
includes the dynamic generation of thrombin. Thrombin is thought to be one of the 
most potent platelet aggregatory agents and its formation on the surface of platelets 
would anticipate a high local concentration. Therefore research has been invested 
into thrombin receptor antagonists and drugs which inhibit thrombin formation, most 
notably heparin which blocks the action of thrombin and through its effect on 
antithrombin III, inhibits early steps of the coagulation sequence (Packham and 
Mustard, 1980). However, only thrombin-dependent thrombus formation would be 
expected to be inhibited by these drugs, and other cell types possessing thrombin 
receptors would also be affected by thrombin receptor antagonists unless selectivity 
of a platelet thrombin receptor antagonist could be achieved. The thrgmbin receptor 
has however recently been cloned and shown to transmit transmembrane signals by 
a novel mechanism in which thrombin cleaves its receptor's amino-terminal extension 
to create a new receptor amino terminus that functions as a bound ligand, this novel 
mechanism of receptor activation may allow the development of specific antagonists 
to the thrombin receptor (Vu et al. 1991). Another receptor which has also recently 
been cloned is the receptor for platelet-activating factor, which has led to the first 
direct evidence that receptor activation induces phosphoinositide turnover through G- 
proteins (Nakamura et al. 1991). The procurement of human PAF receptor cDNA 
should create the opportunity for the development of therapeutic drugs.
Agents which inhibit platelet functional responses by other mechanisms include 
sulfinpyrazone, which is thought to inhibit platelet cyclo-oxygenase in a competitive 
manner, although it is also believed to have an endothelial protective effect for which 
no mechanism has been defined. However, whereas sulfinpyrazone has a significant 
beneficial effect in preventing sudden death due to myocardial infarction in one study 
it has proven ineffective in two clinical trials where its effect in stroke and unstable 
angina were monitored. Another drug, ticlopidine however appears more promising, 
it has been demonstrated to inhibit ADP induced aggregation and also aggregation
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and release induced by collagen, epinephrine, AA and thrombin reviewed in (Packham 
and Mustard, 1980). Although the mechanism of this drug is unknown, it is thought 
possibly to act on the plasma membrane to alter its reactivity to activating stimuli, 
perhaps by blocking von Willebrand factor and fibrinogen interactions with platelets, 
reviewed in (Fuster et al. 1987).
Ca++ is one of the most important signal molecules and is of central importance 
in cell activation, therefore regulating the elevation of [Ca++], could be one mechanism 
of governing platelet activation. One possibility for an antiplatelet drug could be a 
Ca++ channel blocker, which would impair Ca + + movement into platelets. There is 
now evidence for the presence of receptor operated channels (ROC) in platelets which 
are capable of carrying a Ca++ current and are dependent on ADP (Mahaut-Smith et 
al. 1990). The data presented in this study also provide evidence for the presence 
of a ROC able to carry Ca + + ions, coupled to the PAF receptor. Recently, the Ca+ + 
channel blocking compound SKF 96365 was demonstrated to inhibit agonist-induced 
aggregation in thrombin-stimulated platelets (Merritt et al. 1990), and although this 
compound was relatively weak, it represents a possible starting point for the 
development of more potent and selective Ca + + channel blockers.
Mobilization of Ca + + from intracellular stores has recently been identified as a 
function of lns(1,4,5)P3 binding to specific receptors on internal Ca++ stores. One 
of the recent major advances in Ca++ signalling has been the cloning and sequencing 
of the lns(1,4,5)P3 receptor and the identification of the homology between the 
lns(1,4,5)P3 and the ryanodine receptor, which is the Ca + + releasing channel of 
skeletal muscle (Supattapone et al. 1988; Mignery et al. 1989; Furuichi et al. 1989). 
Platelet activation by most agonists is believed to cause Ca + + mobilization in advance 
of Ca++ influx (Alonso et al. 1991), suggesting that influx is dependent on some 
aspect associated with Ca++ mobilization, for example the production of second 
messengers, or the state of filling of the intracellular dischargeable Ca + + stores (Sage 
et at. 1989). Therefore controlling Ca + + mobilization may also subsequently regulate 
the Ca++ influx component. Having identified the lns(1,4,5)P3 receptor it may now 
be possible to develop receptor antagonists to prevent Ca + + mobilization, indeed the
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receptor is known to bind heparin which is able to displace lns(1,4,5)P3 from the 
receptor and inhibit Ca++ mobilization. The development of synthetic, non 
metabolizable, stable analogues of Insd ,4,5)P3 may also provide a starting point for 
the production of an lns(1,4,5)P3 receptor antagonist, however, these antagonists 
would need to be cell permeant. The finding that there is a variation in the binding 
affinity of Insd ,4,5)P3 for its receptors on different tissues and that the IC60 value for 
heparin to displace lnsd,4,5)P3 from its binding sites is different between rat 
cerebellum and bovine adrenal cortex suggests that there may be heterogeneity 
between Insd ,4,5)P3 receptors (Willcocks and Nahorski, 1989). Distinct binding sites 
for lns(1,4,5)P3 for different tissues would raise the possibility of developing an 
lns(1,4,5)P3 receptor antagonist specific for the lns(1,4,5)P3 receptor of platelets, 
which has recently been characterised (O'Rourke and Feinstein, 1990). An alternative 
mechanism of controlling lnsd,4,5)P3 induced Ca++ mobilization is to control the 
removal of lns(1,4,5)P3. lns(1,4,5)P3 is metabolised by inositol
5'phosphomonoesterase to the inactive metabolite Insd ,4,)P2, therefore potentiating 
the activity of this enzyme would reduce lns(1,4,5)P3 levels and limit [Ca + +]j 
elevation. A recent finding of interest is that the Insd ,4,5)P3 receptor is a substrate 
for cAMP-dependent kinase, suggesting this may be one way in which cAMP levels 
are able to regulate [ C a + + ]j levels (Supattapone et al. 1988).
It is becoming increasingly obvious that platelets as well as being involved in 
haemostasis and the pathological extension of this, namely thrombosis together with 
the conditions which result from thrombosis, also participate in and exacerbate many 
other pathological conditions (section 1.3). It is possible that the production of an 
antiplatelet drug would prove beneficial in the alleviation of these conditions, 
particularly in relation to the number of potential cell stimulants including platelet 
derived growth factor, ADP and serotonin which are released from platelet granules 
following agonist stimulation.
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5.1.1 Regulation of protein kinase C
The results of this thesis and earlier studies demonstrate that increasing [Ca++]j 
with a divalent cation ionophore and activating PKC with a phorbol ester causes a 
synergistic increase in platelet activation. This system was thought to mimic the 
subsequent events of Ptdlns(4,5)P2 hydrolysis (ie [Ca + *], elevation by Insd ,4,5)P3 and 
PKC activation by DAG) in agonist stimulated platelets, and suggests that the 
development of a specific, potent PKC inhibitor, may be useful as an antithrombotic 
drug. However, unfortunately this may not be the case, as in this thesis it has been 
demonstrated that the use of an ionophore together with a phorbol ester represents 
a poor model for agonist-induced platelet activation.
In this and in other studies, it has been demonstrated that exogenous activation 
of PKC in agonist-stimulated platelets causes an inhibition of the two signal molecules 
Insd ,4,5)P3 and sn-1,2-DAG providing evidence that PKC exerts a negative feedback 
role. Therefore it would be expected that inhibition of endogenously activated PKC 
would inhibit this negative feedback, and there would be an increase in the signal 
molecules Insd ,4,5)P3 and sn-1,2-DAG, as indeed has been observed in this study 
using both the non-selective inhibitor staurosporine and the selective PKC inhibitors 
Ro 31-7549/001 and Ro-8220/002, further confirming that PKC exerts a negative 
feedback either directly or indirectly over PLC. Inhibition of PKC in agonist stimulated 
platelets also results in a potentiation of the duration of [Ca++]j elevation and TxB2 
generation, but an inhibition of dense granule release and aggregation. This would 
suggest that PKC has a bifurcating role in platelet activation induced by a 
physiological agent, exerting a positive influence over dense granule release and 
aggregation but a negative influence over Ca + + homeostasis and thromboxane 
generation. Therefore, in vivo an inhibitor of PKC rather than having an 
antithrombotic effect would induce a substantial increase in TxA2 and prostaglandin 
endoperoxides, which could have considerable effects, both in the recruitment of 
platelets to a potential thrombotic region and also due to the ensuing vasoconstrictor 
properties of TxA2.
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It is possible however, with the realisation that PKC is a family of isoenzymes, 
that distinct PKC isoenzymes may be responsible for regulating different platelet 
functional responses. For example, if a PKC isoenzyme was recognized which could 
regulate dense granule release (particularly if this enzyme was unique to platelets) and 
an inhibitor was identified which could selectively inhibit this isoenzyme, this inhibitor 
in association with a cyclo-oxygenase pathway inhibitor, such as aspirin, could be
s '
potentially useful as an antithrombotic treatment.
5.1.2 Regulation of tyrosine phosphorylation
Although the presence of PTKases in platelets has been known for some time 
(Tuy et at. 1983) it was only relatively recently recognised that PTKase was activated 
following platelet stimulation with agonists such as thrombin (Ferrell and Martin, 
1988), collagen (Nakamura and Yamamura, 1989) and PAF (Dhar etal. 1990; Murphy 
and Westwick, 1992). The role of PTKase activity, is unknown in platelets, although 
the rapidity with which substrates are phosphorylated following agonist stimulation, 
together with the effects of PTKase inhibitors suggests that it may be involved in 
signal transduction.
In support of a role for PTKase activity in signal transduction is the finding that 
several inhibitors of PTKase are able to inhibit both platelet signal molecule elevation 
and platelet functional responses in agonist stimulated platelets suggesting that 
endogenously activated PTKase(s) has a positive role in signal transduction (Dhar et 
al. 1990; Salari et al. 1990). Indeed, the results presented in this thesis would 
suggest that PTKase(s) has a regulatory role at an early stage of the signal 
transduction pathway in PAF-stimulated platelets, as inhibition of PTKase activity 
caused an inhibition in the elevation on Insd ,4,5)P3. The identification of PTKase(s) 
present in platelets however, together with their characterisation both in terms of 
their substrates and how they are regulated is at a very early stage. Indeed in other 
cell types PLCr is known to be a substrate of PTKase, and therefore may be 
regulated by phosphorylation. It is not known if PLCr is a substrate of PTKase in
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platelets, but if it is the case, this may introduce a mechanism of controlling platelet 
activation at an early stage of the signal transduction pathway.
The finding that members of the src family associate with membrane receptors 
and that they have a key role in platelet signal transduction, coupled with the 
possibility that platelets (as has been demonstrated in T-lymphocytes) may possess 
a PTKase which is specific to platelets, offers an original therapeutic approach in the 
design of novel anti-thrombotic compounds. Moreover, the fact that PTKase(s) 
appear to regulate an early stage of the signal transduction pathway suggests that 
a PTKase inhibitor would suppress all facets of platelet function.
In association with PTKases, is the growing awareness that PTPases, rather than 
merely being responsible for the transient nature of tyrosine phosphorylation following 
cell activation, may have a more important role. The possibility of receptors with 
intrinsic PTPase activity or which are complexed with cytosolic PTPases introduces 
the prospect of a novel signal transduction pathway, initiated by dephosphorylation 
of tyrosine phosphorylated proteins. Very little is known about the PTPases which 
are possessed by platelets (Smilowitz et al. 1991), except that their inhibition leads 
to an increase in granule release (Lerea et at. 1989). It is possible therefore that 
PTPases may also play an important regulatory role in platelet signal transduction, 
both independently and in association with PTKases, such that the regulation of 
tyrosine phosphorylation may also provide an additional mechanism of controlling 
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The relationship between cytosolic Ca2+, s/i-1,2-diacylglycerol 
and inositol 1,4,5-trisphosphate elevation in platelet-activating- 
factor-stimulated rabbit platelets
Influence of protein kinase C on production of signal molecules
Christine T . M U R P H Y ,*  M o ira  E L M O R E ,f  Stuart K E L L IE f  and John W E S T W IC K * *
‘ Pharmacology, School of Pharmacy and Pharmacology, University of Bath, Bath BA2 7AY, U .K ., 
and tYamanouchi Research Institute (U .K .), Littlemore Hospital, Oxford 0 X 4  4X N , U .K .
The temporal and dose-response relationships of platelet-activating-factor (PAF)-induced changes in the concentrations 
of cytosolic Ca2+ ([Ca2+],), Ins(l,4,5)P3 and 1,2-diacylglycerol (D A G ) were examined. In addition, phosphorylation of 
protein kinase C (PKC) substrate (40-47 kDa protein) was determined. In high-dose PAF-activated platelets, all three 
signal molecules increased rapidly and transiently, with the peak Ins(l,4,5)i>3 concentration preceding maximal elevation 
of [Ca2+]i by 5 s. In low-dose PAF-activated platelets there were large increases in [Ca2+]j and dense-granule release, 
without any increase in Ins(l,4,5)P3 and D A G  or 40-47 kDa protein phosphorylation. Staurosporine, a non-specific PKC  
inhibitor, produced enhanced elevations in the concentrations of Ins(l,4,5)P3, D A G  and thromboxane B2, and the duration 
of the Ca2+ signal in platelets stimulated with a high dose, but not a low dose, of PAF. These results suggest there are 
both phospholipase C-dependent and -independent changes in Ca2+ homoeostasis. Endogenously activated PKC regulates 
the formation of signal molecules.
IN TR O D U C TIO N
Receptor-activated hydrolysis of PtdIns(4,5)P2 via the action 
of phospholipase C generates Ins(l,4,5)Ps (Berridge & Irvine, 
1984) and sn-1,2-diacylglycerol (D A G ) (Rittenhouse-Simmons, 
1979). Both of these products are thought to be intracellular 
signal molecules which regulate certain aspects of cell activation 
(Berridge, 1984, 1987).
Ca2+ mobilization from intracellular stores is induced in 
permeabilized platelets by Ins(l,4,5)P3 (O ’Rourke et al., 1985; 
Brass & Joseph, 1985), whereas influx of Ca2+ across the plasma 
membrane via signal-molecule-operated Ca2+ channels may be 
regulated by Ins(l,4,5)P3 working in concert with one of its 
phosphorylated products, Ins( 1,3,4,5)P4 (Irvine, 1989, 1990). The 
only well-characterized source of Ins(l,4,5)P3 is the hydrolysis 
of PtdIns(4,5)/>2, whereas its removal is regulated either by 
phosphorylation to Ins(l,3,4,5)P4 by Ins(l,4,5)P3 kinase or by 
degradation to Ins(l,4)P2 by 5-phosphomonoesterase (Batty 
etal., 1985; Connolly et al., 1987; Mitchell et al., 1989).
The hydrolysis of (poly)phosphoinositides is probably the 
major source of D A G  (Rittenhouse-Simmons, 1979), although 
an additional source may be via the action of phospholipase D  
on phosphatidylcholine (Pai et al., 1988; Loffelholz, 1989). In 
platelets, however, the presence and role of phospholipase D  
have yet to be verified (Rubin, 1988). Receptor-activated D A G  
elevation is transient, probably owing to its phosphorylation by 
DAG  kinase to phosphatidic acid (Tysnes et al., 1988) and its 
degradation by D A G  lipase to fatty acid and glycerol (Bell et al., 
1979; Mahaevappa &  Holub, 1986). This short-lived increase in 
DAG  is thought to activate protein kinase C (PKC) (Nishizuka, 
1984; Lapetina et al., 1985), a family of ubiquitously distributed 
isoenzymes which have been implicated as having many different 
roles, including the regulation of cell activation (Nishizuka,
1984, 1988). The main substrate for PKC in platelets is a 
40-47 kDa protein of unknown function (Kaibuchi et al., 1983; 
Touqui et al., 1986).
Little work has been carried out on intact platelet preparations 
to study the relationship between the signal molecules cytosolic 
Ca2+, Ins(l,4 ,5)/>3 and D A G . In this study we have determined 
the temporal and dose-response relationships of platelet-acti­
vating-factor (PAF)-induced elevations in [Ca2+]j to changes in 
the levels of Ins(l,4,5)P3 and D A G  in intact rabbit platelets. As 
an alternative experimental approach we have used the potent, 
although non-specific, PKC inhibitor staurosporine (Tamaoki 
et al., 1986) to examine the role of endogenously activated PKC  
in the regulation of receptor-stimulated changes in the con­
centrations of [Ca2+]j, Ins(l,4,5)P3 and D A G .
M A TER IA LS  A N D M E T H O D S  
Materials
Prostacyclin was generously provided by Dr. B. J. R. Whittle, 
Wellcome Laboratories, Beckenham, Kent, U .K . It was stored 
solid and dry at —20 °C, and stock portions were dissolved in 
0.5 M-Tris/HCl (pH 10.5) and were stored at a concentration of 
40 ,«g/40/d at — 20 °C. Immediately before use a portion was 
thawed and diluted as required in 0.01 M-Tris/HCl (pH 10.5), 
and then stored on ice. D A G  assay reagents system (code 
RPN 200), [3H]Ins(l,4,5)P3 assay system (code T R K  1000), 
[32P]ATP (3 Ci/mmol), 5-hydroxy[14C]tryptamine (5-HT) 
creatinine sulphate (54m Ci/m m ol, 50//,Ci/m l) and [32P]P; 
(5 m Ci/m l) were purchased from Amersham International, thin- 
layer plates (silica gel 60 H PTLC aluminium; 20 cm x 20 cm) 
were purchased from Merck, and X-ray film was from Fuji. 
Fura-2 A M  (acetoxymethyl ester; cell-permeant) obtained from 
Molecular Probes, Eugene, OR, U.S.A. was stored dry at
Abbreviations used: DAG, 1,2-diacylglycerol; [Ca2+]4, cytosolic Ca2+ concn.; [Ca2+]e, extracellular Ca2+ concn.; PAF, platelet-activating factor; 
PKC, protein kinase C; HBT, Hepes-buffered Tyrode’s solution; TxB2, thromboxane B2; 5-HT, 5-hydroxytryptamine; PMA, phorbol 12-myristate 
13-acetate.
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—20 °C. A  stock solution at a concentration o f 5m M in an­
hydrous dimethyl sulphoxide was also stored at — 20 °C. PA F  
(l-0-octadecyl-2-acetyl-j«-glycero-3-phosphocholine) was sup­
plied by Bachem (Bubendorf, Switzerland). A  stock solution of 
10 mM made up in chloroform/methanol (4:1, v /v ) was stored at
— 20 °C, and working solutions (0.1 mM) were prepared in 
Ca2+/M g 2+-free phosphate-bulfered saline to which 2.5 mg of 
BS A /m l had been added. W EB 2086, a gift from D r. H . Huer 
(Boehringer, Ingelheim, Germany), was dissolved in phosphate- 
buffered saline. Phorbol 12-myristate 13-acetate (P M A ) was 
obtained from Sigma, dissolved in dry acetone and stored at
— 20 °C. Staurosporine was purchased from Fluka Chemicals, 
Glossop, U .K ., dissolved in dimethyl sulphoxide and stored at
— 20 °C. Thromboxane B2 (TxB2) standard was obtained from  
Sigma, [3H ]T xB2 (125 Ci/m m ol, 50 nC i/m l) was from New  
England Nuclear, and anti-(rabbit TxB2) antibody was gener­
ously supplied by D r. F. Carey, IC I, Macclesfield, Cheshire, U .K .
Preparation of platelets
Washed rabbit platelets were prepared as described for human 
platelets by Poll &  Westwick (1986), by a modification o f an 
original method by Blackwell et al. (1982). The resulting platelet 
pellet from this preparation was suspended in Hepes-buffered 
Tyrode’s (H B T) solution (10 mM-Hepes, 145 mM-NaCl, 5 mM- 
KC1, 1 m M-MgCl2, 0.5 mM-Na2H P 0 4, 5.5 mM-glucose and 
0.25 %  BSA, p H  7.4) and the platelet count was adjusted.
Protein phosphorylation
Platelets (8 x 109/m l) were incubated for 2 h with 200 f iC i of 
[32P]Pj/m l o f platelets, washed in H B T, and the platelet count 
was adjusted to 109/m l. Batches o f platelets (300 / / I ; 109/m l)  
were equilibrated at 37 °C in the presence o f 1 mM-[Ca2+]e. 
Platelets were incubated with a dose range of PAF, and activation 
was terminated with 300 p \ of 2 x Laemmli (1970) SDS reducing 
gel-sample buffer (100 °C) at 30 s after PA F addition. The 
samples were then boiled for 5 min, and centrifuged at 8000 g  
for 2 min to remove any particles. Proteins (100 /^g/track) were 
separated by SDS/10 % -polyacrylamide-gel electrophoresis; 
protein bands and molecular markers were stained with 
Coomassie Blue, and [32P]phosphorylated bands were observed 
by autoradiography. The phosphorylated bands were excised 
and quantified by liquid-scintillation counting.
Measurement of DAG production
Platelet D A G  production was determined with the D A G  assay 
reagents system (Amersham International, R P N  200), which 
used an adaptation of the method described by Preiss e ta l.  
(1986). Briefly, 1 ml portions o f platelets (109/m l) were dispensed 
into cuvettes and the [Ca2+]e was adjusted to 1 mM. Platelets were 
continually stirred and allowed to equilibrate to 37 °C before 
addition o f drug/vehicle control. A ll drugs were incubated for 
2 min before addition o f PAF. D A G  production was stopped at 
pre-determined times by removing 0.8 ml into 3 ml o f ice-cold 
methanol/chloroform (2:1, v /v ), and samples were extracted by 
a modification o f the method o f Bligh &  Dyer (1959). The assay 
employed was a radio-enzymic assay using Escherichia coli D A G  
kinase and defined mixed-micelle conditions to solubilize the 
D A G  present and allow its quantitative conversion into 
[32P]phosphatidic acid in the presence o f [32P]ATP. The sensitivity 
of the assay was < 1 0  pmol, and the working range was 
31-1000 pmol/tube.
Determination of Ins(l,4,5)P3 production
Experiments were carried out as described for D A G  de­
termination. The reaction was terminated and Ins(l,4,5)P3 was 
extracted by mixing the cell suspension with 0.2 vol of ice-cold
20 % (v /v ) H C 104 and after 20 min sedimenting the proteins by 
centrifugation. The supernatant was then titrated to pH 7.5 with 
1.5 m -KO H containing 60 mM-Hepes buffer and Universal in­
dicator. The Ins(l,4,5)P3 present in the samples was determined 
by use of a binding assay which employed unlabelled Ins(l,4,5)P3, 
[3H]Ins(l,4,5)P3 and a bovine adrenal-membrane preparation 
(Challiss et al., 1988). The sensitivity of the assay was <  0.2 pmol, 
and the working range o f Ins(l,4,5)P3 detected by this assay was 
0.2-25 pmol/tube.
Determination of [Ca2+]j
Platelets were loaded with 2.5 ^M-fura-2 A M  for 30 min at 
37 °C, the platelet suspension was then washed in HBT to 
remove excess fura-2 A M , and the platelet count adjusted to 
2 x 108/m l. To measure the changes in [Ca2+]j, fluorescence 
readings were recorded at 37 °C with an Aminco Bowman 
spectrophotofluorimeter (excitation at 339 nm; emission at 
500 nm ; 4 nm slit width) fitted with a thermostatically regulated 
cuvette compartment holder with stirring attachment. Samples 
(1 ml) of platelets were dispensed into cuvettes, and [Ca2+]e was 
adjusted to 1 mM. The Ca2+-fu ra-2  fluorescence was calibrated as 
we have previously described by using E G T A  quench (Ward & 
Westwick, 1988). Platelets were equilibrated to 37 °C before the 
addition o f drugs or drug vehicles, which were incubated for 
2 min before addition of PAF.
Measurement of percentage [14C]5-HT release
Platelets (8 x 108/m l) were incubated with 200 nCi of [14C]5- 
H T /m l, then washed in H B T, and the count was adjusted to 
2 x 108 platelets/ml. [Ca2+]e was adjusted to 1 mM, and platelets 
were equilibrated to 37 °C before addition of a drug or vehicle 
control. To determine 5-H T  release from the platelets, sub­
samples o f platelets (400 fi\) were withdrawn 3 min after addition 
o f the agonist into ice-cooled tubes containing 40 p\ of 100 mM- 
E D T A  and 30 /tM-indomethacin. The samples were centrifuged 
at 12000 g  for 2 min and 2 x 100 ju\ samples of the supernatant 
were removed and the amount o f [14C]5-HT was determined by 
liquid-scintillation spectroscopy. Percentage 5-HT release was 
determined as previously described (Holmsen e ta l., 1981).
Measurement of TxB2 generation
TxB2 generation was determined in 1 ml samples of platelets 
(2 x 108/m l), with [Ca2+]e adjusted to 1 mM. Platelets were equili­
brated to 37 °C before addition o f drug or drug vehicle, which 
was added 2 min before PAF. To terminate TxB2 generation, 
sub-samples o f platelets (400 /d) were withdrawn at pre­
determined times (3 min unless otherwise stated) into 40 /i\ of 
ice-cold 100 m M -E D TA /30 ^M-indomethacin. The samples were 
centrifuged, the supernatant was removed and the TxB2 content 
determined by radioimmunoassay (Johnston et al., 1984).
Statistics
Data in the Figures are means ± s .e .m . of at least three 
experiments each performed in either duplicate or triplicate. To 
determine the levels of significance between sets of data, a paired 
Student’s t test was employed. The levels of significance are 
denoted by *P  <  0.05, * * P < 0 .0 1 ,  * * * / * <  0.005. The
Bonferroni correction was applied where necessary (Wallenstein 
et al., 1980).
RESULTS
PAF-induced elevation of [Ca2+]j and concentrations of 
Ins(l,4,5)P3 and DAG
Addition o f 300 nM-PAF induced a rapid elevation of platelet 
[Ca2+]j from a basal concentration of 152 +  11 nM (n =  30) to a
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Fig. 1. Time courses for the production of DAG, Ins(l,4,5)/*3 and |Ca2+lj 
in 300 nM-PAF-stimulated platelets
DAG production induced by 300 nM-PAF is shown in (a), and 
I  [Ca2+], elevation (O) together with Ins(l,4,5)P3 elevation (■ )  are 
shown in (b). The values in all Figures were obtained by subtracting 
the basal pre-PAF value from those obtained at the stated times 
after administration of 300 nM-PAF. The values are means + S.E.M.
E of at least three experiments. The s .e .m . bars are absent when 
symbols are larger than the s .e .m .
Table 1. Effect of 2 min pre-treatment with the PAF receptor antagonist 
WEB 2086 on PAF-induced Ins(l,4,5)P, and DAG generation
Treatment
Generation (% of control) 
Ins(l,4,5)P3* DAGJ
Vehicle+  300 nM-PAF 100 100
30 nM-WEB 2086 + 300 nM-PAF 24.0+14 22.5 +  16
300 nM-WEB 2086 + 300 nM-PAF 4.7 +  3.2 0
* Measured 5 s after PAF addition, 
t Measured 10 s after PAF addition.
peak elevation of 1023 ± 7 2  nM at 7.3 ± 0 .6  s (n =  13) after PAF  
addition. This elevation was transient, and quickly declined 
(Fig. 1). Similarly, in the same platelet preparations 300 nM-PAF 
induced a rapid elevation in the concentration of Ins(l,4,5)P3, 
with a peak increase at 2 s o f 38.9 ± 2 .2  pmol/109 platelets above 
a basal level of 9.7 7 ±  1.72 pmol/109 platelets (Fig. 1). This 
elevation rapidly declined to basal levels by 15 s after PAF,
, followed by a gradual increase at 30 and 60 s after PAF.
Superimposition of the Ins(l,4,5)P3 and [Ca2+], time curves 
demonstrates that the Ins(l,4,5)P3 peak clearly precedes the peak 
[Ca2+]j by approx. 5 s.
Platelets had a basal concentration of 117 ±  3 pmol of 
DAG/109 platelets. After addition of 300 nM-PAF, there was a 
rapid and transient increase in the platelet D A G  concentration, 
to a peak at 10 s with a value of 280 ±  52 pm ol/109 platelets 
(« =  9) above basal. After 10 s the concentration of D A G  rapidly 
declined, and by 15 s reached a level above basal, at which it 














Fig. 2. Effect of increasing concentrations of PAF on production of DAG 
and Ins(l,4,5)P, (a) and |Ca2+)j elevation and 5-HT release (A)
DAG incubations were terminated at 10 s after PAF, and those for 
Ins(l,4,5)P3 at 5 s. 5-HT release was terminated at 3 min after 
activation and [Ca2+]( is the peak elevation after stimulation. The 
values were obtained by subtracting the basal pre-PAF value from 
those obtained after addition of PAF. The values are means ±  s .e .m . 






Fig. 3. Effect of replacing 1 mM-Ca2! with 2 mvi-EGTA on PAF-induced 
|Ca2+lj elevation
[Ca2+]j is the value obtained by subtracting the basal pre-PAF value 
from the peak post-PAF value. Each value represents the 
mean + s .e .m . of at least three experiments each performed in 
triplicate. Key: O, control; # ,  +2mM-EGTA.
Addition of PAF vehicle did not produce changes in the basal 
concentrations of [Ca2+]j, Ins(l,4 ,5 )/>3 or D A G  (results not 
shown).
Table 1 demonstrates that pre-treatment of the platelets with 
the PAF-receptor antagonist W EB 2086 (300 nM) inhibited to 
the same degree PAF-induced elevation of Ins(l,4,5)P3 and 
DA G .
Dose-response relationship of PAF-induced platelet activation
The relationship of the concentrations of the three putative 
signal molecules, [Ca2+],, Ins(l,4,5)P3 and D A G , to the release of 
5-HT was determined (Fig. 2).
PAF is a powerful dense-granule releasing agent, and the 
dose-response relationship is shown in Fig. 2(b). The higher
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Fig. 4. Effect of increasing concentrations of PAF on phosphorylation of 
the 40 kDa substrate of PKC
(a) Autoradiograph showing phosphorylation of the 40 kDa 
substrate of PKC by PAF vehicle (track 1) or by 0.3, 3, 30 and 
300 nM-PAF respectively (tracks 2-5) and with 100 nM-PMA (track 
6). The phosphorylated PKC substrate band was excised and 
subjected to scintillation counting, and the results are given in (b) as 
a percentage of phosphorylation with PAF vehicle.
doses of PAF, 30 and 300 nM, which are maximal and supra­
maximal for 5-HT release, produced highly significant 
(P  <  0.005) elevations in [Ca2+]}, in addition to a rise in the 
concentrations of Ins(l,4,5)/>3 (measured at 5 s) and D A G  
(measured at 10 s) (Fig. 2a). However, a lower concentration of 
PAF, such as 3 nM, which induced approx. 60 %  5-HT release 
and a 400 nM increase above the basal [Ca2-^ ,  induced no 
detectable increase in either Ins(l,4,5)P3 or D A G . Replacing 
[Ca2+]. with the Ca2+ chelator E G TA  inhibited [Ca2^  elevation 
at all concentrations of PAF tested (Fig. 3). A t the higher 
concentrations of PAF, 30 and 300 nM, and to a lesser extent at 
3 nM, [Ca2+]j elevation was due to two components, the major 
one being dependent on [Ca2+]e, whereas the minor one was 
independent of [Ca2+]c. A t the lower concentration of 0.3 nM- 
PAF, however, [Ca2+], elevation was completely dependent on 
the presence of [Ca2+]e. In relation to the findings for D A G , 
activation of PKC, measured as phosphorylation of its 40 kDa  
substrate, was increased dose-dependently with increasing con­
centrations of P A F ; 3 nM-PAF induced some activation of PKC  
after 30 s, but, again in agreement with the findings for D A G , no 
phosphorylation with 0.3 nM-PAF was detected (Fig. 4).
These results suggest that there is a good correlation between 
both PtdInsP2 hydrolysis/Ca2+ mobilization and granule release 
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Fig. 5. Effect of PKC activation or inhibition on generation of DAG and 
Ins(l,4,5)P3 induced by 3 nM- and 300 nM-PAF
PKC was pre-activated with 100 nM-PMA or pre-inhibited with 
1 /iM-staurosporine. DAG incubations (b) were terminated 10 s after 
the addition of PAF, and Ins(l,4,5)P3 incubations (a) were 
terminated at 5 s. Each value represents the mean + s.e.m. of at least 
three experiments each performed in duplicate. Key: □ , control; 0,
1 /iM-staurosporine; 0 ,  100 nM-PMA.
Relationship between PKC and PAF-induced platelet activation
To explore the role of endogenous activators of PKC on the 
regulation of PAF-induced formation of Ins(l,4,5)P3, DAG, 
T xB2 and changes in Ca2+ homoeostasis, the effect of the potent 
PKC inhibitor staurosporine on these parameters was examined: 
1 /iM-staurosporine was used, as we have previously 
demonstrated that this concentration inhibits at least 70% of 
PKC activation (Murphy &  Westwick, 1990).
Ins(l,4,5)P3 and DAG. Pretreatment of the platelets with 1 /iM- 
staurosporine did not modify the basal concentrations of either 
Ins(l,4,5)P3 or D A G  (Fig. 5). Thus PKC does not exert a tonic 
control over these parameters in the unstimulated platelets. The 
effect of staurosporine on PAF-stimulated formation of 
Ins(l,4,5)P3 and D A G  was dependent on the concentration of 
PAF employed. Staurosporine produced a 2- and 3-fold en­
hancement of Ins(l,4,5)P3 and D A G  formation respectively in 
response to 300 nM-PAF (Fig. 5). When 3 nM-PAF was used, 
which alone failed to produce an increase in Ins(l,4,5)P3 or DAG 
over the basal levels, pretreatment with staurosporine did not 
produce any detectable increase over this.
Pretreatment of the platelets with the PKC activator PMA 
(100 nM) produced a significant decrease in basal and PAF- 
stimulated levels of D A G  (Fig. 5).
Ca2+ homoeostasis. Pretreatment of platelets with 1/iM- 
staurosporine did not modify the basal [Ca2+]t of platelets (results 
not shown). In addition, preincubation of platelets with 
staurosporine had no significant effect on the rate of elevation or 
the maximum elevation of [Ca2+],, stimulated with either 3 nM- or 
300 nM-PAF (Fig. 6). However, the duration of the Ca2+ signal, 
measured as the time taken to return to half-maximum elevation 
above basal (fi), was significantly potentiated by staurosporine 
for both concentrations of PAF (Fig. 6). The increase in h in 
platelets stimulated with 3 nM-PAF was only 30%, in contrast
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Fig. 6. Effect of staurosporine on PAF-induced |Ca2+]j elevation
Effect of 1 /tM-staurosporine on the peak elevation of [Ca2+]j or on 
the tk (time for decay of elevated [Ca2+]j to half-maximal elevation 
over basal) in platelets stimulated with 3 nM- or 300 nM-PAF. (a) 
Representative trace of fluorescence output transformed to [Ca2+]j 
from fura-2-loaded platelets, demonstrating the concepts of peak 
[Ca2+], and t\. (b) Effect of staurosporine on maximal [Ca2+], 
elevation, (c) Effect of staurosporine on the ti. [Ca2+], is the value 
obtained by subtracting the basal pre-PAF value from the peak 
post-PAF value. Each value represents the mean + s .e .m . of at least 













Fig. 7. Effect of 1 //M-staurosporine on PAF-induced TxB2 generation
TxB2 generation was determined 3 min after addition of PAF. The 
points represent means ± S .e .m .  of three experiments each performed 
in triplicate. Key: □ , control; # .  staurosporine.
with the 200 % increase in ti observed in 300 nM-PAF-stimulated 
platelets.
T xB2 formation. Only trace amounts of TxB2 ( <  1 pmol/ml) 
were detected after platelet activation with either 0.3 nM- or 
3 nM-PAF, and these levels were not affected by staurosporine 
(Fig. 7). However, at higher concentrations of PAF (30-300 nM) 
there was a dose-dependent increase in the TxB2 generated, and 
this was potentiated at least 2-fold with staurosporine (Fig. 7). 
To determine whether the staurosporine-enhanced T xA 2
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formation was responsible for the increased D A G  formation 
(Fig. 5), the effect of indomethacin on this system was examined. 
Pretreatment of the platelets with 2.8 /iM-indomethacin, which 
caused > 9 9 %  inhibition of TxB2 formation, had no significant 
(P  >  0.05) effect on basal, PAF-induced or staurosporine- 
enhanced levels of D A G  (results not shown).
D ISCU SSIO N
We have examined the relationship between the three putative 
signal molecules, namely Ins(l,4,5)P3, D A G  and [Ca2+]i5 in PAF- 
stimulated rabbit platelets, in both the absence and the presence 
of an inhibitor of PKC.
A  very rapid and transient elevation of all three signal 
molecules was induced by the addition of a high concentration of 
PAF. The concentration of Ins(l,4,5)P3 reached a peak at 2 s 
after PAF addition, which preceded the peak concentration of 
[Ca2+]j by 5 s. In addition, the peak concentration of Ins(l,4,5)P3 
was 45 pmol/109 platelets, which is equivalent to 4.5 jum (as­
suming that 109 platelets have a cytosolic volume of I /A; 
Rittenhouse &  Sasson, 1985), close to the 5 /«M-Ins(l,4,5)P3 that 
is required for maximum release of 45Ca2+ from permeabilized 
human platelets (Brass &  Joseph, 1985) and membrane vesicles 
(O ’Rourke et al., 1985). Thus our observations in intact platelets, 
using high concentrations of PAF, provide good support for the 
proposal that Ins(l,4,5)P3 is responsible for mobilizing intra­
cellular Ca2+ (Berridge &  Irvine, 1984).
The time course and the amount of D A G  formed, compared 
with Ins(l,4,5)P3, suggests that PtdInsP2 hydrolysis may not be 
the only source of D A G . Possible additional sources include the 
hydrolysis of other phosphoinositides or the action of phospho­
lipase D  on phosphatidylcholine (Loffelholz, 1989). Whatever 
the source of D A G , the 3-fold increase over basal reported in the 
present study with PAF-stimulated rabbit platelets corresponds 
well to the 2-3-fold D A G  elevation found in thrombin-stimulated 
human platelets, when the same assay for D A G  was used (Preiss 
eta l., 1986). The parallel inhibition of PAF-induced elevations 
of Ins(l,4,5)P3 and D A G  by W EB 2086 (Casals-Stenzel e ta l.,
1986) indicates that these events are closely coupled to a single 
class of PAF receptor.
The higher concentrations of PAF (30 and 300 nM) produced 
dose-related increases in the amounts of [Ca2+]j, Ins(l,4,5)P3, 
DA G , 40 kDa phosphorylation and granule release. However, 
sub-maximal concentrations of PAF (0.3 and 3 nM), which caused 
considerable dense-granule release and elevation of [Ca2+]j, failed 
to induce a detectable increase over basal in the concentration of 
either Ins(l,4,5)P3 or D A G . Thus, in platelets activated with sub- 
maximal levels of PAF, neither the Ins(l,4,5)P3-dependent 
mobilization of Ca2+ from intracellular stores nor the D A G - 
dependent activation of PKC would be expected. The lack of 
[Ca2+]j elevation in the absence of [Ca2+]e at low levels of PAF, 
together with the decreased phosphorylation of PKC substrate 
with sub-maximal levels of PAF, support this.
These findings have several implications. Firstly, at higher 
concentrations of PAF, there is a good correlation between 
products of PtdInsP2 hydrolysis and platelet activation, but at 
the lower concentrations of PAF, platelet activation, including 
Ca2+ mobilization, occurs independently of PtdlnsP, hydrolysis. 
Indeed, in other cell types a lack of correlation between PKC  
activation and functional response, or Ins(l,4,5)P3 elevation and 
[Ca2+]j elevation, has been found. A  lack of correlation between 
D A G  accumulation and superoxide-anion production after 
stimulation of neutrophils with either concanavalin A  (Rider 
&  Niedel, 1987) or A-formylmethionyl-leucyl-phenylalanine 
(Koenderman et al., 1989) has been observed. In vascular 
smooth-muscle cells stimulated with PAF, the time to peak
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[Ca2+]j elevation is reached before any elevation in Ins(l,4,5)P3 
(Schwertschlag &  Whorton, 1988), and it has been suggested that 
other mechanisms are responsible for regulating PAF-induced 
Ca2+ mobilization, namely a receptor-operated Ca2+ channel 
independent o f phosphatidylinositol polyphosphate hydrolysis. 
Similarly, in ADP-stimulated platelets Ca2+ entry was found 
clearly to precede internal discharge, and it was suggested that 
receptor occupancy is closely coupled to the opening o f plasma- 
membrane bivalent-cation channels (Sage et al., 1989). Further­
more, in hepatocytes the formation o f Ins(l,4,5)P3 has been 
found to require a higher concentration o f receptor-operated 
hormone than does [Ca2+]. elevation (Lynch et al., 1989). This 
finding has been explained as either Ins(l,4,5)P3 elevation and 
[Ca2+]j elevation not being causally related, or by the presence of 
spare receptors for agonists that mobilize Ca2+. Moreover, PA F  
has been shown to increase [Ca2+]j in neutrophils where 
phospholipase C activation, and therefore Ins(l,4,5)P3 
production, have been inhibited by pertussis toxin (Naccache 
et al., 1985).
To determine the role o f P K C  in the regulation o f early post­
receptor events, we used the potent, although non-specific, PKC  
inhibitor staurosporine (Tamaoki e ta l., 1986; Watson e ta l.,  
1987). A  concentration of 1 /iM-staurosporine was selected, as we 
had previously shown that this concentration inhibited, by at 
least 70% , 300 nM-PAF-induced PKC-substrate phosphoryl­
ation (M urphy &  Westwick, 1990). Both D A G  and Ins(l,4,5)P3 
production induced by 300 nM-PAF were significantly poten­
tiated by PK C  inhibition; however, there was no effect on 
Ins(l,4,5)P3 or D A G  levels in platelets stimulated with 3 nM- 
PAF. Previous studies, using phorbol esters or membrane- 
permeant D A G  to activate P K C  before agonist or fluoride 
stimulation in platelets, showed that some functional responses 
were inhibited by pre-activation o f P K C  (Poll &  Westwick, 1986; 
Poll e ta l., 1986; Krishnamurthi e ta l., 1986). This led to the 
theory that, when activated, PK C  caused a negative feedback, 
inhibiting generation o f both D A G  and Ins(l,4,5)P3 at the level 
of production (at either phospholipase C  or a controlling G- 
protein) (Watson &  Lapetina, 1985; Zavoico e ta l.,  1985). The 
level of Ins(l,4,5)P3 was further suppressed as activation o f PKC  
increased its metabolism to Ins(l,4)P2 (M olina y Vedia &  
Lapetina, 1986; Connolly e ta l.,  1986).
W e suggest that in our system, where PK C  is activated by 
higher concentrations o f P AF, D A G  and Ins(l,4,5)P3 levels are 
depressed by negative feedback. However, when P K C  is inhibited 
the negative feedback is removed and a full elevation of D A G  
and Ins(l,4,5)P3 induced by 300 nM-PAF stimulation results. A t 
lower concentrations o f P A F  no negative feedback would be 
exerted by PKC , and therefore the inhibition o f PK C  would, as 
observed, have no effect. However, although the findings suggest 
that PK C  is exerting its effect on the production o f Ins(l,4,5)P3 
and D A G , as they are both formed from the hydrolysis of 
PtdInsP2 by phospholipase C, the findings do not dismiss the 
possibility that P K C  may also have a role in the removal of 
Ins(l,4,5)P3 and D A G  (King &  Rittenhouse, 1989). Another 
interesting point from these findings is that the activator o f PKC, 
namely D A G , appears to be self-regulating.
W e also attempted to correlate the effect o f P K C  inhibition 
on generation o f D A G  or Ins(l,4,5)P3 with the effect on the 
functional responses o f [Ca2+]j elevation and TxB2 generation. 
Firstly, staurosporine had no significant effect on either 3 nM- or 
300 nM-PAF-induced peak [Ca2+]j elevation, despite an increase 
in Ins(l,4,5)P3 on stimulation by 300 nM-PAF. This could be due 
to the limits o f detection o f [Ca2+]i elevation being reached after 
stimulation with 300 nM-PAF, and therefore any further increase 
in [Ca2+]j being indistinguishable, or that maximal intracellular 
Ca2+ mobilization had already been achieved. There was no
C. T . Murphy and others
increase in Ins(l,4,5)P3 at 3 nM-PAF, however, and although it 
would have been possible to detect an increase in [Ca2+]j at this 
concentration o f P A F, no significant increase was observed. 
However, when investigating the h  o f the decay of [Ca2+]j it was 
found that P K C  inhibition produced a 200 % increase in the h of 
elevated [Ca2+]j in 300 nM-PAF-stimulated platelets, but only a 
30 % increase in h  in platelets stimulated with 3 nM-PAF. These 
findings are in agreement with the work o f Watson & Hambleton 
(1989), where an increase in h  o f [Ca2+]j decay was observed in 
thrombin-stimulated platelets pretreated with 1 /tM-stauro- 
sporine, despite no evidence o f a potentiation of Ins(l,4,5)P3 
(Watson e ta l.,  1987).
These results taken together also suggest that PKC may be 
acting to restore the elevated [Ca2+]j to basal levels, as was shown 
by Poll &  Westwick (1986) and Pollock et al. (1987) in human 
platelets. Alternatively, our findings are in agreement with those 
o f King &  Rittenhouse (1989), in respect o f PKC inhibition 
potentiating Ins(l,4,5)P3 levels, although unlike us they found 
that this caused an increase in [Ca2+]j elevation. Moreover, King 
&  Rittenhouse (1989) found no potentiation in thrombin-induced 
D A G  levels by 10 /tM-staurosporine. This is interesting, because 
Bishop et al. (1989) found that, with a high concentration of the 
P K C  inhibitor sphingosine, the D A G  elevation induced by 
thrombin was abolished, but at lower concentrations of sphing­
osine the D A G  level was potentiated, and they attributed the 
inhibition by sphingosine to an inhibition o f proximal portions 
of the signal-transduction pathway at this higher concentration 
of inhibitor. Therefore it may be that the concentration of 10 jxu- 
staurosporine used in the study by King &  Rittenhouse (1989), 
which is 10-fold higher than that used in our study, has masked 
any potentiatory response which may have been observed at a 
lower concentration of staurosporine.
We also examined the effect o f staurosporine on PAF-induced 
TxB2 generation. A t lower concentrations of PAF (0.3-3 nM), 
only trace amounts o f TxB2 were detected, but at higher PAF 
concentrations (30 nM and 300 nM) TxB2 was dose-dependently 
increased, and this increase was potentiated by inhibition of 
PKC. Earlier studies have shown that pre-activation of PKC 
causes an inhibition of agonist-induced TxB2 generation (Murphy 
&  Westwick, 1989) and fluoride-induced TxB2 generation (Poll 
et al., 1986). Inhibition o f PKC, and therefore inhibition of the 
negative feedback exerted by activated PKC, would indeed 
predict a potentiation in TxB2 generation. The increase in TxB2 
induced by PK C  inhibition may be attributed to a number of 
events. Firstly, phospholipase A 2 is Ca2+-dependent, and it may 
be that the sustained duration of elevation of [Ca2+]j induced by 
P K C  inhibition is increasing the activation of this enzyme and 
thus causing the observed potentiation in TxB2. Alternatively, 
the increased production o f D A G  could provide, via DAG 
lipase, increased levels of arachidonic acid and ultimately TxB, 
production (conversely, the use of indomethacin provided evi­
dence that the increase in T x A 2 was not responsible for the 
increase in D A G  production). Finally, it is also possible that 
P K C  is exerting a direct effect on phospholipase A 2 or a closely 
coupled GTP-binding protein (Silk et al., 1990) or that it is 
affecting TxB2 production by modulating a family of proteins 
called lipocortins which, if  present, may be responsible for 
inhibiting phospholipase A 2 activity (Touqui et al., 1986).
Several conclusions can be drawn from the present work. The 
relationship between the concentrations of the signal molecules 
and the platelet functional responses is very dependent on the 
dose of P A F  employed. In  high-dose-PAF-activated platelets we 
have shown that the elevation o f Ins( 1,4,5) P3 clearly precedes the 
[Ca2+]j elevation, supporting the proposal that Ins(l,4,5)P3 is 
responsible for this mobilization of intracellular Ca2+ stores. In 
contrast, in low-dose-activated platelets, elevation of [Ca2+]j and
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granule release occurs in the absence o f detectable increases in 
the concentration o f Ins(l,4,5)P3 or D A G , as well as an absence 
of Ca2+ mobilization from intracellular stores or PKC-substrate 
phosphorylation.
These results suggest that in platelet activation induced by low 
concentrations of agonist, mechanisms other than polyphospho­
inositide bisphosphate hydrolysis are utilized for platelet activ­
ation. The existence o f these separate mechanisms is supported 
by experiments with an inhibitor o f PKC , which results in a 
marked potentiation of D A G , Ins(l,4,5)P3 and TxB2 production 
as well as a protracted Ca2+ signal induced to a much greater 
extent by the higher doses of P AF. Finally, the results dem­
onstrate that endogenously activated P K C  operates as a powerful 
negative-feedback regulator o f signal molecules.
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Comparison of the role of protein kinase C in platelet functional 
responses induced by three different mechanisms, PAF, 
ionomycin and arachidonic acid
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The role of protein kinase C (PKC) in modulating platelet activation has been examined in platelets pre-incubated 
with either the PKC activator 12-0-tetradecanoylphorbol 13-acetate (TPA) or the non-specific protein kinase 
inhibitor, staurosporine. In order to determine where in the signal transduction pathway PKC is exerting its effect 
platelets were activated either with a receptor-operated stimulus platelet activating factor (PAF) or by direct 
elevation of [Ca2+]j (ionomycin) or with arachidonic acid which is converted into thromboxane B2 (TxB2). In  
PAF-stimulated platelets activation of PKC inhibited both [Ca2+]j elevation and TxB2 generation but had no effect 
on 5-hydroxytryptamine (5-HT) release whilst staurosporine increased the duration of [Ca2+]j elevation and 
potentiated TxB2 generation but inhibited 5-HT release. In ionomycin-stimulated platelets modulation of PKC had 
no effect on [Ca2+]j elevation but in contrast to PAF-stimulated platelets PKC activation caused potentiation of 
TxB2 generation and 5-HT release whilst inhibition of PKC caused inhibition of TxB2 generation and 5-HT release. 
Modulation of PKC did not affect arachidonic acid-induced TxB2 generation. These findings suggest that in 
receptor activated platelets endogenously activated PKC is exerting a negative feedback role, however, when [Ca2+]j 
elevation is not modified by PKC activation or inhibition (such as in ionomycin stimulated platelets) the 
relationship between the state of PKC activation and subsequent platelet functional responses corresponds more 
closely. The findings from this study suggest a different relationship between PKC and TxB2 generation than 
between PKC and dense granule release in PAF-stimulated platelets.
Introduction
Receptor-mediated activation of platelets initiates a 
* ries of biochemical events leading to shape change, 
?gation, dense granule release and eicosanoid gen- 
on. Agonist-receptor coupling acts via a guanine- 
otide-binding protein to activate phospholipase C
Abbreviations: PLC, phospholipase C; PIP2, Phosphatidyl-inositol- 
4,5-bisphosphate; Ins(l,4,5)P3, inositol 1,4,5-trisphosphate; DAG, 
1,2-diacylglycerol; cytosolic calcium, [Ca2+ ];; extracellular calcium, 
[Ca2+]e; PKC, protein kinase C; TPA, 12-O-tetradecanoylphorbol 
13-acetate; TxB2, thromboxane B2; 5-HT, 5-hydroxytryptamine; PAF, 
platelet activating factor; AA, arachidonic acid; HBT, HEPES 
buffered Tyrode’s solution; 1,2-DHG, 1,2-dihexanyl-sn-diacyl- 
glycerol; PLA2, phospholipase A 2.
Correspondence: C.T. Murphy, Pharmacology, School of Pharmacy 
and Pharmacology, Bath University, Bath, Avon, BA2 7AY, U.K.
(PLC) [1], which catalyses the subsequent hydrolysis of 
phosphatidylinositol bisphosphate (PIP2) to give two 
products, inositol 1,4,5-trisphosphate (Ins(l,4,5)P3) and 
sn-1,2-diacylglycerol (DAG). Ins(l,4,5)P3 is thought to 
mobilise calcium from intracellular stores [2], although 
cytosolic calcium ([Ca2+]j) is also increased due to an 
agonist-induced transient permeability of the plasma 
membrane, allowing extracellular calcium to enter the 
cells [3]. DAG is a putative endogenous activator of 
protein kinase C (PKC) [4], a calcium and phospholipid 
dependent kinase. At least 7 isoenzymes of PKC have 
been reported [5] of which at least two, namely type II 
(j8 chain) and type III ( a  chain) are thought to exist in 
human platelets [6].
The role of PKC in platelet activation and in partic­
ular eicosanoid generation is still uncertain, despite the 
availability of potent and specific protein kinase C 
activators, such as 12-O-tetradecanoylphorbol 13- 
acetate (TPA) [7], Indeed, phorbol esters and mem­
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brane permeable DAGs cause both dense granule re­
lease [7,8] and platelet aggregation [13] in the absence 
of any agonist. This led to the hypothesis that a link 
existed between phosphorylation of a major 40-47 kDa 
protein substrate of PKC and secretion and aggrega­
tion [4,8,10], although a direct relationship has been 
questioned.
The use of phorbol esters to modulate PKC activity 
has led to two main theories for the role of PKC in 
platelet activation. Firstly in platelets which have been 
permeabilized or treated with ionophores, phorbol es­
ters synergize with increased [Ca2+]j to potentiate acti­
vation [11], demonstrating the requirement for both 
increased PKC activity and [Ca2+]s elevation in order 
to achieve full platelet responses and suggesting a 
positive role for PKC. In contrast, however, phorbol 
esters inhibit platelet activation induced by agonists 
indicating a negative feed back role for PKC [12]. This 
work has led to the suggestion that PKC may have a 
dual role in platelet activation.
To further elucidate the role of PKC in platelet 
activation we have used an alternative experimental 
approach. We have compared the effect of activation 
of PKC with the phorbol ester (TPA) with the potent 
although non-specific protein kinase inhibitor stau­
rosporine [13] on platelet thromboxane (Tx) B2 genera­
tion, 5-hydroxytryptamine (5-HT) release and [Ca2+]j 
elevation in platelets stimulated either by a receptor 
operated stimulus (platelet activating factor, PAF), or 
by direct cytosolic calcium elevation (ionomycin) or by 
arachidonic acid (AA) which is metabolised directly 
into thromboxane. Part of this work has been previ­
ously published in abstract form [14].
Materials and Methods
Materials
Prostacyclin (PGI2) was generously provided by Dr.
B.J.R. Whittle, Wellcome Laboratories, U.K. PGI2 was 
stored solid and dry at — 20°C whilst stock aliquots 
were dissolved in 0.5 M Tris-HCl (pH 10.5) and were 
stored at a concentration of 40 jug/40 jiil at -20°C. 
Immediately prior to use an aliquot was thawed and 
diluted as required in 0.01 M Tris-HCl (pH 10.5) and 
stored on ice. Fura-2, AM (cell permeant) obtained 
from Molecular Probes Inc., U.S.A. was stored dry at 
-  20°C. A stock solution at a concentration of 5 mM in 
anhydrous dimethyl sulfoxide (DMSO) was also stored 
at -20°C . 5-[14C]Hydroxytryptamine creatinine sul­
phate (54 mCi/mmol, 50 ^tCi/ml) was stored at — 20°C 
and [32P]Pj (10 mCi/ml) was stored at 4°C, both were 
obtained from Amersham International. Thromboxane 
B2 standard was obtained from Sigma and [3H]throm- 
aoxane B2 (125 Ci/mmol, 50 nC i/m l) was obtained 
from New England Nuclear, both were dissolved in 
ethanol. Rabbit anti-TxB2 antibody was a gift from Dr
F. Carey, ICI, Macclesfield. Platelet activating factor 
(l-0-octadecyl-2-acetyl-sn-glycero-3-phosphocholine) 
was supplied by Bachem (Bubendorf, Switzerland). A  
stoSk so lu tion  o f 1 0 “ 2 M m ade up in 
chloroform: methanol (4:1) was stored at — 20°C and 
working solutions (10 “4 M) were prepared in 
Ca2+/M g 2+ free phosphate buffered saline (PBS) 
buffer containing 2.5 m g/m l bovine serum albumin 
(BSA). Arachidonic acid obtained from Sigma was 
dissolved in ethanol at 25 m g/m l and stored under 
nitrogen at — 20°C. The divalent cation ionophore, 
ionomycin was purchased from Calbiochem and stored 
at — 20°C in DMSO at 5 m g/m l. TPA obtained from 
Sigma was dissolved (1 m g/m l) in dry acetone and 
stored at — 20°C. 1,2-dihexanyl-sn-glycerol was a kind 
gift from Dr. L. Garland, Wellcome, it was dissolved in 
ethanol and stored at -20°C . Staurosporine was pur­
chased from Fluka Chemicals Ltd., U.K., dissolved in 
DMSO and stored at — 20°C.
Methods
Preparation o f  platelets. Washed rabbit platelets were 
prepared as described for human platelets by Poll and 
Westwick [12] using an adaptation of the method of 
Blackwell et al. [15]. The resulting pellet from this 
preparation was resuspended in HEPES buffered Ty- 
rode’s solution (HBT: 10 mM HEPES, 145 mM NaCl, 
5 mM KC1, 1 mM MgCl2, 0.5 mM Na2H P 04, 5.5 mM 
glucose and 0.25% BSA, pH 7.4) and the platelet count 
adjusted.
Protein phosphorylation. Platelets (8 • 109/m l) were 
incubated for 2 h with 200 f i d  [32P]Pj/ml, then washed 
in HBT and the platelet count adjusted to 109/m l. 
Aliquots of platelets (300 /xl) were equilibrated at 37°C 
in the presence of 1 mM extracellular calcium ([Ca2+]e). 
Platelets were pre-incubated with staurosporine or its 
vehicle (0.01% DMSO) for 2 min prior to addition of 
PAF. Activation was terminated at 30 s after PAF 
addition with 300 /xl of 2 X  Laemmli SDS-gel sample 
buffer (100°C). The samples were then boiled for 5 
min, and centrifuged at 8000 X  g to remove any parti­
cles. Proteins (100 /xg/track) were separated by 10% 
polyacrylamide SDS-gel electrophoresis [16], protein 
bands and molecular markers were stained using 
Coomaissie blue and [32P]Pj phosphorylated bands vi­
sualised by autoradiography. The phosphorylated bands 
were excised and quantitated by liquid scintillation 
counting.
Determination o f  [C a 2+] i . Platelets (8 • 108) were 
incubated with 2.5 /iM  Fura-2-acetoxymethyl ester for 
30 min at 37°C, the platelet suspension was then washed 
in HBT and the platelet count adjusted to 2 • 108/m l. 
After loading and washing the intracellular concentra­
tion of Fura-2 was found to be between 10-20 juM. In 
order to measure changes in [Ca2+]j, fluorescence 
readings were recorded at 37°C using an Aminco Bow­
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man Spectrophotofluorimeter (exc. = 339 nm; emission 
= 500 nm: 4 nm slot width) fitted with a thermostatted 
cuvette compartment holder with stirring attachment. 1 
ml aliquots of platelets were dispensed into cuvettes 
and [Ca2+]e adjusted to 1 mM. Calibration of the 
calcium-fura-2-fluorescence was carried out as de­
scribed previously [17,18].
Measurement o f % 5 - [14C ]-H T  release. Platelets (8 • 
108/m l) were incubated with 200 nCi/ml 5-[14C]-hy- 
droxytryptamine (5-HT), then washed in HBT and the 
platelet count adjusted to 2.108 platelets/ml. [Ca2+]e 
was adjusted to 1 mM and platelets were equilibrated 
to 37°C prior to the addition of a drug or vehicle 
control. In order to determine 5-HT release from the 
platelets, sub-aliquots (400 jul) were withdrawn 3 min 
after the addition of the agonist into ice-cooled tubes 
containing 40 /xl of 100 mM EDTA and 30 /xM indo- 
methacin. 5-HT release was determined at 3 min post­
stimulation as there was no further 5-HT release after 
this time. The samples were centrifuged at 12000 X g 
and 2 X 100 /x 1 samples of the supernatant were re­
moved and the amount of 14C-5-HT determined by 
liquid scintillation spectroscopy. Percentage 5-HT re­
lease was determined as described by Holmsen et al. 
[19].
Measurement o f TxB2 generation. Experiments to 
determine TxB2 generation were carried out as for 
5-HT release, except using unlabelled platelets. TxB2 
generation was terminated after maximal generation of 
T xB 2 had occurred (3 min after platelet stimulation) in 
the same way as described for dense granule release. 
The T xB 2 content of the supernatant of the samples 
generated was determined by radio-immunoassay as 
previously described [20].
Statistics. Except when stated data for the figures is 
the mean ±  S.E. of at least 3 experiments each per­
formed in triplicate. In order to determine the levels of 
significance between sets of data a paired Student’s t 
test was employed. The levels of significance are de­
noted by * P  <0.05; * * P <  0.01; * * * P <  0.005. A 
Bonferroni correction was employed when necessary 
[21].
Results
Inhibition o f  PKC substrate phosphorylation by stau- 
rosporine
Staurosporine inhibited 300 nM PAF-induced phos­
phorylation of the 40-47 kDa PKC substrate in a 
dose-dependent manner over the range 30-1000 nM 
with an IC50 of 500 nM (Fig. 1). This finding gave a 
suitable dose range of staurosporine to use in order to 
investigate the effect of PKC inhibition on platelet 
functional response.
PKC modulation and PAF-induced platelet activation
Activation of PKC by a 2 min pre-incubation with 
either 1-30 nM 12-0-tetradecanylphorbol 13-actetate 
(TPA) or 6.8-68 /xM of the membrane permeable 
diacylglycerol, 1,2-dihexanyl-sn-diacylglycerol caused a 
dose-dependent inhibition of both the rate and maxi­
mal height of [Ca2+]j elevation induced by a submaxi- 
mal concentration of PAF (3 nM) (Fig. 2A,B). In 
contrast, 30-1000 nM staurosporine, had no significant 
effect on either the rate or maximal height of 3 nM 
PAF-induced [Ca2+]j elevation (Fig. 2C). Neither TPA, 
DHG nor staurosporine had any effect on basal levels 
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Fig. 1. Inhibition of phosphorylation of the 40-47 kDa substrate of PKC by staurosporine in platelets. Right panel: autoradiograph representing 
track 1 = phosphorylation in resting platelets, track 2 = 300 nM PAF induced phosphorylation in the presence of staurosporine vehicle (0.01ft 
DMSO) and tracks 3-6 = pretreatment with 30, 100, 300 and 1000 nM SS, respectively, followed by 300 nM PAF stimulation. Left panel: 
phosphorylation of the PKC substrate as a % of that phosphorylated by 300 nM PAF. Phosphorylation was quantified by scintillation counting of
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yas generated in a dose dependent manner in 
to platelet stimulation over a range of PAF 
itions (data not shown). Only trace amounts 
<0.1  pm ols/108 platelets) were generated in 
stimulated with 3 nM PAF and therefore a 
ial dose of 30 nM PAF was used for the TxB2 
its. As was found for [Ca2+]; elevations, pre- 
i of PKC with TPA caused a dose dependent 
of TxB2 generation (Fig. 2D). Conversely, 
ition of PKC significantly potentiated TxB2 
n but only at the highest concentration of 
irine, 1 /xM (Fig. 2E). Neither TPA or stau- 
had any effect on the basal level of TxB2 
n of <0.1  pm ol/108 platelets over a 3 min
ependence of TxB2 generation on [Ca2_l_]i 
was determined by replacing extracellular 
[[Ca2+]e) with the calcium chelator EGTA 
Removal of [Ca2+]e inhibited both [Ca2+]i 
and T xB 2 generation induced by PAF sug- 






















Fig. 2. Effect of PKC modulation on [Ca2+]j elevation and TxB2 
generation induced by PAF. The left panel demonstrates the effect 
of a 2 min pre-incubation with the PKC activators (A) TPA and (B) 
DHG or the PKC inhibitor (C) staurosporine on 3 nM PAF induced 
[Ca2+ ]j elevation. The [Ca2+ ]; value was obtained by subtracting the 
basal pre-PAF value from the peak post-PAF value. The right panel 
demonstrates the effect of a 2 min pretreatment of (D) TPA and (E) 
staurosporine on 30 nM PAF induced TxB2 generation. TxB2 gener­
ation was determined at 3 min after PAF addition.
The inhibition of [Ca2+]; elevation induced by 30 
nM TPA was dose-dependently abrogated by stau­
rosporine in 3 nM PAF stimulated platelets (Fig. 4), 
indicating that the inhibition of [Ca2+]j elevation by 
TPA and 1,2-DHG was mediated by PKC.
PKC modulation and ionomycin-induced platelet activa­
tion
In contrast to its effect on [Ca2+]; elevation induced 
by PAF, TPA had no effect on [Ca2+]j elevation in 
platelets stimulated with a submaximal concentration 
(5 f iM )  of ionomycin (Fig. 5A). Inhibition of PKC with 
staurosporine also had no effect on ionomycin induced 
[Ca2+]j elevation (Fig. 5B). Addition of 2.8 /xM indo- 
methacin had no effect on ionomycin stimulated [Ca2+]; 
elevation either in the presence or absence of TPA or 
staurosporine (not shown).
TxB 2 generation in ionomycin stimulated platelets 
was, however, modified by both PKC activation and 
inhibition. PKC activation with TPA (1-30 nM) caused 
a dose dependent potentiation of TxB2 generation 
(Fig. 5C), whereas PKC inhibition with staurosporine
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Fig. 3. The effect of replacing 1 mM extracellular calcium with 1 mM 
EGTA on PAF-induced (A) [Ca2+]j elevation and (B) TxB2 genera­
tion. The top panel shows peak [Ca2+]j elevations after subtraction 
of the basal pre-PAF value, and the lower panel TxB2 generation 
determined 3 min after the addition of PAF. Open circles denote the 
presence of 1 mM [Ca2+ ]e and closed circles 1 mM [EGTA]e.
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Fig. 4. Reversal of TPA-induced inhibition of [Ca2+]; elevation by 
staurosporine in 3 nM PAF-stimulated platelets. Staurosporine w 
added 2 min before TPA (30 nM) which was added 2 min prior to 
stimulation with 3 nM PAF. [Ca2+]j is the value obtained by sub­
tracting the basal pre-PAF value from the maximal post-PAF value.
centration for cell functional responses it was impor­
tant to establish that this concentration of ionomycin 
was not causing non-specific cell permeabilization or 
cell lysis, therefore we examined the supernatant of 
ionomycin stimulated cells for lactate dehydrogenase 
activity, a marker for cell damage and we also exam­
ined for low molecular weight molecule leakage by 
testing for leakage of Fura-2 from the cells. At 5 /iM 
ionomycin, there was no lactate dehydrogenase activity 
in the supernatant nor did any Fura-2 leak from the 
cells into the extracellular medium until a concentra­
tion of above 50 /xM ionomycin was added to the 
platelets.
caused a dose dependent inhibition of TxB2 generation 
(Fig. 5D). 
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Fig. 5. PKC modulation on 5 aiM ionomycin induced [Ca2+]j elevation and TxB2 generation. The traces in the upper panel represent tit 
fluorescent output of fura-2 loaded platelets which have been pretreated for 2 min with (A) 30 nM TPA or (B) 1 /u,M staurosporine ami 
stimulated with ionomycin. The lower panel is the effect of pretreatment with (C) TPA or (D) staurosporine (SS) on TxB2 generation induced by
ionomycin. TxB2 generation was determined 3 min post stimulation.
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platelets, TPA caused a dose dependent inhibition of 
[Ca2+]j elevation whilst staurosporine had no effect on 
[Ca2+]; elevation in platelets stimulated with arachi- 
donic acid (AA) (results not shown). Neither PKC 
activation nor inhibition had any effect on TxB2 gener­
ation in platelets stimulated with AA (Fig. 6A,B). TxB2 
generation stimulated by PAF, ionomycin or AA could 
be completely inhibited by the addition of 2.8 juM 
indomethacin. A  concentration of 30 /xM arachidonic 
acid was found to be submaximal for both [Ca2+]i 
elevation and TxB2 generation. It was important to 
establish 30 ;uM AA was not causing non-specific cell 
permeability or lysis, therefore we examined the super­
natant of AA stimulated platelets for lactate dehydro­
genase, a marker for cell damage and for Fura-2 leak­
age from the cell upon AA stimulation. There was no 
lactate dehydrogenase activity in the supernatant nor 
bad any Fura-2 leaked into the extracellular medium of 
platelets stimulated with 30 /xM AA.
PKC modulation on PAF and ionomycin-induced 5 -H T
release
Washed platelets released 5-HT from their dense 
granules in response to stimulation with either PAF or 
ionomycin (Fig. 7). Activation of PKC with TPA alone 
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Fig. 7. Effect of (A) TPA or (B) staurosporine on 3 nM PAF 
(triangles) or 5 /iM  ionomycin (circles) induced 5-HT release. Re­
sults are given as a % of total possible 5-HT release. The closed 
symbols denote release of 5-HT by PAF or ionomycin in the pres­
ence of TPA vehicle or staurosporine vehicle. % 5-HT release was 
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Fig. 6. PKC modulation on arachidonic acid (AA)-induced TxB2 
generation. Platelets were pretreated for 2 min with either (A) TPA 
or (B) staurosporine and stimulated with 30 jaM  arachidonic acid. 
TxB2 generation was measured at 3 min post-stimulation.
at 30 nM TPA. In platelets stimulated with submaximal 
PAF (3 nM) pre-activation of PKC with 1-30 nM TPA 
had no significant effect on 5-HT release (Fig. 7A). 
Staurosporine, however, inhibited 5-HT release with 
an IC50 of 800 nM, causing up to 70% inhibition with 1 
/xM  staurosporine (Fig. 7B).
In ionomycin stimulated platelets however, TPA 
caused a significant potentiation of 5-HT release with 
100% release at 30 nM TPA (Fig. 7A). This potentia­
tion was not due to the potentiation of TxB2 genera­
tion by TPA in ionomycin stimulated platelets, as 2.8 
/xM indomethacin had no effect on TPA potentiated 
ionomycin-induced 5-HT release. In direct contrast 
staurosporine caused a significant inhibition of 5-HT 
release with an IC50 of 150 nM, and produced almost 
100% inhibition at only 300 nM SS (Fig. 7B). Stau­
rosporine was therefore a weaker inhibitor of 5-HT 
release in platelets stimulated via a receptor operated 
mechanism (PAF) than in platelets directly activated 
via calcium elevation (ionomycin). Experiments mea­
suring 5-HT release were carried out in both platelets 
loaded with the fluorescent dye Fura-2 used to mea­
sure [Ca2+]i elevation and in platelets not loaded with 
Fura-2. Fura-2 loading had no effect on 5-HT release 
in either PAF or ionomycin stimulated platelets, indi­
cating that Fura-2 was not chelating cytosolic calcium 





The most abundant eicosanoid produced in platelets 
is the cyclo-oxygenase product TxA2 which is both a 
platelet agonist, a vasoconstrictor and is also involved 
in platelet-vessel wall interactions [22]. TxA2 is synthe­
sised from AA via the cyclo-oxygenase pathway and 
T xA 2 synthetase [23]. AA is produced from two sources, 
the most important of which is thought to be its release 
from membrane phospholipids such as phosphatidyl­
choline and phosphatidlyinositol by the action of the 
calcium and phospholipid dependent enzyme phospho- 
lipase A 2 (PLA2). The second source of AA is from 
the action of diacylglycerol and monoacylglycerol lipase 
on sn-1,2 DAG produced by the hydrolysis of PIP2 by 
PLC [24]. By studying both activation and inhibition of 
PKC, we have demonstrated that PKC is one of the 
factors capable of modulating TxA2 generation, but 
that depending on the method of platelet stimulation, 
it can play either an inhibitory or a potentiatory role.
It is well established that pre-activation of PKC in 
platelets stimulated with various agonists causes an 
inhibition of [Ca2+]j elevation (eg Ref. 25). In agree­
ment with this we have demonstrated that pretreat­
ment with either the phorbol ester TPA, or the mem­
brane permeable diacylglycerol, 1,2 dihexanyl-sn- 
diacylglycerol causes inhibition of subsequent [Ca2+]j 
elevation in platelets stimulated by PAF. This negative 
feedback pathway is thought to be partly due to the 
PKC activation inhibiting PLC activity, and therefore 
the production of the second messenger Ins(l,4,5)P3 
which is believed to mobilise intracellular calcium stores 
[2], and in combination with its metabolite inositol 
1,3,4,5-tetrakisphosphate regulate second messenger 
operated calcium channels [26]. Pre-activation of PKC 
also increases the rate of Ins(l,4,5)P3 dephosphoryla­
tion to inactive I(1,4)P2 [27,28]. Indeed it has been 
suggested that 5'-phosphomonoesterase is a substrate 
of PKC [28], Activating PKC by increasing endogenous 
DAG by the use of the DAG kinase inhibitor R44949 
also inhibits [Ca2+]; elevation in agonist stimulated 
platelets [29], suggesting that endogenously activated 
PKC is exerting a similar mechanism to that seen with 
exogenously activated PKC.
We have demonstrated that by replacing [Ca2+]e 
with the calcium chelator EGTA, PAF-induced [Ca2+]j 
elevation and also TxB2 generation were significantly 
inhibited. As PLA2 is a calcium-dependent enzyme 
inhibition of [Ca2+]j elevation may lead to a reduction 
in its activity and consequently inhibition of AA pro­
duction. In addition, inhibition of PLC activity by PKC 
activation will inhibit DAG production which is also a 
source of AA and therefore TxB2 [24]. This suggests 
that inhibition of [Ca2+]; elevation by TPA may be 
responsible for the subsequent inhibition of TxB2 gen­
eration observed in our study. This may not be true of
all agonists, however, as collagen has been shown to 
activate PLA2 independently of changes in [Ca2+]j 
[18]. Alternatively, there are now several lines of evi­
dence which suggest PLA2 may be directly coupled to 
membrane receptors via GTP-binding proteins [30] in­
dicating activity of PLA2 is not subsequent to PLC 
activation but a separate event. One way PLC may be 
is modulated by PKC is via phosphorylation of the 
G-proteins that link PLC to membrane receptors. It 
should not be ruled out, therefore, that PKC is exert­
ing its effect over PLA2 in the same way. It is more 
likely however, that PLA2 activity is modified by a 
number factors. Inhibition of PKC using the non­
specific kinase inhibitor staurosporine had no effect on 
either the rate or maximal elevation of [Ca2+]j induced 
by sub-maximal levels of PAF (3 nM). However, in 
agreement with Watson et al. [10], we found that 
inhibition of PKC with 1 /rM staurosporine caused an 
increase in duration of calcium elevation. This finding 
supports previous studies where activation of PKC ’ 
increases the rate of decline of agonist-induced [Ca2+]; 
[31] and suggests a role for PKC in calcium homeosta­
sis. In direct contrast to the effect of PKC activation, 
staurosporine potentiated TxB2 generation supporting 
the theory that endogenously activated PKC exerts a 
negative feedback over PLC and in addition linking 
changes in [Ca2+]j to those in TxB2 generation. Re­
cently several inhibitors with an improved specificity 
for PKC have been developed, namely Ro 31-7549/001 i 
and Ro 31-8220/002 [32]. We have compared the ef­
fect of these inhibitors to staurosporine on PAF-in­
duced platelet functional responses, and have demon- j 
strated that like staurosporine the selective inhibitors j 
of PKC have no effect on maximal elevation of [Ca2+]| 
whilst increasing the duration of [Ca2+]; elevation and i 
T xB 2 generation (unpublished observation). This would 
indicate that the effects observed with staurosporine 
are likely to be due to its inhibitory effect on PKC and 
not other kinases. Indeed we have also demonstrated 
that inhibition of tyrosine kinase with the selective 
inhibitor genistein [33] causes an inhibition of both 
maximal [Ca2+]j elevation and TxB2 generation which j 
is in direct contrast to the effects of staurosporine 
(unpublished observation). j
A  direct increase in [Ca2+]j in combination with 
PKC activation has been found to act synergistically tc 
increase platelet activation [11]. Our results confirmi 
and extend these observations by demonstrating that 
whilst pre-incubation with the PKC activator TPA has 
no effect on maximal [Ca2*]; elevation induced by 
ionomycin, both 5-HT release and TxB2 generation are 
significantly potentiated. Halenda et al. [34] demon­
strated that phorbol esters do not interfere with the 
reincorporation of AA into phospholipids, therefore 
the potentiation of TxB2 found with TPA cannot be 
attributed to modulation of phospholipid reincorpora­
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tion. Staurosporine also has no effect on maximal 
iCa2+]j elevation induced by ionomycin, however in 
contrast to PKC activation both 5-HT release and TxB2 
generation are significantly inhibited. Therefore in ion- 
omycin-stimulated platelets activation of PKC potenti­
ates functional responses whilst inhibition suppresses 
ihem. Although ionomycin has been demonstrated to 
liberate arachidonic acid directly, indomethacin had no 
effect on either ionomycin-induced [Ca2+]j elevation 
nor 5-HT release in this study indicating the release of 
AA by ionomycin is not influencing these responses. 
Thus the effect of PKC modulation in platelets stimu­
lated with ionomycin differs greatly from that in recep­
tor-activated platelets, and makes the use of ionophores 
together with PKC activators a poor model to use to 
investigate the role of endogenously activated PKC.
In ionomycin-stimulated platelets therefore, [Ca2+]j 
elevation is not affected by PKC modulation but TxB2 
generation is affected. Indeed it is thought that in 
onomycin stimulated platelets, platelet activation is 
independent of PLC activity, with all PLC activation 
being due entirely to the generation of cyclo-oxygenase 
products [35]. It maybe, therefore, that an influx of 
calcium by ionomycin directly activates PLA2, to form 
AA, production of which may be directly modulated by 
PKC-induced phosphorylation at the enzyme site. The 
form this modulation may take is not known, but it is 
possible that PKC may interact directly with PLA2 or a 
coupled G-protein, or may act to remove the inhibitory 
effect on PLA2 of an intermediary protein (eg. an 
annexin) [36]. Indeed a 35-36 kDa protein with a 
similar pi to that reported for annexin is phospho- 
rylated in platelets stimulated with ionophore and the 
phorbol ester, PMA [37]. It has also been shown that 
annexins are phosphorylated in vitro by PKC [38]. 
Since neither TPA nor staurosporine were found to 
modify arachidonic acid-induced TxB2 generation this 
indicates that the site of PKC modulation is unlikely to 
be the cyclo-oxygenase pathway or TxB2 synthetase.
PKC activation and inhibition respectively potenti­
ate and inhibit dense granule release in ionomycin 
stimulated platelets, indicating a modulatory role for 
PKC in ionomycin-induced 5-HT release. In contrast, 
in PAF-stimulated platelets activation of PKC with 
TPA had no effect on 5-HT release, whilst compared 
to its effects in ionomycin stimulated platelets, stau­
rosporine caused only a weak inhibition. A  good corre­
lation is thought to exist between the phosphorylation 
state of the major 40-47 kDa protein substrate of PKC 
and 5-HT release [8]; indeed we and others have found 
that PKC activation with TPA alone causes a release of 
5-HT [8]. Our findings indicate that 5-HT release, as 
opposed to T xB 2 generation, may have a closer affinity 
to the phosphorylation state of PKC substrates. As the 
effect of PKC inhibition is the same in ionomycin as in 
PAF-stimulated platelets this may indicate that PLC is
not involved. However, staurosporine is a weaker in­
hibitor of PAF-induced 5-HT release than ionomycin- 
induced 5-HT release, indicating perhaps that PKC is 
less important in modulating agonist-induced dense 
granule release than modulating ionomycin-induced 
dense granule release.
In conclusion therefore, PKC is able to modulate 
thromboxane generation in both PAF and ionomycin- 
stimulated platelets, but with opposite effects. The 
results suggest that in ionomycin-activated platelets 
(where elevation of [Ca2+]j elevation is not effected by 
PKC activation or inhibition) the activation state of 
PKC is directly related to TxB2 generation. In PAF- 
stimulated platelets however, the effect of PKC activa­
tion/inhibition on [Ca2+]j elevation appears to be 
important in modulating TxB2 generation although 
additional factors as discussed may also play an impor­
tant role. In addition the findings of this study also 
demonstrate that a different type of relationship exists 
between PKC and dense granule release than between 
PKC and TxB2 generation in PAF-stimulated platelets.
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Selective inhibition of protein kinase C
Effect on platelet-activating-factor-induced platelet functional responses
159
Christine T. MURPHY and John WESTWICK*
Pharmacology, School of Pharmacy and Pharmacology, University of Bath, Bath BA2 7A Y , U .K .
The role of protein kinase C (PKC) in platelet-activating-factor (PAF)-induced platelet activation was examined by using 
two selective inhibitors of PKC, namely Ro 31-7549/001 and Ro 31-8220/002. Both inhibitors dose-dependently inhibited 
PAF-induced phosphorylation of the major 40-47 kD a protein substrate of PKC, with 50%  inhibition at 4.5 /*m -R o 31- 
7549/001 and 0.7 /tM-Ro 31-8220/002. Inhibition of P K C  had no effect on maximal elevation of intracellular Ca2+ [Ca2+]j 
produced by either a high or a low dose o f P AF, but significantly increased the duration of the Ca2+ signal and the 
thromboxane B2 (TxB2) generation in high-dose PAF-stimulated platelets. The inhibitors also abrogated the effect o f the 
PK C  activator phorbol 12-myristate 13-acetate on PAF-induced [Ca2+]j elevation. Sub-maximal PAF-induced dense- 
granule release and platelet aggregation were dose-dependently inhibited by Ro 31-7549/001 and Ro 31-8220/002. 
The findings suggest that endogenously activated PK C  holds a bifurcating role in PAF-activated platelets, negatively 
affecting duration of both [Ca2+]j and TxB2 generation, and positively influencing dense-granule release and aggre­
gation.
IN T R O D U C T IO N
Protein kinase C (PKC) is thought to hold a pivotal role in 
agonist-initiated signal transduction in the platelet (Nishizuka, 
1984). Agonist-receptor-coupled platelet activation induces the 
hydrolysis of phosphoinositides, producing the two signal mole­
cules sn-1,2-diacylglycerol (D A G ) and Ins (1,4,5)P3 (MacIntyre  
& Pollock, 1983; Agranoff et al. 1983). D A G  is the putative 
endogenous activator of PK C  (Lapetina et al., 1985), a 
family of Ca2+-and-phospholipid-dependent isoenzymes, which 
phosphorylate target proteins. In  platelets their major substrate 
is a 40-47 kD a protein of unknown function (Tyers et al., 1988). 
Phorbol esters such as phorbol 12-myristate 13-acetate (P M A ) 
activate PKC by increasing its affinity for Ca2+ and phospholipid 
(Castagna et al., 1982). As a consequence, phorbol esters have 
been widely used to try to establish the role of PK C  in signal 
transduction. However, owing to the use of permeabilized platelet 
preparations in many of these studies (Halenda et al., 1985; 
Kaibuchi et al., 1983; Mobley &  Tai, 1985) and also the 
differences between P M A  and endogenous D A G , including both 
their permeability and longevity (Bazzi &  Nelsestuen, 1989), 
these studies are difficult to relate to the physiological situation. 
On the other hand, an inhibitor of PKC would allow the role of 
endogenously activated PK C  to be examined.
Some of the earliest P K C  inhibitors described include chlor- 
promazine, dibucaine and other phospholipid-interacting drugs 
(M ori et al., 1980), including polymyxin B (Mazzei et al., 1982), 
which inhibit P K C  by competing with phospholipid. Later it was 
found that members o f the isoquinoline sulphonamide family, 
particularly H-7, were capable of inhibiting P K C  by competing 
with A TP for its binding site on P K C  (Hidaka et al., 1984; 
Yamamoto &  Hidaka, 1984). In  1985 the non-steroidal triphenyl- 
acrylonitrile (TPE) tamoxifen used in the treatment of breast 
cancer was shown to inhibit P K C  (O ’Brian et al., 1985), and 
more recently was shown to be relatively selective for PKC  
(Spacey et al., 1990). Depending on the structure o f the TPE, it
inhibits P K C  either at the regulatory or the catalytic domain 
(Bignon et al., 1989). In  order for the role of PK C  to be 
unambiguous, however, an inhibitor would need to be both 
potent and selective for P K C  above other protein kinases. Until 
the discovery of staurosporine (Tamaoki et al., 1986) and 
members of the same family, including K252a (Yamada et al., 
1987) and UCN01 (Ruegg &  Burgess, 1989), all inhibitors of 
PK C  had low potency and, except tamoxifen, were non-selective. 
Staurosporine and related compounds were found to be potent 
inhibitors of PKC, but because they inhibited by competing with 
A T P  for the A TP  co-substrate site common to all protein 
kinases, they had limited selectively for PK C  (Ruegg &  Burgess, 
1989). Since the introduction of staurosporine, other PKC  
inhibitors, including amino acrides (Hannun &  Bell, 1988; Smal 
et al., 1989), pseudo-substrate analogues of PK C  (Ricouart et al., 
1989) and calphostin C (Kobayashi et al., 1989), have been 
produced which are thought to inhibit PKC at the catalytic and 
regulatory sites, at the substrate-binding site and at the regulatory 
domain respectively.
Several potent and selective inhibitors of P K C  have been 
described (Davis et al., 1989). In  this study we have used two of 
these, namely Ro 31-7549/001 and Ro 31-8220/002, which, 
although structured on staurosporine and inhibiting PKC by 
competing with A TP for the co-substrate site, have been 
demonstrated to be selective for PK C  over both protein kinase A  
and Ca2+/calmodulin dependent kinase (Davis et al., 1989). We 
have used these two compounds in order to examine the role of 
endogenously activated P K C  in the signal-transduction pathway 
in platelet-activating-factor (PAF)-stimulated rabbit platelets.
M A T E R IA L S  A N D  M E T H O D S  
Materials
Prostacyclin was generously provided by D r. B. J. R. Whittle, 
Wellcome Laboratories, Beckenham, Kent, U .K . Stock samples 
were dissolved in 0.5 M -Tris/H C l (pH  10.5) at a concentration of
Abbreviations used: PKC, protein kinase C; DAG, sn-l,2-diacylglycerol; PMA, phorbol 12-myristate 13-acetate; TPE, triphenylacrylonitrile; PAF, 
platelet-activating factor; HBT, Hepes-buffered Tyrode’s solution; TxB2, thromboxane B2; [Ca2+]15 intracellular Ca2+; 5-HT, 5-hydroxytryptamine; 
IC50, concn. giving 50 % inhibition; PLC, phospholipase C.
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Fig. 1. Inhibition of PAF-induced phosphorylation of the 40-47 kDa substrate of PKC by Ro 31-7549/001 (a) and Ro 31-8220/002 (b)
5 6
The right panels in (a) and (b) are autoradiographs representing: in track 1, phosphorylation in resting platelets; in track 2, 300 nM-PAF-induced 
platelet phosphorylation in the presence of the respective PKC inhibitor vehicle; and in tracks 3-6 respectively, either a 20 min preincubation with 
0.3 /am-, 1 /am-, 3 /am-, 10 /a m -R o  31-7549/001 (a) or 0.1 /am-, 0.3 /am-, 1 /am-, 3 /a m -R o  31-8220/002 (b), followed by 300 nM-PAF stimulation for 
30 s. On the left, phosphorylation was quantified by liquid-scintillation counting of the excised [32P]P;-labelled PKC substrate. The data are 
expressed as phosphorylation of the PKC substrate, as a percentage of that phosphorylated by 300 nM-PAF alone (# ;  control), and each point 
is the mean +  s.e.m. of three separate experiments.
40/Ag/40 /A. Working samples were diluted in 0.01 M-Tris/HCl 
(pH 10.5) and kept on ice. 5-Hydroxy[14C]tryptamine (5-H[14C]T) 
creatinine sulphate (54m Ci/m m ol; 5 0 /rC i/m l) and [32P]P; (5 
m C i/m l) were purchased from Amersham International. X-ray 
film was purchased from Fuji. Fura-2 A M  (acetoxymethyl ester; 
cell-permeant) was obtained from Molecular Probes, Eugene, 
OR, U.S.A., and a stock solution at a concentration of 5 m M  in 
anhydrous dimethyl sulphoxide was stored at — 20 °C. Throm­
boxane B2 (TxB2) standard was obtained from Sigma, 
[3H]TxB2 (125 C i/m m o l; 50 nCi/m l) from New England Nuclear 
and anti-(rabbit TxB2) antibody was generously supplied by Dr. 
F. Carey, IC I, Macclesfield, U .K . PAF (l-O-octadecyl-2-acetyl- 
5«-glycero-3-phosphocholine) was supplied by Bachem (Buben- 
dorf, Switzerland). P M A  was obtained from Sigma, dissolved 
in dry acetone and stored at — 20 °C. PKC inhibitors Ro 31- 
7549/001 and Ro 31-8220/002, were kindly given by Dr. J. S. 
Nixon, Roche, Welwyn, Herts., U .K . Both PKC inhibitors were 
dissolved at 10 m M  in dimethyl sulphoxide, and further dilutions 
were made in Hepes-buffered Tyrode’s solution (HBT).
Methods
Preparation of platelets. Washed rabbit platelets were prepared 
as described for human platelets by Poll &  Westwick (1986a) by 
a modification of an original method by Blackwell et al. (1982). 
The resulting platelet pellet from this preparation was suspended 
in HB T (10 mM-Hepes, 145 mM-NaCl, 5 mM-KCl, 1 mM-MgCl2, 
0.5 mM-Na2HPQ 4, 5.5 mM-glucose and 0.25% BSA, pH 7.4) and
the platelet count adjusted. All experiments were carried out at 
37 °C in the presence of 1 m M  extracellular Ca2+.
Protein phosphorylation. Platelets (8 x 109/ml) were incubated 
for 2 h with 200 / i d  of [32P]Pj/ml of platelets, washed in HBT, 
and the platelet count was adjusted to 109/ml. Samples of 
platelets (300 /a1; 109 cells/ml) were preincubated with a dose 
range of the PKC inhibitors or their vehicle for 20 min before 
activation with 300 nM-PAF. Activation was terminated with 
300 //I of 2xLaem m li (1970) SDS reducing gel sample buffer 
(100 °C) 30 s after PAF addition. The samples were then boiled 
for 5 min, and centrifuged at 8000 g for 2 min to remove any 
particles. Proteins (100 //g/track) were separated by SDS/PAGE 
(10%  gel), and protein bands and molecular markers were 
stained with Coomassie Blue. The gels were then dried and 
[32P]phosphorylated bands were detected by autoradiography. 1 
The phosphorylated bands were excised and quantified by liquid- 
scintillation counting.
Determination of intracellular Ca2+ concn. (|Ca2Hjj). Platelets 
were loaded with 2.5 /am  fura-2 A M  for 30 min at 37 °C, the 
platelet suspension was then washed in HBT to remove excess 
fura-2 A M , and the platelet count adjusted to 2 x l0 8/ml. In 
order to measure the changes in [Ca2+](, fluorescence readings 
were recorded with an Aminco-Bowman spectrophoto-1 
fluorimeter (excitation at 339 nm, emission at 500 nm; 4 nm slit 
width) fitted with a thermostatically controlled cuvette com­
partment holder with stirring attachment. The Ca2+/fura-2- 
fluorescence was calibrated as previously described (Grynkiewicz
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Fig. 2. Effect of the PKC inhibitors on maximal ICa2+|j elevation (a) and 
the duration of |Ca2+]j elevation (b) in 3 nivi- and 300 nM-PAF- 
stimulated platelets
Platelets were incubated with 10 //m-Ro 31-7549/001 22, 3 //m-Ro 
31-8220/002 (0 )  or their appropriate vehicle (□ , control; <  0.1 %
I  dimethyl sulphoxide) 20 min before addition of PAF. [Ca2+], is the 
I  maximal elevation of cytosolic Ca2+ after subtracting the basal pre- 
R PAF value, h is the time for Ca2+ to decrease to half-maximal above 
I  basal levels; results are expressed as percentages of the control &.
I ttal., 1985; Pollock et al., 1986). Addition of the PKC inhibitors 
ior their vehicle was made 20 min before stimulation with PAF.
Measurement of TxB2 generation. This was done with 1 ml 
samples of platelets (2 x 108/m l), and PKC inhibitor/vehicle was 
I added 20 min before PAF. To determine TxB2 generation, sub­
samples of platelets (400 /d) were withdrawn at 3 min into 40 fi\ 
jof ice-cold 100 mM-EDTA and 30 /^M-indomethacin. The samples 
I Were centrifuged for 2 min at 12000#, the supernatant was 
i temoved and the TxB2 content was determined by radioimmuno­
assay (Johnston et al., 1984).
Measurement of 5 -H |14C]T release. Platelets (8 x  108/m l) were 
incubated with 200 nCi of 5-H[14C]T/m l, then washed in HBT, 
and the platelet count was adjusted to 2 x 108/m l. Addition of a 
PKC inhibitor or its vehicle control was made 20 min before 
stimulation with 3 nM-PAF. The 5-HT release from the platelets 
was terminated as described for termination of TxB2 generation. 
After the samples were centrifuged two 100 /1\ samples of the 
supernatant were removed and the amount of 5-H[14C]T was 
determined by liquid-scintillation spectroscopy. Percentage 5- 
HT release was determined as previously described (Holmsen &  
bangelmaier, 1989).
Platelet aggregation. This was continually monitored by a 
itwin-channel Ca2+ aggregometer, and the results were expressed 
'as a percentage increase in light transmission. Samples of platelets 
1(2 x 108/m l) were pretreated with the PKC inhibitors for 20 min 
[before addition of PAF. The 100% light transmission was that 
produced by diluting the platelets to 2 x  107/m l. Platelets were 
continually stirred throughout experimentation at 900 rev./min.
Statistics. Data are means ±  s .e .m .  of at least three experiments 
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Fig. 3. Effect of the PKC inhibitors on dense-granule release induced bv 
PAF
Platelets were treated for 20 min with Ro 31-7549/001 (O) or Ro 
31-8220/002 ( A )  before activation with 3 nM-PAF. The percentage 
5-HT release induced by the highest concentration of each PKC 
inhibitor alone (C) is shown as ■  in each panel, and the effect of the 
PKC-inhibitor vehicle (V) on 3 nM-PAF-induced granule release is 
shown as •  and A  for Ro 31-7549/001 and Ro 31-8220/002 
respectively. Dense-granule release was terminated 3 min after 
addition of PAF.
significance between sets o f data, a paired Student’s t test was 
employed. The levels of significance are denoted by *P  <  0.05, 
* * P < 0 .0 1 ,  * * * p  <  0.005. The Bonferroni correction was 
applied where necessary (Wallenstein et al., 1980).
RESULTS
Inhibition of phosphorylation of the major substrate of PKC
A 20 min preincubation with the selective PKC inhibitors Ro 
31-7549/001 and Ro 31-8220/002 inhibited 300 nM-PAF-induced 
phosphorylation of the 40-47 kDa major PKC substrate in a 
dose-dependent manner (Figs. la  and 16). Ro 31-7549/001 
inhibited phosphorylation with an IC 50 (concn. giving 50 % in­
hibition) of 2.5 jum, and Ro 31-8220/002 inhibited phosphoryl­
ation with an IC 50 of 0.45 fiu .
Effect of PKC inhibition on PAF-induced functional responses
|C a 2+lj elevation. The effect of inhibition of PKC on [Ca2+]j 
elevation was investigated by using platelets stimulated with 
both sub-maximal (3 nM) and maximal (300 nM) doses of PAF  
(Fig. 2). Doses of 10 fim -R o  31-7549/001 and 3 /*m -R o  31-8220/ 
002 were used, as these concentrations were found to inhibit 
PKC activation by >  90%  (Fig. 1). Preincubation with either 
Ro 31-7549/001 or Ro 31-8220/002 for 20 min had no effect on 
maximal [Ca2+]j elevation induced by either 3 nM- or 300 nM- 
PAF; however, both inhibitors significantly increased the dur­
ation of the Ca2+ signal (Fig. 2). Moreover, whereas in 300 nM- 
PAF-stimulated platelets inhibition of PKC caused up to a 
180% increase in duration of the Ca2+ signal, it only caused 
about a 50 % increase with 3 nM-PAF (Fig. 2b).
Reversal of PMA-induced PKC activation by using Ro 31- 
7549/001 and Ro 31-8220/002. The ability of the PKC inhibitors
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Table I. Abrogation of PMA-induced inhibition of |Ca2+|j elevation by 
Ro 31-7549/001 and Ro 31-8220/002
Platelets were preincubated with the PKC inhibitors or vehicle 
20 min before addition of the PKC activator PMA (30 nM) and then 
incubated for 2 min before stimulation with 3 nM-PAF. [Ca2+]j is the 
value obtained by subtracting the basal pre-PAF value from the 
maximal post-PAF value. Data were taken from three separate 
experiments each performed in triplicate.
Table 2. Elfect of 10 / / m - R o  31-7549/001 and 3 / /m - R o  8220/002 on TxB, 
generation in 30 nivt-PAF-stimulated platelets and the abrogation 
of PMA-induced inhibition of TxB2 generation by the PKC 
inhibitors
Platelets were preincubated with the PKC inhibitors or vehicle 
20 min before addition of the PKC activator PMA (30 nM) which 
was incubated for 2 min before stimulation with 30 nM-PAF. TxB2 
generation was measured at 3 min after PAF.









- 30 3 12 ±  5
Ro 31-7549/001
0.3 30 3 24+10
1 30 3 93 + 41
3 30 3 562 + 22
10 30 3 524 ±53
Ro 31-8220/002
0.1 30 3 5 + 4
0.3 30 3 42 + 8
1 30 3 450 ±86
3 30 3 441 ±47
to abrogate the effect of PKC activation was studied by in­
vestigating their ability to reverse the effect of the PKC activator 
P M A  on PAF-induced [Ca2+]j elevation (Table 1). Activation of 
PKC with 30 nM-PMA inhibited [Ca2+], elevation in PAF- 
stimulated platelets. A 20 min preincubation with the PKC  
inhibitors completely abrogated the effect on [Ca2+]j caused by 
PM A.
T xB2 generation. With 10/rM-Ro 31-7549/001 and 3 / /m - R o  
31-8220/002 (concentrations which inhibited PKC substrate 
phosphorylation by >  90% ), the effect of inhibition of PKC on
TxB2 (pmol/108 platelets) 
Vehicle + 30 nM-PMA
Control 15.6 ±1.8 4.4 ±0.5**
10/tM-Ro 31-7549/001 65.1 ±10** 51.3± 1.9**
3 / /m -R o  31-8220/002 50.9±9.9* 56.2±10*
T xB2 generation was investigated in platelets stimulated with 
30 nM-PAF (Table 2). Both PKC inhibitors caused a 3-5-fold 
increase in TxB2 induced by 30 nM-PAF. Similarly to the results 
for [Ca2+], elevation, inhibition of TxB2 generation by PMA was 
abrogated by the PKC inhibitors (Table 2). These findings 
indicate that the inhibition of [Ca2+]j elevation and TxB, gen­
eration by PM A  in PAF-stimulated platelets is mediated by PKC 
and can be reversed by preincubation with either PKC inhibitor.
5-H T release. The 5-HT release induced by 3 nM-PAF was 
dose-dependently inhibited when platelets were subjected to a 
20 min preincubation with increasing concentrations of Ro 31- 
7549/001 (0.3,1, 3, 10 /im ) or Ro 31-8220/002 (0.1,0.3,1, 3 //m). 
The IC 50 for Ro 31-7549/001 was 4.7 /im , and for Ro 31 -8220/002 
it was 0.55 /m  (Fig. 3).
Aggregation. Aggregation of platelets induced by a sub­
maximal concentration of PAF (1 n M )  was dose-dependendy 
inhibited with increasing concentrations of either PKC inhibitor, 
with almost total inhibition of platelet aggregation at 10 //M-Ro
Ro 31-7549/001
Vehicle 1 jUM 10 flM






1 nM-PAF 1 nM-PAF 1 nM-PAF 1 nM-PAF 1 nM-PAF
Fig. 4. Traces showing the effect of PKC inhibition on PAF-induced platelet shape change and aggregation
Platelets were preincubated for 20 min with a dose range of Ro 31-7549/001 (0.3-10 /im, top panel) or Ro 31-8220/002 (0.1-3 fiM, lower panel). 
The second arrow in each trace indicates addition of PAF.
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31-7549/001 or 3 ^m-Ro 31-8220/002. The IC 50 for Ro 31- 
7549/001 was 1.8 /m. and for Ro 31-8220/002 it was 0.47 /um 
(Fig. 4). However, the PK C  inhibitors did not affect 1 nM-PAF- 
induced shape change in platelets.
DISCUSSION
The use o f the selective P K C  inhibitors Ro 31-7549/001 and 
Ro 31-8220/002 (Davis et al., 1989) in this study has 
demonstrated that P K C  has a bifurcating role in PAF-induced 
platelet activation. Earlier studies by both ourselves (Murphy et 
al., 1990, 1991) and others (Conolly et al., 1990; Watson &  
Lapetina, 1985) demonstrated that activating PK C  with ex­
ogenous activators such as phorbol esters or membrane-permeant 
DAG, followed by receptor-operated platelet activation, leads to 
an inhibition of the two products o f phospholipase C (PLC) 
activity, namely Ins(l,4 ,5)P3 and D A G . This suggests that 
activated PKC is exerting a negative-feedback role which results 
in the inhibition of PLC either by inactivation of the receptor by 
phosphorylation, or at the level o f the GTP-binding proteins 
coupling PLC to the receptor, or as a direct inactivation of the 
PLC enzyme.
In addition, other forms o f platelet activation are inhibited as 
a consequence of exogenous P K C  activation in agonist- 
stimulated platelets including [Ca2+]j elevation (Poll &  Westwick, 
1986a; Valone &  Johnson, 1987; M urphy &  Westwick, 1989) 
and TxB2 generation (Murphy &  Westwick, 1989,1990; Wheeler- 
Jones et al., 1990). Inhibition of both these responses is possibly 
a direct result of inhibition o f PLC  and the production of the two 
signal molecules Ins(l,4,5)P3 and D A G . Ins(l,4 ,5)P 3 causes 
mobilization o f Ca2+ from intracellular stores (Brass &  Joseph, 
1985; Berridge &  Irvine, 1984), and together with Ins(l,3,4,5)P4 
possibly regulates second-messenger-operated Ca2+ channels 
(Irvine, 1989, 1990). The inhibition o f receptor-operated Ca2+ 
influx and Ca2+ mobilization would prevent the activation of 
Ca2+-dependent phospholipase A 2 (P L A 2), which is probably 
responsible for most of the TxB2 production (Mahaevappa &  
Holub, 1986). In  addition, inhibition of P LC  would remove the 
second source of arachidonic acid production and therefore 
TxB2 generation, which is the action o f D A G  lipase on D A G  
(Bell et al., 1979; Mahaevappa &  Holub, 1986). However, 
recently there is increasing evidence to suggest that P L A 2 is also 
coupled to receptors by intermediate G-proteins, and it may be 
that PKC is exerting a negative feedback on P L A 2 via these G- 
proteins or indeed acting directly on P L A 2 (Silk et al., 1990; 
Kajiyama et al., 1989).
Nevertheless, i f  endogenously activated P K C  is also exerting 
this negative-feedback effect, then inhibition o f P K C  would be 
expected to potentiate both [Ca2+]j elevation and TxB2 generation 
in receptor-activated platelets. In  this study, two selective in­
hibitors of PK C  employed at a concentration which caused 
greater than 90 % inhibition of P K C  substrate phosphorylation 
considerably potentiated the duration o f [Ca2+]1 elevation, par­
ticularly at the higher concentrations o f P A F ; however, the 
maximal [Ca2+]j elevation was not significantly altered. These 
results suggest that a potentiation o f maximal [Ca2+]j elevation 
with either PK C  inhibitor is not seen in high-dose PAF-stimulated 
platelets, either because the fluorescent dye used in this study has 
become saturated, or because maximal elevation of [Ca2+]i has 
been achieved and further elevation of Ins( 1,4,5) P3 cannot release 
any additional Ca2+, but simply increases the duration of the 
signal molecule. Another possibility is that the Ins(l,4,5)P3 5- 
phosphatase is normally activated by PKC, thus rapidly de­
creasing the cytosolic concentration o f Ins(l,4,5)P3. We have 
recently demonstrated that staurosporine, the non-selective P K C  
inhibitor, produces a significant enhancement of the Ca2+ signal
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(M urphy et al., 1991), which was accompanied by a 2-3-fold  
increase in the products of PLC activation, namely Ins(l,4 ,5)P3 
and D A G .
The increase in duration o f [Ca2+], elevation relates well to 
earlier findings that activation o f P K C  decreases the duration of 
[Ca2+]j elevation either by increasing [Ca2+]j efflux or decreasing 
[Ca2+]j influx or mobilization (Poll &  Westwick, 19866; Pollock 
et al., 1987), therefore removal of the effect of PKC activation 
with an inhibitor has produced the opposite effect. The more 
pronounced effect at the higher concentration o f PA F may be 
due to inhibition of a greater negative feedback induced by a 
higher concentration of P A F ; indeed, without this negative 
feedback at the higher concentration o f P A F  it is possible that 
Ca2+ may reach cytotoxic concentrations. As predicted, if  en­
dogenously activated P K C  is exerting a negative feedback over 
PLC and/or P L A 2, TxB2 generation was potentiated by in­
hibition of PKC. Moreover, in vivo the 3-5-fold increase in TxB2 
production, and thus thromboxane A 2 and prostaglandin endo- 
peroxides, could have considerable effects, depending on the 
availability of prostacyclin synthase or vascular tissue responsive 
to the vasoconstrictor actions of thromboxane A 2 (Moncada &  
Higgs, 1986).
In  contrast with the above results, this study has demonstrated 
that two selective inhibitors of PK C  are potent inhibitors of 
dense-granule release and platelet aggregation, with similar IC 50 
values to those for the inhibition of PAF-induced phosphoryl­
ation of 40-47 kD a protein in intact platelets. These findings, 
together with the data demonstrating the specificity of these 
compounds, support the contention that inhibition of platelet 
dense-granule release and aggregation is a result of an inhibition 
of platelet PKC. In  support of this, previous studies have shown 
that activation of PK C  with a phorbol ester alone causes both 
dense-granule release and platelet aggregation (Zucker et al., 
1974; Castagna et al., 1985), and it has been suggested that there 
is a direct link between phosphorylation of the major 40-47 kD a  
substrate of P K C  and dense-granule release and aggregation 
(R ink et al., 1983; Castagna et al., 1985; Watson et al., 1987).
Our results suggest that the relationship between P K C  and 
[Ca2+]j or T xB2 generation is different from that between PKC  
and dense-granule release or platelet aggregation. In  addition, 
the results indicate that the regulation of dense-granule release 
and aggregation by PK C  is possibly independent of [Ca2+], or 
T xB2 generation. Indeed, there appears to be a more direct 
relationship between PKC-induced protein phosphorylation and 
either dense-granule release or aggregation.
Comparing the effects of these selective PK C  inhibitors on 
PAF-induced platelet activation with the effects of the non- 
selective PK C  inhibitor staurosporine, many of the findings were 
similar. Both selective and non-selective inhibitors potentiated 
TxB2 generation and the duration o f the Ca2+ signal (M urphy et 
al., 1991; Watson et al., 1987), while inhibiting 5-H T  release 
(Murphy &  Westwick, 1989) and platelet aggregation (Oka et al., 
1987; Watson et al., 1987; Schachtele et al., 1988). However, 
whereas in platelets activated with sub-maximal concentrations 
of P A F  staurosporine was found to inhibit platelet aggregation 
only partially (Watson &  Hambleton, 1989), Ro 31-7549/001 
and Ro 31-8220/002 caused total inhibition o f aggregation while 
not affecting platelet shape change. I t  is therefore possible that 
staurosporine was inhibiting another protein kinase which was 
counteracting the effect o f P K C  inhibition on platelet aggre­
gation. For example, increasing cyclic A M P  levels activates pro­
tein kinase A , which inhibits platelet aggregation (Blache et al.,
1987); inhibition o f protein kinase A  by staurosporine would 
therefore remove this inhibitory effect and may therefore lead to 
only a partial possible inhibition of aggregation by staurosporine. 
The findings suggest therefore that sub-maximal-dose PAF-
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induced platelet aggregation is PKC-dependent, whereas PA F- 
induced platelet shape change is PKC-independent.
In  conclusion, the use of selective P K C  inhibitors in PAF- 
stimulated rabbit platelets has demonstrated a bifurcating role 
for PKC. Ro 31-7549/001 and Ro 31-8220/002 were both selec­
tive inhibitors of platelet P K C  and were potent inhibitors of 
PAF-induced dense-granule release and platelet aggregation, 
while producing a significant prolongation of the Ca2+ signal and 
a considerably enhanced TxB2 generation.
We are grateful to the British Heart Foundation for financial support, 
and to Dr. J. S. Nixon of Roche for Ro 31-7549/001 and Ro 31- 
8220/002.
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MODULATION OF RABBIT PLATELET THROMBOXANE B2 GENERATION BY PROTEIN 
KINASE C
C.T. Murphy & J. Westwick, Department o f Pharm acology, Royal College o f Surgeons, 
L incolns Inn F ields, London WC2A 3PN
We and  o th ers  have shown th a t  ac tiv a to rs  o f p ro te in  k in ase  C (PKC) in h ib it  fluo ride  
o r  ag o n is t-s tim u la ted  throm boxane B2 g eneration  by human p la te le ts  (Poll e t  al., 
1986,1987; K rishnam urthi e t  al., 1986). The aim o f th is  s tu d y  was to  compare the  
e ffe c t o f  a PKC ac tiva to r,. TPA w ith a  PKC in h ib ito r , s tau ro sp o rin e  (Tamaoki e t 
al.,1986) on ra b b it p la te le t  TxB2 generation induced  by PAF, ionomycin o r  arachidonic 
acid  (AA). Cytosolic free  calcium concen tra tion  ([Ca +]j), dense g ran u le  re lease  and 
TxB2 generation  were m easured as described  p rev io u sly  (Poll e t  al., 1986) using 
p ro stacy clin  washed ra b b it p la te le ts  loaded w ith  F ura 2. R esu lts a re  th e  mean ± se 
mean o f 3-6 experim ents.
Incubation  of p la te le ts  w ith  1, 3, 10 and 30 nM 12-0-te tradecanoyl phorbo l 13-acetate 
(TPA) fo r  two mins reduced submaximal PAF (3 nM) e lev a ted  [Ca++]^ from 455 ± 34.5 
to  400.5 ± 4.2, 303 ± 26, 157 ± 11.5 and 21 ± 6 nM re sp ec tiv e ly  and the  
corresponding TxB2 generation  (30 nM PAF) from  18.4 ± 1.8 to  19.77 ± 1.4, 6.7 ± 1.0, 
2.4 ± 0.5 and 0.64 ± 0.1 pmol/108 p la te le ts  re sp ec tiv e ly . However TPA produced only 
a  weak non-sign ifican t in h ib itio n  of PAF induced  5HT re lease . In  c o n tra s t, TPA a t 
1, 3, 10, and 30 nM increased  ionomycin (5pM)-induced TxB2 g en era tio n  from 161.2 ±
9.7 to  137.6 ± 31.7, 200.6 ± 9.3, 254 ± 29 and 259.6 £  12 p mol/108 p la te le ts  
resp ec tiv e ly  and 5HT re lease  was p o ten tia ted  from 59.6 ± 2.24 to  75.4 ± 5.9, 84.8 ± 
17.1, 95.85 ± 4.1 and 99.6 ± 0.4% respectively . The AA (10 pM )-induced elevation  of 
[Ca +]^ was reduced from 192 ± 17 to  143 ± 19, 29 ± 13.5 w ith no d e tec tab le  [Ca++]£ 
e lev a tio n  when. TPA values reached 10 nM and  above. With a ll  concen tra tions of 
TPA examined AA-induced TxB2 generation  was n o t m odified (p>0.05).
Incubation  of p la te le ts  w ith 30, 100, 300 and 1000 nM s tau ro sp o rin e  fo r  two m inutes 
d id  n o t modify PAF (3nM) elevated  [Ca++] j  (N=4) n o r was th e re  any s ign ifican t 
p o ten tia tio n  of TxB2 generation w ith 30 nM PAF excep t w ith 1 pM stau rosporine . 
However, 5HT re lease  w ith 3 nM PAF was in h ib ited  from 58.4 ± 2.5 to  52.7 ± 6, 46.1 
± 6.6, 43 ± 3.7 and 20.1 ± 8.1 % respectively  (N=4). As w ith  TPA, s tau ro sp o rin e  did 
n o t modify [Ca++]^ elevated  by 5 pM ionomycin (N=3) how ever in  d ire c t  co n tra s t to  
th e  re s u lts  obtained  w ith TPA, TxB2 g en e ra tio n  w ith  5 pM ionomycin was in h ib ited  
from  151.4 ± 13.4 to  142.3 ± 30, 79.5 ± 9.7, 66.8 ± 7.4 and 34.8 ± 9.8 pmol/108 
p la te le ts  respectively , and 5HT re lease  was reduced  from 54.4 ± 3.5 to  47.2 ± 4.7, 
42.2 ± 0.4, 8.8 ± 6.5 and 6.15 ± 1.6 %. S tau ro sp o rin e  (30-1000 nM) as w ith  TPA did 
n o t modify th e  amount of TxB? generated  in  response  to  subm axim al AA (30 pM) 
(N=3).
T herefore these  re s u lts  suggest th a t  re c e p to r  s tim ulated  e lev a tio n  o f [Ca++]^ and 
TxB2 generation  a re  n o t contro lled  by endogenous PKC a c tiv a to rs , a s  dem onstrated 
w ith  s tau rosporine . Although i f  th e  [Ca++]: is  n o t lim iting, as  w ith  ionomycin, TxB2 
generation  can be m arkedly enhanced o r in h ib ite d  w ith  PKC a c tiv a to rs  o r  in h ib ito rs  
respectively . The s i te  o f m odulation by PKC is  probably  n o t th e  cyclo-oxygenase or 
throm boxane sy n th e tase  enzymes as AA-induced TxB2 g en era tio n  is  n o t modified.
We are  g ra te fu l to  th e  B ritish  H eart Foundation  fo r  sup p o rt.
K rishnam urthi, S. e t  al. (1986) Biochem. J . 238, 193-199.
Poll, C. e t al. (1986) Biochim. Biophys. Res. Commun. 136, 381-389.
Poll, C. e t al. (1987) Thrombos. Haemostas. 58, 1676.
Tamaoki,T. e t  ad. (1986) Biochim. Biophys. Res. Commun. 135 397-402
1989 Br.J.Pharmacol. 98: 844P
844P
CHARACTERISATION OF PLATELET-ACTIVATING FACTOR-INDUCED DIACYLGLYCEROL 
GENERATION IN RABBIT PLATELETS
C T Murphy* and  J  W estw ick , D e p t, o f  P h a rm ac o lo g y , H u n te r ia n  
I n s t i t u t e ,  R o y al C o lle g e  o f  S u rg e o n s , London WC2A 3PN, UK.
We h av e  p r e v io u s ly  d e m o n s tra te d  t h a t  io n o m y c in - in d u c e d  5-HT r e l e a s e  
and th rom b o x an e  ' Bz (TxBz) g e n e r a t i o n  a r e  r e a d i l y  m o d u la ted  by 
a c t i v a t i o n  o r  i n h i b i t i o n  o f  p r o t e i n  k in a s e  C (PKC). However, s u b -  
o p tim a l  p l a t e l e t - a c t i v a t i n g  f a c t o r  (P A F )-in d u ced  e l e v a t io n  o f  
c y t o s o l i c  c a lc iu m  :; c 9 n c e n t r a t i o n  ( [Ca*4] t ) , 5-HT. r e l e a s e  and TxB2
g e n e r a t io n  a r e  n o t  s i m i l a r l y  m o d if ie d  (Murphy & W estw ick , 1 9 8 9 ). To 
a n a ly s e  t h i s  p a ra d o x , we h av e  d e te rm in e d  P A F -in d u ced  fo rm a tio n  o f 
d i a c y l g l y c e r o l  (DAG), th e  en d o g en o u s a c t i v a t o r  o f  PKC. DAG was 
m easu red  u s in g  th e  Amersham k i t ;  [Ca*+]i and TxB2 g e n e r a t i o n  w ere 
m easu red  a s  p r e v io u s l y  d e s c r ib e d  (Murphy & W estw ick , 1989; P o l l  e t  
a l . ,  1986) i n  r a b b i t  p l a t e l e t s .
A d d it io n  o f  300nM PAF p ro d u c e d  a r a p id  e l e v a t i o n  o f  DAG 
c o n c e n t r a t i o n ,  w h ich  p eak ed  a t  1 0 s ;  th e  v a lu e s  a t  5 , 1 0 , 15 , 20 , 30 
and 60s w ere  8 6 .8 ± 1 5 , 280±52, 65±11, 87±31, 66±18 .and  69±10
pm oles/10*  p l a t e l e t s ,  above th e  b a s a l  v a lu e  o f  117±3 (n = 3 -9 ) . T h is  
h ig h  c o n c e n t r a t i o n  o f  PAF p ro d u c e d  a p eak  e l e v a t i o n  o f  [Ca**]i o f  
1023 ± 72 nM, w h ich  o c c u r re d  a t  7 .3 ± 0 .6 s  (n=13) an d  62.7±12.9%  o f  
t o t a l  TxBa was p ro d u c e d  w i th in  1 0 s .  A t 10s a f t e r  t h e  a d d i t io n  o f  
0 .3 ,  3 , 30 and 300 nM PAF, th e  g e n e r a t i o n  o f  18±6, 8±6, 80±19 and 
280±52 pmol DAG/10* p l a t e l e t s  (n = 3 -9 ) above b a s a l  v a lu e s  was in d u c e d . 
Thus s u b -o p t im a l  c o n c e n t r a t i o n s  o f  PAF (0.3-3nM ) do n o t  in c r e a s e  DAG 
above b a s a l  v a l u e s .  T h e r e f o r e ,  i t  i s  u n l i k e l y  t h a t  PKC can  e x e r t  a 
n e g a t iv e  fe e d b a c k  on lo w -d o se  P A F -a c t iv a te d  s y s te m s .  F o r exam ple , 
p r e - t r e a tm e n t  o f  p l a t e l e t s  f o r  2 m in w ith  lpM s t a u r o s p o r in e  (an  
i n h i b i t o r  o f  PKC, Tam aoki e t  a l . , 1 9 8 6 ) , c a u sed  an a p p ro x im a te ly  3 - 
f o l d  enhancem en t o f  300 nM P A F -induced  DAG l e v e l ,  from  413±8 .5  to  
1147±227, b u t  had  no s i g n i f i c a n t  e f f e c t  on 3nM P A F -in d u ced  DAG l e v e l ,  
from  1 1 2 .5±7 to  146±35 pm ol/10* p l a t e l e t s .  T h e se  r e s u l t s  a r e  
p a r a l l e l e d  by th e  s t a u r o s p o r in e  ( ly M )- in d u c e d  t r i p l i n g  o f d u r a t io n  
o f 300nM (b u t  n o t  3nM) P A F -e le v a te d  [Ca44]i from  t>£ 34±4 to  105±4 s .  
S im i l a r ly ,  th e  300nM P A F -induced  TxB2 g e n e r a t i o n  i s  d o u b led  by 
p r e t r e a tm e n t  w ith  lpM s t a u r o s p o r in e  from  170±19 to  307±17 pmol 
TXB2 / IO 8 p l a t e l e t s .
P r e t r e a tm e n t  w ith  ex o g en o u s PKC a c t i v a t o r  1 2 - 0 - t e t r a d e c a n o y l  p h o rb o l 
1 3 - a c e t a t e  (lOOnM) re d u c e d  3nM and 300nM P A F -induced  DAG fo rm a tio n  
from  112±5 to  45±32 and from  4 1 3 ± 8 .5  to  140±37 .4  p m o l/1 0 9 p l a t e l e t s  
r e s p e c t i v e l y .
T hus, w ith  h ig h  c o n c e n t r a t i o n s  o f  PAF, th e  d i a c y l g l y e r o l  l e v e l s ,  
d u r a t io n  o f  e l e v a t i o n  o f  [CaM ] i  and  g e n e r a t io n  o f  TxB 2 a r e  
s i g n i f i c a n t l y  en h a n ced  by i n h i b i t i o n  o f  PKC.
We a r e  g r a t e f u l  f o r  s u p p o r t  from  th e  B r i t i s h  H e a rt F o u n d a tio n .
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CHARACTERISATION OF PLATELET ACTIVATING FACTOR INDUCED INOSITOL (1,4,5)- 
TRISPHOSPHATE PRODUCTION IN PLATELETS: MODULATION BY PROTEIN KINASE C
C.T. Murphy, M.A. Elmore*, S. Kellie* and J . Westwick, Departments of Pharmacology and 
*Biochemistry, Hunterian In s titu te , Royal College of Surgeons, London WC2A 3PN, U.K.
In a  previous study we found th a t ionomycin-stimulated p la te le t activation  was readily  
modified by protein k inase C (PKC) activation  o r inhibition , however th is  was not tru e  fo r 
sub-maximal PAF stim ulation (Murphy & Westwick, 1989a). F u rth er investigations which 
examined PAF-induced form ation o f diacylglycerol (DAG) (Murphy & Westwick, 1989b), the  
endogenous ac tiva to r o f PKC, suggested th a t th e re  was a  d isp arity  between DAG production 
and functional response. We have investigated  these findings by examining the effec t of 
s taurosporine (the poten t although non-specific PKC in h ib ito r -  Tamaoki e t al, 1986) on PAF 
induced inosito l-(l,4 ,5)-trisphosphate (IP3) production in rab b it p la te le ts  v ia  use of the 
Amersham binding assay, p ro tein  phosphorylation in 32P labelled p la te le ts  and cytosolic 
calcium ([Ca44],)  elevation in  Fura-2 loaded p la te le ts.
Addition of 300 nM PAF produced a rap id  elevation in IP3 concentration which peaked a t  
2s with values of 45.8 2.2, 21.7 6.9, 6.9 4, 1.3 1.7, 1.1 1.6, 2.5 2.1 and 9.0 3.1 pmols IP3/109 
p la te le ts  a t 2,5,10,15,20,30 and 60s respectively, above a basal level of 11.8 0.6 pmols/109 
p la te le ts . A peak elevation of [Ca44], o f 1023 72 nM occurred a t  7.3s a f te r  stim ulation w ith 
300 nM PAF. The peak IP3 production th ere fo re  precedes th e  peak elevation o f [Ca44], 
induced by 300 nM PAF.
Using concentrations of PAF (0.3,3,30,300 nM) which increased maximal [Ca44], to  199 45, 
435 45, 628 34 and 1023 72 nM respectively  above a basal concentration of 109 9 nM we 
measured IP3 production. At 5 seconds, 0.3,3,30 and 300 nM PAF were found to  generate
8.8 1.0, 12.7 1.3, 23.6 4.8 and 30.2 1.9 pmols IP3/109 p la te le ts  respectively, compared w ith th e  
basal value of 11.8 0.6 pmols/109 p la te le ts . Thus sub-optim al concentrations of PAF do not 
appear to  increase IP3 above basal concentrations, these re su lts  are  in agreement with 
ea rlie r  findings th a t sub-optim al concentrations of PAF (0.3,3 nM) did not increase DAG 
above resting  levels. Indeed, in  support o f th is  we have found th a t there  is  a good 
corre la tion  between DAG production and th e  ab ility  of 0.3,3,30, and 300 nM PAF to  
phosphorylate the 40-47 kDa p ro tein  su b s tra te  of PKC.
The effec t of PKC inh ib ition  on IP3 elevation was investigated  using staurosporine. Dose 
response studies dem onstrated 1 pM staurosporine to  almost completely inh ib it 300 nM PAF- 
induced PKC su b stra te  phosphorylation w hilst having no effec t on resting  IP3 levels. At 
5 seconds post-PAF a 2 minute pre-incubation with 1 pM staurosporine induced a  2 fold 
po ten tiation  in 300 nM stim ulated IP3 levels from 30.2 1.9 to  55.15 3.8 pmols/109 p la te le ts , 
w hilst having no effect on 3 nM PAF stim ulated IP3 with values o f 12.7 1.3 and 9.5 0.5 pmols 
IP3/109 p la te le ts  fo r contro l and staurosporine p re -trea ted  respectively. Moreover, we 
investigated  the effect of staurosporine (1 pM) on maximal [Ca44], elevation and on the T1/2 
(the time fo r elevated [Ca44], levels to  decline to  1/2 maximal) in  PAF-stimulated p la te le ts . 
S taurosporine had no effect on maximal height of [Ca44], induced by e ith e r 3 or 300 nM PAF, 
however in accord with the  effect of s taurosporine on IP3 production, i t  induced a 200%
increase in the T1/2 of 300 nM PAF elevated [Ca44], whilst inducing only a 30% increase in
the T1/2 of 3 nM PAF elevated [Ca44],.
In conclusion, there  is a good correlation  between the effec t of PKC inhib ition  on IP3 
production and DAG production induced by d iffe ren t concentrations of PAF. Thus p la te le t 
ac tivation  by lower concentrations of PAF may not involve phosphoinositide hydrolysis o r 
ac tivation  of PKC.
We are g ra tefu l to  the B ritish  Heart Foundation fo r support.
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EFFECT OF PROTEIN KINASE C MODULATION ON TXB2 GENERATION IN PAF AND  
IONOMYCIN STIMULATED RABBIT PLATELETS. Murphy. C-T. and Westwick, J. Department 
of Pharmacology, Royal College of Surgeons, London, WC2A 3PN, UK.
This study aimed to compare the effect of a PKC activator, 12-O-tetradecanyl-phorbol 1 3 -  
acetate (TPA) with a PKC inhibitor, staurosporine (SS) on platelet cytosolic calcium ((Ca+ Jj) elevation 
and TxB2 generation induced by PAF or ionomycin.
Pre -  incubation of platelets with 1 -3 0  nM TPA reduced sub-maximal PAF (3 nM) elevated 
[Ca++] 1 by 95% and correspondingly TxB2 generation (30 nM PAF) was inhibited by almost 100%. 
In contrast however, whereas TPA had no effect on ionomycin (5 pM) induced (Ca^+] i elevation, it 
potentiated TxB2 generation upto 1.6 fold. A  concentration range of SS (30-1000 nM) which dose 
dependently inhibited PKC activation (measured by inhibition of PAF induced phosphorylation of the 
47 KDa protein substrate of PKC) did not modify maximal [Ca++) f elevation induced by 3 nM PAF 
however, it dose dependently reversed the inhibitory effect of 30 nM TPA on 3 nM PAF induced 
(Ca++)1 elevation. TxB2 generation was significantly potentiated at the highest concentration of SS 
used (1 pM). As with TPA, SS did not modify ionomycin induced [Ca**^ elevation however in direct 
contrast to the results obtained with TPA, TxB2 generation was inhibited bt 78%. Neither TPA nor 
SS modified arachidonic acid-induced TxB2 generation indicating that neither cyclo-oxygenase or 
T xB2 synthetase is likely to be the site of PKC modulation. Replacing [Ca++)e with EGTA and 
thereby inhibiting PAF-induced [Ca++Ji elevation significantly inhibited TxB2 generation suggesting 
that the inhibition of {Ca++] i elevation by TPA may correlate with the subsequent inhibition in TxB2 
generation. However, when [Ca++Ji is unaffected by PKC modulation as in ionomycin stimulated 
platelets TxB2 generation can be directly modulated by PKC.
We are grateful to the British Heart Foundation for support.
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CHARACTERISATION OF P A F-IN D U C ED  DIACYLGLYCEROL AND INOSITOL (1,4,5)- 
TRISPHOSPHATE PRODUCTION IN  RABBIT PLATELETS. Murphy. C.T. and Westwick, J. 
Department of Pharmacology, Royal College of Surgeons, London WC2A 3PN, UK.
We have explored the role of endogenous protein kinase (PKC) activators in regulating the levels 
of diacylglycerol (DAG), inositol (1,4,5) -  trisphosphate (IP3) and cytosolic calcium ((Ca++]1) in PAF 
stimulated rabbit platelets.
300 nM PAF produced a rapid and transient elevation in DAG , IP3 and [Ca++]1 levels. DAG  
peaked at 10s with a 2.4 fold increase, IP3 peaked at 2s with a 3.8 fold increase and [Ca++]1 peaked 
at 73 s with a 10 fold increase over basal levels. Sub-maximal concentrations of PAF (03, 3 nM) 
elevated [Ca++]1 but did not elevate either DAG or IP3 above basal levels. However, 30 and 300 nM 
PAF induced a dose dependent increase in DAG, IP3 and [Ca++] i . PKC activity measured by P A F -  
induced phosphorylation of the 47 KDa protein substrate of PKC supported these findings. Inhibition 
of PKC with 1 pM staurosporine (SS) potentiated DAG levels 3.6 fold and IP3 levels 2 fold in 300 
nM PAF stimulated platelets, but had no effect in platelets stimulated with 3 nM PAF. 1 pM SS also 
induced a 200% increase in the time for elevated [Ca++].j to decay to 1/2 maximal (T 1/2) whilst only 
inducing a 30% increase in the T 1/2 of 3 nM PAF elevated (Ca++]1. Conversely, pretreatment with 
exogenous PKC activator 1 2 - 0 - tetradecanylphorbol 13-acetate (100 nM) inhibited 3 and 300 nM 
PAF-induced DAG levels by 60% and 66% respectively.
In conclusion, it is unlikely that PKC can exert a negative feedback in low dose PAF -  activated 
systems, as there is no DAG elevation, and neither IP3 nor DAG levels are elevated by PKC inhibition. 
We are grateful to the British Heart Foundation for support.
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Modulation of the activation of platelets by genistein, an inhibitor of tyrosine kinase(s)
C.T, Muiphy & J. Westwick, Department of Pharmacology, University of Bath, Claverton Down, Bath, Avon, BA2 7AY
We have explored the role of tyrosine kinases in the signal transduction of PAF-activated rabbit platelets. Rabbit platelets were 
prepared, signal molecules Quantitated and dense granule release determined as described previously (Murphy et al, 1991). Tyrosine 
phosphorylation of rabbit platelet proteins was determined by Western blotting of platelet lysates with PY20, a monoclonal anti- 
phosphotyrosine antibody (Glenney et al, 1988). Resting platelets exhibited at least four tyrosine phosphorylated (TP)-proteins of 
52-62 kDa. Stimulation with 300 nM PAF induced a rapid increase in TP-proteins visible within 5 secs of both low (35-45 kDa) 
and high (66-90 kDa) molecular weight. Pretreatment of platelets with genistein (10-300 ^M) for 20 min produced a dose related 
inhibition of tyrosine phosphorylation of a number of the 66-150 kDa and 35-45 kDa proteins, although was much less effective 
against the proteins of 52-62 kDa. Genistein (Akiyama et al, 1987) was an effective inhibitor of PAF-induced calcium elevation 
([Ca++]i), inositol 1,4,5-trisphosphate (IP3) formation, thromboxane (Tx) B2 generation and the release of dense granules (14C- 
5HT) sec table.
Treatment [Ca++]i (nM) IP3(pmol/109pl) TxB2(pmol/108pl) 14C-5HT (%)
Unstimulated 107 ±12 7.5 ±1,5 <0.1 <0.1
Vehicle + PAF 490 ± 22 34 ±5.5 44 ±3.2 58 ±1.5
10/*M Genistein + PAF 434 ±17.5 -  25.5 ±0.31 46 ±0.7
30 Genistein + PAF 421 ± 15 22 ± 2  3.4 ±1.6 39 ±2.8
100 ftM Genistein + PAF 341 ±24 15 ±0.8 <0.1 13.8 ±2.3
300 fM  Genistein + PAF 135 ±13 10.2 ±2.7 <0.1 3 ±0.5
We have demonstrated that PAF induces a rapid tyrosine phosphorylation of approximately 17 proteins in three molecular weight 
ranges. This probably involves a number of tyrosine kinases as genistein is an effective inhibitor of only a limited number of 
proteins. However, these TP proteins appear to be crucial in the very early signal transduction events of PAF activated platelets as 
genistein is an effective inhibitor of these events.
We are grateful to the British Heart Foundation for support.
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